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 ABSTRACT 
Streptococcal collagen-like protein 1, Scl1, modulates group A Streptococcus 
adhesion, biofilm formation and virulence 
Beth A. Bachert 
Background: The collagens comprise a large family of versatile proteins found in all three 
domains of life. The streptococcal collagen-like protein 1, Scl1, of group A Streptococcus 
(GAS) binds extracellular matrix components (ECM), cellular fibronectin and laminin, via 
the surface-exposed globular domain. GAS strains express Scl1 and form biofilm in vitro, 
except for M3-type strains that are particularly invasive to humans. Hypothesis: Lack of 
Scl1 adhesin in M3 GAS results in decreased adherence and biofilm formation, and 
increased virulence. Results and Discussion: First crystal structure of the globular domain 
revealed a unique six-helical bundle fold, consisting of three pairs of alpha helices 
connected by variable loops. ECM binding by Scl1 promotes the formation of stable tissue 
microcolonies, which was demonstrated in vitro during infection of wounded human skin 
equivalents. A conserved nonsense mutation was identified in the scl1 allele of the M3-type 
strains (scl1.3) that truncates the coding sequence, presumably resulting in a secreted Scl1 
variant. Absence of Scl1 on the surface of M3-type GAS was demonstrated experimentally, 
as well as diminished expression of the scl1 transcript in M3 strains relative to other M-
types. Therefore, M3-type strains have reduced biofilm capacity on ECM coatings relative 
to other M-types. Constructed full-length recombinant Scl1.3 protein displayed binding 
capacity to cellular fibronectin and laminin, and M3 strains complemented with functional 
Scl1.3 adhesin displayed increased biofilm formation. The isoallelic M3 strain, carrying a 
rare “carrier” allele encoding cell-associated Scl1.3 variant, showed decreased pathology 
in mice, compared to the invasive M3 strain. Similarly, scl1 inactivation in biofilm-capable 
M28- and M41-type GAS led to increased lesion size during subcutaneous infection. 
Conclusions: The studies presented here demonstrate the importance of surface Scl1 in 
modulating biofilm formation and virulence of GAS, and provide insight into the structure 
and function of Scl proteins. 
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Preface  
The Ph.D. Thesis presented here represents a subset of research performed by Beth 
Bachert that is thematically focused on the importance of the major surface adhesin, the 
streptococcal collagen-like protein 1 (Scl1), in the pathogenesis of group A 
Streptococcus. The chapters herein correspond to published peer-reviewed research 
papers and are grouped into two parts that address: Part I) the role of Scl1 in adherence, 
biofilm formation, and virulence, and Part II) structural analysis of the Scl proteins. 
Additional published data are presented in Part III that resulted from Author’s projects, 
focused on utilization of collagen-like genes as epidemiological and detection markers, 
which were carried out under a two-year Graduate Fellowship in Nanotechnology Sensing 
Advances in Field and Environment (NanoSAFE).  
Research included in Part I demonstrates that Scl1 significantly contributes to 
biofilm formation in multiple M-types, except for invasive M3-type strains that were 
naturally diminished in the capacity to form biofilm (Chapter 1). Non-invasive M28- and 
M41-type strains produced significant biomass and biofilm structure associated with 
extracellular glycocalyx. Biofilm phenotype was significantly reduced in scl1 isogenic 
mutants but was gained following heterologous complementation of Lactococcus lactis 
with Scl1. A unique scl1.3 allele is reported that is conserved in M3 strains, which contains 
a null mutation in the collagen-like region, resulting in a truncated secreted protein. 
Research in Chapter 2 assesses the effect of this null mutation on adherence and biofilm 
formation. The absence of Scl1 on the surface of M3-type GAS was demonstrated, as 
well as diminished scl1-transcript level in comparison to other M-types. Complementation 
of Scl1-deficient M3 GAS with full-length Scl1.3 surface protein conferred biofilm 
formation by these strains. The M3 wild-type strain lacking surface Scl1 did not form tissue 
microcolonies in an in vitro pseudo-organ skin equivalents, whereas Scl1-expressing M41 
strain formed glycocalyx-embedded microcolonies. Inactivation of scl1 in M28 and M41 
GAS resulted in increased virulence in mice. Research in Chapter 3 focuses on M3 
strains harboring a rare carrier allele of scl1.3, which restored the open reading frame 
and the expression of full-length Scl1.3 protein. These strains were attenuated for 
virulence and had increased host cell adherence compared to the wild-type strain.  
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Part II focuses on crystallization and structural characterization of Scl proteins. 
The globular non-collagenous domain of Scl2 from M3-type GAS was crystallized 
(Chapter 4), and revealed a six-helical bundle fold that is rare in bacterial proteins 
(Chapter 5).  
Overall, studies presented in Parts I and II demonstrate the importance of Scl1 in 
adherence and biofilm formation, while revealing an inverse correlation with invasiveness. 
Importantly, our studies provide new insights into the structure-function relationship of Scl 
proteins. 
Additional data presented in Part III, describe interdisciplinary projects aimed at 
development of bacterial models for the microfluidic assessment of epidemiology of group 
A streptococcal strains (Chapter 6) and the detection of the select agents, Burkholderia 
pseudomallei and B. mallei, by targeting collagen-like genes (Chapter 7).  
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 1 
GENERAL INTRODUCTION 
COLLAGEN-LIKE PROTEINS OF PATHOGENIC STREPTOCOCCI: BIOLOGY, 
STRUCTURE AND FUNCTION 
 
Summary 
The collagen domain, which is defined by the presence of the Gly-X-Y triplet repeats, is 
amongst the most versatile and widespread known structures found in proteins from 
organisms representing all three domains of life. The streptococcal collagen-like (Scl) 
proteins are widely present in pathogenic streptococci, including Streptococcus 
pyogenes, S. agalactiae, S. pneumoniae, and S. equi. Experiments and bioinformatic 
analyses support that all Scl proteins are homotrimeric and cell wall-anchored. These 
proteins contain the rod-shaped collagenous domain proximal to cell surface, as well as 
a variety of outermost non-collagenous domains that generally lack predicted functions 
but can be grouped into one of six clusters based on sequence similarity. The well-
characterized Scl1 proteins of S. pyogenes show a dichotomous switch in ligand binding 
modalities between human tissue and blood environments. Scl1 adhesin specifically 
recognizes the wound microenvironment, resists killing by neutrophil extracellular traps, 
promotes adhesion and biofilm formation, and modulates S. pyogenes virulence. In blood, 
binding modalities include components of the complement and coagulation-fibrinolytic 
systems, as well as plasma lipoproteins. In all, the Scl proteins signify a large family of 
structurally related surface proteins, which contribute to the ability of streptococci to 
colonize and cause diseases in humans and animals. 
 
Overview of collagens and collagen-like proteins 
A common structure among diverse proteins 
Collagens are ubiquitous in nature. The common feature of the collagen module is a triple-
helical structure consisting of three polyproline-II-like helices supercoiled in a right-
handed direction around a central axis (1). The tight packing of the polypeptide chains 
requires a glycine every third residue, defining the Gly-X-Y repeat motif, where proline 
and hydroxyproline often occupy the X and Y positions of human collagen, respectively. 
Current knowledge on collagen structure is a culmination of fiber diffraction studies, 
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modeling, and crystallographic studies on collagen mimetic peptides. Since a history of 
the structural dissection of collagen is out of the scope of this review, we direct the reader 
to several excellent reviews (2-5). The collagens emerged as essential group of modular 
proteins of metazoans (6). It is a versatile structure, appearing in human extracellular 
matrix proteins, host defense proteins, and anchoring fibrils (5). The collagen domain is 
also present in important proteins in invertebrates, such as the exoskeleton collagens of 
sponges (7), holdfast structure of the mussel byssus (8), and basement membrane and 
cuticle collagens of the nematode Caenorhabditis elegans (9). There has been a large 
number of 18,874 collagen-like proteins (CLPs) annotated in bacteria, 695 in viruses, and 
157 in archaea (search conducted on 9/24/16 in Uniprot database). The name 
streptococcal collagen-like proteins, Scl, in S. pyogenes was coined (10), which was 
followed by Bacillus proteins Bcl (11,12), pneumococcal protein Pcl (13), Lcl of Legionella 
pneumophila (14), and Bucl proteins of Burkholderia spp. (15). However, only a small 
proportion of predicted bacterial CLPs have been investigated thus far.  
 
Origin of the collagenous domain in bacteria  
The origin of the collagenous domain in prokaryotes is still unknown. However, the 
composition of the collagen domain in human and bacterial collagens differs considerably. 
In human collagens, proline and hydroxyproline residues are found preferentially in the X 
and Y positions, respectively, with frequencies of 27% and 38% (3). The abundance of 
hydroxyprolines in mammalian collagens is a major contributor to structural stability of the 
triple helix (16,17) but prokaryotes lack the prolyl hydroxylase enzyme to perform this 
post-translational modification. Therefore, in bacteria more than 30% of proline residues 
are found in the X position but only 5% in the Y position (18). Despite the lack of 
hydroxyproline residues, bacterial CLPs have been shown to form stable triple helices, 
with thermal stabilities similar to human collagens, in the range of 35°-39°C, (19-23). 
These CLPs rely on other mechanisms of helix stabilization, including hydration-mediated 
hydrogen bonding networks, electrostatic interactions between side chains, and the 
presence of specific stabilizing tripeptide repeats (19,24). Proper folding of the triple helix 
is necessary for collagen functionality.  
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Horizontal transfer of collagenous sequences from eukaryotes to prokaryotes has 
been proposed (25). However, recent studies have shown that collagen-like repeats 
arose independently via separate repeat amplification (26). Low-complexity repeats of the 
collagen triple helix could emerge by spontaneous mutations and amplify via simple 
repeat expansion, supporting the hypothesis that eukaryotic and prokaryotic collagens 
may have emerged by convergent evolution. Here, we present clustering analysis, which 
identified common domains in Scl proteins from different streptococcal species and 
subspecies, suggesting that horizontal scl-gene transfer is possible between bacteria that 
share the same human and animal hosts.  
 
Classification of Scl proteins  
CLuster ANalysis of Sequences (CLANS) 
CLANS analysis was performed to obtain a sequence-based classification of Scl proteins. 
This analysis groups protein sequences based on all-against-all pairwise sequence 
similarities without phylogenetic reconstruction (27). CLANS identified six distinct clusters 
(1-6) of Scl proteins across pathogenic streptococci and two clusters (7-8) with phage 
proteins that will not be discussed here (Figure 1A). All Scl proteins share a distinct set 
of conserved features and a similar domain organization (Fig. 1B). They contain a signal 
peptide (not shown), an N-terminal non-collagenous sequence-variable (V) domain, a 
central collagen-like (CL) domain, and a cell-wall associated domain containing the 
LPXTG anchor motif (Gram-positive anchor). The CL domains of different Scl proteins 
are comprised of varying types of Gly-X-Y triplet repeats, and exhibit significant length 
variation due to the expansion and contraction of these repeats. 
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Figure 1. Sequence similarity and structure of Scl proteins in streptococci.  
A. Clustering of Scl proteins using CLuster Analysis of Sequences (CLANS). CLANS clusters and 
visualizes groups of protein sequences based on all-against-all pairwise sequence similarities (e-value 
cutoff for analysis was 10-13) without phylogenetic reconstruction. Each point on the plot represents a Scl 
amino acid sequence, while the connecting lines represent BLAST high-scoring segment pairs. High 
confidence clusters are indicated by circles, while a single low confidence cluster is indicated by a dashed 
circle. A list of Scl proteins identified in each cluster is provided in Table 1. clusters 7 and 8a/8b consist of 
phage-associated proteins and are not discussed in this review.  
B. Cartoon representation of domain organization shared by mature Scl proteins. The Scl proteins consist 
of an N-terminal noncollagenous variable domain (V), a collagen-like domain (CL) containing repeats of 
the classical Gly-X-Y motif, and a C-terminally located cell wall-associated Gram-positive anchor with 
LPXTG motif.  
C. Ribbon and surface models of the homotrimeric Scl2-protein globular domain. Left. Side view of the six-
helix bundle, containing three pairs of antiparallel helices, colored green, orange and magenta, and the 
point of CL-region attachment. Right. Top view, showing the location of exposed hypervariable loop 
regions between each alpha helix pair and the arrangement of the three external helices wrapped around 
three internal helices. 
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Scl proteins of S. pyogenes (clusters 1,2) 
The Scl1 and Scl2 proteins (also known as SclA and SclB) of S. pyogenes are the first 
bacterial CLPs to be reported and studied (10,28-31). Both proteins are homotrimeric and 
contain the globular V domain projected away from the cell surface by the rod-shaped CL 
domain. The V region sequences differ significantly both between and within Scl1 and 
Scl2 variants; for each Scl protein, variants are conserved in strains of the same M-type 
but vary between M-types. The scl1 and scl2 genes have been found in all S. pyogenes 
strains tested and are co-expressed in the exponential phase of growth, although their 
expression is regulated differently. Transcription of the scl1 gene is positively regulated 
by the multiple gene regulator of S. pyogenes, Mga (28,30,32,33). Scl2 expression 
depends on phase variation associated with CAAAA repeats located downstream of the 
start codon (28,29,31).  
 
Scl proteins in streptococci pathogenic to animals (clusters 3, 4 and 6) 
The Scl3, 4 and 6 proteins are found in S. zooepidemicus, a commensal organism found 
in domesticated animals rarely transmitting to humans, and S. equi, a causative agent of 
the serious disease strangles in horses (34). CLANS classified several Scl3 proteins, 
originally denoted SclC for group C 
Streptococcus (35), as well as the 
related proteins SclD-I and SclZ.1-5, 
7 and 12 (36), as belonging to the 
same cluster 3, whereas SclF (37) 
formed an independent cluster 4. 
SclC was shown to be expressed 
during strangles infection, and 
immunization with the recombinant 
SclC protein partially protects against 
infection in both mouse and horse 
models (38-40). An effective multi-
component vaccine for strangles was 
developed that include recombinant 
Table 1. Scl classification by CLANS analysis 
 
Cluster 
No. 
Proteins 
identified 
Organisms* 
1 Scl1 (SclA) S. pyogenes (GAS) 
2 Scl2 (SclB) S. pyogenes (GAS) 
3 SclC, D, E, G, 
H, I 
SclZ.1-5, 7, 12 
S. equi,  
S. zooepidemicus (GCS) 
4 SclF S. equi,  
S. zooepidemicus (GCS) 
5 PclA S. pneumoniae,  
S. agalactiae (GBS)  
6 SclZ.6, 9, 10 
FneC, E, F 
S. equi,  
S. zooepidemicus (GCS) 
7 Phage minor 
structural 
protein 
S. pneumoniae,  
S. agalactiae (GBS) 
8a/b Phage-
associated 
hyaluronidase 
S. pyogenes (GAS),  
S. equi and  
S. dysgalactiae (GCS) 
*Abbreviations in parentheses refer to group A, B,  
and C Streptococcus 
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SclC (40). Several cluster 3 proteins share signature sequences with cluster 2 proteins 
(35), suggesting some Scl3 variants are related to Scl2 and could emerge via inter-
species horizontal gene transfer. A second group of proteins found in both S. equi and S. 
zooepidemicus, classified in cluster 6, included the SclZ.6, 9, and 10 proteins (36), as 
well as FneC, E, and F that were annotated as fibronectin-binding proteins (41).  
 
Scl proteins in S. pneumoniae and S. agalactiae (cluster 5)  
The pneumococcal CLP, PclA (13), is a large surface protein (265 kDa) that contains 
predicted G5 and FIVAR domains, though FIVAR was predicted with low confidence. The 
G5 domain is associated with binding to N-acetylglucosamine and biofilm formation for a 
variety of proteins found in streptococcal and staphylococcal species (42), as well as the 
mycobacterial protein, RpfB, which also contains a triple helix motif (43,44). The FIVAR 
domain is found in surface-associated proteins SasC of Staphylococcus aureus and 
Embp of S. epidermidis that promote fibronectin binding and biofilm formation (45,46). 
The S. agalactiae CLPs also contain the G5 domain, but lack the FIVAR domain. The 
presence of pclA gene was correlated with pneumococcal adherence (13) and also with 
resistance to penicillin and trimethoprim-sulfamethoxazole (47).  
 
The non-collagenous domain in streptococcal CLPs 
The best structurally characterized streptococcal collagens are the two CLPs, Scl1 and 
Scl2, of S. pyogenes. The proteins form stable triple-helical structures when expressed 
as recombinant (rScl) polypeptides (20,24). The non-collagenous V region constitutes 
trimerization domain that augments proper collagen assembly to avoid the misfolding of 
the triple helix due to its repeating structure. However, the V domain of Scls is not 
necessary for triple helix formation in vivo, since the CL region of Scl1 can be expressed 
without the V region as recombinant protein in a folded triple helical state; still, this rScl-
CL construct could not re-fold after thermal denaturation in vitro (20,48). These results 
suggest that V domains of Scls present both structural and ligand-binding functions 
reviewed below.  
Recently, the crystal structure of the V domain of Scl2 from M3-type S. pyogenes 
was reported (49,50). The V domain folds into a six-helical bundle, with three pairs of 
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antiparallel alpha helices each connected by a variable loop region. Three of the helices 
are wound in a left-handed super-helix forming the inner core, which is further wrapped 
by three external alpha helices antiparallel to the internal helices (Fig. 1C). The six-helix 
bundle forms an elongated cylinder measuring about 30 Å in diameter and 60 Å in height. 
This fold is consistent with previous secondary structure predictions that deduced a helix-
loop-helix motif in the primary amino acid sequence (30,51) and is predicted to be 
conserved among Scl1 and Scl2 proteins. Indeed, hydrophobic residues located at 
regular positions of Scl sequences were shown to play a central role in the stabilization 
of the inner core of the 6-helix bundle fold. In addition, the variable loops adopt a well-
defined polyproline II conformation (50).  
 
Scl proteins in pathogenesis: dichotomy of Scl1-ligand binding in human tissue 
and blood 
The Scl1 variants of S. pyogenes bind a wide range of host ligands. The nature of Scl1-
binding modalities between tissue and blood environments is highly significant, as 
described below (Fig. 2). In contrast, the Scl2 proteins failed to bind the majority of ligands 
and their role in pathogenesis is less understood.  
 
Binding modalities in tissue to extracellular matrix and cell receptors 
Scl1 selectively binds cellular fibronectin (cFn), but not plasma fibronectin (pFn), and 
laminin (Lm) (Caswell et al., 2010). Cellular fibronectin is deposited by a variety of cells 
as an insoluble crosslinked protein in tissues and humans express over 20 cFn isoforms 
(52,53). Both pFn and cFn are encoded by a single fibronectin gene and contain a 
conserved structure, consisting of three regions of repeats, type I, II, and III. cFn differs 
from pFn via the inclusion by alternative splicing of extra domains A (EDA) and B (EDB), 
as well as varying numbers of the variable V domain (53). Scl1 proteins specifically bind 
cFn via recognition of the type III repeat, EDA (54). EDA/cFn isoforms are found in low 
levels in normal adult tissue but are upregulated in wounded tissue (55,56), where the 
EDA domain interacts with keratinocyte integrin receptors (57) and is important in the 
wound healing processes (58). S. pyogenes strains may express multiple fibronectin-
binding proteins, including SfbI/PrtF1, PrtF2, SOF, FbaB, SfbX, and Shr, reviewed in (59) 
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that bind the type I and type II repeats; thus, Scl1 binds cFn via unique mechanism 
different from other Fn-binding proteins of S. pyogenes  
Laminin binding was observed for the same Scl1 variants that bind EDA/cFn 
isoforms (60). The molecular basis for recognizing both ligands is undetermined due to a 
lack of sequence similarity between EDA and Lm chains α, β, or γ. At least 15 laminin 
heterotrimers have been identified in human tissues and binding studies with individual 
laminins represent a technical challenge. Two Lm-binding proteins, Lbp and Shr, in S. 
pyogenes have been reported in addition to Scl1 (61-63). Given the localization of some 
laminins to basement membranes, Lm binding by S. pyogenes likely represents a relevant 
pathogenesis trait.  
The Scl1.41 variant, expressed by M41-type strains, directly binds human collagen 
receptors α2β1 and α11β1 integrins through the GLPGER motif in the Scl1-collagenous 
domain (64,65). A similar binding motif GF/LOGER (O represents hydroxyproline), as well 
as derived sequence motifs GR/AOGER and GASGER, were identified in human 
collagens as integrin-binding sites (66). Other Scl-integrin binding motifs are found in 
Scl2-CL regions, such as RGD and KGD sequences. In addition, the GAPGER and 
GKPGER motifs are found in SclZ/Scl3 proteins (36).  
 
Significance of ligand-binding modalities in tissue 
S. pyogenes forms biofilms, or microcolonies, in infected tissue (67,68). In vitro assays 
showed enhanced biofilms formed by strains of multiple M-types on ECM coatings, 
including Fn and collagens type I and IV (69,70). Scl1 plays an important role in biofilm 
formation, as isogenic scl1-inactivated mutants had significantly reduced overall biofilm 
biomass and decreased biofilm thickness (71). In addition, enhanced Scl1-mediated 
biofilms were observed on simple cFn and Lm coatings, as well as on complex 
extracellular matrix deposited by human dermal fibroblasts (54). Furthermore, inhibition 
experiments employing EDA-derived peptide and anti-EDA mAb showed significantly 
reduced adherence of S. pyogenes cells to fibroblast-derived matrix, indicating the Scl1-
EDA/cFn interaction supports bacterial adherence  
The M3-type S. pyogenes strains, which are particularly invasive to humans, lack 
Scl1 protein due to a null mutation within the CL-region coding sequence (10), and form 
 9 
insignificant biofilms (71). Restoration of full-length Scl1 on the surface of M3-type S. 
pyogenes restored biofilm formation on cFn and Lm coatings (72). Also, biofilm-capable 
Scl1-expressing M41-type strain produced glycocalyx-embedded tissue microcolonies in 
an in vitro skin equivalent infection model, while biofilm-poor Scl1-lacking M3 strain did 
not. Rare M3 strains containing the “scl1.3 carrier allele”, with restored open reading 
frame, were less invasive in a mouse model of necrotizing fasciitis than typical M3 strains 
lacking Scl1 (73). Scl1-deficient mutants of M28- and M41-type S. pyogenes as well as 
M3-type S. pyogenes naturally lacking Scl1, displayed increased invasiveness in mice 
(72). Altogether, these results support the concept that S. pyogenes adherence to ECM 
and stable biofilm formation that are conferred by surface-attached Scl1, promote 
localized infection over invasive spread.  
Scl1 binding to the α2β1 integrin promoted fibroblast adhesion and spreading, and 
induced intracellular signaling typical of integrin pathway, thus, mimicking the functional 
role of human collagen. Direct binding of Scl1 to the α2β1 integrins promotes S. pyogenes 
internalization by epithelial cells, resulting in increased intracellular pools as well as 
increased re-emergence of bacteria (74). The α2β1 and α11β1 integrins are expressed by 
fibroblasts, endothelial, and epithelial cells (75,76), indicating Scl1 has the potential to 
adhere to and invade a variety of cell types in the human host. Additionally, the RGD and 
KGD sequences that are cryptic within the collagen triple helix, become available for 
binding during tissue remodeling (77).  
A recent study reported a novel role for Scl1 of M1 S. pyogenes in resistance to 
neutrophil extracellular traps (NETs). The Scl1-deficient mutant produced smaller skin 
lesions in mice in vivo, compared to the parental strain, which was associated with 
increased killing by NETs in vitro. Neutrophils incubated with Scl1-deficient mutant in vitro 
displayed increased NET formation than with wild-type strain, indicating Scl1 inhibited 
NET production by neutrophils. Moreover, Scl1-deficient S. pyogenes had increased 
sensitivity to cathelicidin killing in vitro (78). Additional studies would confirm if Scl1 
variants from divergent M-types also harbor this function. 
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Figure 2. Dichotomous nature of ligand binding by Scl1 in human tissue and blood.  
A. Binding modalities in tissue. S. pyogenes accesses human tissue via portal of entry (skin, pharyngeal mucosa) 
represented here as a breach of skin epidermis extending into the underlying dermis. The globular domain of Scl1 
surface adhesin selectively recognizes the EDA-containing isoforms of cellular fibronectin (EDA/cFn) and laminin (Lm). 
Scl1-mediated tissue microcolonies, embedded in glycocalyx, are formed and stabilized by interactions between Scl1 
and the surrounding wound microenvironment. The collagenous domain of Scl1 directly binds human collagen 
receptors, integrins α2β1 and α11β1 on the host cell surface, promoting pathogen internalization, survival and 
reemergence. Scl1 decreases the formation of extracellular traps (NETs) produced by infiltrating neutrophils and killing 
by NET-associated cathelicidin. B. Binding modalities in blood. During dissemination to the blood and deeper tissue, 
Scl1 contributes immune evasion and survival of S. pyogenes via several mechanisms. Binding to complement factor 
H (CFH) mediates cleavage of C3b by factor I, thus, preventing S. pyogenes opsonization, while binding to factor H-
related protein 1 (CFHR1) prevents the formation of the C5 convertase and assembly of the membrane attack complex 
(MAC). Scl1-mediated adsorption of plasma lipoproteins LDL/HDL on the S. pyogenes surface may prevent immune 
recognition and/or promote LDL/HDL receptor-mediated endocytosis, intracellular survival and reemergence. Scl1 
binding to and activation of the thrombin-activatable fibrinolysis inhibitor (TAFI) prevents clot breakdown, providing a 
protective niche for streptococci. 
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Binding modalities in blood  
The Scl1 proteins from M6- and M55-type S. pyogenes bind the complement factor H 
(CFH) and complement factor H-related protein 1 (CFHR1) via Scl1’s globular V domain 
(79). The CFH protein is composed of 20 short consensus repeats (SCRs) that facilitate 
ligand binding and co-factor function for complement factor I (CFI)-mediated C3b 
degradation; the C-terminal SCRs 18-20 are involved in binding to cell surfaces, while 
SCRs 1-4 harbors the co-factor function (80). The CFHR1 protein comprises five SCRs, 
of which the C-terminal SCRs 3-5 share 99% sequence identity, and therefore surface-
binding function, with the SCRs 18-20 of CFH. CFHR1 inhibits the C5 convertase and the 
formation of the membrane attack complex (81). Using recombinant fragments of the CFH 
proteins, the Scl1 binding site was mapped in the C-terminal SCRs 19-20 of CFH and 
SCR 4 of CFHR1 (82). Notably, other known CFH-binding proteins of S. pyogenes, such 
as certain M and M-like proteins and Fba, bind to SCR7 of CFH, as well as complement 
factor H-like (CFHL) protein (82). Borrelia burgdorferi also expresses surface proteins 
with similar CFH-binding characteristics via the C-terminus (83,84).  
Recombinant Scl1 proteins derived from diverse M-types bind the apolipoprotein 
ApoB100 of low density lipoprotein (LDL) (51). Binding of rScl1 constructs to LDL was 
facilitated by the Scl1-globular V domain with binding affinities of KD values in the 
nanomolar range. Importantly, LDL from human plasma was absorbed by the wild-type 
cells of S. pyogenes but not by the scl1-inactivated mutant cells (51). A similar binding 
with ApoAI apolipoprotein and high density lipoprotein (HDL) was demonstrated for rScl1 
construct derived from M41-type S. pyogenes (85). HDL binding was inhibited by low 
concentration of the nonionic detergent Tween20, suggesting hydrophobic interaction to 
both rScl1 protein and S. pyogenes cells.   
Some recombinant Scl proteins also bind thrombin-activatable fibrinolysis inhibitor 
(TAFI) with KD values in the nanomolar range (86) and the binding site was mapped to 
residues 205-232 within the TAFI protein (87). TAFI is a zinc-dependent 
procarboxypeptidase, which acts as an important fibrinolysis regulator and inflammatory 
mediator upon activation by thrombin, thrombin-thrombomodulin complex, or plasmin. 
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Significance of ligand-binding modalities in blood 
Diverse pathogens express surface proteins that bind complement regulatory proteins, 
including Neisseria gonorrhoeae, Borrelia burgdorferi, Yersinia enterocolitica, and several 
streptococcal species (88). CFH binding to the cell surface prevents C3b deposition and 
phagocytosis, as well as downstream complement-mediated cell lysis. In vitro, rScl1-
bound CFH retained its co-factor function, mediating the proteolytic breakdown of C3b by 
CFI (79). Similarly, CFHR1 binding to rScl1 inhibited the formation of the membrane 
attack complex in vitro. Both CFH and CFHR1 bound to M6-S. pyogenes cells. However, 
CFH binding by M5 S. pyogenes did not contribute significantly to phagocytosis 
resistance or virulence (89). Since M6 protein, was the first bacterial CFH-binding protein 
reported (90), CFH binding by Scl1, in addition to M6 protein, might be necessary for anti-
phagocytic phenotype observed for M6 S. pyogenes. 
Plasma lipoproteins are being increasingly recognized as innate immune 
components. For example, HDL and LDL neutralize LPS endotoxin (91) and 
Staphylococcus aureus α-toxin (92), and HDL is known to downregulate host adhesion 
molecules and inflammatory cytokines (93). Elevated lipoprotein levels may be protective 
against bacterial infections and sepsis in humans (94), and LDL-deficient mice showed 
increased susceptibility to infections with Gram-negative bacteria and Candida albicans 
(95,96). Interaction between Yersinia pestis and ApoB-containing lipoproteins, mediated 
by the pH6 antigen, prevented binding of the bacteria to macrophages in vitro (97). In 
contrast, LDL and HDL could act as opsonins to increase S. pyogenes phagocytosis and 
killing via a CD36-mediated endocytosis (98,99). Notably, half of S. pyogenes strains 
express serum opacity factor, which binds and disrupts the HDL structure (100), which 
could protect S. pyogenes from lipoprotein-mediated opsonization. Clearly, the Scl1-
lipoprotein interactions may have multiple functions during infection and in vivo studies 
are required to determine the effects of these interactions on the host. 
Scl-recruited TAFI to the S. pyogenes cell surface was cleaved and activated by 
plasmin and thrombin-thrombomodulin (86). TAFI functions by removing exposed C-
terminal lysine residues from fibrin during blood clot formation, thereby preventing 
recognition and cleavage of these residues by the tissue-type plasminogen activator, 
ultimately inhibiting fibrinolysis, or the breakdown of clots (101). Additionally, it can 
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regulate inflammation by cleaving the C-terminal residues of bradykinin, osteopontin, and 
the chemoattractants C3a, C5a, and chemerin (102). Therefore, binding and prolonged 
activation of plasmin on the surface of S. pyogenes could contribute significantly to TAFI 
activation. Additionally, activation of TAFI on the S. pyogenes cell surface induced 
inflammation via modulation of the kallikrein/kinin system (103). Since this interaction 
maintains the formation of clots, it may also represent a mechanism for bacteria to remain 
associated with the fibrin clot and evade recognition by immune defenses. 
 
Final Remarks  
 
i) Modular collagens evolved in higher eukaryotes as members of 
extracellular matrix to support tissue structure and provide an essential 
network for cell function. Bacterial collagens likely emerged by convergent 
evolution via simple Gly-X-Y-repeat amplification; sequence similarity 
amongst Scl proteins suggests horizontal gene transfer between closely 
related species.  
ii) Scl proteins are homotrimeric and surface attached, and have several 
modalities of sensing host surroundings. The amino-terminal globular 
“sensing” domain is variable in primary sequence but displays a 
conserved structure.   
iii) Scl1 proteins have adapted binding modalities in tissue and blood to 
mediate S. pyogenes colonization and immune evasion.  
iv) Scl1 down-modulates virulence by fostering the formation of stable tissue 
microcolonies, thus, promoting a focused nidus of infection.  
v) The majority of Scl proteins remain uncharacterized and may exert similar 
functions to those described for Scl proteins of S. pyogenes that are 
important in pathogenesis. 
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PART I 
ROLE OF SCL1 IN ADHERENCE, BIOFILM, AND VIRULENCE
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CHAPTER 1 
THE STREPTOCOCCAL COLLAGEN-LIKE PROTEIN-1 (SCL1) IS A SIGNIFICANT 
DETERMINANT FOR BIOFILM FORMATION BY GROUP A STREPTOCOCCUS 
Heaven A Oliver-Kozup, Meenal Elliott, Beth A Bachert, Karen H Martin, Sean D Reid, 
Diane E Schwegler-Berry, Brett J Green, and Slawomir Lukomski 
Published in BMC Microbiology 2011 11:262 
 
ABSTRACT 
Background: Group A Streptococcus (GAS) is a human-specific pathogen responsible 
for a number of diseases characterized by a wide range of clinical manifestations. During 
host colonization GAS-cell aggregates or microcolonies are observed in tissues. GAS 
biofilm, which is an in vitro equivalent of tissue microcolony, has only recently been 
studied and little is known about the specific surface determinants that aid biofilm 
formation. In this study, we demonstrate that surface-associated streptococcal collagen-
like protein-1 (Scl1) plays an important role in GAS biofilm formation.  
Results: Biofilm formation by M1-, M3-, M28-, and M41-type GAS strains, representing 
an intraspecies breadth, were analyzed spectrophotometrically following crystal violet 
staining, and characterized using confocal and field emission scanning electron 
microscopy. The M41-type strain formed the most robust biofilm under static conditions, 
followed by M28- and M1-type strains, while the M3-type strains analyzed here did not 
form biofilm under the same experimental conditions. Differences in architecture and cell-
surface morphology were observed in biofilms formed by the M1- and M41-wild-type 
strains, accompanied by varying amounts of deposited extracellular matrix and 
differences in cell-to-cell junctions within each biofilm. Importantly, all Scl1-negative 
mutants examined showed significantly decreased ability to form biofilm in vitro. 
Furthermore, the Scl1 protein expressed on the surface of a heterologous host, 
Lactococcus lactis, was sufficient to induce biofilm formation by this organism.  
Conclusions: Overall, this work (i) identifies variations in biofilm formation capacity 
among pathogenically different GAS strains, (ii) identifies GAS surface properties that 
may aid in biofilm stability and, (iii) establishes that the Scl1 surface protein is an important 
determinant of GAS biofilm, which is sufficient to enable biofilm formation in the 
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heterologous host Lactococcus. In summary, the GAS surface adhesin Scl1 may have an 
important role in biofilm-associated pathogenicity. 
 
INTRODUCTION 
Microbial biofilm formation is an important virulence mechanism, which allows immune 
evasion and survival against antibiotic treatments (1,2). Many bacterial nosocomial 
infections are associated with biofilms formed on contaminated medical devices. 
Dispersal of biofilm has also been proposed to augment infection spread (3-8). For group 
A Streptococcus (GAS), biofilm research is an emerging field and little is known about the 
specific surface determinants that aid in biofilm formation. GAS is characteristically 
associated with significant human morbidity and it is responsible for the clinically common 
superficial throat and skin infections, such as pharyngitis and impetigo, as well as invasive 
soft tissue and blood infections like necrotizing fasciitis and toxic shock syndrome (9). 
Although GAS biofilm has not been associated with implanted medical devices, tissue 
microcolonies of GAS encased in an extracellular matrix were demonstrated in human 
clinical specimens (10). Studies reported to date support the involvement of GAS surface 
components in biofilm formation, including the M and M-like proteins, hyaluronic acid 
capsule, pili and lipoteichoic acid (11-13). As shown by Cho and Caparon (11), multiple 
genes are upregulated during biofilm formation and development, including the 
streptococcal collagen-like protein-1 (Scl1).   
The scl1 gene encoding the Scl1 protein has been found in every GAS strain 
investigated and its transcription is positively regulated by Mga (14-18), indicating that 
Scl1 is co-expressed with a number of proven virulence factors. Structurally, the 
extracellular portion of Scl1 protein extends from the GAS surface as a homotrimeric 
molecule composed of distinct domains that include the most outward N-terminal variable 
(V) region and the adjacent collagen-like (CL) region composed of repeating GlyXaaYaa 
(GXY) sequence. The linker (L) region is close to the cell surface and contains a series 
of conserved direct repeats. The Scl1 protein can bind selected human extracellular 
matrix components (19) and cellular integrin receptors (20-22), as well as plasma 
components (23-27).  
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In this study, we investigated the importance of Scl1 in GAS biofilm using defined 
isogenic wild-type and scl1-inactivated mutant strains of GAS. We report that (i) the 
pathogenically diverse M41-, M28-, M3- and M1-type GAS wild-type strains have varying 
capacities to produce biofilm on an abiotic surface; (ii) Scl1 plays an important role during 
the main stages of biofilm formation with Scl1-negative mutants having an abrogated 
capacity for adhesion, microcolony formation and biofilm maturation; and (iii) variations in 
surface morphology as well as in extracellular matrix associated with bacterial cells 
suggest two distinct but plausible mechanisms that potentially stabilize bacterial 
microcolonies. We additionally show that expression of Scl1 in Lactococcus lactis is 
sufficient to support a biofilm phenotype. Overall, this work reveals a significant role for 
the Scl1 protein as a cell-surface component during GAS biofilm formation among 
pathogenically varying strains. 
 
MATERIALS AND METHODS 
GAS strains and growth conditions  
The wild-type GAS strains M41- MGAS6183, M1- MGAS5005, and M28-type MGAS6143, 
as well as their scl1-inactivated isogenic mutants and complemented M41Δscl1 mutant 
have been previously described (22,27,28). In addition, a set of the wild-type M3-type 
GAS strains MGAS158, MGAS274, MGAS315, MGAS335, MGAS1313, and MGAS2079 
was also used. GAS cultures were routinely grown on brain–heart infusion agar (BD 
Biosciences) and in Todd–Hewitt broth (BD Biosciences) supplemented with 0.2% yeast 
extract (THY medium) at 37oC in an atmosphere of 5% CO2–20% O2. Logarithmic phase 
cultures harvested at the optical density (600 nm) of about 0.5 (OD600 ~0.5) were used to 
prepare GAS inocula for biofilm analysis. Colony counts were verified by plating on tryptic 
soy agar with 5% sheep’s blood (Remel). Lactococcus lactis subsp. cremoris strain 
MG1363 (provided by Dr. Anton Steen) were grown using M17 broth or agar media 
(Oxoid) supplemented with 0.5 M sucrose and 0.5% glucose (SGM17 media) at 30oC in 
an atmosphere of 5% CO2–20% O2. 
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Heterologous Scl1 expression in Lactococcus lactis 
Lactococcus transformation: To obtain electrocompetent cells, 500 ml of SGM17 broth 
supplemented with 2% glycine was inoculated with an overnight culture and grown until 
OD600 ~0.4 was reached. Cells were harvested and washed twice with ice-cold solution 
A (0.5 M sucrose, 10% glycerol); cells were then re-suspended in solution A (1/1000 of 
original culture volume) and stored at -80oC (29). For transformation, cells were thawed 
on ice and mixed with 1 l of DNA of the Scl1.41-expressing plasmid pSL230 or pJRS525-
vector(22); and transferred to a cold 1-mm electrode-gap cuvette. Cells were pulsed with 
2.0 kV at 25 F and 400 ohms. Immediately following, suspensions were mixed with 1 ml 
outgrowth medium (SGM17 broth supplemented with 20 mM MgCl2 and 2 mM CaCl2) and 
incubated for 2.5 h before plating on SGM17 agar supplemented with spectinomycin (30). 
 
Molecular characterization of transformants: The pSL230 was detected in 
Lactococcus lactis MG1363 transformants by PCR amplification directly from bacterial 
colonies with scl1.41-gene specific primers 232up (5’-CTCCACAAAGAGTGATCAGTC) 
and 232rev (5’-TTAGTTGTTTTCTTTGCGTTT); pSL230 plasmid DNA was used as a 
positive control. PCR samples were analyzed on 1% agarose gel in Tris-acetate-EDTA 
buffer and stained with ethidium bromide. Inocula from colonies of L. lactis MG1363, as 
well as colonies harboring either pJRS525 vector or pSL230 construct were used in 
subsequent experiments.  
 
Western blot analysis: Cell-wall extracts were prepared as previously described (22). 
Briefly, cells grown to OD600 ~0.4 were harvested, washed with TES (10 mM Tris, 1mM 
EDTA, 25% Sucrose), re-suspended in TES-LMR (TES containing 1mg/ml hen egg 
lysozyme, 0.1 mg/ml mutanolysin, 0.1 mg/ml RNAseA and 1 mM PMSF) and incubated 
at 37⁰C for 1 h. After centrifugation at 2500g for 10 min, the supernatants were 
precipitated with ice-cold TCA (16% final) at -20⁰C overnight. Precipitates were rinsed 
thoroughly with ice-cold acetone and dissolved in 1x sample buffer at 250 l per unit 
OD600. Samples were subjected to 10% SDS-PAGE, transferred to nitrocellulose, and 
probed with anti-P176 antiserum followed by goat anti-rabbit-HRP and detected 
employing chemiluminescent substrate (Pierce). 
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Flow cytometry: Bacterial cells were grown to mid-log phase (OD600 ~0.4), washed once 
with filtered DPBS containing 1% FBS and re-suspended in the same buffer. Five million 
cells were incubated with 1:400 dilution of primary reagents, either rabbit pre-bleed 
(control) or rabbit anti-P176 antiserum for 30 min on ice, washed with DPBS-FBS and 
then incubated with 1:200 dilution of second reagent donkey anti-rabbit-APC (Jackson 
ImmunoResearch) for 30 min on ice. After a final wash and re-suspension in DPBS-FBS, 
flow cytometric data were acquired with FACSCaliber (BD Biosciences) and analyzed 
employing FCS Express (De Novo Software). 
 
Analysis of biofilm formation 
Crystal violet staining assay:  Biofilm formation was tested using tissue culture treated 
polystyrene 24-well plates. 1.5 ml of logarithmic-phase GAS or Lactococcus cultures were 
seeded without dilution into wells and incubated at 37oC for GAS and 30oC for 
Lactococcus in an atmosphere of 5% CO2–20% O2 according to indicated time points 
upon which medium was aspirated. Wells were washed with PBS and 500 µl of 1% crystal 
violet was added to each well, and incubated at room temperature for 30 min. Dye was 
then aspirated, wells were washed with PBS, and stain was solubilized with 500 µl of 
100% ethanol. Spectrophotometric readings at OD600 were recorded for each sample per 
time point. Samples were analyzed in triplicate in at least three experiments. 
 
Confocal Laser Scanning Microscopy (CLSM):  To visualize GAS and L. lactis strains 
by CLSM, bacterial cells were transformed with a GFP-encoding plasmid, pSB027 (31). 
15-mm glass cover slips were placed into 24-well tissue culture plate wells. Logarithmic-
phase bacterial cultures were inoculated without dilution and grown for 24 h. Cover slips 
were rinsed with PBS and fixed with 3% paraformaldehyde at room temperature for 30 
min. Biofilms present on cover slips were washed with PBS and mounted onto slides 
using Prolong Gold mounting media (Invitrogen). Confocal images were acquired using 
a 63x/1.40 Plan-Apochromat objective and a Zeiss LSM 510 laser scanning confocal on 
an AxioImager Z1 microscope. An orthogonal view of the Z-stacks was used to display 
and measure biofilm thickness using Zeiss LSM software. Ten representative images 
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within a single experiment were used to calculate the average vertical thickness 
measured in micrometers.  
To visualize extracellular matrix associated with GAS cells, 24 h biofilm samples 
were reacted with 100 g of tetramethyl rhodamine isothiocyanate- (TRITC)-conjugated 
concanavalin A (TRITC-ConA) (Invitrogen) for 30 min at room temperature in the dark 
prior to mounting with Prolong Gold medium. An average of ten microscopic views within 
each sample was reviewed using the 63x/1.40 objective, as described above. 
 
Field emission scanning electron microscopy (FESEM):  GAS biofilm samples were 
grown for 24 h on glass cover slips, washed with PBS, and fixed with 3% 
paraformaldehyde for 2 h and post-fixed in osmium tetroxide. Samples were next 
dehydrated in an ethanol gradient, dried using hexamethyldisalizane, mounted onto 
aluminum stubs and sputter-coated with gold/palladium. The samples were then imaged 
on a Hitachi S-4800 field emission scanning electron microscope. 
 
Quantitation of hydrophobicity   
A modified hexadecane method (12,32,33) was used to determine the cell hydrophobicity. 
Briefly, 5 ml of the logarithmic-phase GAS or Lactococcus cultures (OD600 ~0.5) were 
pelleted, washed and re-suspended in 5 ml of PBS. One ml of hexadecane was added, 
vortexed for 1 min and incubated for 10 min at 30oC. Mixtures were then vortexed for an 
additional 1 min and allowed to stand for 2 min for phase separation at room temperature. 
The absorbance of the lower aqueous phase was read at OD600 and compared against 
the PBS control. Actual hydrophobicity value was calculated using the following equation: 
Actual Value = [1 – (A/Ao)] x 100, where A is OD600 value after hexadecane treatment and 
Ao is OD600 prior to hexadecane treatment.  
 
Statistical analysis   
Statistical significance was determined using a two-tailed paired Student’s t-test. The 
results were considered statistically significant with P ≤ 0.05 (*) and P ≤ 0.001 (**). 
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RESULTS 
Wild-type GAS strains have heterogeneous capacity for biofilm formation on 
abiotic surfaces  
Biofilm formation was compared between M41-, M28-, M3- and M1-type GAS strains 
representing distinct epidemiological traits (Figure 1). To assess biofilm formation after 
24 h, we used spectrophotometric measurements recorded following crystal violet 
staining (Figure 1a). Both the M41- and M28-type strains produced more biomass as 
compared with M1 strain. Furthermore, the M3-type strain produced the lowest 
absorbance values in a crystal violet assay, indicative of lower cell biomass, as compared 
with the other wild-type strains. These experiments confirm previous observations (1,34) 
that GAS strains have varying capacity to form biofilm in vitro.  
The failure of M3-type strain MGAS315 to produce substantial cellular biomass in 
the above assay was intriguing because sequence analysis of the scl1.3 allele found in 
MGAS315 revealed the presence of a TAA stop codon in the 11th GXY repeat of the 
Scl1.3-CL region containing a total of 25 GXY triplets (35). This premature stop codon 
results in a truncated Scl1.3 variant composed of 102 amino acids (~11.4 kDa), which 
does not contain the cell wall-membrane (WM) associated region, thus, preventing it from 
anchoring to the bacterial cell surface (Figure 1b). This prompted us to investigate the 
biofilm formation by five additional M3-type strains, all harboring the same scl1.3 allele. 
Five additional M3-type strains, MGAS335, MGAS1313, MGAS2079, MGAS274 and 
MGAS158, all harboring the same scl1.3 allele (35) also produced poor biofilm under 
static conditions, as measured by crystal violet staining. Confocal laser scanning 
microscopy (CLSM) of three representative strains (MGAS315, MGAS2079, and 
MGAS158) corroborated results obtained from the crystal violet assay, indicating that 
these M3-type strains lack the ability to form appreciable biofilm structure. Our data 
suggest that the lack of capacity for biofilm-formation among M3-type GAS strains 
examined here might be correlated, at least in part, with lack of surface-attached Scl1.3 
protein. 
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Microscopic evaluation reveals differences in biofilm surface morphology 
We next conducted microscopic analysis of the biofilms formed by the wild-type (WT) 
M41-, M28-, and M1-type GAS strains. First, we examined the overall structural 
characteristics of biofilms formed after 24 h using CLSM (Figure 4 d-f); Additional file 1: 
Figure S1 a-f). The average biofilm thickness (see Methods section) differed among all 
three strains with M1 producing considerably thinner biofilm (mean value of 9 m) 
compared to M28 (12 m) and M41 (15 m), a result consistent with lower 
spectrophotometric absorbance values (Figure 1a). In addition to measured differences 
in biofilm thickness, closer examination of the X-Y orthogonal Z-stack views, representing 
biofilm cross-sections, revealed architectural differences among the M41, M28, and M1 
biofilms. The M1 biofilm, although the thinnest, seems to consist of densely-packed cells 
that form continuous layers, while the M28 and especially M41 biofilms seem to be less 
dense but exhibit more elevated supracellular assembly. We therefore used field emission 
scanning electron microscopy (FESEM) to define more accurately these supracellular 
differences observed by CLSM between the biofilms produced by the WT M1 and M41 
GAS (Figure 2). FESEM exposed notable architectural differences between biofilms 
formed by these two strains. The M41 (Figure 2, panel a) biofilm was characterized by 
more diverse surface architecture with the evidence of depressions or crypts, whereas 
the M1 biofilm (panel b) seems to lack such pronounced surface characteristics. At higher 
magnification, the M41 cells have a studded cell surface morphology with protrusions 
linking both sister cells and cells in adjacent chains (panel c). In contrast, the M1 cells 
had a relatively smoother appearance likely due to the rich bacterial-associated 
extracellular matrix (BAEM) surrounding these cells and covering their surface (panel d). 
BAEM material, which was clearly seen at higher resolution between the M1-type cells, 
was not as evident between cells of the M41-type GAS.  
 
GAS biofilms differ in production of bacterial-associated extracellular matrix  
The production of BAEM has been shown to be an integral component in the structural 
integrity of a biofilm, imparting protection from dehydration, host immune attack, and 
antibiotic sensitivity (36,37). GAS cells encased in a glycocalyx were first identified by 
Akiyama et al. in skin biopsies obtained from impetigo patients. We therefore compared 
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the production of BAEM within biofilms employing GFP-expressing GAS strains of the M1 
and M41 type (Figure 3). Cells were grown to form biofilms on glass cover slips for 24 h 
and stained with TRITC-concanavalin A (ConA), a fluorescently-labeled lectin that binds 
to the extracellular polysaccharides in biofilms (38). Fluorescent microscopy was 
performed to compare matrix production (red staining) by GAS strains (green). Visual 
screening of both biofilms indicated that the M41-type strain formed a more dispersed 
extracellular matrix as compared to the M1 strain, which had a dense, more closely 
associated matrix. In addition, averages of at least 10 fields of ConA stained matrix by 
CLSM support our FESEM observations that more BAEM is deposited within the biofilm 
by the M1 GAS cells as compared to M41 GAS. This is in agreement with the report from 
Akiyama et al that showed a substantial FITC-ConA stained matrix associated with T1-
type GAS microcolonies in vivo and in vitro (10).  
 
Scl1 protein significantly contributes to biofilm formation by GAS 
Variations in GAS pathogenicity and capacity to form biofilm are driven by specific 
proteins and components present on the cell surface or are secreted by the organism. It 
has been shown that deletion of the M and M-like surface proteins or capsule, as well as 
increased expression of the secreted SpeB protease decreases biofilm formation 
dramatically for some strains of GAS (12,39,40). Therefore, we investigated the role of 
Scl1 in biofilm formation by comparing biofilms formed by GAS WT and scl1-inactivated 
(Δscl1) mutant strains (Figure 4; Additional file 1: Figure S1 a-f). Bacterial biomass was 
evaluated spectrophotometrically following crystal violet staining at 1, 6, 12, and 24 h time 
points, representing different stages of biofilm formation, and absorbance values 
rendered for the WT and Δscl1 isogenic mutant strains were compared. The M41Δscl1 
mutant showed a 29-35% decrease in biofilm formation (the OD600 value obtained for the 
WT strain at each time point was considered 100%), which was sustained throughout all 
time points. This reduction was statistically significant at initial adherence (1 h), as well 
as during biofilm development (6-12 h) and at maturation (24 h) (Figure 4a; P ≤ 0.05 at 1 
and 12 h, P ≤ 0.001 at 6 and 24 h). Complementation of Scl1.41 expression in the 
M41Δscl1 mutant (M41 C) restored its ability to form biofilm to WT levels. Similarly, the 
M28Δscl1 mutant had a significantly decreased capacity for biofilm formation in the range 
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of 29-44% as compared to WT strain (Figure 4b; P ≤ 0.05 at 1 and 6 h, P ≤ 0.001 at 3, 12 
and 24 h). Likewise, there was a statistically significant decrease in M1Δscl1 biofilm 
biomass by ~42-75% compared to the WT strain (Figure 4c; P ≤ 0.001 at 1-24 h). CLSM 
analysis of corresponding 24-h biofilms of these strains confirmed our crystal violet 
staining results at 24 h. The Δscl1 mutants had substantially decreased average biofilm 
thickness by more than 50% (mean values) as compared to the parental WT organisms 
(Figure 4d-f). While these low average biofilm thickness values measured for the 
M1Δscl41 (6 M) and M28Δscl1 (5 M) correspond to residual biofilms made by those 
mutants (Figure S1a-d), by comparison, the M1Δscl1 (4 M) was shown not to produce 
a continuous biofilm layer under these conditions (Figure S1e-f). Our data support the 
hypothesis that the Scl1 protein plays an important functional role during GAS biofilm 
formation and that Scl1 contribution varies among GAS strains with different genetic 
backgrounds. 
 
Scl1 expression affects surface hydrophobicity 
The surface hydrophobicity of GAS has been shown to influence the adherence to abiotic 
surfaces. The presence of pili (13) , M and M-like proteins, and lipoteichoic acid 
contributes to cell surface hydrophobic properties (12,41), which in turn may influence 
biofilm formation by GAS. Here, we have investigated the contribution of Scl1 to surface 
hydrophobicity of M41-, M28-, and M1-type GAS strains using a modified hexadecane 
binding assay (12,33,42). As shown in Table 1, the M28-type GAS strain MGAS6143 
gave the highest actual hydrophobicity value of 94.3 ± 0.73, followed by the M41-type 
strain MGAS6183 (92.6 ± 0.86). In contrast, the overall surface hydrophobicity of the M1-
type GAS strain MGAS5005 (80.3 ± 0.89) was significantly lower compared to both M28 
and M41 strains (P ≤ 0.001 for each comparison). Inactivation of scl1.41 in M41-type GAS 
resulted in a modest, although statistically significant, reduction in the hydrophobicity 
index (100% for WT vs. 92% for mutant, P ≤ 0.001). In-trans complementation of the 
Scl1.41 expression in M41Δscl1-C restored the hydrophobic phenotype of the cells to WT 
level (hydrophobicity index ~105%). In comparison, the contribution of the Scl1.1 and 
Scl1.28 proteins to surface hydrophobicity is more substantial, as evidenced by a ~21% 
and ~22% reduction of the hydrophobicity indices of the mutants as compared to the 
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corresponding WT strains, respectively (P ≤ 0.001 for both). Thus, the Scl1-mediated 
GAS-cell surface hydrophobicity reported here may contribute to the ability of this 
organism to form biofilm, as suggested for other cell surface components (12,41). 
 
Scl1 is sufficient to support biofilm formation in Lactococcus lactis 
To assess whether Scl1 expression is sufficient to confer the ability for biofilm formation, 
we chose to express this protein in a heterologous L. lactis system (43,44). The wild-type 
L. lactis strain MG1363 was transformed with plasmid pSL230 encoding the Scl1.41 
protein (22) or with the shuttle vector pJRS525 alone. As shown in Figure 5a, PCR 
amplification of the scl1.41 gene employing specific primers yielded no product from the 
WT L. lactis MG1363 (lane 1) and the MG1363::pJRS525 transformant (lane 2). A product 
of the expected size of 1.4 kb was amplified from the pSL230 plasmid DNA control (lane 
4,) as well as was amplified from the MG1363::pSL230 transformant (lane 3). Surface 
expression of Scl1.41 was confirmed by immunoblot analysis of cell-wall extracts 
prepared from L. lactis WT, and the MG1363::pJRS525 and MG1363::pSL230 
transformants, as well as MGAS6163 (WT M41 GAS). As shown in Figure 5b, rabbit 
antiserum raised against purified recombinant Scl1.41 protein P176 lacking the WM 
region detected the corresponding immunogen (lane 1), and the homologous full length 
protein in cell-wall extracts of MGAS6183 (lane 5) as well as MG1363::pSL230 L. lactis 
transformant (lane 4). This band was absent in cell-wall extracts prepared from the WT 
L. lactis MG1363 (lane 2) and MG1363::pJRS525 transformant (lane 3). Expression of 
Scl1.41 at the cell surface was further established by flow cytometry. Rabbit anti-p176 
antibodies stained Scl1.41 MG1363::pSL230 transformant, confirming the expression of 
Scl1.41 protein at the cell surface in the heterologous host L. lactis (Figure 5c, red trace). 
This protein was absent at the surface of WT MG1363 (black trace) and 
MG1363::pJRS525 transformant (green trace).   
The capacity of L. lactis expressing Scl1.41 to form biofilm was evaluated 
spectrophotometrically following crystal violet staining. As shown in Figure 5d, the 
MG1363::pSL230 transformant demonstrated a significant increase in biofilm-associated 
biomass at 24 h, as compared to wild type L. lactis or L. lactis-containing pJRS525 vector 
(P ≤ 0.001). Crystal violet stained wells were photographed for visual representation of 
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biofilm formation prior to spectrophotometric assay. Biofilm thickness and architecture 
were evaluated by CLSM (Figure 5e; Additional file 1: Figure S2 a-c). The 
MG1363::pSL230 transformant produced a substantially thicker biofilm (14 m) as 
compared to both MG1363 WT (6 m) and the vector-only transformant 
MG1363::pJRS525 (6 m). The MG1363::pSL230 cells formed highly aggregated 
structures, thus, acquiring a phenotype consistent with biofilm formation. As shown in 
Table 2, the MG1363::pSL230 transformant, expressing Scl1.41 surface protein, had 
significantly enhanced cell surface hydrophobicity (hydrophobicity index of ~137% vs. 
100% WT, P ≤ 0.001) with an actual value of 82.0 ± 2.6, when compared to the MG1363 
WT (59.7 ± 7.2) and the vector-only MGAS1363::pJRS525 control (56.6 ± 5.5). These 
data suggest a direct relationship between Scl1 expression and cell surface 
hydrophobicity and establish their involvement in the microorganism’s ability to form 
biofilm in vitro. 
 
DISCUSSION 
Group A Streptococcus strains vary because of the vast number of M-protein types, and 
this variation is associated with varying frequency of isolation and exacerbation of disease 
(45,46). The M41-, M28-, M3-, and M1-type strains selected for the current study 
represent a significant intraspecies diversity among clinical isolates of GAS. M41 GAS 
was a major causative agent of superficial skin infections (47-49), and strain MGAS6183, 
harboring the Scl1.41 protein, has been studied extensively (19,21,22). M28-type GAS 
(strain MGAS6143) has historically been associated with puerperal fever and currently is 
responsible for extensive human infections world-wide (50). M1T1 GAS, represented by 
strain MGAS5005, is a globally disseminated clone responsible for both pharyngitis and 
invasive infections (51-53). The M3-type strains of GAS cause a disproportionally large 
number of invasive GAS infections that are responsible for traumatic morbidity and death 
(54,55).  
Initial studies by Lembke et al. that characterized biofilm formation among various 
M types of GAS typically included several strains of the same M type (1,34). These studies 
reported a significant strain-to-strain variation in ability to form biofilms within each M type. 
Studies that followed compared biofilm formation by defined isogenic WT and mutant 
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strains to assess the contribution of specific GAS surface components responsible for a 
biofilm phenotype, including M and M-like proteins, hyaluronic acid capsule, lipoteichoic 
acid, and pili (12,13). In the current study, we have assessed the role and contribution of 
the surface protein Scl1 in the ability to support biofilm formation by GAS strains of four 
distinct M types. 
Recent advances in molecular mega- and pathogenomics has enabled the 
characterization of numerous M3-type strains with a single nucleotide resolution (56,57). 
Interestingly, all five M3-type strains MGAS158, 274, 315, 335, and 1313 that were 
originally used for scl1-gene sequencing (14), plus an additional strain MGAS2079 (not 
reported) harbor the same scl1.3 allele containing a null mutation that would result in 
secretion of a truncated Scl1.3-protein variant. Here, we demonstrate that these GAS 
strains do not form biofilm on an abiotic surface. Recently, bioinformatic screening of the 
sequences of ~250 invasive M3-type strains isolated globally, has led to the detection of 
this single nucleotide polymorphism that results in disruption of Scl1.3 protein (Steve 
Beres and Jim Musser, personal communication). Lembke et al. reported heterogeneous 
biofilm formation among four M3-type GAS strains examined over a 24, 48, and 72-hour 
period (34). Biofilm was detected for one strain at a 48 h time point, on a fibrinogen-coated 
surface; however, it is not known whether this clinical isolate forms biofilm on abiotic 
surface, whether it expresses the truncated or full-length Scl1.3 protein, and whether it 
produces an unknown fibrinogen-binding protein, which could augment the attachment 
and biofilm formation. Therefore, additional studies are necessary to define the 
contributions of other biofilm-formation determinants in M3-type strains. 
Inasmuch as, variation in biofilm formation among GAS isolates of the same M-
type has been established, the molecular basis of this phenotypic variation is not known. 
Several GAS surface-associated and secreted components were shown to contribute to 
variation in biofilm (12,13,39). In addition, transcription regulators, such as Mga, CovR, 
and Srv are likely to play substantial roles in GAS biofilm formation (11,39) due to their 
transcriptional regulation of numerous genes. Therefore, it is logical to assume that the 
combination of genomic/proteomic make up, allelic polymorphisms, and transcription 
regulation all contribute to this phenomenon. In addition, discrepancies between in vitro 
data obtained with laboratory-stored strains and microcolony formation in vivo likely exist 
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and add yet another unknown to the complexity of GAS biofilm/microcolony formation and 
its role in pathogenesis. Despite this complexity, the analyses involving isogenic strains 
of the same genetic background provide valuable information that allows assessment of 
the role and contribution of a given GAS component to biofilm formation. 
The M1 MGAS5005 strain was shown to form biofilm in vitro and in experimental 
animals (8,39,58), and the present study demonstrates a significant role of Scl1.1 in this 
process. Likewise, the MGAS6183 strain, representing M41-type isolates often 
associated with pyoderma, produced a more robust biofilm biomass under the same 
experimental conditions and Scl1.41-deficient mutant was found to be an important 
determinant in this process. Similarly, Scl1.28 protein significantly contributes to a robust 
biofilm made by the M28-type strain MGAS6143. However, a recent study reported that 
another surface protein, designated AspA, found in M28-type GAS significantly 
contributed to biofilm formation (59). The aspA isogenic mutant showed 60% reduction 
in biofilm formation. The strain MGAS6180, which they used, expresses the same Scl1.28 
variant present in the MGAS6143 strain we used; our Scl1.28 mutant showed ~44% 
reduction in 24 h biofilm. We propose that several surface proteins contribute to biofilm 
formation by M28-type strains including proteins AspA and Scl1.28, and potentially, 
proteins F1/SfbI and F2 that are also present in these strains (22). This redundancy is 
likely responsible for the observed residual biofilms produced by the AspA- and Scl1.28-
deficient mutants. 
The observed heterogeneity in biofilm architecture of different GAS strains was 
previously observed by Lembke et al. (34) and was also documented in the current study 
using FESEM. In addition, here we report the differences in GAS-cell surface morphology 
and within cell-to-cell junctions in biofilms formed by M1- and M41-type strains. The 
structural and genetic determination of these differences is not known since M41 genome 
has not been sequenced, but may be associated with the presence of additional surface 
proteins, such as the F2 protein (60) encoded by prtf2 gene found in this strain (22). Even 
more striking was an observed difference in the amount of the extracellular material 
associated with each strain, referred to as BAEM (bacteria-associated extracellular 
matrix). It has been shown that extracellular matrix, also called glycocalyx, is produced 
by biofilm-forming bacteria. DNA, lipids, proteins (39), polysaccharides and dead cell 
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debris (61) were identified in this matrix and for gram-positive bacteria, teichoic acids 
have also been detected (62,63). The exopolysaccharide component of the glycocalyx is 
detected using carbohydrate-binding lectins, such as concanavalin A (ConA) (10). Both 
FESEM analysis and ConA staining detected more BAEM associated with M1 biofilm 
compared to M41, which produced larger biofilm. These observations suggest that GAS 
biofilm is stabilized differently by different strains and that higher BAEM production does 
not necessarily pre-determine larger biofilm mass. Consequently, a combination of biofilm 
features rather than biofilm size alone may be more relevant to pathogenicity of a given 
GAS strain. 
Diminished adherence and biofilm formation could be associated with changes in 
cell surface hydrophobicity (64) of the scl1 mutants. Indeed, the lack of Scl1 resulted in 
both decreased hydrophobicity and the ability to form biofilm, albeit in a somewhat 
disproportionate manner. A decrease in the hydrophobicity index by only ~8%, as 
compared to the wild type-strain, was measured for the M41scl1 mutant and this modest 
decrease was accompanied by a rather large reduction in biofilm formation capacity after 
24 h by 30%. Greater decrease in cell-surface hydrophobicity was measured for the 
M1scl1 (~21%) and M28scl1 (~22%) mutants, which was accompanied by a significant 
loss in biofilm formation after 24 h by both isogenic strains by ~55% and ~41% (P ≤ 0.001 
for each comparison), respectively. In addition, heterologous expression of Scl.41 in L. 
lactis increased hydrophobicity index of this organism to ~137% of the WT level, which 
was accompanied by significant increase in its ability to form biofilm. Similar observations 
have been reported for the M and M-like protein mutants that typically, but not always, 
exhibit concurrent loss of both biological features (12). For example, isogenic Mrp49 
mutant had a non-significant drop in hydrophobicity (~2%) but significantly lower biofilm 
formation after 48 h by ~30%, whereas Emm1 mutant lost ~78% hydrophobicity and 
~44% biofilm formation capacity. In summary: (i) here we report that the Scl1 adhesin is 
also a hydrophobin with varying contribution to the overall surface hydrophobicity among 
GAS strains representing different M types and (ii) Scl1-associated surface 
hydrophobicity is likely to contribute to Scl1-mediated biofilm formation.  
To test whether Scl1 alone could support biofilm formation, we used a 
heterologous L. lactis strain, which provides an expression system for membrane-bound 
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proteins of gram- positive bacteria with LPXTG cell-wall anchoring motifs (30,44,65,66), 
including the group A streptococcal M6 protein (43,67). In a recent study by Maddocks et 
al. (59) it was shown that heterologous expression of AspA GAS surface protein was able 
to induce a biofilm phenotype in L. lactis MG1363. We were also able to achieve a gain-
of-function derivative of the L. lactis WT MG1363 strain, (MG1363::pSL230), displaying 
an altered phenotype associated with biofilm formation, as compared to wild-type parental 
and vector-only controls. These data support our current model that Scl1 protein is an 
important determinant of GAS biofilm formation. 
As shown by crystal violet staining and CLSM, biofilm formation by the Scl1-
negative mutants was compromised during the initial stage of adherence, as well as 
microcolony stabilization and maturation. Consequently, their capacity for biofilm 
formation as compared to the respective WT controls was greatly reduced. This 
comparison identifies for the first time that the Scl1 protein contributes significantly to 
biofilm assembly and stability. Based on these observations, as well as previous work by 
us and others, we propose the following model of Scl1 contribution to GAS tissue 
microcolony formation (Figure 6). First, the Scl1 hydrophobin (current study) initiates 
bacterial adhesion to animate surfaces within the host (64). Next, the Scl1 adhesin 
anchors the outside edge of growing microcolony in tissue by direct binding to tissue 
extracellular matrix components, cellular fibronectin and laminin (19). Microcolony 
development is stabilized by Scl1-Scl1 scaffolding resulting from Scl1’s capacity to form 
head-to-head dimers (68) between molecules located on adjacent chains. This model will 
be tested experimentally in future studies.  
 
CONCLUSIONS 
In the present work, using pathogenically differing GAS strains, we have demonstrated 
three concepts. First, we have confirmed previous observations that biofilm formation is 
an innate property of GAS strains. The M41-type strain used formed a more robust biofilm 
when compared to M28-type strain as well as M1-type strain. Importantly, the highly 
invasive M3-type strains devoid of the surface-associated Scl1 also lack the ability to form 
biofilm. Secondly, the absence of surface-associated Scl1 decreases GAS-cell 
hydrophobicity suggesting that Scl1 plays a role on the GAS surface as a hydrophobin. 
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Thirdly, we have established that the Scl1 protein is a significant determinant for GAS 
biofilm formation. This concept was further tested by the heterologous expression of Scl1 
in Lactococcus, an organism found in dairy fermentation environments, enabling it to form 
biofilm. Altogether, these data underscore the importance of Scl1 in biofilm-associated 
regulation of GAS pathogenicity. Recently published work has shown that the 
recombinant Scl1 binds to the extracellular matrix components, cellular fibronectin and 
laminin (19). Our current research provides a foundation warranting additional 
investigation as to whether direct Scl1-ECM binding may promote GAS biofilm as a 
bridging mechanism within host tissues. 
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Figure 1 
 
Variation in biofilm formation among GAS strains. (a) Wild type M41-, M28-, M3-, and 
M1-type GAS strains were grown 24 h under static conditions and analyzed 
spectrophotometrically following crystal violet staining (top). Visual representation of 
corresponding wells is shown below. (b) Schematic representation (not to scale) of Scl1.3 
protein of M3-type GAS. Translated GXY repeats within the collagen-like (CL) region are 
shown with an asterisk representing the location of the premature stop codon resulting in 
a truncated protein. V, variable region; L, linker region; WM, wall-membrane associated 
region. Below, spectrophotometric measurements of 24-h biofilms following crystal violet 
staining are graphed for M3-type GAS strains. Absorbance values (OD600) are averages 
of at least three experiments done in triplicate wells. Corresponding confocal analyses of 
24-h biofilms of MGAS315, MGAS2079, and MGAS158 are shown. Images are X-Y 
orthogonal Z-stack views and average vertical thickness is indicated in micrometers (top 
right). 
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Figure 2 
 
Field emission scanning electron microscopy of GAS biofilms. 24-h biofilms of the 
M1- and M41-type GAS strains were grown on glass cover slips and analyzed by FESEM. 
(a-b) Architecture of GAS microcolonies shown at low magnification. (c-d) Cell surface 
morphology and cell-to-cell junctions observed at higher magnification. Enlargements of 
cell-to-cell junctions are shown below. 
 39 
 
 
Figure 3 
 
Production of bacterial-associated extracellular matrix. GFP-expressing wild type 
(WT) M41- and M1-type GAS strains were grown on glass cover slips for 24 h and stained 
with TRITC-conjugated concanavalin A (ConA). Confocal laser scanning microscopic 
(CLSM) images were separated to represent green GFP-expressing GAS cells (left 
images) and red ConA-TRITC staining (right images) for detection of extracellular matrix 
associated with each strain. Images are from one representative experiment. 
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Figure 4 
 
Biofilm formation by wild type and scl1-inactivated isogenic mutants. Crystal violet 
staining and confocal laser scanning microscopy (CLSM) of the GFP-expressing GAS 
were used to compare biofilm formation by GAS strains. Wild type (WT) M41-, M28-, and 
M1-type strains, scl1-inactivated mutants (scl1), and M41 mutant complemented for 
Scl1.41 expression (M41 C) were used. (a-c) Isogenic GAS strains were grown under 
static conditions for 24 h and bacterial biomass was detected spectrophotometrically at 
indicated time points following crystal violet staining. Absorbance values at OD600nm are 
representative of at least three experiments performed in quadruplicate. Statistical 
significance is denoted as *P ≤ 0.05 and **P ≤ 0.001. (d-f) CLSM analysis of 
corresponding 24 h biofilms from same experiment. Images are X-Y orthogonal Z-stack 
views of WT (top) and mutant (bottom) GAS strains. Views are representative of ten 
images within a single experiment. Average vertical biofilm thickness is indicated in 
micrometers (top right). 
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Figure 5 
 
Scl1 expression in L. lactis promotes biofilm formation. L. lactis was transformed 
with the plasmid construct pSL230 to express Scl1.41 surface protein or with pJRS525 
vector. (a) PCR analysis of L. lactis transformants using scl1.41-gene-specific primers; 
lanes: (1) MG1363 wild-type (WT) cells; (2) MG1363::pJRS525 vector-only control; (3) 
MG1363::pSL230 transformant; (4) control pSL230 plasmid DNA. (b) Scl1.41 expression 
by western blot analysis of cell-wall extracts prepared from transformed L. lactis and 
control GAS strains using anti- P176 (rScl1.41) antibodies; lanes: (1) purified recombinant 
P176 protein (truncated Scl1.41); (2) MG1363 WT strain; (3) MG1363::pJRS525 vector; 
(4) MG1363::pSL230 transformant; (5) MGAS6183 (M41) control. (c) Analysis of Sc1.41 
expression by flow cytometry with anti-P176 (rScl1.41) rabbit polyclonal antibodies on the 
surface of MGAS1363 WT strain (black trace), MGAS1363::pJRS525 vector-only control 
(green trace) and MG1363:pSL230 transformant (red trace). (d) Crystal violet staining of 
24 h biofilms formed by L. lactis WT strain, MG1363::pJRS525 vector-only control or 
MG1363::pSL230 transformant (top) with visual representation of the corresponding wells 
(bottom). Statistical significance is denoted as **P ≤ 0.001. (e) CLSM analysis of 24 h 
biofilms from same experiment shown in (d). Images are X-Y orthogonal Z-stack views 
representative of ten images within a single experiment. Average vertical biofilm thickness 
is indicated in micrometers (top right). 
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Figure 6 
 
Scl1-mediated model of GAS biofilm (not to scale). Scl1 hydrophobin (current study) 
initiates bacterial adhesion to animate surfaces (64) within the host (blue field). Scl1 
adhesin anchors the growing microcolony by direct binding to tissue extracellular matrix 
(ECM) components, cellular fibronectin and laminin (19), initiating microcolony formation 
and anchoring the outside edge of GAS microcolony in tissue (yellow field). Microcolony 
scaffolding is stabilized by the formation of head-to-head dimers between Scl1 molecules 
on adjacent chains (pink field). Inset shows Scl1-Scl1 head-to-head dimers formed by 
rScl1.1 as viewed by electron microscopy after rotary shadowing (68). Bar: 50 nm. 
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Table 1. Cell surface hydrophobicity of GAS strains  
GAS Strain M-Type Actual Value† Hydrophobicity 
Index‡ 
MGAS6183 WT M41 92.6 ± .86 100 
MGAS6183 Δscl1 M41 85.2 ± 2.2 **92 
MGAS6183 Δscl1-C M41 98.0 ± .31 105 
MGAS5005 WT M1 80.3 ± .89 100 
MGAS5005 Δscl1 M1 63.3 ± 3.2 **79 
MGAS6143 WT M28 94.3 ± .73 100 
MGAS6143 Δscl1 M28 72.6 ± .62 **78 
† Actual hydrophobicity values were calculated based on hexadecane binding as 
described in Methods. Values are representative of three separate experiments with ten 
replicates ±SD. 
‡ Hydrophobicity Index represents the ration of actual hydrophobicity value for each  
strain to that of the isogenic wild-type (WT) strain multiplied by 100.  
** Asterisks denote a statistically significant difference of Δscl1 mutants versus WTs at P 
≤ 0.001. 
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Table 2. Cell surface hydrophobicity of Lactococcus strains  
Lactococcus Strain  Actual Value† Hydrophobicity 
Index‡ 
L.lactis 1363 WT  59.7 ± 7.2 100 
L. lactis 1363::pJRS525  56.6 ± 5.5 98 
L. lactis 1363::pSL230  82.0 ± 2.6 **137 
† Actual hydrophobicity values were calculated based on hexadecane binding as 
described in Methods. Values are representative of three separate experiments with ten 
replicates ±SD. 
‡ Hydrophobicity Index represents the ration of actual hydrophobicity value for each  
strain to that of the isogenic wild-type (WT) strain multiplied by 100. 
** Asterisks denote a statistically significant difference of Δscl1 mutants versus WTs at P 
≤ 0.001.
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ABSTRACT 
The streptococcal collagen-like proteins 1 and 2 (Scl1 and Scl2) are major surface 
adhesins that are ubiquitous among group A Streptococcus (GAS). Invasive M3-type 
strains, however, have evolved two unique conserved features in the scl1 locus: (i) an 
IS1548 element insertion in the scl1 promoter region and (ii) a nonsense mutation within 
the scl1 coding sequence. The scl1 transcript is drastically reduced in M3-type GAS, 
contrasting with a high transcription level of scl1 allele in invasive M1-type GAS. This 
leads to a lack of Scl1 expression in M3 strains. In contrast, while scl2 transcription and 
Scl2 production are elevated in M3 strains, M1 GAS lack Scl2 surface expression. M3-
type strains were shown to have reduced biofilm formation on inanimate surfaces coated 
with cellular fibronectin and laminin, and in human skin equivalents. Repair of the 
nonsense mutation and restoration of Scl1 expression on M3-GAS cells, restores biofilm 
formation on cellular fibronectin and laminin coatings. Inactivation of scl1 in biofilm-
capable M28 and M41 strains results in larger skin lesions in a mouse model, indicating 
that lack of Scl1 adhesin promotes bacterial spread over localized infection. These 
studies suggest the uniquely evolved scl1 locus in the M3-type strains, which prevents 
surface expression of the major Scl1 adhesin, contributed to the emergence of the 
invasive M3-type strains. Furthermore these studies provide insight into the molecular 
mechanisms mediating colonization, biofilm formation, and pathogenesis of group A 
streptococci. 
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INTRODUCTION 
Group A Streptococcus (GAS) or Streptococcus pyogenes is a human-specific Gram-
positive pathogen responsible for significant morbidity and mortality worldwide (1,2). The 
clinical outcomes resulting from GAS infection range from superficial pharyngitis and 
impetigo to severe life-threatening diseases, such as streptococcal toxic shock syndrome 
and necrotizing fasciitis, as well as post-infectious sequelae, including rheumatic fever, 
rheumatic heart disease, and post-streptococcal glomerulonephritis (3). Historically, GAS 
has been a significant cause of puerperal sepsis, scarlet fever, erysipelas, and pharyngitis 
(4). GAS strains are epidemiologically subtyped based on nucleotide sequence variation 
at the 5’-end of the emm gene, reflecting differences in the hypervariable N-terminal 
region of the anti-phagocytic surface protein M. Over 240 M-types have been identified 
(http://www.cdc.gov/abcs/index.html), and certain M-types have been shown to have 
nonrandom associations with specific disease outcomes (3,5). Since the 1980’s there has 
been resurgence in invasive GAS diseases in the U.S. and other parts of the world. 
Numerous epidemiology studies conducted in the U.S. (6-11), Canada (12-15), and 
Europe (16-19) have found associations between infections with M1- and M3-type strains 
and invasive diseases. Specifically, M3-type strains have been associated with severe 
invasive disease (6,19) and fatal outcomes (14,16,17).  
These epidemiological observations have spurred significant whole genome 
sequencing efforts aimed at identification of the underlying genetic basis for virulence in 
M3-type GAS. The complete annotated genomes of invasive M3 strains MGAS315 and 
SSI-1 have been reported (20,21). These studies have revealed that differing phage 
elements, insertion sequences, and the large-scale chromosomal inversion identified in 
SSI-1, contributed to much of the genetic variation between M3 and other M-types. 
Acquisition of prophages and SNP’s drive the expansion of different M3 subclones during 
epidemic waves of infection (22,23). Additionally, strains causing pharyngitis and those 
causing invasive infections are derived from the same pool of M3 strains (24). In addition, 
genetic variation in virulence regulators, including RopB and CovRS, which are “hot-
spots” for the accumulation of mutations, also contributes to the hypervirulence of M3 
strains (23-28). The cause of the hyper-invasive phenotype of M3 strains is multifactorial 
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and involves multiple virulence factors controlled by complex regulatory networks that 
continually undergo remodeling.  
The streptococcal collagen-like proteins 1 and 2, or Scl1 and Scl2 (also known as 
SclA and SclB), are major GAS surface adhesins known to contribute to pathogenesis. 
Both Scl proteins contain an N-terminal variable region, followed by a collagen-like region 
containing Gly-X-Y repeats and a cell-wall-anchored C-terminal region (29-33). 
Transcription of scl1 is positively regulated by the multiple gene regulator Mga (30,32,34). 
Scl1 binds cellular fibronectin and laminin (35), and contributes to the formation of biofilm 
by strains of multiple M-types (36,37). GAS adherence and biofilm formation is enhanced 
on extracellular matrix (ECM) coatings and on fibroblast-deposited ECM network (37,38), 
supporting a role for Scl1 in tissue-microcolony formation described during GAS skin 
infection (39). While the scl1 gene has been found in every GAS strain tested (29,32), the 
scl1.3-allele in M3-type strains harbors a null mutation within the coding sequence (29). 
A rare natural reversion of this polymorphism was identified in a small subset of M3 carrier 
strains (40). 
Scl2-protein expression is regulated during translation by varying numbers of short 
CAAAA repeats downstream of the start codon that determine whether the protein-coding 
sequence is in-frame or translation will be prematurely terminated (30,31); genome 
sequencing indicates majority of the M3-type strain contain in-frame scl2.3 alleles (18,22). 
Scl2 has been shown in some strains to bind the human thrombin-activatable fibrinolysis 
inhibitor (41) and contribute to adherence to fibroblasts (31), although its role in GAS 
pathogenesis is less understood. Recently, the crystal structure of the Scl2.3 globular 
domain, which is structurally conserved between Scl1 and Scl2, has been reported 
(42,43) providing insight into the potential binding interactions with host ligands.  
In this study, we show that invasive M3-type GAS harbor two unique conserved 
features of the scl1 locus including the IS1548 insertion in the promoter region and the 
null mutation in the coding sequence, which results in a secreted instead of cell-attached 
Scl1 protein. We demonstrate significantly different expression patterns of scl1 and scl2 
in M3-type GAS compared to representative strains of M1-, M28- and M41-types. We 
demonstrate that the expression of the Scl1 adhesin is deficient in serotype M3 strains, 
as opposed to M1-, M28-, and M41-type strains. However, the Scl2 protein is upregulated 
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in M3 strains compared to M1, M28, and M41 GAS. The M3 strains lacked significant 
biofilms on cellular fibronectin and laminin coatings, compared to M41-type GAS, and did 
not form tissue microcolonies in a wounded pseudo-organ skin equivalent model of 
infection. Recombinant Scl1.3 specifically bound cellular fibronectin and laminin, and 
restoration of surface expression of Scl1.3 conferred significant biofilm formation by M3 
strains. Inactivation of Scl1 expression in biofilm-capable M28- and M41-type GAS 
resulted in larger skin lesions produced by the mutants in a mouse model of subcutaneous 
infection, supporting a role for Scl1 in maintaining a localized infection. Our model 
advocates that the lack of surface-associated Scl1 adhesin in M3-type strains causes 
decreased tissue adherence and decreased capacity for stable microcolony formation, 
thus, promoting bacterial spread over localized nidus of infection.  
 
MATERIALS AND METHODS 
1. Bacterial strains and growth 
MGAS315 and MGAS10870 are fully sequenced invasive M3-type strains (20,23). 
MGAS315 was isolated from a patient with streptococcal toxic syndrome in the 1980’s (6) 
and MGAS10870 was isolated from a patient with soft tissue infection in Ontario in 2002 
(23). Additional strains from epidemiologically diverse M-types were used for comparison: 
MGAS6183 (M41), MGAS5005 (M1), and MGAS6143 (M28). The MGAS6143∆scl1-, 
MGAS6183∆scl1-, and MGAS10870∆scl1-inactivated mutant strains have been 
previously described (40,44,45). Group A Streptococcus cultures were grown in Todd-
Hewitt broth (Becton Dickinson and Co.) supplemented with 0.2% yeast extract (THY 
medium) and on Brain Heart Infusion agar (Becton Dickinson and Co.) at 37°C in an 
atmosphere with 5% CO2. For antibiotic selection, erythromycin (5 µg mL-1), 
chloramphenicol (10 µg mL-1), kanamycin (200 µg mL-1), and spectinomycin (100 µg mL-
1) were added to the medium.  
Cloning experiments were performed in XL-1 Blue and TB1 E. coli cells, while 
protein expression experiments were performed in BL21 and TB1 E. coli cells grown in 
Luria-Bertani media (Difco Laboratories) at 37°C. For antibiotic selection, 
chloramphenicol (10 µg mL-1), kanamycin (50 µg mL-1), spectinomycin (100 µg mL-1), and 
ampicillin (100 µg mL-1) were added to the medium. 
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2. PCR assays 
2.1. Analytical PCR 
2.1.1. Detection of IS element upstream of scl1 in GAS strains 
The presence of IS1548 upstream of scl1 was determined by PCR with primers IS1548F 
and Scl1R (Figure 1) using Qiagen Taq DNA polymerase (Qiagen, Germantown, MD) as 
follows: 95°C, 5 min-[95°C 1 min, 62°C 1 min, 72°C 1 min] x30 cycles- 72°C, 10 min. 
Sequences of primers used in all PCR assays are listed in Table S1. 
 
2.1.2. PCR amplification of scl1.3 and scl2.3 alleles 
PCR was performed on genomic DNA isolated from M3 strains with primer pairs 232 Up/ 
232 Rev for scl1.3 amplification and sequencing, and Scl2.3 F/R and SclUp/ SclRev for 
length polymorphism analysis and sequencing of scl2.3, respectively. Amplification was 
performed using Qiagen Taq DNA polymerase as follows: scl1.3: 95°C, 5 min-[95°C 1 
min, 55°C 1 min, 72°C 1 min] x30 cycles- 72°C, 10 min; scl2.3: 95°C, 5 min-[95°C 1 min, 
51°C 1 min, 72°C 1 min 45 sec] x30 cycles- 72°C, 10 min. All PCR products were 
analyzed in a 1% agarose gel with 1 kb Plus DNA ladder as a molecular size marker (Life 
Technologies, Grand Island, NY). 
 
2.2. Quantitative reverse transcription PCR (qRT-PCR) 
2.2.1. RNA isolation 
Total RNA was isolated from the logarithmic phase (OD600 0.5) GAS cultures using 
RNeasy Protect Bacteria Mini kit (Qiagen), employing an additional pretreatment step 
with 250 µg lysozyme, 100 µg proteinase K, and 12.5 U mutanolysin per sample to 
augment cell wall disruption. Trace genomic DNA was removed by incubation with 
TurboDNase enzyme (Ambion). RNA quality was assessed in 1% agarose gel and 
spectrophotometrically; A260/280 and A260/230 ratios of >1.8 were considered 
acceptable. RNA was used immediately in cDNA synthesis or stored at -80°C for no more 
than 1 week.  
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2.2.2. Determination of transcription by qRT-PCR  
Synthesis of cDNA was performed using iScript Select cDNA synthesis kit (Bio-Rad) with 
1 µg of RNA per reaction and random primer mix. For each sample, a no reverse 
transcriptase control was performed, containing only RNA, reaction buffer, and random 
primer mix, to ensure the absence of genomic DNA. Incubations were carried out on a 
Bio-Rad C1000 Touch Thermal cycler: 25°C 5 min, 42°C 30 min, 85°C 5 min, and cDNA 
was stored at -20°C until used in qRT-PCR. qRT-PCR reactions were performed with 250 
nM primers using SsoAdvanced SYBR Green Universal Supermix (Bio-Rad). For each 
qRT-PCR reaction, template cDNA, diluted 1:20, control genomic DNA, or no reverse 
transcriptase control were used. PCR was performed using the following conditions on a 
Bio-Rad CFX96 Thermal cycler: 95°C 2 min- [95°C 5 sec, 60°C 30 sec]x30- [65°C- 95°C, 
5 sec, 0.5°C/ step]. Standard curves were generated for each primer set using cDNA from 
MGAS315 to determine the linear range and estimate reaction efficiency. Gene 
expression of scl1, scl2, emm, and mga was normalized against the expression of tufA 
gene, which has previously been identified and validated as an appropriate endogenous 
control (46). The ∆∆Ct method was utilized to compare gene expression between 
MGAS315 and other M3 strains, as well as M1, M28, and M41-type strains. Data was 
averaged from three independent experiments, each containing three technical 
replicates. Statistical significance was determined using an unpaired t-test. 
 
3. Recombinant Scl (rScl) proteins 
3.1. Cloning, expression, and purification of M3-derived rScl proteins  
The rScl proteins were generated using the Strep-tag II cloning, expression and 
purification system (IBA-GmbH, Gottingen, Germany). Proteins were expressed with a C-
terminal affinity tag and purified on Strep-Tactin sepharose, as described (47). rScl 
proteins rScl1.3V and rScl1.3FL are derived from MGAS315, whereas rScl2.3 protein is 
derived from the M3 strain MGAS3375. The recombinant Scl2.3V protein has been 
described previously (42). Construct containing the recombinant full-length Scl1.3FL 
(rScl1.3FL) protein was previously described (40). Briefly, the scl1.3 coding region from 
MGAS315 was cloned into the E. coli/GAS shuttle vector pJRS525 (48), generating 
plasmid pSL501. PCR mutagenesis was used to convert the internal TAA stop codon into 
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a GAA glutamate codon, resulting in plasmid pSL502 with continuous full-length scl1.3FL 
allele. This sequence was subsequently cloned into the pASK-IBA2 expression vector for 
recombinant Scl1.3FL protein production; each clone was verified by sequencing. Protein 
expression constructs are listed in Table 1. 
Protein expression was induced by the addition of anhydrotetracycline at 0.2 µg 
mL-1 for 3 hours. Cells were centrifuged and resuspended in high sucrose buffer (100 mM 
Tris-HCl, 1 mM EDTA, pH 8.0, 500 mM sucrose) or Cell Lytic B Buffer (Sigma), for 
separation of the periplasmic fraction and subsequent affinity purification. Proteins were 
dialyzed against 25 mM HEPES, pH 8.0, and analyzed by SDS-PAGE stained with 
RAPIDstainTM (G-Biosciences). Protein sequence was confirmed using mass 
spectrometry (University of Nebraska Medical Center) and N-terminal Edman 
Degradation sequencing (Iowa State University).  
 
3.2. Electron microscopy of rotary shadowed rScl proteins 
Electron microscopy visualization of the rotary shadowed preparations of rScl1.3FL and 
rScl2.3 was used to assess the domain organization of rScl proteins, as employed 
previously (49). The rScl proteins were dialyzed against 0.1 M ammonium bicarbonate 
and mixed with glycerol to a final concentration of 70% (vol:vol). Samples were nebulized 
onto mica chips with an airbrush and rotary-shadowed with carbon/platinum using an 
electron beam gun. Photomicrograph images were acquired using a transmission 
electron microscope FEI G2 operated at 80KV. 
 
3.3. Mass spectrometry analysis 
Samples from in-gel trypsin digested proteins were cleaned using a Millipore µC18 ZipTip, 
then resuspended in 0.1% formic acid. Samples were fractionated on a Eksigent cHiPLC 
column (75 µm x 15 cm ChromXP C18-CL 3 µm 120 Å), and resulting peptides were 
sequenced using 5600 TripleTOF (typical gradient 2-60% ACN in 60 minutes). Peptides 
identified were searched against the NCBI protein database with Protein Pilot software 
employing the following settings: search effort, thorough; taxonomy, none. Positive 
identification was considered as the identification of two or more unique peptides at high 
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confidence ≥95%, FDR=0.05, 0.01, or 0.001, which matched the same protein entry in 
the database searched.  
 
3.4. Binding of rScl proteins to extracellular matrix proteins and synthetic peptide 
3.4.1. ELISA binding assays 
Binding of rScl proteins to extracellular matrix proteins, cellular fibronectin (cFn) and 
laminin (Lm), was tested by ELISA (35). rScl proteins were immobilized onto Strep-
Tactin® coated microplate wells (IBA GmbH) at 0.5 µM at room temperature for 1.5 hours, 
then blocked with Tris-buffered saline (TBS) containing 1% bovine serum albumin (BSA) 
overnight at 4°C. The cellular fibronectin from human foreskin fibroblasts (Sigma) and 
murine laminin (Invitrogen) were added to the wells at 1 µg per well and incubated at 
room temperature for 1 hour. Bound ECM proteins were detected with rabbit anti-laminin 
at 1:100 (Sigma) and anti- human fibronectin at 1:4,000 (Sigma) polyclonal antibodies. 
Secondary antibody goat anti-rabbit IgG (H+L) HRP conjugate (Bio-Rad) was next used 
with 1-step ABTS substrate (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt) (ThermoScientific). Absorption was measured using Spectramax 190 
at a wavelength of 415 nm. Statistical analysis is based on three independent 
experiments each containing three technical replicates, using an unpaired t-test.  
 In antibody inhibition assay, the IST-9 mAb targeting the C-C’ loop of EDA domain was 
utilized (37). cFn was either untreated or pre-treated with increasing concentrations of 
IST-9 blocking mAb (0.1 µg- 1.0 µg), and added to Strep-Tactin®-coated microplate wells 
immobilized with rScl proteins, then incubated for 1 hour. Bound ECM proteins were 
detected as above. 
 
3.4.2. Design and synthesis of the C-C’ cyclic peptide 
The C-C’ cyclic peptide was designed based on the crystal structure of the EDA domain 
of cFn (PDB code 1J8K). In particular, the region, which was reported to be involved in 
Scl1 binding, connecting to two β-strands C and C’ of EDA was elongated to the whole 
C-C’ β-hairpin by allowing the formation the electrostatic interaction between Arg33 and 
Glu45. The terminal Tyr32 and Pro48 were mutated to Cys to stabilize the β-hairpin by 
introducing a disulfide bond (Figure S4). The obtained sequence, 
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CRVTYSSPEDGIHELFC (molecular weight: 1997.1 Da), endowed with a cyclic structure 
to mimic the structure of this region in EDA, was acetylated and amidated at the N- and 
C-terminus, respectively. Synthesis of the designed peptide was performed employing 
the solid phase method on a 50 μmol scale initially following standard Fmoc strategies 
(50). Due to aspartimide formation during traditional acylation reactions, peptide synthesis 
was carried out employing microwave technology (51). Cyclization was achieved by 
treating the peptide at 0.1 mg/mL (to avoid intermolecular disulphide formation) with buffer 
carbonate 50 mM, pH=9, overnight. The peptide was purified by RP-HPLC and the 
identity and purity (> 97%) was assessed by LC-MS (data not shown). 
 
3.4.3. Surface plasmon resonance (SPR) experiments 
Real time binding assays were performed at 25 °C on a Biacore 3000 Surface Plasmon 
Resonance (SPR) instrument (GE Healthcare). For immobilization, rScl1.3FL protein 
containing the C-terminal Strep-tag II was injected at a concentration of 40 µM on 
streptavidin-coated sensor chip, SA Biacore, until the desired level of immobilization was 
achieved (averaged value of 100 RU). Binding assays were carried out by injecting the 
C-C’ cyclic peptide at concentrations ranging between 10-500 µM. Experiments were 
carried out in HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, pH 7.4). The 
association phase (kon) was followed for 270 s, whereas the dissociation phase (koff) was 
followed for 300 s. The reference chip sensorgrams were subtracted from sample 
sensorgrams. Experiments were carried out in duplicates. Kinetic parameters were 
estimated assuming a 1:1 Langmuir binding model and using version 4.1 Evaluation 
Software (GE Healthcare).  
 
3.4.4. Fluorescence binding analysis 
rScl1.3FL protein, at a concentration of 30 μM, was incubated with increasing 
concentrations of C-C’ cyclic peptide (0 - 300 μM) at 25.0 °C, using an excitation 
wavelength of 298.0 nm and a fluorescence emission wavelength ranging from 300 to 
400 nm. The acquisition parameters were set as follows: excitation and emission slits at 
5 nm; 120 nm/min scan rate; 1.00 nm data interval averaging time at 0.500 s, PMT voltage 
at “high”. Fluorescence values were recorded at 333 nm, and subtracted from the 
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fluorescence intensity of the ligand-free protein, generating -∆fluorescence. The -
∆fluorescence values were plotted against the peptide concentration. (52). Experiments 
were carried out in duplicates. A control assay was carried out employing the buffer as 
titrant to assess that the dilution effect was under 3%, not affecting the results.  
 
4. Complementation of GAS strains with full-length Scl1.3FL  
For trans-complementation experiments, plasmid pSL502, encoding full-length cell-
associated Scl1.3FL protein, was electroporated into MGAS315 WT and 
MGAS6183Δscl1 electrocompetent cells. The pJRS525 vector was electroporated as a 
control. Transformants were selected on BHI agar containing 100 µg mL-1 spectinomycin, 
and plasmids were re-sequenced. For MGAS10870∆scl1, which contains a 
spectinomycin resistance cassette in place of the scl1.3 allele, the spectinomycin 
resistance marker in pSL502 was replaced with a kanamycin resistance, generating the 
plasmid pSL518 and colonies were selected on BHI agar containing 150 µg mL-1 
kanamycin.  
 
4.1. Determination of Scl1.3- and Scl2.3-protein expression in wild-type and 
complemented GAS strains 
4.1.1. Western blot analysis 
Expression of the Scl1.3 and Scl2.3 proteins was determined by western immunoblotting 
of the bacterial cell wall and culture supernatant protein fractions, as described before 
(29,30). Briefly, bacterial cultures were grown to an OD600 of 0.5 and cells were harvested 
by centrifugation. Culture supernatant proteins were precipitated with trichloroacetic acid 
(Sigma) to a final concentration of 10% (vol:vol). The cell wall protein fraction was 
obtained after cell digestion with lysozyme and mutanolysin in a high sucrose buffer. A 
total of 10 µg of protein samples were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane. Detection of Scl1.3, Scl2.3, and M3 proteins was performed 
using the same sample preparations with rabbit polyclonal antibodies generated against 
the truncated rScl1.3WT protein (anti-Scl1 1:15,000 dilution, reported in (40)) and the 
rScl2.3V region (anti-rScl2.3V 1:2,500; generated by Proteintech (43)). Horseradish 
peroxidase-conjugated goat anti-rabbit IgG (H+L) secondary antibody (Bio-Rad), 
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combined with PierceTM ECL western blotting substrate (Thermo Scientific) was used for 
detection. Images were acquired using a ChemiDoc Touch Imaging System (Bio-Rad). 
 
4.1.2. Flow cytometry analysis 
Surface detection of Scl1.3 and Scl2.3 proteins was determined by flow cytometry. 
Bacteria grown to an OD600 of 0.5 were harvested by centrifugation, and washed with flow 
cytometry buffer (sterile phosphate-buffered saline containing 10% Todd-Hewitt broth 
supplemented with 0.2% yeast extract). Cells were incubated with polyclonal antibodies 
against Scl1.3 and Scl2.3 described above at a dilution of 1:100 for 30 minutes on ice, 
then washed and incubated with Allophycocyanin (APC)-conjugated donkey anti-rabbit 
IgG (H+L) (Jackson ImmunoResearch) for 30 minutes on ice. Cells were washed and 
fixed in 0.4% paraformaldehyde, and stored at 4°C until analysis. Before analysis, cells 
were washed twice and resuspended in flow cytometry buffer. Cells were analyzed using 
a BD LSRFortessa, and 50,000 events were collected per sample. Data was analyzed 
using the FCS Express Flow 5 software.  
 
5. Assessment of biofilm formation 
5.1. Crystal violet staining assay 
Wild-type, mutant, and complemented strains were grown to OD600 of 0.5 and seeded 
into 24-well culture plates coated with ECM at 2 µg per well, then incubated at 37°C with 
5% CO2 for 24 hours. Wells were washed with PBS followed by the addition of 0.5 mL 
1% crystal violet solution (Fisher Scientific) diluted in PBS and incubation at room 
temperature for 30 minutes. Wells were rinsed twice with PBS and stain was solubilized 
with 0.5 mL of 75% ethanol. Spectrophotometric readings were taken for each sample at 
OD600. Statistical analysis is shown based on three independent experiments, each 
containing three technical replicates, using an unpaired t-test. 
  
5.2. Confocal laser scanning microscopy (CLSM) 
To visualize GAS by CLSM, bacterial cells were transformed with a GFP-encoding 
plasmid pSB027 (53), as before (36). 15-mm glass cover slips were placed into 24-well 
tissue culture plate wells and coated with 2 µg of cFn or Lm per well. Bacterial cultures 
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grown to logarithmic-phase were added to the wells and allowed to form biofilms for 24 
hours. Wells were rinsed with PBS and bacterial cells were fixed with 3% 
paraformaldehyde at room temperature for 30 min. Wells were washed again and 
coverslips were mounted onto slides using ProLong Gold Antifade Mountant (Thermo 
Scientific). Confocal images were acquired using a 63×/1.40 Plan-Apochromat objective 
and a Zeiss LSM 510 laser scanning confocal microscope.  
 
6. In vitro and in vivo GAS infection models 
6.1. GAS infection of in vitro cultured human skin equivalents 
Wounded full-thickness skin equivalents, EpiDerm-FT (MatTek, Boston, MA) were used. 
The tissues are discs 8 mm in diameter, which are provided in transwells. A 3-mm wound 
is generated by performing a punch biopsy to remove the keratinocyte layer. Immediately 
upon arrival, tissues were equilibrated in antibiotic-free manufacturer’s medium overnight 
at 37°C in atmosphere with 5% CO2. Wounds were infected with 10 µL of GFP-expressing 
log-phase group A streptococcal inocula and incubated in a humid environment at 37°C 
with 5% CO2 in daily-fresh media; a total of 4 experiments were performed and variables 
included the inoculum size of 3 x 106 -1.8 x 107 CFU and collection time points between 
1-5 days. Tissues designated for histopathological evaluation were fixed in 10% formalin, 
whereas tissues for two-photon fluorescence (TPF) microscopy imaging were fixed in 4% 
paraformaldehyde for several hours and then transferred to petri dishes containing PBS. 
For visualization of glycocalyx produced by GAS strains, tissues were permeabilized with 
0.1% Triton X-100 in 1 x PBS and blocked with 0.05% Triton X-100 in 1x PBS with 1% 
BSA before staining with concanavalin A- tetramethylrhodamine (Molecular Probes). 
Tissues were then rinsed and stored in PBS at 4°C until TPF imaging was performed. For 
TPF analysis, an Olympus 60x/ 1.2NA water dipping objective was used. Fixed tissues 
were imaged by two-photon microscopy with the Ti:sapphire laser (Mira, Coherent) 
intensity at 60 mW and input wavelength of 850 nm. Laser scanning images were 
collected at 0.5- 1 µm incremental depths using ScanImage (Janelia Farms, HHMI). 
Images were saved in a single TIFF file with 16 bit depth. Deconvolution of the images 
was performed using AutoQuant x3 and 3D models of z-stacks were generated using 
Imaris software. 
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6.2. Mouse model of soft tissue infection  
Animal experiments were conducted in compliance with the regulations and standards 
under the Animal Welfare Act, the Public Health Service Policy on Humane Care and Use 
of Laboratory Animals, and the Guide for the Care and Use of Laboratory Animals. The 
protocol was approved by the West Virginia University Institutional Animal Care and Use 
Committee (IACUC). 
Subcutaneous infections of mice were carried out as described previously (54). 
Briefly, 5-week-old male, immunocompetent, hairless mice (strain Crl:SKH1-hrBR) were 
used (Charles River, Wilmington, MA). Groups of 10-15 mice anesthetized with isoflurane 
were infected subcutaneously at the right flank with ~109 GAS CFU of WT or scl1-mutant 
strains, and mice were observed for 14 days. The weight and abscess dimensions (length 
[L] and width [W]) of each mouse were recorded daily during the first week and every 
other day thereafter. To analyze differences between mice infected with WT and scl1-
mutant GAS, the area of each abscess was calculated with the equation for the area (A) 
of an spherical ellipsoid: A=(L/2)x(W/2); statistical differences were calculated using the 
student’s t-test. At the conclusion of the experiments, mice were anesthetized and 
sacrificed by cervical dislocation. 
 
RESULTS 
M3-type GAS contain unique insertion of IS1548 element and nonsense mutation 
within the scl1.3 locus  
Since the resurgence of invasive GAS infections in the 1980s and an advent of molecular 
epidemiology fostered by large-scale sequencing, significant efforts have been made to 
define the molecular basis for the invasive phenotype of M3-type strains. In parallel to 
these advances, we identified two unique genomic traits in the scl1.3 locus, encoding 
streptococcal collagen-like protein 1: (i) the presence of an insertional sequence element, 
IS1548, in the promoter region and (ii) the presence of a nonsense mutation within the 
coding sequence of scl1.3 allele that was absent in other M-types.  
Studies employing mga-inactivated mutants have indicated that Scl1 expression 
was positively regulated by the GAS-global transcriptional regulator, Mga (30,32). Two 
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putative Mga binding sites were identified upstream of the scl1 coding sequence in the 
M1-type strain SF370 and experiments demonstrated that the Mga binding site distal to 
scl1 was responsible for transcription activation (34). Identical Mga binding sites I and II 
were also identified upstream of scl1.3 in the sequenced M3-type strain MGAS315 with 
IS1548 element inserted 38 bp upstream of the distal Mga I-binding site (Figure 1A). To 
determine if the IS1548 insertion was specific to M3 strains, we BLAST-searched this 
element in 45 completed GAS genomes representing 21 different M-types. We observed 
the presence of IS1548 in all strains searched with varying locations and occurrences 
from one to twelve per genome (Figure 1B). However, the IS1548 insertion upstream of 
the scl1.3 allele was only found in the sequenced genomes of M3-type strains MGAS315, 
SSI-1, and M3-b. Interestingly, a complete IS1548 element was not present upstream of 
scl1.3 in the recently reported genome of the M3 strain STAB902, which represents a 
non-invasive isolate (55); instead, a 34-bp remnant of IS1548, including the inverted 
repeat and additional 14 bp, was found. Based on this bioinformatics data, we examined 
the presence of the IS1548 element upstream of scl1 by PCR in a panel of 40 M3-type 
strains, using primers located in the IS1548 and scl1.3 sequences (IS1548F and Scl1R, 
Table S1). All M3-type strains examined were positive for the IS1548-scl1.3 amplicon, 
while M1, M41, and M28-type controls were negative (Figure 1C), demonstrating a broad 
and conserved presence of the IS1548 insertion in this location among M3-type GAS. 
 The nonsense mutation in the 11th Gly-X-Y repeat in the Scl1.3-CL collagenous region 
(Figure 1A, red box), presumably results in a truncated secreted variant, which consists 
of the Scl1-V variable region and 10 Gly-X-Y repeats but lacks the cell wall anchor. This 
polymorphism was originally identified in five M3-type invasive GAS strains but was 
absent in 45 other strains analyzed, representing 20 different M-types (29). It was later 
shown in 98.7% of 479 sequenced invasive M3-type isolates (40). We performed targeted 
PCR amplification of scl1.3 from 46 additional M3-type strains and observed identical 
amplicon sizes in all of them (Figure S1A). Sequencing showed that all tested strains 
harbored an identical scl1.3 allele, containing 25 Gly-X-Y repeats in the collagenous 
domain with the null mutation in the 11th repeat (Data Set S1). A complete lack of genetic 
variation within scl1.3 is surprising and differs from the length variation that is commonly 
observed among scl alleles from other M-types (29,32,33). These results demonstrate 
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that the IS1548 insertion and null mutation we identified in the scl1.3 locus are unique to 
and conserved among M3-type GAS. Based on these results, we hypothesized M3 strains 
produce a truncated, but potentially biologically active Scl1.3 variant, which is secreted 
instead of being cell-attached. 
 
scl1.3 expression is diminished in M3-type GAS 
Original reports showed scl1 transcripts in northern blots, as well as full-length Scl1 
proteins (both cell-associated and cell-free fractions) in western blots for strains of emm 
types 1, 28, 52, and 41 (29,30,32,45). To analyze the expression of the truncated Scl1.3 
protein in M3-type GAS, western blot analysis was performed on cell-wall (CW samples) 
and culture-supernatant (Sup samples) protein fractions of several M3-type strains grown 
to exponential phase (Figure 2A). The expected truncated Scl1.3 protein was not detected 
by anti-Scl1 antibodies, whereas the rScl1.3V positive control, corresponding to the V 
region of Scl1.3 variant, produced the expected immunoreactive band of ~8.3 kDa. In an 
additional control experiment, the same panel of M3 strains was tested for Scl1.3 on the 
cell surface using flow cytometry (Figure 2B). No shift in median fluorescence intensity 
was observed in M3 strains incubated with anti-Scl1 antibody compared to a secondary-
only antibody control, indicating a lack of Scl1 on the cell surface among M3 strains.  
Given the unique IS1548-scl1.3 location and the lack of truncated Scl1.3 products 
in culture supernatants, we investigated scl1.3 expression by qRT-PCR. Total RNA was 
isolated from exponential phase cultures of 5 M3-type strains, as well as from previously 
characterized control strains of emm types 1, 28, and 41 (29,30,32,45). Expression of 
scl1 from each strain was compared to scl1.3 transcription in M3 strain MGAS315 (Figure 
2C). Each non-M3-type strain tested had significantly higher transcription level of 
respective scl1 allele compared to MGAS315. The M1 strain had the most increased 
expression by 21-fold, while M28 and M41 strains exhibited 6-fold and 8-fold higher scl1 
expression, respectively. Interestingly, the scl1.3 transcripts examined in four additional 
M3-type MGAS strains 158, 335, 1313, and 10870 were significantly reduced as 
compared to MGAS315, with a range of 25-45-fold decrease. Overall, we observed that 
M3-type GAS harboring the IS element upstream of scl1.3 have drastically decreased 
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scl1.3 transcript levels and lack the Scl1 protein product, as assessed by western blot 
and flow cytometry.  
Since scl1 is regulated by the transcriptional activator Mga, we investigated 
whether the decreased scl1.3 transcripts in M3 strains were due to lack of mga gene 
expression in these strains. In parallel, we assessed transcript levels of the emm gene 
encoding the M surface protein, a key virulence factor regulated by Mga. For comparison, 
we included the M1 strain, which had significantly increased scl1 expression compared 
to the M3 strains. With the exception of MGAS335, which had significantly downregulated 
mga and emm expression, we found no significant differences in either mga or emm gene 
expression between MGAS315 and the other M3 strains or M1 strain (Figure 2D). 
Furthermore, M3 protein was highly expressed, as it was found in both cell wall and 
supernatant fractions, except for the MGAS335 strain, consistent with transcription data 
(Figure 2E). These results demonstrate that the striking downregulation of scl1.3 in M3-
type GAS is not due to decreased mga expression or non-functional Mga protein, as emm 
is normally expressed in these strains. 
 
scl2.3 is expressed in M3-type GAS 
Scl2 shares a similar structure with Scl1 but its biological function is poorly understood. 
One study demonstrated in a different M-type background that isogenic mutant devoid of 
Scl2.55 variant had lower adhesion to human skin fibroblasts (Rasmussen and Bjӧrck, 
2001); however, the Scl2.3 variant present in M3-type GAS has not been investigated for 
expression and ECM binding. Therefore, we next assessed scl2.3/Scl2.3 expression in 
M3 strains. PCR amplification and sequencing showed that the majority of M3 strains 
contained in-frame scl2.3 allele (Figure S1B, Table S2).  
Western blot analysis of cell wall (CW samples) and supernatant (Sup) protein 
fractions found Scl2.3 protein was expressed by M3 strains MGAS315, 10870, 158, 9517 
and 1313, whereas samples obtained from strain MGAS335, which contains an out-of-
frame scl2.3 allele, generated no immunoreactive band; rScl2.3V control produced the 
expected 10.1-kDa band (Figure 3A). Mass spectrometry confirmed the identity of the 
presumed immunoreactive Scl2.3-protein band from MGAS315 (Table S3). Consistently, 
Scl2.3 was detected on the surface of all five M3 strains containing in-frame scl2.3 alleles 
 61 
by flow cytometry, with a positive shift in median fluorescence intensity ranging in 67-131-
fold change, as compared to the secondary-only antibody control (Figure 3B). We next 
compared the scl2-transcription level in M3 strain MGAS315 with scl2-transcription levels 
in M1-, M28-, and M41-type strains. In striking contrast to the pattern of scl1.3 
transcription, scl2 transcripts were significantly decreased in the M1-type strain by 13-
fold, as well as in the M28 (6-fold) and M41 (3-fold) strains (Figure 3C). Additionally, there 
was no significant difference between scl2 expression in MGAS315 and the M3 strains 
MGAS158, 335, 1313, and 10870 (Table S4). These results confirm that the M3 scl2.3 
allele is transcribed at high levels, resulting in considerable expression of the Scl2.3 
protein. These results suggested that Scl2 has an important biological function in M3 
strains and warranted subsequent experiments assessing Scl2.3 function.  
 
GAS infection disseminates through human tissue and inhibits wound healing  
A wounded human skin equivalent, devoid of an inflammatory component, was utilized 
as a “mechanistic model” of GAS tissue colonization. The epidermal wound of each skin 
equivalent was infected with GFP-expressing M3-type invasive strain MGAS315 or M41-
type non-invasive strain MGAS6183, and analyzed after 1-5 days by standard 
histopathology (H&E and Gram’s stain) and using two-photon fluorescence (TPF) 
microscopy. H&E of uninfected tissue controls harvested at day 0 showed the absence 
of a keratinocyte layer where the punch biopsy was performed (Figure 4A). Complete 
healing of the wound was observed after 5 days, with a newly-generated intact 
keratinocyte layer covering the punch biopsy site (Figure 4B). In contrast, tissue infected 
with either GAS strain exhibited delayed wound closure as late as day 5 post-infection 
(Figure 4E, H). H&E staining of skin equivalents infected with either M3 or M41 after 24 
hours revealed bacterial colonization of the exposed dermal surface, as well as bacterial 
invasion into puncture-associated defects extending deep into the dermal layer, largely 
located at the wound edges (Figure 4D, G). Notably, extensive bacterial growth and 
spread was largely confined to tissue crevices in the dermis, whereas the presence of 
large bacterial colonies directly below the wound bed was rarely seen on microscopic 
examination. By day 5 of infection, bacterial invasion via these dermal defects extended 
to the bottom of the dermis for both strains, presenting both vertical and lateral spread of 
 62 
bacteria (Figure 4E, H). Gram stain of infected tissues showed the formation of superficial 
colonies near dermal surfaces, as well as biofilm formation on the surface of exposed 
dermis (Figure 4J-L). Additionally, epidermal tissue neighboring the wound bed exhibited 
~60% decreased thickness of the viable keratinocyte layer in tissues infected with 
MGAS315 and MGAS6183 by day 5, relative to uninfected tissues (Figure 4C, F, I). This 
suggests bacterial infection of the wound affects epidermal cells distant from the site of 
infection in this model.  
 TPF analysis was then performed on whole infected skin equivalents on day 5 
post-infection in order to assess bacterial spread directly below the wound bed. This 
method allowed us to visualize bacterial structures within tissue that were not apparent in 
H&E or Gram-stained sections. Tissue microcolonies were observed in samples infected 
with M41 GAS (Figure 4N), whereas M3 cells had a scattered appearance (Figure 4P). 
TRITC-concanavalin A (TRITC-conA) was utilized to visualize glycocalyx associated with 
bacteria. TRITC-conA stain colocalized with bacterial microcolonies formed by the M41 
GAS (Figure 4O, Figure S3), indicating microcolonies were encased in a glycocalyx, 
much like a classic biofilm. In contrast, TRITC-conA stain was associated with scattered 
M3-GAS chains located at the bottom cell layer in MGAS315-infected skin equivalents 
(Figure 4Q). These results indicate that M41 GAS, but not the M3 GAS, forms 
microcolonies in the tissue during a human skin infection that are encased in a glycocalyx, 
consistent with the observation that M41, but not M3, GAS forms robust biofilm in vitro on 
ECM coatings. In addition, M3 GAS disseminates in a form of scattered chains or single 
cells through the tissue.  
 
M3-type GAS strains form poor biofilms on extracellular matrix coatings  
It was previously reported that M3-type strains have no substantial biofilm formation in 
vitro on an inanimate surface (36). Here, we tested biofilm formation on cellular fibronectin 
(cFn) and laminin (Lm) coatings by a panel of representative M3 strains isolated from 
invasive cases of GAS disease, as compared to the non-invasive biofilm-capable M41-
type model strain MGAS6183. As expected, wells coated with either cFn or Lm supported 
robust biofilm formation by the M41 strain, whereas significantly less bacterial biomass 
was measured for all M3-type GAS on both ECM coatings (Figure 5A). There was also 
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no correlation between Scl2 expression and biofilm formation. We hypothesized that M3-
type GAS, devoid of Scl1 adhesin, have decreased binding to cFn and Lm ECM 
components, thus, preventing the formation of tissue microcolonies, and that restoration 
of full-length Scl1.3 (Scl1.3FL) on the GAS cell surface will confer binding to host ECM, 
as well as biofilm capacity in vivo (Figure 5B).  
 
Full-length recombinant Scl1.3 binds cellular fibronectin and laminin 
To test this hypothesis, we: (i) constructed Scl1.3- and Scl2.3-derived recombinant 
proteins, (ii) characterized their structural organization, and (iii) assessed their ECM-
binding capacities.  
First, rScl1.3FL and rScl2.3 proteins were assessed for purity and integrity by SDS-
PAGE (Figure 6A). The expected 20.6-kDa rScl1.3FL migrated at ~34 kDa, which is 
consistent with previous reports of aberrant migration of rScl proteins (29,30), whereas 
the rScl2.3 protein migrated according to the expected molecular mass of 16.2 kDa; both 
proteins were verified by mass spectrometry (Table S3). Rotary shadowed rScl1.3FL and 
rScl2.3 constructs, exhibited the characteristic lollipop-like structural organization (Figure 
S2), as observed for previously characterized rScl proteins (47,49). Interestingly, 
rScl1.3FL formed aggregates that were mediated by the intermolecular interactions 
between the globular domains; such interactions, however, were not observed between 
rScl2.3 molecules. The appearance of Scl1-Scl1 aggregates implies an attractive 
hypothesis that V-to-V-region interactions between the Scl1 molecules, but not between 
the Scl2 molecules, on the surface of neighboring GAS chains may support biofilm 
structure, as proposed in our model (Figure 5B).  
It has been established that Scl1 proteins selectively bind cellular, but not plasma, 
fibronectin and laminin (35), and that selective cFn binding is achieved by a unique 
binding mechanism involving the C-C’ loop of the extra domain A in cFn (EDA-cFn) (37). 
Here, we pre-incubated cFn with increasing concentrations of EDA-blocking IST-9 mAb 
(0.1, 1.0 µg), then added to wells containing immobilized rScl proteins and allowed for 
binding. We observed significant dose-dependent inhibition of cFn binding to rScl1.3FL, 
with a 36% inhibition at 0.1 µg and a 60% inhibition at 1.0 µg of IST-9 (Figure 6B). In 
addition, the rScl2.3 protein did not bind cFn, which is consistent with our previous data 
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employing several different rScl2 proteins (35). Surface plasmon resonance (SPR) 
measurements of binding affinity between rScl1.3FL and EDA-derived C-C’ cyclic peptide 
provided a dissociation constant of KD= 63.3 µM (Figure 6C). To corroborate the 
rScl1.3FL-EDA binding affinity, an in-solution fluorescence binding assay was performed, 
in which the variation in tryptophan fluorescence of rScl1.3FL was recorded as a measure 
of positive binding to the C-C’ cyclic peptide. Tryptophan fluorescence emission at 333 
nm showed a dose-response quenching upon addition of the C-C’ cyclic peptide and - 
fluorescence intensity was plotted against peptide concentration (Figure 6D). Data were 
fitted with a 1:1 model of interaction, providing a KD = 44.54 ±9 μM, in agreement with 
SPR data (56). 
We next assessed binding of rScl1.3FL and rScl2.3 proteins to laminin (Lm) by 
ELISA. We determined rScl1.3FL had significant Lm binding, whereas rScl2.3 had not 
(Figure 6E), consistent with previous findings that Scl1-derived recombinant proteins, but 
not the Scl2-derived, bind ECM proteins (35). Collectively, these results demonstrate 
specific binding of Scl1.3FL to the EDA domain of cFn and to Lm and its capacity of being 
surface adhesin. 
 
Homologous complementation of M3 strains with full-length surface-exposed 
Scl1.3 adhesin confers biofilm formation on ECM 
To assess the effect of cell-surface Scl1.3FL expression on the capacity to form biofilm, 
an in-trans complementation of two representative invasive M3 strains was performed, 
MGAS315 wild-type (WT) strain, naturally lacking Scl1.3 expression, and a previously 
generated scl1-inactivated mutant of MGAS10870 (10870Δscl1), with plasmids pSL502 
(SpR) and pSL518 (KmR), respectively, both encoding the full-length Scl1.3FL protein. As 
a control, MGAS315 was complemented with a shuttle vector pJRS525. The cell wall-
associated expression of Scl1.3FL in complemented M3-type GAS was first tested by 
western blot analysis of the cell wall protein fractions and on the GAS-cell surface by flow 
cytometry. An expected ~35-kDa immunoreactive band in complemented strains was 
observed, which was absent in the parent strains (Figure 7A). Mass spectrometry analysis 
of the corresponding bands extracted from the gel confirmed they represented the 
Scl1.3FL protein, with five unique peptides identified with 17% sequence coverage for 
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complemented MGAS315 and four unique peptides identified with 11% sequence 
coverage for complemented MGAS10870 (Table S3). A 6.8-fold increase in median 
fluorescence intensity of Scl1.3FL-complemented MGAS315 cells was measured by flow 
cytometry, as compared to the vector-complemented and WT control strains (Figure 7B). 
The Scl1.3FL-complemented 10870Δscl1 exhibited a 2.2 -fold increase in median 
fluorescence intensity, as compared to the mutant control (Figure 7B). These results 
indicate the Scl1.3FL is indeed expressed and surface-exposed in the complemented M3-
type strains. 
 Biofilm formation by the complemented and parent strains was then assessed after 
24 hours following crystal violet staining and using confocal laser scanning microscopy 
(CLSM). Scl1.3FL-expressing MGAS315 showed significantly increased biomass on both 
cFn and Lm coatings compared to the WT parent organism, as well as vector-
complemented control; 3.6 or 2.5- and 2.5 or 2.1-fold OD600 increases on cFn and Lm, 
respectively, were measured compared to MGAS315 WT or to vector-complemented 
MGAS315 (Figure 7C). Significantly thicker biofilm formed by Scl1.3FL-complemented 
MGAS315 was imaged by CLSM. We observed on average a 2.8-fold (P= 0.0002) and 
2.6-fold (P= 0.0002) increased biofilm thickness on cFn and Lm, respectively, compared 
to MGAS315 WT, and a 2.0-fold (P= 0.0036) and 4.8-fold (P= 2.1x10-5) increased biofilm 
thickness on cFn and Lm, respectively, compared to vector-complemented MGAS315 
(Figure 7D and E, representative images). Similar results were obtained for the 
complemented 10870Δscl1 mutant, which had 1.7-fold increase in biomass staining on 
both cFn and Lm compared to the MGAS10870 WT strain, and 2.2- and 2.6-fold increase 
in biomass staining on cFn and Lm, respectively, compared to the 10870Δscl1 mutant 
strain (Figure 7C). CLSM data, however, could not be rendered for MGAS10870 strains 
due to poor GFP expression for unknown reasons. Altogether, it was demonstrated that 
null mutation in the scl1 gene, which ablates surface Scl1.3 protein and is unique to M3-
type GAS, is responsible for the decreased biofilm capacity since restoration of the full-
length surface-exposed Scl1.3 adhesin significantly fosters stable biofilm formation. 
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Heterologous complementation of M41 Δscl1 mutant strain with full-length surface-
exposed Scl1.3 restores biofilm formation on ECM 
In a previous study we showed that scl1.41-inactivation in a non-invasive biofilm-rich M41 
strain MGAS6183 resulted in significantly decreased biofilm capacity, which was restored 
to wild-type level by complementation with surface Scl1.41 (37). Notably, this M41 strain 
expresses at least one additional major Fn-binding protein, protein F2 (45), which binds 
both plasma and cellular fibronectin by a mechanism different from Scl1 (57). Here, we 
hypothesized that expression of rScl1.3FL in the heterologous M41 GAS will confer 
biofilm formation. Western immunoblotting of the cell wall protein fractions detected the 
~35-kDa immunoreactive band, corresponding to full-length Scl1.3, associated with 
complemented cells, while the M41Δscl1 mutant and WT cells were signal-negative 
(Figure 8A). Mass spectrometry of the corresponding band extracted from the gel 
confirmed Scl1.3FL expression, with 3 unique peptides identified, covering 13% of the 
amino acid sequence (Table S3). In addition, we showed the expression of the larger 
Scl1.41 variant in the cell wall of M41 WT, but not in the ∆scl1 mutant, by re-probing a 
portion of the blot with anti-rScl1.41 antibody, using rScl1.41 protein as a positive control. 
Similarly to complementation with homologous Scl1.41 protein, the heterologous 
complementation of the M41Δscl1 mutant with Scl1.3FL also restored biofilm to M41 WT 
levels on cFn and Lm (Figure 8B-D). Crystal violet staining showed increased bacterial 
biomass (Figure 8B) and confocal microscopy revealed significantly thicker biofilms, on 
average 3-fold increased, as compared to the parental M41Δscl1 mutant strain on both 
cFn (Figure 8C) and Lm (Figure 8D) coatings (cFn, P= 0.0105; Lm, P= 0.0011).  
 
Expression of Scl1 adhesin attenuates GAS during subcutaneous infection 
We have previously shown that an M3 strain harboring a carrier scl1.3 allele, producing 
a shorter cell-attached Scl1.3 variant, had an attenuated phenotype in a murine model of 
necrotizing fasciitis (40). Here, we tested our hypothesis that Scl1 adhesin in biofilm-rich 
M28 and M41 background promotes stable colonization and localized infection, using a 
murine skin infection model. Hairless, immunocompetent SKH1 mice were 
subcutaneously infected with ~109 GAS CFU of the M28 and M41 wild-type (WT) or their 
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isogenic scl1-inactivated mutant (scl1) strains (44,45), and mice were assessed for 
changes in gross pathology of the skin. 
Skin lesions caused by both the WT and scl1 strains were observed as early as 48 
hours post-infection, and the lesions began to regress after day 7 with complete resolution 
of the lesion by the completion of the experiment. The areas of the skin lesions calculated 
for mice infected with the scl1 mutant strains were significantly larger than those of WT-
infected mice (Figure 9A; 96 hour time-point is shown); images of lesions of 
representative mice demonstrate differences in lesion severity between WT- and scl1-
GAS infected mice for both the M28- and M41-infected groups (Figure 9B). Thus, the in 
vivo data, using GAS strains expressing surface Scl1 proteins and producing rich biofilms, 
support our hypothesis that decreased adhesion and biofilm formation, due to the 
absence of Scl1.3 on the surface of M3 strains, bears an inverse correlation to the 
invasive potential of the infecting GAS strain.  
 
DISCUSSION 
Since the resurgence of invasive GAS disease in the 1980’s, and emergence of invasive 
M3-type isolates, significant efforts have been made to determine the molecular basis for 
the invasive phenotype of M3-type strains. Numerous whole-genome sequencing 
projects have identified specific genomic features of M3 strains that were correlated with 
their potential to cause invasive infections. In this study, we show that Scl1-negative M3-
type GAS have reduced adhesion and biofilm formation within host tissue, and therefore 
are predisposed to invasive spread over superficial infection (Figure 10).  
 
Unique topography and expression patterns of scl loci 
First, the insertion of IS1548 element in the promoter region of scl1 exclusively found in 
the M3-type strains is an intriguing observation, given the abundance of IS1548 insertions 
across GAS genomes representing a variety of M-types. IS elements are known to cause 
genomic rearrangements and affect the expression of important genes that contribute to 
bacterial virulence (58). For example, the insertion of IS1548 element (59) into the scpB-
lmb intergenic region in group B Streptococcus has been shown to upregulate lmb-gene 
transcription and Lmb-adhesin surface expression, resulting in enhanced laminin binding 
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(60). The IS1548 insertion in the scl1.3 promoter was conserved in the genomes of 
sequenced M3 strains MGAS315, SSI-1, and M3-b, as well as in 40 additional M3 strains 
tested by PCR. However, the recently sequenced STAB902 M3 strain (55), which 
represents a non-invasive isolate, contained a 34-bp IS1548 remnant, suggesting that M3 
circulating strains exist with this polymorphism. We hypothesize that the proximity of the 
IS1548 insertion to the Mga I binding site in M3 strains affects scl1.3 transcription. 
Comparative qRT-PCR analysis showed significantly higher levels of scl1 transcription, 
particularly in M1, as well as in M28 and M41 strains, relative to M3-type strains analyzed.  
Variation in the Mga coding sequence and autoregulated mga promoter has been 
reported to significantly affect Mga-dependent gene expression and virulence properties 
in GAS (26,27,61). For example, a 12-bp deletion of a single repeat in the VNTR region 
of the mga promoter is present in M3 carrier strains and absent in the invasive M3 strains, 
causing a downregulation of Mga expression and Mga-regulated genes in the carrier 
strains (27). We identified an analogous 12-bp deletion in the VNTR of the mga promoter 
of the M1-type MGAS5005 and in M3 strains, MGAS335 and MGAS1313, but not in 
MGAS315, MGAS158 and MGAS10870. It is likely that the variation observed in the 
VNTR region impacts Mga expression but could not, alone, explain differences in scl1 
transcription patterns observed in this work. Consequently, qRT-PCR analyses showed 
mga and emm transcripts (emm is second downstream target of Mga within the Mga 
regulon) were expressed at similar levels in MGAS5005 and M3 strains, except for the 
MGAS335, indicating a mechanism of scl1 downregulation in M3 strains, which is 
independent from the level of Mga transcription. The presence of emm transcripts and 
M3-protein products indicate that Mga is present and functional in the majority of M3 
strains tested, and therefore the polymorphism we observed in the mga promoter did not 
affect Mga expression or activity of Mga-controlled scl1.3 promoter. Altogether, our data 
hint at the insertion of the IS1548 in the downregulation of scl1.3 expression, specifically 
in M3-type GAS, although additional studies are required to firmly establish whether the 
IS element insertion is responsible. 
It is intriguing that scl1 and scl2 expression patterns were drastically different 
between M1 and M3-type GAS, both associated with invasive infections. The scl1.3 
transcript was decreased by 21-fold in MGAS315, and even further in the remaining M3 
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strains studied (additional 20-45 fold), as compared to the M1-type strain MGAS5005. 
The upregulation of scl1 in M1-type GAS has previously been shown in invasive M1 
isolates, including MGAS5005, as compared to pharyngeal M1 isolates (62). Studies 
comparing wild-type and isogenic scl1.1 mutants in M1-type GAS reported that Scl1.1 
contributed to immune evasion by inhibiting neutrophil extracellular trap production and 
by protecting bacteria from the cathelicidin LL-37 (63). We conclude the differences we 
observed in scl1 expression are related to different pathogenicity requirements for Scl1 
protein in M1- versus M3-type strains. In contrast, Scl2 expression is highly upregulated 
in M3-type strains, as compared to invasive M1-type GAS. While the majority of M3-type 
strains contain in-frame scl2.3 alleles, all 21 M1 strains we analyzed contained out-of-
frame scl2.1 alleles (unpublished data). Although the Scl2.3 human ligands are not 
known, it may have an unidentified biological function, which is important for pathogenesis 
of M3, but not M1, strains. Hence, we are reporting striking differences in the expression 
and features of the Scl1 and Scl2 proteins that evolved in the invasive M1 and M3 strains. 
 
Scl1-mediated adhesion and biofilm formation in vitro 
Scl1 mediates binding to human extracellular matrix components, cellular fibronectin and 
laminin, as well as biofilm formation (35-37). Previous work identified that Scl1 binds 
specifically to the C-C’ loop of the type III-repeat EDA domain of cellular fibronectin (37). 
This represents a novel mechanism of fibronectin binding, which is distinct from the 
mechanism employed by other GAS fibronectin-binding proteins that bind to the N-
terminal type I repeats of fibronectin (64). Here, we determined that rScl1.3FL binds to 
cellular fibronectin via the same C-C’ loop-dependent mechanism. It is important for our 
overall model to acknowledge that the EDA-cFn isoform is specifically produced during 
embryogenesis and during wound healing in adult tissue (65-67), which indicates Scl1 
evolved with a unique function for targeting wounded tissue, a presumed pathogen portal 
of entry. We also demonstrate significant binding of rScl1.3FL to laminin, a major 
basement membrane protein at the epidermal-dermal junction; none of those ECM 
ligands were bound by rScl2.3, consistent with previous knowledge that Scl1, but not 
Scl2, variants exhibit binding to cFn and Lm (35). These studies show that full-length 
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Scl1.3, if expressed on the M3-GAS cell surface, would bind ECM, contributing to tissue 
colonization.  
 The diminished Scl1.3 expression and poor biofilm formation, led us to hypothesize that 
lack of surface-expressed Scl1 in M3-type GAS reduces host ECM binding and stable 
microcolony formation in tissue, thus, shifting the balance towards invasive spread, 
augmented by other virulence factors expressed by these strains. Recombinant rScl1.3FL 
formed aggregates that were mediated by the V-to-V region interactions, which could 
represent a mechanism of biofilm and microcolony stabilization by Scl1 molecules on 
adjacent GAS cells. Two representative invasive M3 isolates, MGAS315 and 
MGAS10870, acquired biofilm formation on cFn and Lm when homologous 
complementation was performed with surface-attached Scl1.3FL. MGAS315 has been 
shown to contain a missense mutation in the covS gene, causing upregulation of CovRS-
regulated virulence genes and enhanced virulence during subcutaneous infection of mice, 
compared to an isogenic strain containing the WT covS allele (68). Additionally, 
MGAS315 contains a mutation in the regulator of protein B allele, ropB, which produces 
a nonfunctional RopB variant, while MGAS10870 contains a wild-type covR/S and ropB 
alleles (28), allowing us to demonstrate the effect of Scl1.3FL function in the presence of 
differing regulatory networks. Similarly, heterologous complementation with surface 
Scl1.3FL in a scl1.41-mutant of the non-invasive biofilm-capable strain M41-type 
MGAS6183, restored its biofilm capacity to the wild-type level. These results indicate that 
M3-derived Scl1.3FL variant has the full capacity to support biofilm formation to a similar 
degree as Scl1 from a divergent M-type. The robust biofilm observed in vitro on ECM 
coatings validates the concept that biofilm capacity combined with adherence to the 
surrounding host ECM would reinforce the formation of stable tissue microcolonies in 
vivo.  
  
In vitro skin equivalent model of wound colonization and microcolony formation 
We observed inhibition of wound re-epithelization by GAS infection of wounded skin 
equivalents, as well as the thinning of the viable epidermal layer at sites distant from the 
infected wound. In addition to our study, others have reported changes in skin 
histopathology and wound healing, resulting from bacterial infections. An in vivo study 
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has reported epidermal defects as a result of GAS infection in a humanized mouse model 
with human skin graft (69). Previous study of M3-type GAS infection using a skin 
equivalent model showed that hyaluronic acid capsule interactions with CD44 receptor 
on keratinocytes induced intracellular signaling, resulting in cytoskeletal rearrangement 
and monolayer disruption (70). Infection of an in vitro skin model containing a burn wound 
with Pseudomonas aeruginosa caused a loss of the keratinocyte layer and basement 
membrane, while intact epidermis was observed in burned but uninfected tissue (71). 
Impairment of wound healing has also been demonstrated by staphylococcal infections. 
Infection of dermal wounds in rabbit ears with Staphylococcus aureus showed the 
formation of biofilm, production of a persistent, low grade inflammatory response, and 
significantly delayed wound healing (72). Similarly, delayed wound healing by both S. 
aureus and S. epidermidis biofilms was observed in a mouse model of cutaneous wounds 
(73). The inhibition of wound healing we describe here is by and large consistent with 
reports by other laboratories generated using in vivo animal and in vitro human skin 
infection models. 
Microcolonies have been identified within human streptococcal impetigo lesions 
(39) and in tonsils from patients with recurrent GAS pharyngeal tonsillitis (74), and likely 
represent a superficial or persistent state of GAS colonization. However, streptococcal 
infections can result in invasive disease due to biofilm disruption and bacterial 
dissemination (75,76). We observed large rounded microcolonies formed in tissue during 
infection with M41 strain, while M3 GAS remained scattered throughout the tissue as 
single cells and chains. Microcolony formation has been previously observed with S. 
aureus infection in organotypic skin model (77). Moreover, wound infection in rabbit ears 
with S. aureus produced mature biofilms encased in exopolysaccharide, as revealed by 
concanavalin A staining (72). Similarly, we also demonstrated that microcolonies in M41-
infected tissue were encapsulated in bacterial-associated glycocalyx. However, a lack of 
glycocalyx-encapsulated microcolonies was associated with infection by M3-type GAS.  
These results support our hypothesis that biofilm-poor M3 strains are abolished in 
stable microcolony formation in vivo, in part due to a lack of the ECM-binding Scl1 protein 
and an overall lack of surface adhesins, although they likely express the FbaB protein, 
 72 
identified in M3 GAS to be involved in the adherence and invasion into epithelial and 
endothelial cells (78-80).  
 
In vivo mouse model of skin infection 
Recent study reported that a small proportion of non-invasive M3-type strains (~1.3%) 
were found to harbor the scl1.3 “carrier allele”, which resulted from an in-frame deletion 
in the collagenous region, encompassing the null mutation, producing a shorter cell-
attached Scl1.3 variant. This MGAS10870 strain containing the scl1.3 carrier allele was 
attenuated following intramuscular infection (40). In this study, we utilized the M28- and 
M41-type strains, representing biofilm-rich producers, for subcutaneous inoculation. We 
observed that scl1.28- and scl1.41-inactivated isogenic mutants produced significantly 
larger skin lesions as compared to the wild-type parent strains. These results, again, 
support the hypothesis that lack of Scl1 surface adhesin destabilizes focused nidus of 
infection, resulting in a shift towards increased tissue spread. However, previous studies 
performed in a M1 GAS background, utilizing scl1.1-mutants for subcutaneous infection, 
reported smaller skin lesions in the mutant groups, which likely reflects a differing 
predominant function of Scl1.1 in M1-type GAS (29,63). Investigations using intranasal 
and intraperitoneal mouse infection models of Streptococcus pneumoniae have shown 
that culture-grown bacteria disseminated to the ear and lungs, while biofilm-grown 
bacteria stably colonized the nasopharynx (81,82). A similar study on Streptococcus 
pyogenes showed that bacteria grown in biofilms have downregulated virulence genes 
and tend to colonize the nasal associated lymphoid tissue of mice, while culture-grown 
bacteria had significantly increased dissemination and were more virulent in a septicemia 
model (83). Previous studies reported that inactivation of some GAS genes resulted in 
increased skin pathology produced by the mutants compared to their wild-type organisms, 
and these genes often encoded surface proteins, including SpyCEP (84), Mrp (85), 
protein F1 (86), and Spy0128, encoding a major pilus subunit (87). Similarly, the covS 
mutant of group A streptococcal M1T1 strain with upregulated SpeB-protease activity was 
hypervirulent and had reduced capacity to bind human epithelial cells and fibronectin, and 
also to form biofilm due to increased cleavage of surface proteins (88). Altogether, the 
concept that expression of a surface adhesin, such as Scl1, involved in biofilm formation 
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and host tissue attachment, is inversely related to strain invasiveness has gained support 
from several studies, including this study.   
We show the invasive M1- and M3-type GAS evolved scl1 and scl2 alleles with 
opposite expression patterns, with scl1 downregulated and scl2 upregulated in M3 
compared to M1 GAS. We show M3-type GAS, devoid of surface-expressed Scl1.3, 
lacked biofilm formation on ECM coatings and microcolony formation during infection of 
in vitro wounded skin equivalent. Complementation with surface Scl1.3FL restored biofilm 
capacity of M3-type GAS on ECM coatings. Mouse infection with the isogenic scl1 
mutants of biofilm-rich M28- and M41-type GAS produced larger lesions, supporting the 
role of Scl1 in a localized tissue infection. Lastly we developed a model for Scl1-mediated 
microcolony formation (Figure 10), whereby Scl1 expressed on the GAS surface 
strengthens host colonization by attachment to cFn and Lm expressed within wounded 
tissue, as well as biofilm formation via Scl1-Scl1 interactions, resulting in a local, 
stabilized microcolony. Conversely, when Scl1 is absent on the GAS cell surface, as is 
the case for M3-type GAS, bacteria lack stable anchoring in the surrounding host ECM, 
as well as structural strength within microcolony, promoting cells to disperse more freely.  
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Figure 1 
 
M3-type GAS strains harbor unique polymorphisms in the scl1.3 locus. (A) Schematic 
representation and nucleotide sequence are based on the scl1.3 locus in the M3-type strain 
MGAS315 genome. The scl1.3 promoter region contains two putative Mga binding sites, Pscl1-I 
with Mga I and Pscl1-II with Mga II. IS1548 is inserted 38 bp upstream of the preferred *Pscl1-
I/Mga I promoter, which was shown to be necessary for scl1 transcription. Transcriptional start 
site (solid dot), -10 and -35 boxes are shown upstream of scl1.3 coding sequence. Scl1 regions 
are designated as follows: SS, signal sequence; V, variable region; CL, collagen-like region; L, 
linker region; WM, wall-membrane region; LPATG, cell-wall anchor. The null mutation in the 11th 
Gly-X-Y repeat of the CL region is depicted by the red box, presumably resulting in a truncated 
secreted Scl1.3 protein. Relative location of primers, IS1548F and Scl1R, used to generate 
amplicons in (C) are shown. (B) IS1548 insertion upstream of scl1.3 is unique to M3 genomes. 
BLAST search in the NCBI nucleotide (nr/nt) database using IS1548 (1,317 bp) sequence as 
query identified insertions in 45 GAS genomes representing 21 different M-types. Only genomes 
of M3-type strains harbored IS1548 element upstream of the scl1 allele (bold text). (C) IS1548 
insertion upstream of scl1.3 is conserved among M3 strains. Genomic DNA was isolated from a 
collection of 40 M3-type strains and analyzed by PCR for the presence of IS1548 upstream of 
scl1 using primers IS1548F and Scl1R (located in conserved scl1 signal sequence). Additional 
M1-, M41-, and M28-type control strains, and a no template control (NTC) are included. Expected 
amplicon size, 963 bp; M, 1 kb Plus DNA Ladder. MGAS designation applies to all strain numbers 
shown above gel wells, with the exception of strain AM3. 
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Figure 2 
 
Assessment of Scl1.3 expression. (A) Assessment of Scl1.3 production by M3-type GAS. Cell 
wall (CW) and culture supernatant (Sup) protein fractions prepared from exponential phase 
cultures of several M3-type strains were analyzed by western immunoblotting, using anti-Scl1 
rabbit polyclonal antibody. Recombinant protein rScl1.3V, corresponding to the variable region of 
Scl1.3, was used as a positive control. Expected molecular masses: Scl1.3, 11.4 kDa; rScl1.3V, 
8.3 kDa. M, PageRulerTM Plus Prestained Protein Ladder. (B) Detection of Scl1.3 on the surface 
of M3-type GAS. Flow cytometry analysis of several M3-type strains is shown using anti-Scl1 
antibody described in part (A) (color-shaded histograms) or a secondary only control (2o sample, 
black outlined histogram). Median fluorescence intensities (MFI) are shown in parentheses for 
each strain. (C) Assessment of scl1 transcription. Fold-change of scl1 transcript levels are shown 
compared to scl1.3 transcription in M3-type strain MGAS315. qRT-PCR was performed on RNA 
obtained from exponential phase cultures. Results are shown from three independent 
experiments, each performed in triplicate wells. Standard errors and statistical analysis were 
computed from averaged ΔCt values for each biological replicate prior to normalization against 
the endogenous reference gene tufA; *P≤0.05, **P≤0.01, ***P≤0.001 (student’s t-test). (D) 
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Assessment of mga and emm transcription. Relative expression levels of mga and emm genes 
were compared between MGAS315 and four additional M3 strains or the M1 strain MGAS5005. 
Results are shown from three independent experiments, each performed in triplicate wells. 
Standard errors and statistical analysis were computed from averaged ΔCt values for each 
biological replicate prior to normalization against the endogenous reference gene tufA; **P≤0.01. 
(E) Assessment of M3-protein production by M3-type GAS. The same cell wall (CW) and culture 
supernatant (Sup) protein samples prepared from exponential phase cultures of M3-type strains 
(used in panel A) were analyzed by western immunoblotting, using anti-M3 protein rabbit 
polyclonal antibody. Expected molecular mass: 65 kDa. M, PageRulerTM Plus Prestained Protein 
Ladder. 
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Figure 3 
 
Characterization of the scl2.3 locus in M3-type GAS. (A) Assessment of Scl2.3 production by 
M3-type GAS. The same cell wall (CW) and culture supernatant (Sup) protein samples prepared 
from exponential phase cultures of several M3-type strains (used in Fig. 2A, E) were analyzed by 
western immunoblotting, using anti-rScl2.3V rabbit polyclonal antibody. Recombinant protein 
rScl2.3V, corresponding to the variable region of Scl2.3 protein, was used as a positive control. 
Expected molecular masses based on MGAS315: Scl2.3, 52.5 kDa; rScl2.3V, 10.1 kDa. Aberrant 
migration of detected Scl2.3 variants is characteristic of Scl proteins. M, PageRulerTM Plus 
Prestained Protein Ladder. (B) Detection of Scl2.3 on the surface of M3-type GAS. Flow 
cytometry analysis of several M3-type strains is shown using anti-rScl2.3V rabbit polyclonal 
antibody (color-shaded histograms) or a secondary-only control (2o sample, black outlined 
histogram). Median fluorescence intensities (MFI) are shown in parentheses for each strain. (C) 
Assessment of scl2 transcription. Fold-change of scl2 transcription levels are shown compared to 
scl2.3 transcription in M3-type MGAS315. qRT-PCR was performed on reverse-transcribed RNA 
obtained from exponential phase cultures. Results are shown from three independent 
experiments, each performed in triplicate wells. Standard errors and statistical analysis were 
computed from averaged ΔCt values for each biological replicate prior to normalization against 
the endogenous reference gene tufA; *P≤0.05, **P≤0.01 (student’s t-test). 
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Figure 4 
 
In vitro skin equivalent model of GAS infection. (A-I) H&E stained sections of uninfected (A-
C) or infected (D-I) wounded skin equivalents at 40x magnification; scale bar: 1000 µm. 
Uninfected wound at day 0 (A) shows a lack of the epidermal layer where biopsy punch was 
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performed, which healed by day 5 (B). At day 1, infection of wounded skin equivalents with M3 
and M41 GAS revealed superficial colonization of the wound bed, as well as invasion into the 
defects formed at the wound edge (D, G, arrows). By day 5, bacteria had disseminated throughout 
tissue laterally and vertically (arrows), reaching the bottom of the dermis layer (E, H). (C, F, I) 
H&E stained sections of the keratinocyte layer of intact skin surrounding the biopsy punch; scale 
bar: 100 µm. The thickness of the viable keratinocyte layer outside the wound (C, double arrow) 
was significantly reduced in tissues infected with M3 (F) and M41 (I) by day 5. (J, L) Gram stained 
sections of wounded tissue, corresponding to boxed areas in panels D and H, show tissue 
microcolonies (arrows) and superficial bacterial colonization (arrowheads). (J, scale bar: 400 µm; 
L, scale bar: 200 µm). (K, M) 1000x magnification micrographs of surface biofilms shown in J and 
L (scale bar: 10 µm). (N-Q) Two-photon fluorescence microscopy analysis of infected skin 
equivalents. Vertical dissemination through the wound bed and glycocalyx formation by the GFP-
expressing M41- (N-O) and M3-type (P-Q) GAS at day 5. 3D projections of z-stacks are shown 
from the top view of the z-stack (top panels) or the side view (bottom panels). Multi-channel 
images show GFP fluorescence of GAS cells (N, P) and TRITC-conA stain of glycocalyx (O, Q). 
All images were acquired at 600x magnification. 
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Figure 5 
 
In vitro biofilm formation and hypothetical model of microcolony formation by invasive M3-
type GAS. (A) Limited in vitro biofilm formation by invasive M3 strains on coatings with cellular 
fibronectin and laminin. A panel of invasive M3-type strains was compared to a non-invasive 
biofilm-capable M41-type strain MGAS 6183. Crystal violet staining was used to assess biomass 
formed after 24 hours of growth in wells coated with cellular fibronectin (cFn) and laminin (Lm); 
results represent averaged values from at least 3 independent experiments performed in triplicate 
wells. **P≤0.01 (student’s t-test). (B) Hypothesis model. Top: Infection of wounded skin with wild-
type M3-type GAS. Inherent lack of surface-expressed Scl1.3 causes decreased binding to cFn 
and Lm expressed in wounded tissue, and reduces biofilm and tissue microcolony formation by 
M3-type bacteria (red circles). Bottom: In-trans complementation of M3-type GAS with full-length 
cell-associated Scl1.3, Scl1.3FL, restores binding to cFn and Lm in tissue, which confers biofilm 
and tissue microcolony formation during infection. 
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Figure 6 
 
Construction and binding characterization of recombinant full-length Scl1.3FL and Scl2.3 
proteins. (A) Affinity purified rScl1.3FL and rScl2.3 proteins were analyzed by 4-20% gradient 
SDS-PAGE; expected molecular masses: rScl1.3FL, 20.6 kDa and rScl2.3, 16.2 kDa. (B-D-) 
Binding of rScl1.3FL to extra domain A (EDA) of cellular fibronectin. (B) IST-9 antibody inhibition 
identifies rScl1.3FL binding to the C-C’ loop of EDA-cFN. Inhibition of rScl1.3FL binding to EDA-
cFn was tested by ELISA following pre-incubation of cFn with blocking IST-9 mAb specific to the 
C-C’ loop. Significance of inhibition by 0.1 and 1.0 µg of IST-9 mAb was determined by student’s 
t-test as compared to the untreated cFn. A lack of significant cFn binding by rScl2.3 was evident, 
as compared to rScl1.3FL-cFn binding; student’s t-test. (C) rScl1.3FL binding to a cyclic peptide 
mimicking the C-C’ loop of EDA using surface plasmon resonance. Overlay of sensorgrams for 
the interaction between immobilized rScl1.3FL and EDA-derived C-C’ cyclic peptide is shown. 
The experimental curves corresponding to different concentrations of peptide (10-500 μM) were 
fitted according to a single binding model with 1:1 stoichiometry. (D) rScl1.3FL binding to a C-C’ 
cyclic peptide using tryptophan fluorescence assay. Tryptophan fluorescence quenching analysis 
shows  the dose-response curve of the fluorescence values of rScl1.3FL at 333 nm plotted against 
the concentration values of C-C’ cyclic peptide. (E) Laminin binding to rScl1.3FL and rScl2.3 by 
ELISA. Recombinant rScl proteins were immobilized onto Strep-Tactin-coated wells and 
incubated with laminin. Bound laminin was detected with specific primary pAbs and HRP-
conjugated secondary Abs. Laminin binding was compared between rScl1.3FL and rSc2.3 and 
evaluated statistically using student’s t-test. Results for panels C and F represent averaged values 
from at least 3 independent experiments performed in triplicate wells. *P≤ 0.05, **P≤ 0.01, ***P≤ 
0.001. 
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Figure 7 
 
Homologous complementation of M3-type GAS with full-length surface-expressed Scl1.3 
protein confers biofilm formation. (A) Western blot detection of full-length Scl1.3 in cell wall 
fractions of MGAS315 and MGAS10870∆scl1 complemented in-trans with the scl1.3FL allele. 
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Parent strains were included as negative controls and rScl1.3FL was used as a positive control 
for detection. (B) Flow cytometry detection of Scl1.3FL on the GAS cell surface. Left: 
Fluorescence intensity of Scl1.3FL-complemented MGAS315 WT strain was compared to vector-
complemented or WT parent strain. Right: Fluorescence intensity of Scl1.3FL-complemented 
MGAS10870∆scl1 was compared to WT and ∆scl1 parent strains. Median fluorescence intensities 
are shown in parentheses for each strain. (C) Crystal violet assessment of bacterial biomass after 
24 hours of growth in cFn- or Lm-coated wells. MGAS315 WT complemented in-trans with 
pJRS525 (SpcR vector) or pSL502 (Table 1) harboring the scl1.3FL allele was compared to WT 
parental strain. Spectinomycin resistant MGAS10870∆scl1 mutant was complemented in-trans 
with KanR pSL518 (Table 1), harboring the scl1.3FL allele. Biofilm biomass of the complemented 
strain was compared to MGAS10870 WT and scl1-inactivated parental strains. Results represent 
averaged values from at least 3 independent experiments performed in triplicate wells. *P≤ 0.05, 
**P≤ 0.01, ***P≤ 0.001; students t-test. (D, E) Confocal laser scanning microscopy analysis of 
biofilm formation by GFP-expressing MGAS315 vector and scl1.3FL- complemented strains. 
Biofilms were grown for 24 hours on cFn-coated (D) or Lm-coated (E) coverslips. Maximum 
intensity projections of GAS biofilms with cross-sectional views (left panels) are representative of 
z-stacks from ten fields within a single experiment. Average vertical thickness is indicated in 
micrometers. 3D projections of z-stacks (right panels) are shown from the side view. 
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Figure 8 
 
Heterologous complementation of scl1-deficient mutant of M41-type GAS with full-length 
Scl1.3 restores biofilm formation. (A) Left blot: western blot detection of full-length Scl1.3 
protein in cell wall fraction of M41∆scl1::scl1.3FL using anti-Scl1 polyclonal antibody. The 
M41∆scl1 and M41 WT strains were included as negative controls, and rScl1.3FL was included 
as a positive control. Right blot: western blot detection of Scl1.41 in M41∆scl1 and M41 WT strains 
using anti-rScl1.41 antibody and rScl1.41 as a positive control. (B) Crystal violet assessment of 
biofilm biomass after 24 hours of growth in cFn- or Lm-coated wells. M41 scl1-inactivated 
(M41∆scl1) mutant was complemented in-trans with either homologous scl1.41 allele harbored 
on pSL230 or with heterologous scl1.3FL allele harbored on pSL502 (Table 1). M41 WT, ∆scl1 
mutant and two complemented mutant strains were assessed for biofilm formation and statistical 
significance was assessed by students t-test as compared to M41∆scl1; *P≤ 0.05, **P≤ 0.01. (C, 
D) Confocal laser scanning microscopy analysis of biofilm formation by GFP-expressing 
M41∆scl1 or M41∆scl1:: scl1.3FL. Biofilms were grown for 24 hours on cFn-coated (C) or Lm-
coated (D) coverslips. Maximum intensity projections of GAS biofilms with cross-sectional views 
(top panels) are representative of z-stacks from ten fields within a single experiment. Average 
vertical thickness is indicated in micrometers. 3D projections of z-stacks (bottom panels) are 
shown from the side view. 
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Figure 9 
 
Skin pathology of SKH1 hairless mice infected subcutaneously with wild-type and scl1-
inactivated mutants of M28- and M41-type GAS. (A) Mean area of skin lesions in mice infected 
with M28- or M41-type isogenic GAS strains. The severity of skin lesions was compared following 
infection with wild-type (WT) or scl1-mutant (scl1) GAS; 96-hour time-point is shown. The mean 
lesion area and standard deviation were calculated and compared between experimental groups. 
Data represents mean lesion size from at least 10 mice per experimental group. Statistical 
differences were calculated using the student’s t-test; **P≤ 0.01, ***P≤ 0.001. (B) Gross pathology 
of the skin lesions. Digital images of the skin lesions of representative animals infected with either 
WT or scl1-mutant GAS. The images show skin lesions developed after 96 hours post-infection, 
and scale bar represents 10 mm. 
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Figure 10 
 
Model of Scl1-mediated GAS adhesion, biofilm formation, and host colonization. M28- and 
M41-type GAS express full-length cell-attached Scl1, which mediates adherence to cFn and Lm. 
ECM binding promotes biofilm formation in wounded tissue and allows the formation of superficial 
tissue microcolonies resulting in non-invasive colonization. On the contrary, in M3-type GAS, 
naturally lacking full-length cell-attached Scl1.3 adhesin, bacterial cells have reduced adherence 
to cFn and Lm and reduced capacity for biofilm formation, thereby circumventing the formation of 
localized tissue microcolonies; infection balance is shifted towards dissemination through tissue, 
promoting invasive spread. 
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Table 1. Constructs used in this study 
Plasmid Description Source 
pJRS525 E. coli / S. pyogenes shuttle vector  McIver and Scott. 1997 
pSL230 pJRS525 with scl1.41 allele  Caswell et al. 2007 
pSL501 pJRS525 with scl1.3WT allele  Flores et al. 2015 
pSL502 pSL501 with repaired allele scl1.3FL  Flores et al. 2015 
pSL518 pSL502 with KanR in place of SpcR  This study 
pASK-IBA2 E. coli expression vector IBA, Göttingen 
pSL154 pASK-IBA2 encoding rScl1.3V This study 
pSL503 pASK-IBA2 encoding rScl1.3FL Flores et al. 2015 
pSL514 pASK-IBA2 with rScl2.3  This study 
pSB027 GFP-encoding plasmid Cramer et al. 2003 
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A STREPTOCOCCUS INCREASES ADHERENCE AND DECREASES INVASIVE 
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Anthony R. Flores, Brittany E. Jewell, Erika M. Versalovic, Randall J. Olsen, Beth A. 
Bachert, Slawomir Lukomski and James M. Musser 
Published in Infection and Immunity 2015 83: 1122-1129 
 
ABSTRACT 
Group A Streptococcus (GAS) predominantly exists as a colonizer of the human 
oropharynx that occasionally breaches epithelial barriers to cause invasive diseases. 
Despite the frequency of GAS carriage, few investigations into the contributory molecular 
mechanisms exist. To this end, we have identified a naturally occurring polymorphism in 
the gene encoding the streptococcal collagen-like protein A (SclA) in GAS carrier strains. 
All previously sequenced invasive serotype M3 GAS possess a premature stop codon in 
the sclA gene truncating the protein. The carrier polymorphism is predicted to restore 
SclA function and was infrequently identified by targeted DNA sequencing in invasive 
strains of the same serotype. We demonstrate that a strain with the carrier sclA allele 
expressed a full-length SclA protein while the strain with the invasive sclA allele 
expressed a truncated variant. An isoallelic mutant invasive strain with the carrier sclA 
allele exhibited decreased virulence in a mouse model of invasive disease and decreased 
multiplication in human blood. Further, the isoallelic invasive strain with the carrier sclA 
allele persisted in the mouse nasopharynx and had increased adherence to cultured 
epithelial cells. Repair of the premature stop codon in the invasive sclA allele restored the 
ability to bind the extracellular matrix proteins laminin and cellular fibronectin. These data 
demonstrate that a mutation in GAS carrier strains increases adherence and decreases 
virulence and suggest selection against increased adherence in GAS invasive isolates. 
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INTRODUCTION 
The bacterial pathogen Streptococcus pyogenes (group A Streptococcus, GAS) causes 
a wide range of disease in humans. GAS causes severe invasive infections such as toxic 
shock syndrome and necrotizing fasciitis but is also the cause of milder, more benign 
infections (e.g. pharyngitis). In addition to causing disease, GAS colonizes the throats of 
humans in the absence of symptoms. Asymptomatic colonization rates range between 5-
15% in healthy children (1), a rate that far exceeds that of GAS invasive disease (2). 
However, despite the high prevalence of GAS carriage, little is known about the molecular 
factors that contribute to asymptomatic colonization. 
 Colonization of the host epithelium is a key first step to establishing GAS carriage or 
disease. GAS elaborates several key surface proteins that contribute to this process 
including the M protein, fibronectin binding proteins, the GAS pilus, and streptococcal 
collagen-like (Scl) proteins. The collagen-like protein SclA (also known as Scl1) is found 
in all GAS serotypes examined to date (3) and is positively regulated by the well-
characterized regulator Mga (4). The SclA protein extends from the GAS cell surface in a 
homotrimeric, ‘lollipop-like’ fashion (5). The outermost region consists of a globular head 
that varies considerably between GAS serotypes followed by a repeating Gly-X-Y (GXY) 
collagen-like sequence that is in turn linked to the cell wall through a proline-rich linker 
region (Figure 1A). SclA contributes to GAS adherence and colonization through binding 
cellular fibronectin and laminin via the variable globular head (6) and integrins through 
the collagen-like region (7,8). Variability in the degree of binding between GAS serotypes 
to these and other host molecules is predicted based on the differences in the V and CL 
regions of SclA.  
While several studies have begun to unravel the role of SclA as an adhesin, its 
contribution to phenotypic differences based on source of GAS isolation (e.g. invasive 
versus carrier) is unknown. Expression of GAS surface proteins may enhance adherence 
to host surfaces but may also reduce virulence. Expression of pili in serotype M1 GAS 
promotes adherence but enhances GAS killing through neutrophil extracellular traps 
(NETs) reducing systemic virulence (9). Similarly, the fibronectin-binding protein PrtF1 
increased adherence to human cells but decreased dissemination in a mouse model of 
GAS infection (10). Similar paradoxical observations exist for surface proteins in 
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Staphylococcus aureus (11). In contrast to other GAS serotypes, it has been shown that 
the sclA gene in serotype M3 GAS harbors an internal stop codon truncating the predicted 
protein (Figure 1A) (12). In fact, the truncated sclA gene was identical in recent whole 
genome sequencing of >200 invasive serotype M3 GAS (13), suggesting selection 
against a full-length, surface-attached protein. The impact of the truncated sclA allele on 
the pathogenesis of invasive serotype M3 GAS remains unknown. 
Here, we report that human carrier strains of serotype M3 GAS contain a natural 
variant of sclA that restores the full open-reading frame. Expression of the full-length SclA 
in an invasive strain correlates with increased adherence to epithelial cells in vitro and 
decreases virulence in invasive disease in mice. The data presented also suggest that 
the truncated sclA allele contributes to pathogenesis in invasive serotype M3 GAS. Our 
findings suggest that mutations negatively affecting virulence and enhancing colonization 
of mucosal surfaces may contribute to asymptomatic carriage in GAS. 
 
MATERIALS AND METHODS 
Bacterial strains used and culture conditions 
GAS strains are listed in Table S1 and were grown on trypticase soy agar containing 5% 
sheep blood agar (SBA) (Becton Dickinson), in Todd-Hewitt broth containing 0.2% 
(wt/vol) yeast extract (THY) (Difco Laboratories), or on THY agar. When needed, GAS 
media was supplemented with chloramphenicol (Sigma-Aldrich) at 10 μg/mL or 
spectinomycin (Sigma-Aldrich) at 150 μg/ml. E. coli DH5α or TOP10 (Invitrogen) grown 
in Luria-Bertani (LB) broth or on LB agar (Difco Laboratories) were used for cloning and 
supplemented with ampicillin (Sigma-Aldrich) at 100 μg/mL or chloramphenicol (Sigma-
Aldrich) at 20 μg/mL when appropriate.  
 
PCR amplification and sequencing of sclA 
Primers for PCR and sequencing of sclA in GAS strains are listed in Table S2. Growth of 
strains, genomic DNA extraction, PCR amplification and Sanger sequencing were 
performed as previously described (14). 
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Generation of isoallelic and isogenic mutants in MGAS10870 
Plasmids and primers used in this study are listed in Tables S1 and S2. The procedure 
used in generating the isoallelic mutant MGAS10870sclACarrier was as described (15). 
Briefly, the sclACarrier allele was amplified using the primers 2902F and 2487R from the 
carrier strain MGAS23440 and subsequently ligated into the temperature sensitive E. coli-
Gram positive shuttle vector pJL1055 using BamHI and XhoI (16) to generate pJSF41. 
Electrocompetent cells of MGAS10870 were transformed with pJSF41 and allelic 
replacement carried out as previously described (17). The isoallelic mutant was confirmed 
using Sanger sequencing (Applied Biosystems). 
Insertional inactivation of sclA in MGAS10870 was performed as previously 
described (18). Briefly, a three-step process was used to generate a PCR fragment in 
which 810 bases of the sclA open reading frame (ORF) were removed. Primer pair 0488R 
and MSP184 were used to generate a 824-bp fragment including the first 18-bp of the 
sclA ORF. Likewise, primer pair 2901F and MSP183 were used to generate a 791-bp 
fragment containing the last 18-bp of the sclA ORF. Primer pair MSP181 and MSP182 
were used to amplify aad9 with ends homologous to the first and last 18-bp of the sclA 
ORF. The three PCR fragments were then used to generate a 2,581-bp fragment using 
primer pair 2901F and 0488R in a ligation PCR in which all but 36-bp (12 amino acids) of 
the sclA gene were replaced, in-frame, by the spectinomycin cassette aad9. All isoallelic 
and isogenic mutants were confirmed by Sanger sequencing (Applied Biosystems).  
 
RNA isolation and quantitative real-time PCR analysis 
Transcript levels of sclA were assayed as previously described (15). Briefly, RNA was 
isolated and purified using an RNeasy kit according to the manufacturer’s instructions 
(Qiagen). Reverse transcription of RNA to produce cDNA was done with a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan quantitative real-time 
PCR (qQRT-PCR) was performed with an ABI 7500 Fast Real-Time and tufA used as the 
endogenous control gene. TaqMan primers and probes used in analyses are listed in 
Table S2. All reactions were performed in quadruplicate using RNA purified from at least 
three biologic replicates. 
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Generation of anti-SclA rabbit antibodies and western immunoblot analysis of SclA 
The sclAInvasive gene was PCR amplified using primers MSP263 and MSP264 (Table S2) 
and cloned into the expression vector pET15b (Novagen) to generate pJSF66. The His-
tagged SclAInvasive protein was overexpressed in E. coli (BL21) and purified using nickel 
affinity chromatography. Affinity-purified rabbit polyclonal anti-SclA antibody was 
generated by LifeTein (Hillsborough, NJ).  
Complementation (in trans) of the isogenic deletion mutant MGAS10870ΔsclA 
utilized the Gram-positive expression vector pDC123 (19). The primer pair MSP275 and 
MSP277 were used to amplify the sclA gene from either MGAS10870 (sclAInvasive) or 
MGAS23440 (sclACarrier) and ligated into the EcoRV/HindIII sites of pDC123. The resulting 
plasmids (Table S1) were electroporated into MGAS10870ΔsclA to generate the 
individually transcomplemented strains. Isolation of bacterial proteins and western 
immunoblot analysis was carried out as described (15). 
 
Cloning, expression, and purification of full-length SclA (SclAM3-FL) 
All plasmids and primers are listed in Tables S1 and S2. The sclA coding region of the 
serotype M3 strain MGAS315 was amplified by PCR using the forward primer 232 Up 
and the reverse primer ME7, digested with EcoRI and HpaI enzymes, and, cloned into 
the E. coli/GAS shuttle vector pJRS525. The resulting plasmid, pSL501 served as a 
template for PCR mutagenesis to obtain the full-length sclA allele (pSL502). The forward 
PCR primer pJRS525F1 was used with the reverse primer ME6, which contains a single 
base pair substitution encoding a glutamate residue (GAA) instead of the stop codon 
(TAA) naturally present in the 11th GXY repeat of sclA wild-type allele. 
The recombinant full-length SclA protein (rSclAM3-FL) was generated employing the 
Strep-tag® II expression and purification system (IBA-GmbH, Goettingen, Germany), as 
described previously (5,20). PCR amplification was performed using pSL502 DNA 
template, with the primers Scl1.3 M3VF and Scl1.28WMR. PCR product was digested 
with HindIII and EaeI enzymes and cloned into the pASK-IBA2 E. coli vector designed for 
periplasmic expression, resulting in pSL503 encoding rSclAM3-FL. Each clone, pSL501-
503, was confirmed by sequencing. Protein rSclAM3-FL was affinity purified on Strep-
Tactin® sepharose, dialyzed against 25 mM HEPES, pH 8.0, and analyzed on SDS-
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PAGE stained with RAPIDstainTM (G-Biosciences). Protein identity was confirmed by N-
terminal Edman degradation (Iowa State University, Protein Facility). 
 
Mouse virulence experiments 
Female CD1 mice (Harlan Laboratories) were used for virulence studies as described 
previously (21). Mice were inoculated in the right hind limb with 1 x 107 CFU of GAS in 
100 l PBS for intramuscular infection or intranasally with 1 x 107 CFU in 50 μl PBS for 
nasopharyngeal colonization. Near-mortality was determined by observation using pre-
defined criteria for mice infected intramuscularly (21). Mouse nasopharyngeal 
colonization was performed as previously described (22). All mouse experiments were 
approved by the Institutional Animal Care and Use Committee of Houston Methodist 
Research Institute. 
 
Growth in human blood 
Experiments assessing the ability to grow in human blood were conducted under a 
Houston Methodist Research Institute Institutional Review Board human subjects 
protocol and carried out as described (22,23). A minimum of two healthy, non-immune, 
adult donors were used for each experiment. 
 
Human epithelial cell adherence assays 
GAS adherence to cultured epithelial cells was carried out as previously described (22). 
Assays were performed in quadruplicate. Percentage adherence was calculated by 
dividing the recovered CFU by the original inoculum. 
 
ECM binding assay 
To assess ECM binding by ELISA, recombinant Scl (rScl) proteins (0.5 µM) were 
immobilized onto Strep-Tactin® coated microplate wells (IBA-GmbH), as described 
before (6,24). The cellular fibronectin (cFn) from human foreskin fibroblasts (F2518, 
Sigma), and laminin (Lm) (23017-015, Invitrogen) were added to wells containing rScls 
at 1 µg per well. Rabbit anti-human fibronectin (F3648, Sigma) and anti-laminin (L9393, 
Sigma) primary antibodies were used at concentrations of 1:1000 and 1:250, respectively. 
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Secondary antibody goat anti-rabbit IgG (H+L) HRP conjugate (BioRad), was used at a 
concentration of 1:2000, followed by addition of the HRP substrate 2,20-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (37615, 1-step ABTS, ThermoScientific); 
absorption was measured at a wavelength of 415 nm. OD values from BSA-coated control 
wells were subtracted from the OD values of each test well. Shown are combined results 
from three independent experiments performed in triplicate. 
 
Statistics 
A two-tailed t-test (unequal variance) was used to compare multiplication factors between 
strains grown in human blood, adherence of strains to epithelial cells, and ECM binding 
of recombinant Scl proteins. Kruskal-Wallis analysis of variance was used to compare 
rates of nasopharyngeal colonization between strains. A P-value less than 0.05 was 
considered significant for all statistical tests. 
 
RESULTS 
The variant sclA allele occurs infrequently in serotype M3 GAS invasive strains and 
results in expression of a full-length protein 
In an effort to identify key molecular genetic differences contributing to asymptomatic 
carriage of GAS, we performed whole genome sequencing of 37 serotype M3 GAS 
isolates cultured serially from 9 individuals over time (22). We discovered that 4 strains 
recovered from one subject contained a variant sclA allele compared to the reference 
serotype M3 genome. The variant carrier allele (sclACarrier) differed from all previously 
sequenced serotype M3 sclA (sclAInvasive) by a 153-bp deletion removing the internal stop 
codon within the collagen-like region and restoring the complete open-reading frame 
(Figure 1A). The predicted SclACarrier protein has highest homology (>71% identity) to the 
SclA proteins from serotypes M6 and M5 GAS. 
 All invasive serotype M3 GAS strains studied to date possess the sclA allele with an 
internal stop codon (sclAInvasive) (13). The predominance of the truncated sclA allele in 
invasive serotype M3 GAS suggests host selective pressure against expression of the 
full-length SclA protein in invasive disease. However, the possibility exists that variant 
sclA alleles restoring the open-reading frame and potentially expressing a complete SclA 
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protein are found in more geographically diverse invasive serotype M3 GAS. We 
hypothesized that the frequency of variation in sclA would be substantially less in a 
population of invasive serotype M3 GAS than that found in the carrier population 
examined. To test our hypothesis we performed targeted DNA sequencing of sclA using 
strains obtained from the Centers for Disease Control Active Bacterial Core surveillance 
spanning the years 1998 to 2008 (http://www.cdc.gov/abcs) (14). Very few (6/479, 1.3%) 
of the geographically and temporally diverse invasive serotype M3 GAS isolates harbored 
the same 153-bp deletion in sclA as identified in the GAS carrier strains. The sclA allele 
in the remaining invasive strains contained the internal stop codon as in the reference 
serotype M3 genome (MGAS315).  
 Given that the sclAInvasive allele contains an internal stop codon, it is possible invasive 
strains do not produce sclAInvasive transcript or that it is unstable and quickly degraded. We 
previously showed that peak sclA transcript coincides with peak mga transcript levels in 
serotype M3 GAS (15). Thus, we hypothesized that sclA transcript would be produced in 
a strain with either sclAInvasive or sclACarrier. To test this hypothesis, we generated an 
isoallelic mutant strain that differed from the invasive parental strain MGAS10870 only by 
the presence of the sclACarrier gene (MGAS10870sclACarrier). We subsequently assayed 
sclA transcript in vitro after growth in rich medium (THY). As predicted, we detected sclA 
transcript and observed no significant differences between the isoallelic mutant and 
parental strains (Figure 1B). 
We next hypothesized that the full-length SclACarrier protein is expressed in GAS. 
To test this hypothesis, we complemented in trans the invasive strain MGAS10870 
lacking completely the sclA gene (MGAS10870ΔsclA) with a plasmid expressing either 
sclACarrier or sclAInvasive under the native sclA promoter. Total protein of the knockout and 
trans-complemented strains were probed using a polyclonal anti-SclA antibody generated 
using purified SclAInvasive protein (Figure 1A). Consistent with our hypothesis, we identified 
the SclACarrier protein at the predicted size (~ 21 kDa) in MGAS10870pDCsclACarrier (Figure 
1C). In addition, we also identified an approximately 12-kDa SclAInvasive protein, consistent 
with the predicted protein size based on the premature stop codon, in 
MGAS10870pDCsclAInvasive (Figure 1A). Thus, the variant sclA allele identified in the 
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serotype M3 carrier strains restores expression of a full-length protein, however, a 
shorter, truncated version of SclA is also expressed in invasive serotype M3 GAS. 
 
A serotype M3 invasive strain with sclACarrier has reduced virulence.  
Inasmuch as expression of cell surface adhesion proteins has been shown to reduce 
virulence in GAS (9,10), we next tested the hypothesis that invasive serotype M3 GAS 
with sclACarrier will have decreased virulence compared to invasive strains with sclAInvasive. 
To test this hypothesis, we used a mouse model of necrotizing fasciitis to compare the 
parental MGAS10870 to the isoallelic mutant MGAS10870sclACarrer. Compared to the 
parental invasive strain the isoallelic mutant MGAS10870sclACarrier formed a localized, 
abscess-like lesion on visual inspection of the infected limb at 48h (Figure 2A). 
Microscopic examination revealed extensive myonecrosis in the parental invasive strain 
while the isoallelic mutant with sclACarrier showed an abscess-like lesion with surrounding 
healthy, viable tissue (Figure 2A). This observation is consistent with decreased 
dissemination of the strain with sclACarrier within the infected tissue. In contrast to the 
isoallelic carrier mutant, MGAS10870 lacking sclA (MGAS10870ΔsclA) showed no 
significant difference following visual and microscopic examination compared to the 
parental strain. 
Given that human antibodies against Scl proteins cross-react with Scl of differing 
serotypes (25), it is possible that surface expression of SclA enhances phagocytosis of 
GAS. To further test our hypothesis that the strain harboring sclACarrier reduces GAS 
virulence we next assessed the ability of the mutants to grow ex vivo in human blood. 
Consistent with differences in mouse tissue destruction, we observed a significantly 
decreased ability of MGAS10870sclACarrier to grow in human blood but no such difference 
in MGAS10870ΔsclA compared to MGAS10870 (Figure 2B), suggesting enhanced 
phagocytosis in the mutant with the carrier allele. Similar to previous studies of GAS 
surface adhesins reducing virulence (9,10), both in vivo mouse and ex vivo human data 
confirm a decreased virulence phenotype in an invasive strain expressing SclACarrier. In 
addition, deletion of the sclAInvasive allele in an invasive strain had no significant effect on 
virulence in the models tested. 
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Invasive strain harboring sclACarrier persists in mouse nasopharyngeal colonization 
and demonstrates increased adherence to human epithelial cells. 
SclA has previously been shown to contribute to adherence to epithelial cells (8). 
Furthermore, others have hypothesized that GAS carrier strains are characterized by 
increased ability to adhere to epithelial surfaces (26). Thus, if our hypothesis is correct 
and SclACarrier increases adherence, the invasive strain with sclACarrier should have 
increased ability to colonize epithelial surfaces. We first tested the invasive strain 
MGAS10870 and the isoallelic mutant with sclACarrier in a mouse nasopharyngeal model 
of colonization. We observed a significant decrease in the proportion of mice colonized 
with the isoallelic mutant MGAS10870sclACarrier compared to MGAS10870 (Figure 3A). 
However, mice were stably and persistently colonized by the isoallelic mutant 
MGAS10870sclACarrier at a level similar to the parental invasive strain at day 14 (Figure 
3A) suggesting an ability to persist on the mouse nasopharyngeal mucosa. We also 
observed a significant decrease in mice colonized by the deletion mutant 
MGAS10870ΔsclA (Figure 3A) compared to the parental strain. In addition to decreased 
colonization, both the carrier (MGAS10870sclACarrier) and deletion (MGAS10870ΔsclA) 
mutants had significantly decreased bacterial burden compared to the parental invasive 
strain (Figure 3B). The finding of decreased bacterial burden in the mouse 
nasopharyngeal model is strikingly similar to that observed in GAS carrier strains deficient 
in capsule production (22). 
To further characterize adherence in MGAS10870sclACarrier we performed in vitro 
adherence assays to cultured epithelial cells. Given the known role of SclA in adherence 
to epithelial surfaces (6), we hypothesized that compared to the parental invasive strain, 
the strain with sclACarrier would better adhere to cultured epithelial cells. We assayed the 
in vitro adherence to both a pharyngeal epithelial cell line (HEp-2) and a skin epithelial 
cell line (HaCaT). Compared to the invasive strain, we observed significantly greater 
adherence to both HEp-2 and HaCaT cells in the isoallelic strain MGAS10870sclACarrier 
and the deletion mutant MGAS10870ΔsclA (Figure 3C-D). Our data are consistent with 
the model that presence of the naturally-occurring variant sclACarrier in serotype M3 GAS 
results in decreased virulence, stable and persistent colonization of the mouse 
nasopharynx, and increased ability to adhere to cultured human epithelial cells. Further, 
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while deletion of sclAInvasive did not affect virulence in the mouse intramuscular or ex vivo 
human models of GAS disease, the observed phenotypic differences in colonization and 
adherence suggest biologic activity of the truncated and secreted SclAInvasive protein. 
 
Full-length serotype M3 SclA protein (SclAM3-FL) binds extracellular matrix 
components, cellular fibronectin and laminin 
Several recombinant SclA (rSclA) constructs derived from GAS of different M protein 
serotypes have been shown to bind human extracellular matrix (ECM) components such 
as cellular fibronectin (cFn) and laminin (Lm) (6,24). Since binding is mediated by the 
SclA variable (V) region, we hypothesized that the observed increase in adherence in 
MGAS10870sclACarrier was at least in part due to the expression of a cell-attached, full-
length SclA protein. To test our hypothesis, we cloned the sclA coding region from 
invasive serotype M3 GAS and repaired the nonsense mutation, generating a GAA codon 
encoding a glutamate residue in place of the TAA premature stop codon (Fig. 1A). The 
resulting full-length sclA allele (sclAM3-FL) was cloned into an expression vector to 
generate full-length recombinant SclA protein (rSclAM3-FL), purified (Fig. 4A), and 
subsequently tested for binding to cFn and Lm by ELISA. SclAM3-FL demonstrated 
significantly greater binding to both cFn and Lm compared to SclBM28 (P < 0.05), an ECM-
binding negative control derived from SclB protein of serotype M28 GAS (Fig. 4B). 
Binding of SclAM3-FL was similar to recombinant SclAM1 and SclAM41 proteins, derived from 
serotype M1 and M41 GAS, respectively, and included as ECM-binding positive controls. 
Our data indicate that the full-length cell-attached serotype M3 SclA protein and thus the 
carrier SclA protein function as adhesins able to bind cFn and Lm in human tissue. 
Together, these data suggest that serotype M3 GAS acquired the unique null mutation 
resulting in secretion of a truncated SclA variant rather than cell-attached protein. 
Consistent with the mouse intramuscular infection model, lack of a cell-attached SclA 
adhesin decreases tissue adherence and thereby promotes dissemination in serotype M3 
GAS. 
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DISCUSSION 
In contrast to our sophisticated knowledge of bacterial mechanisms contributing to 
virulence in invasive disease, comparatively little is known regarding the molecular 
genetic factors contributing to asymptomatic carriage of bacterial pathogens. Several 
studies exist describing mutations, in both virulence genes and virulence regulators, that 
contribute to hypervirulence and increased invasive disease caused by GAS. However, 
despite the much higher prevalence of GAS carriage, few studies have shown that 
specific mutations contribute to a GAS carrier phenotype. Our data not only suggest that 
small genetic changes may contribute to GAS carriage but that study of GAS carrier 
strains may provide greater insight into GAS pathogenesis. 
Our data demonstrating that the presence of sclACarrier is associated with 
decreased virulence and increased adherence are consistent with previous observations 
in GAS carriage. It has long been suggested that key phenotypic features of GAS carrier 
strains include decreased virulence and increased ability to adhere to and persist on 
mucosal surfaces. Further, such a phenotype may contribute to eradication failures in 
cases of GAS pharyngotonisillitis (27). Sela et al. (26) showed that GAS strains from 
subjects with eradication failure following treatment for pharyngotonsillitis had higher 
rates of adherence and internalization compared to strains from subjects with successful 
eradication. Moreover, previous studies have shown an inverse relationship between 
expression of bacterial surface adhesins and virulence (9-11). Thus, the mutation 
identified in sclA is one of the first specific mutations in a surface protein potentially linking 
increased adherence and decreased virulence in GAS carrier strains. 
In addition to shedding new light on GAS carriage, our data suggest positive 
selection to maintain the truncated SclAInvasive protein in the invasive serotype M3 GAS 
population. Invasive strains of serotype M3 have surprisingly few mutations in sclA. Our 
analysis of geographically and temporally diverse serotype M3 invasive GAS strains 
demonstrated that ~1% have the carrier mutation. The remaining invasive strains 
harbored the same sclA allele – the allele containing the premature stop codon – and 
virtually no polymorphisms (467 of 473; 98.7%). The observation that invasive serotype 
M3 GAS express the truncated protein in vitro (Figure 1B) and the isogenic deletion 
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mutant is affected in models of adherence and colonization is intriguing. Recently, it was 
shown that the homologous protein from serotype M1 GAS enhances survival in 
neutrophil extracellular traps (NETs) and interferes with myeloperoxidase release (28). 
Thus, it is possible that expression of a truncated SclA in serotype M3 GAS acts in a 
similar manner to enhance survival in vivo and promote invasive disease but, as it is not 
surface attached, does not directly act as an adhesin and instead facilitates 
dissemination.  
The biologic activity of SclAInvasive appears to be complex and potentially niche-
specific based on the differing phenotypes of the deletion mutant in the models tested. 
The decreased bacterial burden of the deletion mutant in the mouse nasopharynx 
suggests that, at least in this model, SclAInvasive contributes to the ability of invasive 
serotype M3 GAS to multiply at the mucosal surface. However, as indicated by the 
increased ability of the same mutant to better adhere to cultured epithelial cells (similar 
to the SclACarrier mutant), the truncated SclA may interfere with bacterial cell binding of 
host components. The observation that a full-length recombinant SclA protein binds the 
ECM components and that the truncated SclA is conserved among invasive serotype M3 
GAS and has the identical variable region responsible for ECM binding further supports 
this model. Further experimentation is needed to test these hypotheses. 
The mutation identified in sclA in GAS carrier strains is likely one of many 
mutations that may contribute to the carrier phenotype. For instance, it has been 
demonstrated that a mutation in the promoter of the gene for the virulence regulator Mga 
contributes to decreased virulence in GAS carrier strains (15). More recently, mutations 
that eliminate GAS capsule have been shown to arise in vivo during human carriage and 
result in decreased virulence and increased adherence to epithelial cell surfaces (22). 
The current study not only suggests that mutations contribute to GAS carriage but 
enhances understanding of serotype M3 GAS pathogenesis, further emphasizing the 
importance of carriage research. One interpretation of the data presented is that of a 
model in which distinct genetic differences between GAS carrier and invasive strains 
contribute to a carrier phenotype defined by decreased virulence and increased ability to 
adhere to epithelial surfaces (Figure 5). Further research is needed to fully define 
genotype-phenotype relationships in GAS carrier strains. 
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Figure 1 
SclA differs in GAS serotype M3 invasive and carrier strains and is expressed. (A) 
Invasive strains of serotype M3 GAS are characterized by an sclA allele harboring an 
internal stop codon truncating the predicted protein after the 11th GXY repeat (G*Y). The 
shaded region containing the cell wall anchor is untranslated in invasive SclA, indicating 
the protein is not cell-attached. The naturally occurring carrier sclA allele is characterized 
by a deletion removing 17 GXY repeats in the mature protein including the G*R (bold) 
present in the invasive protein. To generate the full-length SclAInvasive protein, the G*R 
(Gly-Stop-Arg) was repaired to GER (Gly-Glu-Arg). (B) TaqMan transcript analysis of 
invasive (MGAS10870), isoallelic (MGAS10870sclACarrier), and isogenic 
(MGAS10870ΔsclA) mutants. P-values determined by t-test (unequal variance). (C) 
Western immunoblot using anti-SclAInvasive antibody and showing SclA expression in 
MGAS10870ΔsclA transcomplemented with either sclACarrier or sclAInvasive. The positive 
control (+ Control) consisted of purified SclAInvasive protein used for generation of rabbit 
anti-SclA antibody. 
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Figure 2 
 
Strain with sclACarrier has reduced virulence compared to the parental invasive 
strain. (A) Visual (top panels, original magnification 4X) and microscopic (bottom panels, 
original magnification 20X) examination of mouse hind limb lesions at 48 hours following 
intramuscular injection of GAS strains. Whereas mice infected with the isoallelic mutant 
(sclACarrier) had a small, circumscribed, abscess-like lesion (white arrowheads), the 
parental invasive strain and isogenic deletion mutant caused a comparatively larger, 
grossly necrotic lesion centered at the inoculation site (boxed). Similarly, compared to the 
extensive spreading myonecrosis observed in the invasive and isogenic deletion strains, 
the isoallelic mutant showed an abscess-like lesion (black arrowheads) on microscopic 
examination. (B) Multiplication after growth in human blood. Shown is multiplication after 
growth in a single donor performed in quadruplicate. Similar results were observed after 
growth using additional donors. Error bars represent standard deviation and asterisk (*) 
indicates P-value < 0.05 as determined by t-test (unequal variance). 
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Figure 3 
 
SclACarrier affects mouse nasopharyngeal colonization and adherence to cultured 
epithelial cells. (A) Mouse nasopharyngeal colonization following inoculation of invasive 
or isoallelic GAS strains. Mice (n=20) were inoculated and swabbed daily for 14 days. (B) 
Bacterial burden of mice colonized after nasopharyngeal infection. Percent of colonized 
mice with >150 CFU after daily swabbing. Asterisk (*) indicates P < 0.05 compared to the 
parental invasive strain as determined by Kruskal-Wallis. (C-D) Adherence of GAS strains 
to cultured epithelial cells. Error bars represent standard deviation and asterisks (*) 
indicate P < 0.05 compared to the parental invasive strain as determined by t-test 
(unequal variance). 
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Figure 4 
 
Recombinant full-length SclA (rSclAM3-FL) binds the human extracellular matrix 
proteins cellular fibronectin (cFn) and laminin (Lm). (A) SDS-PAGE gel of purified 
rSclAM3-FL. Expected size of protein is 20.6 kDa and rSclAM3-FL migrates at approximately 
39 kDa; aberrant migration is characteristic of recombinant Scl proteins. (B) ECM binding 
to rSclAM3-FL protein. Test protein rSclAM3-FL, as well as control ECM-binding positive 
(rSclAM41 and rSclAM1) and binding negative (rSclBM28) control proteins, were immobilized 
onto Strep-Tactin coated wells, and incubated with cFn and Lm. Detection of rScl-bound 
ECM was carried out using specific primary antibodies and HRP-conjugated secondary 
antibodies. Bars represent the mean O.D.415nm values normalized for BSA controls. 
Asterisks represent P-values < 0.05 for rSclAM3-FL, rSclAM1, and rSclAM41 in comparison 
to the negative control rSclBM28 determined from three independent experiments each 
performed in triplicate wells, using one-sample t-test. 
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Figure 5 
 
Model summarizing the effect of invasive (sclAInvasive) or carrier (sclACarrier) sclA 
alleles in serotype M3 GAS. Following establishment of initial infection on an epithelial 
surface, GAS may progress to invasive disease (indicated by red circles) or carriage 
(indicated by blue circles). Invasive strains are characterized by the presence of a 
truncated and secreted SclA protein, decreased adherence to epithelial surfaces, and 
increased tissue destruction. It is postulated that the truncated SclAInvasive protein at least 
partially contributes to decreased adherence to epithelial surfaces and host extracellular 
matrix, and increased ability to disseminate observed in invasive serotype M3 GAS. 
Conversely, carrier strains harboring the sclACarrier allele produce a full-length, surface-
attached SclA protein, have decreased tissue destruction, and have increased adherence 
to host epithelial surfaces. Likewise, it is proposed that the decreased virulence and 
increased adherence in some carrier strains can be attributed to the naturally occurring 
SclACarrier protein.
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PART II 
STRUCTURAL ANALYSIS OF THE SCL PROTEINS
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ABSTRACT 
Streptococcal collagen-like proteins, Scls, are widely expressed by the well-recognized human 
pathogen Streptococcus pyogenes. These surface proteins contains a signature central 
collagen-like region, and an amino-terminal globular domain, termed the variable domain, which 
is protruded away from the cell surface by the collagen-like domain. Despite their recognized 
importance for bacterial pathogenicity, no structural information is hitherto available on proteins 
of the Scl class. The variable domain of Scl2 from invasive M3-type S. pyogenes has 
successfully been crystallized using vapor-diffusion methods. The crystals diffracted to 1.5 Å 
resolution and belonged to space group H32, with unit-cell parameters a =44.23, b =44.23, c 
=227.83 Å. The crystal structure was solved by single wavelength anomalous dispersion using 
anomalous signal from a europium chloride derivative.  
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INTRODUCTION 
Collagen-like proteins that form stable triple-helices have been shown to be present in many 
bacterial species (1) and to play a role in pathogenicity. Best characterized prokaryotic 
collagens are the two collagen-like proteins, Scl1 and Scl2, which have been demonstrated to 
be simultaneously expressed on the cell surface of S. pyogenes and to promote bacterial 
adhesion to the host (2,3). Both Scl1 and Scl2 proteins contain a signal sequence, an N-terminal 
variable globular domain (V), a highly charged collagen-like triple-helix domain (CL) consisting 
of (Gly-Xaa-Yaa)n triplet repeats and a C-terminal Gram-positive cell wall attachment domain. 
The Scl1 and Scl2 proteins form stable triple-helical structures when expressed as recombinant 
proteins (4,5), and their N-terminal globular V domain adjacent to the triple-helix domain 
appears to be important for efficient triple-helix assembly (5-7).  
 Bacterial adherence to host tissues, an early critical step in the infection process, often 
involves surface proteins (8,9). Among these, Scl proteins of S. pyogenes are crucial to host-
pathogen recognition (10). It has been demonstrated that Scl1 can bind selected human 
extracellular matrix components (11), cellular integrin receptors (2,12,13), and plasma 
components (14-17). Importantly, human collagen receptors, such as integrin α2β1, recognize 
the triple helix CL domain of Scl1, and this event results in cell signaling, indicating that 
collagen-like bacterial proteins display not only structural but also functional similarities to 
human collagens (2,12,13). Despite the key role of Scl proteins in bacterial pathogenicity, their 
three-dimensional structure has not been determined. In addition, whereas the triple helical 
structure of CL domain of Scls can be predicted based on sequence identity to collagen (5), no 
structural clues regarding the V domain can be obtain from Scl sequences, owing to poor 
sequence identity with known structures. Here, we report the crystallization and preliminary 
crystallographic investigations of the V domain of Scl2 from invasive M3-type S. pyogenes 
(Scl2.3-V). 
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MATERIALS AND METHODS 
Cloning, expression and purification of recombinant rScl2.3-V protein 
Recombinant rScl2.3-V protein was produced in the Escherichia coli periplasm using the Strep-
tag II expression and purification system (IBA GmbH, Goettingen, Germany), as reported 
previously (4). Briefly, the 5’-portion of the scl2.3 gene from strain MGAS315, encoding the 
amino-terminal Scl2.3-V-region, was PCR-amplified using the forward primer scl2-M3VF (5’-
GAGATGGCCGATGGTGAAGATGCCCAAAAAAG) and the reverse primer scl2-M3VR (5’-
CAGCGTCTCAGCGCTATCAAGGACATGATCTTGTATGCC) and was cloned into pASK-IBA2 
vector, resulting in plasmid pSL155. Escherichia coli strain DH5α was used for cloning and E. 
coli BL21 was used for protein expression. E. coli harboring plasmid pSL155, which encodes 
the rScl2.3-V protein, was grown in Luria-Bertani (LB) liquid medium (BD Biosciences) 
supplemented with ampicillin (100 g mL-1). Plasmid construct pSL155 was confirmed by DNA 
sequencing and the identity of purified recombinant protein rScl2.3-V was confirmed by N-
terminal Edman degradation. 
  
Crystallization experiments 
Crystallization trials were performed at 293 K using the hanging-drop vapor-diffusion method. 
Preliminary crystallization conditions were set up using a robotic station for high throughput 
crystallization screening (Hamilton STARlet NanoJet 8+1) and commercially available sparse-
matrix kits (Crystal Screen, Crystal Screen 2 and Index, Hampton Research). Optimization of 
the crystallization conditions was performed manually by fine-tuning the protein and precipitant 
concentrations. 
 
Data collection and processing 
Diffraction data were collected to 1.52 Å in-house from a native crystal at 100K using a Rigaku 
Micromax 007 HF generator producing Cu Kα radiation and equipped with a Saturn944 CCD 
detector. Cryoprotection of the crystals was achieved without addition of further 
cryoprotectants, given the composition of the crystallization mother liquor, which contained the 
cryoprotectant pentaerythritol ethoxylate (15/4 EO/OH) at 30% (v/v). For phasing purposes, 
native crystals were soaked in solutions containing between 2 and 8 mM EuCl3 for different 
soaking times. Data were collected from several crystals to identify the best single-wavelength 
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Anomalous Diffraction (SAD) signal. The data sets were scaled and merged using HKL2000 
program package (18). Statistics of data collection are reported in Table 1. 
 
Structure determination and refinement 
Phasing was achieved using in-house SAD data. A preliminary evaluation of the anomalous 
signal was performed for all tested crystals using the SCALEPACK software, implemented in 
HKL2000 (18). SHELXD was used to identify europium ion sites (19). Phases were then 
improved by solvent-flattening density modification and phase extension by RESOLVE (20). 
The obtained model was further improved using ARP/wARP (21).  
 
RESULTS AND DISCUSSION 
The recombinant rScl2.3-V protein corresponds to the N-terminal part (residues 1-77) of Scl2.3 
variant from the invasive S. pyogenes M3-type strain MGAS315 (22). This protein construct 
has successfully been purified and crystallized using vapor-diffusion methods. The purified 
rScl2.3-V showed a single band of approximately 10 kDa on SDS–PAGE, which is in good 
agreement with the predicted molecular mass of 10,105 Da. The initial automated crystallization 
screening using commercially available solutions provided the first hints of crystallization 
conditions. Small crystals that were not appropriate for diffractometric experiments were 
obtained in the presence of pentaerythritol ethoxylate. The quality of these crystals was 
improved by fine-tuning the concentration of the protein and of the precipitants. Crystals 
suitable for X-ray diffraction experiments (Figure 1) were obtained in 3 d using a protein 
concentration of 5 mg mL-1 and 0.05 M ammonium sulfate, 0.05M bis-tris pH 6.5, 30% (v/v) 
pentaerythritol ethoxylate (15/4 EO/OH). These crystals, which diffracted to 1.5 Å resolution 
(Figure 2), showed three-fold symmetry and belonged to the space group H32, with unit-cell 
parameters a=44.23, b=44.23, c=227.83 Å (Table 1). Matthews coefficient calculations (23) 
suggested the presence of one molecule per asymmetric unit (VM =2.14 Å3/Da, with 42.6 % 
solvent content). 
Lanthanides can yield high-phasing-power derivatives using in house copper sources 
(24-26). Europium chloride derivative crystals were prepared by soaking the native crystals in 
stabilizing solutions containing between 2 and 8 mM EuCl3 for increasing soaking times. SAD 
data were collected for all crystals at 100K using a Rigaku Micromax 007 HF generator 
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producing Cu Kα radiation. The best SAD data were obtained upon crystal soaking in a solution 
consisting of 8 mM EuCl3, 0.05M ammonium sulfate, 0.05M bis-tris, 30% (v/v) pentaerythritol 
ethoxylate (15/4 EO/OH) at pH 6.5 for 3 hours. The data sets were scaled and merged using 
HKL2000 program package (18) (Table 1). (19), we could identify four Europium sites in the 
asymmetric unit of the protein. With this substructure, a correlation coefficient of 31.4% was 
calculated (CC-all, calculated with all data). The obtained phases were improved by phase 
extension and density modification, using RESOLVE (27) and ARP/wARP (21). Using this 
approach, about 80% of the residues present in the asymmetric unit could be automatically 
modeled (27). Manual model-building sessions (28) aimed at defining the complete Scl2.3-V 
structure are in progress. 
 
ACKNOWLEDGMENTS 
Authors thank the Ministero Italiano dell'Istruzione, dell'Università e della Ricerca (PRIN 2009 
- prot. 200993WWF9, the COST Action BM1003 (COST-Grants-BM1003-00772) and the 
Mizutani Foundation for glycoscience for financial support (to R. B.). This work was supported 
in part by Public Service grant AI50666 from the National Institutes of Health (to S. L.).  
 
REFERENCES 
1. Rasmussen, M., Jacobsson, M., and Bjorck, L. (2003) Genome-based identification and 
analysis of collagen-related structural motifs in bacterial and viral proteins. J.  Biol. 
Chem. 278, 32313-32316 
2. Humtsoe, J. O., Kim, J. K., Xu, Y., Keene, D. R., Hook, M., Lukomski, S., and Wary, K. 
K. (2005) A streptococcal collagen-like protein interacts with the alpha2beta1 integrin 
and induces intracellular signaling. The Journal of biological chemistry 280, 13848-
13857 
3. Rasmussen, M., and Bjorck, L. (2001) Unique regulation of SclB - a novel collagen-like 
surface protein of Streptococcus pyogenes. Mol Microbiol 40, 1427-1438 
4. Han, R., Zwiefka, A., Caswell, C. C., Xu, Y., Keene, D. R., Lukomska, E., Zhao, Z., Hook, 
M., et al. (2006) Assessment of prokaryotic collagen-like sequences derived from 
streptococcal Scl1 and Scl2 proteins as a source of recombinant GXY polymers. Appl 
Microbiol Biotechnol 72, 109-115 
5. Xu, Y., Keene, D. R., Bujnicki, J. M., Hook, M., and Lukomski, S. (2002) Streptococcal 
Scl1 and Scl2 proteins form collagen-like triple helices. The Journal of biological 
chemistry 277, 27312-27318 
6. Lukomski, S., Nakashima, K., Abdi, I., Cipriano, V. J., Ireland, R. M., Reid, S. D., Adams, 
G. G., and Musser, J. M. (2000) Identification and characterization of the scl gene 
 123 
encoding a group A Streptococcus extracellular protein virulence factor with similarity to 
human collagen. Infection and immunity 68, 6542-6553 
7. Mohs, A., Silva, T., Yoshida, T., Amin, R., Lukomski, S., Inouye, M., and Brodsky, B. 
(2007) Mechanism of stabilization of a bacterial collagen triple helix in the absence of 
hydroxyproline. The Journal of biological chemistry 282, 29757-29765 
8. Esposito, C., Pethoukov, M. V., Svergun, D. I., Ruggiero, A., Pedone, C., Pedone, E., 
and Berisio, R. (2008) Evidence for an elongated dimeric structure of heparin-binding 
hemagglutinin from Mycobacterium tuberculosis. Journal of bacteriology 190, 4749-4753 
9. Chagnot, C., Listrat, A., Astruc, T., and Desvaux, M. (2012) Bacterial adhesion to animal 
tissues: protein determinants for recognition of extracellular matrix components. Cellular 
microbiology 14, 1687-1696 
10. Berisio, R., and Vitagliano, L. (2012) Polyproline and triple helix motifs in host-pathogen 
recognition. Curr Protein Pept Sci 13, 855-865 
11. Caswell, C. C., Oliver-Kozup, H., Han, R., Lukomska, E., and Lukomski, S. (2010) Scl1, 
the multifunctional adhesin of group A Streptococcus, selectively binds cellular 
fibronectin and laminin, and mediates pathogen internalization by human cells. FEMS 
microbiology letters 303, 61-68 
12. Caswell, C. C., Barczyk, M., Keene, D. R., Lukomska, E., Gullberg, D. E., and Lukomski, 
S. (2008) Identification of the first prokaryotic collagen sequence motif that mediates 
binding to human collagen receptors, integrins alpha2beta1 and alpha11beta1. The 
Journal of biological chemistry 283, 36168-36175 
13. Caswell, C. C., Lukomska, E., Seo, N. S., Hook, M., and Lukomski, S. (2007) Scl1-
dependent internalization of group A Streptococcus via direct interactions with the 
alpha2beta(1) integrin enhances pathogen survival and re-emergence. Molecular 
microbiology 64, 1319-1331 
14. Gao, Y., Liang, C., Zhao, R., Lukomski, S., and Han, R. (2010) The Scl1 of M41-type 
group A Streptococcus binds the high-density lipoprotein. FEMS microbiology letters 
309, 55-61 
15. Caswell, C. C., Han, R., Hovis, K. M., Ciborowski, P., Keene, D. R., Marconi, R. T., and 
Lukomski, S. (2008) The Scl1 protein of M6-type group A Streptococcus binds the 
human complement regulatory protein, factor H, and inhibits the alternative pathway of 
complement. Molecular microbiology 67, 584-596 
16. Reuter, M., Caswell, C. C., Lukomski, S., and Zipfel, P. F. (2010) Binding of the human 
complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 
(Scl1) via their conserved C termini allows control of the complement cascade at multiple 
levels. The Journal of biological chemistry 285, 38473-38485 
17. Pahlman, L. I., Marx, P. F., Morgelin, M., Lukomski, S., Meijers, J. C., and Herwald, H. 
(2007) Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by 
interacting with collagen-like proteins A and B. The Journal of biological chemistry 282, 
24873-24881 
18. Otwinowski, Z., and Minor, W. (1997). Methods Enzymol. 276, 307–326 
19. Sheldrick, G. M. (2008) A short history of SHELX. Acta Crystallogr A 64, 112-122 
20. Terwilliger, T. (2004) SOLVE and RESOLVE: automated structure solution, density 
modification and model building. J Synchrotron Radiat 11, 49-52 
21. Langer, G., Cohen, S. X., Lamzin, V. S., and Perrakis, A. (2008) Automated 
macromolecular model building for X-ray crystallography using ARP/wARP version 7. 
Nat Protoc 3, 1171-1179 
 124 
22. Beres, S. B., Sylva, G. L., Barbian, K. D., Lei, B., Hoff, J. S., Mammarella, N. D., Liu, M. 
Y., Smoot, J. C., et al. (2002) Genome sequence of a serotype M3 strain of group A 
Streptococcus: phage-encoded toxins, the high-virulence phenotype, and clone 
emergence. Proceedings of the National Academy of Sciences of the United States of 
America 99, 10078-10083 
23. Matthews, B. W. (1968) Solvent content of protein crystals. J Mol Biol 33, 491-497 
24. Ruggiero, A., Squeglia, F., Marasco, D., Marchetti, R., Molinaro, A., and Berisio, R. 
(2011) X-ray structural studies of the entire extracellular region of the serine/threonine 
kinase PrkC from Staphylococcus aureus. Biochem J 435, 33-41 
25. Perez-Dorado, I., Gonzalez, A., Morales, M., Sanles, R., Striker, W., Vollmer, W., 
Mobashery, S., Garcia, J. L., et al. (2010) Insights into pneumococcal fratricide from the 
crystal structures of the modular killing factor LytC. Nature structural & molecular biology 
17, 576-581 
26. Perez-Dorado, I., Sanles, R., Gonzalez, A., Garcia, P., Garcia, J. L., Martinez-Ripoll, M., 
and Hermoso, J. A. (2010) Crystallization of the pneumococcal autolysin LytC: in-house 
phasing using novel lanthanide complexes. Acta crystallographica. Section F, Structural 
biology and crystallization communications 66, 448-451 
27. Terwilliger, T. C. (2003) SOLVE and RESOLVE: automated structure solution and 
density modification. Methods Enzymol 374, 22-37 
28. Jones, T. A. (2004) Interactive electron-density map interpretation: from INTER to O. 
Acta Crystallogr D Biol Crystallogr 60, 2115-2125 
 
  
 125 
 
Figure 1 
Image of typical rScl2.3-V crystals grown using 5 mg mL-1 protein solution and 0.05M 
ammonium sulfate, 0.05M bis-tris, 30% (v/v) pentaerythritol ethoxylate (15/4 EO/OH), pH 6.5. 
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Figure 2 
Diffraction pattern of a rScl2.3-V native crystal. Diffraction data are detectable to 1.5 Å 
resolution.
 127 
Table 1. Data collection statistics. Values in parentheses are for highest resolution 
shells 
† R merge =   
 EuCl3 derivative Native 
Space group H32 H32 
Unit cell parameters a = b = 44.26, c = 228.01, γ = 
120 
a = b = 44.23, c = 227.83, γ = 
120 
Resolution (Å) 1.87 1.52 
Average 
redundancy 
9.5 (7.5) 5.3 (2.6) 
Unique reflections 7545 13802 
Completeness (%) 100 (99.9) 99.2 (86.7) 
Rmerge† (%) 0.043 (0.419) 0.061 (0.345) 
Average I/σ(I) 47.7 (5.1) 49.2 (3.10) 
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ABSTRACT 
The arsenal of virulence factors deployed by streptococci include streptococcal collagen-
like (Scl) proteins. These proteins, which are characterized by a globular and a collagen-
like domain, play key roles in host-adhesion, host immune defense evasion and biofilm 
formation. In this work, we demonstrate that the Scl2.3 protein is expressed on the surface 
of invasive M3-type strain MGAS315 of Streptococcus pyogenes. We report the crystal 
structure of Scl2.3 globular domain, the first of any Scl. This structure shows a novel fold 
among collagen trimerization domains, of either bacterial or human origin. Despite there 
being low sequence identity, we observe that Scl2.3 globular domain structurally 
resembles the gp41 subunit of the envelope glycoprotein from human immunodeficiency 
virus type 1, an essential subunit for viral fusion to human T cells. We combined 
crystallographic data with modeling and molecular dynamics techniques to gather 
information on the entire lollipop-like Scl2.3 structure. Molecular dynamics data evidence 
a high flexibility of Scl2.3, with remarkable inter-domain motions which are likely 
instrumental to the protein biological function in mediating adhesive or immune-
modulatory functions in host-pathogen interactions. Altogether, our results provide 
molecular tools for the understanding of Scl-mediated streptococcal pathogenesis and 
important structural insights for the future design of small molecular inhibitors of 
streptococcal invasion. 
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INTRODUCTION 
Streptococcus pyogenes or group A Streptococcus (GAS) is a human adapted pathogen, 
causing over 700 million cases worldwide annually (1). GAS infections produce a wide 
range of clinical outcomes, from superficial throat and skin infections to life-threatening 
invasive diseases such as streptococcal toxic shock syndrome (STSS) and necrotizing 
fasciitis (2,3). The mortality resulting from the acquisition of invasive infections is high 
with 163000 deaths globally each year (4). It is known that M3-type GAS strains are 
associated with severe infections. In a survey of 108 isolates from the US, 50% of 
invasive diseases were caused by M1 and M3 type strains, and M3 type strains 
contributed to the majority of STSS cases (5). Over the past decade, molecular 
pathogenomics has facilitated our understanding of the molecular basis for the more 
severe invasive diseases caused by M3-type strains (6-10). GAS produces cell-
associated virulence factors that contribute to host colonization and immune evasion, 
and include the streptococcal collagen-like proteins Scl1 and Scl2, also known as SclA 
and SclB (11-15). 
The Scl1 and Scl2 proteins share a similar structural organization, including an N-
terminal variable globular domain (V), a highly charged collagen-like triple-helix domain 
(CL) consisting of (Gly-Xaa-Yaa)n triplet repeats and a C-terminal Gram-positive cell wall 
attachment domain (Figure 1A). Like collagen, an important structural protein in the 
extracellular matrix of animals, Scl1 and Scl2 form stable triple-helical structures (11,16-
19). The collagen triple helix is composed of three left-handed polyproline helices twisted 
into a right-handed supercoiled structure. In mammals, a strong contribution to triple helix 
stability is given by a high content of hydroxyproline (Hyp) residues at the Y position of 
the X-Y-Gly triplets, whereas bacteria lack the prolyl hydroxylase needed for post-
translational modification of proline residues (17,20,21). To explore the basis of bacterial 
collagen triple-helix stability in the absence of Hyp, biophysical studies were carried out 
on recombinant Scl2 protein and a set of peptides modeling the Scl2 highly charged 
repetitive (Gly-X-Y)n sequences (17). These studies showed that bacteria have 
developed alternative strategies to stabilize the triple helix, involving electrostatic 
interactions, inter-chain hydrogen bonds, and a hydration-mediated hydrogen bonding 
network (17,22). 
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Similar to that observed for human collagen, the V-domain was hypothesized to 
be needed for proper folding of the triple helical regions, since their high symmetry 
constitutes an obstacle for optimal folding. However, the observation that the recombinant 
CL domain of Scl1 is expressed as a stable triple helix (16,23) contrasts this hypothesis, 
at least in vivo. Scls have characteristic “lollipop-shaped” domain organization, which 
seems apt for ligand binding. Indeed, antibody mapping and electron microscopy imaging 
analyses confirmed that the stalk-forming CL region projects the globular V region away 
from the bacterial surface (16), a feature which may facilitate interactions of V regions 
with their potential targets. Several biologically-relevant V-region ligands have been 
identified using experimental approaches. Thus, different Scl variants bind human 
extracellular matrix proteins, cellular fibronectin and laminin (24), as well as plasma 
components including the low-density lipoprotein, thrombin-activatable fibrinolysis 
inhibitor, and complement regulatory proteins factor H and factor H-related protein-1 
(18,25-28). In addition, the CL domain of Scl can bind directly to host cells through cellular 
receptors, integrins α2β1 and α11β1 (29-31). Hence, the two main Scl structural domains 
bind human ligands and are essential for GAS adhesion, host-cell entry, and 
immunomodulation of host defenses. Because of the importance of invasive M3-type 
strains in human morbidity and mortality, the presumed expression of Scl2.3 (Scl2 from 
M3 strain) was previously used as an epidemiological marker of S. pyogenes (7), although 
its actual expression has not been shown. Here, we demonstrate that Scl2.3 protein is 
expressed on the cell surface of an invasive M3-type group A Streptococcus. Since no 
structural clues on Scl2 are available, we have combined x-ray crystallography with 
molecular modeling and dynamics to obtain information on the structure of the entire 
molecule. This structure delivers the first atomic description of a Scl protein and opens 
the field for the understanding of structure-function relationship of key proteins that 
mediate essential adhesive and immunomodulatory functions of group A Streptococcus. 
 131 
MATERIALS AND METHODS 
Bacterial strains and growth 
The group A Streptococcus (GAS) M3-type strain MGAS315 (6) used here was isolated 
from an invasive case of a streptococcal toxic-like shock syndrome in Texas (5). GAS 
was routinely grown in Todd-Hewitt broth supplemented with 0.2% yeast extract (THY 
medium) or on tryptose agar with 5% sheep blood (BD Biosciences) at 37°C in 5% CO2-
20% O2 atmosphere.  
The Escherichia coli strain DH5α was used in cloning experiments and E. coli BL21 
was used for protein expression. E. coli strains were grown in Luria-Bertani media (BD 
Biosciences) supplemented with ampicillin (100 µg/ml). 
 
Protein methods 
Recombinant Scl2.3-V region polypeptide, designated rScl2.3-V, was generated using 
the Strep-tag II expression and purification system (IBA-GmbH), as described previously 
(16). Briefly, the 5’-portion of the scl2.3 allele from strain MGAS315, encoding the amino-
terminal variable (V) region of the presumed mature Scl2.3 protein, was PCR-amplified 
using scl2-M3VF (5’-GAGATGGCCGATGGTGAAGATGCCCAAAAAAG) forward primer 
and scl2-M3VR (5’-CAGCGTCTCAGCGCTATCAAGGACATGATCTTGTATGCC) 
reverse primer, and subsequently cloned into an E. coli expression vector pASK-IBA2, 
generating plasmid pSL155.  
The rScl2.3-V polypeptide is fused at the N-terminus to the OmpA signal peptide 
mediating periplasmic expression of recombinant protein. The OmpA is selectively 
cleaved off during protein export by an endogenous signal peptidase, thus, releasing the 
rScl polypeptide; the N-terminal sequence of purified rScl2.3-V was confirmed by Edman 
Degradation. The rScl2.3-V polypeptide also has a short affinity tag, the Strep-tag II 
(WSHPQFEK), at the C-terminus, which allowed for affinity chromatography purification 
on Strep-Tactin Sepharose. Purified rScl2.3-V protein was dialyzed against 25 mM 
HEPES, pH 8.0 and stored -20°C. Recombinant protein rScl2.3-V was tested for purity 
and integrity on TGX 4-20% gradient gel (Bio-Rad) and stained with RAPIDstain™ (G-
Biosciences).  
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The presence of the cell-wall associated Scl2.3 protein was studied using the 
method described before (11,15). MGAS315 was grown in THY medium until mid-
logarithmic phase (OD600 ~0.5) before GAS cells were harvested by centrifugation. The 
cell wall-associated protein fraction was obtained by resuspending the cell pellet in a high-
sucrose buffer (10mM Tris pH 8.0, 20% sucrose), containing 25 U of mutanolysin and 1 
mg/mL of lysozyme, and incubating at 37°C for 1 hour. rScl2.3-V protein and cell-wall-
associated fraction of MGAS315 were analyzed by SDS-PAGE and Western 
immunoblotting, using rabbit polyclonal antibodies raised against rScl2.3-V (Proteintech 
Group, Inc.). Alkaline phosphatase-conjugated anti-rabbit IgG H&L goat polyclonal 
antibodies (Rockland) were used as the secondary antibody, and detection was 
performed using 1-Step™ NBT/BCIP substrate (Thermo Scientific). PageRuler Plus 
Prestained Protein Ladder (Thermo Scientific) was used as a molecular weight marker. 
 
CD spectroscopy 
To analyze the conformational state of rScl2.3-V, far-UV CD spectra were registered at 
20°C. All CD spectra were recorded with a Jasco J-810 spectropolarimeter equipped with 
a Peltier temperature control system (Model PTC-423-S). Molar ellipticity per mean 
residue, [ᶿ] in deg cm2•dmol-1, was calculated from the equation: [ᶿ] = [ᶿ]obs•mrw•(10•l•C)-
1, where [ᶿ]obs is the ellipticity measured in degrees, mrw is the mean residue molecular 
mass (116.1 Da), C is the protein concentration in g•L-1 and l is the optical path length of 
the cell in cm. Far-UV measurements (190-260 nm) were carried out at 20 °C using a 0.1 
cm optical path length cell and a protein concentration of 0.2 mg•mL-1. Thermal 
denaturation studies were conducted at 222 nm with increasing temperature from 20 to 
70°C. Proteins were equilibrated at each temperature point for 2 min, and the temperature 
was increased with an average rate of 0.5 °C/min. Tm was obtained by taking the peak 
of the first derivative of the melting curve. 
 
Multiple light scattering 
Purified rScl2.3-V was analysed by size-exclusion chromatography (SEC) coupled to a 
DAWN MALS instrument (Wyatt Technology) and an OptilabTM rEX (Wyatt Technology). 
1 mg of sample was loaded a S75 10/30 column, equilibrated in 25 mM HEPES, 100 mM 
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NaCl, pH 7.4. A constant flow rate of 0.5 ml/min was applied. The on-line measurement 
of the intensity of the Rayleigh scattering as a function of the angle as well as the 
differential refractive index of the eluting peak in SEC was used to determine the weight 
average molar mass (Mw) of eluted protein, using the Astra 5.3.4.14 software (Wyatt 
Technologies). 
  
Crystallization, data collection and processing  
Crystallization trials were performed at 293 K using the hanging-drop vapor-diffusion 
method. Preliminary crystallization conditions were set up using a robot station for high 
throughput crystallization screening (Hamilton STARlet NanoJet 8+1) and commercially 
available sparse-matrix kits (Crystal Screen kits I and II, Hampton Research, Index). 
Optimization of the crystallization conditions was performed manually by tuning protein 
and precipitant concentrations. Best crystals were grown in 0.05M Ammonium sulfate, 
0.05M Bis-Tris pH 6.5, 30% v/v Pentaerythritol ethoxylate (15/4 EO/OH) (32). For 
structure solution, europium chloride derivative crystals were prepared by soaking a 
native crystal in a solution containing 8 mM EuCl3, 0.05M ammonium sulphate, 0.05M 
Bis-Tris, 30% v/v Pentaerythritol ethoxylate (15/4 EO/OH) for 3 hours at pH 6.5. A single-
wavelength anomalous diffraction experiment (SAD) was recorded in-house at 100K 
using a Rigaku Micromax 007 HF generator producing Cu Kα radiation and equipped with 
a Saturn944 CCD detector. The data sets were scaled and merged using HKL2000 
program package (33) (Table 1). 
 
Structure determination and refinement 
Phasing was achieved using in-house single anomalous dispersion data, using a 
previously adopted protocol (34). Using these data, both SHELXD (35) and SOLVE (36) 
identified five europium ions. Phases, improved by phase extension and density 
modification by RESOLVE (36) and wARP (37), allowed us to trace nearly the entire 
molecule structure. Crystallographic refinement was carried out against 95% of the 
measured data using the CCP4 program suite (38). The remaining 5% of the observed 
data, which was randomly selected, was used in Rfree calculations to monitor the 
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progress of refinement. The structures was validated using the program PROCHECK (39) 
and deposited with the PDB (accession code 4nsm). 
 
Sequence and structure alignments  
Alignments of all available Scl2 sequences were performed using the ClustalW program. 
This sequence alignment was used to obtain phylogenetic relationships. Structure 
alignments were carried out using the DALI server. 
 
Modeling of the full Scl2.3 
Molecular modeling sessions were carried out to model the collagen like domain and 
obtain the entire Scl2.3 structure. The collagen-like domain was modeled using the 
structure of the collagen-like peptide (Pro-Pro-Gly)10 as a template (40). The full sequence 
of Scl2.3 was adjusted on the domain structure using ad hoc made routines. The full 
model was energy minimized using the GROMACS package. 
 
Molecular dynamics simulations 
Molecular dynamics (MD) simulations were performed using the region 7-123 of the 
Scl2.3 as a starting model, including the crystallographic V-domain (residues 7-77) and 
part of the modelled region (residues 78-123). MD simulations were carried out with the 
GROMACS package by using the all-atom AMBER99sb ILDN force field (41) in 
combination with the  TIP4P-ew explicit water model (42). To avoid any bias on the 
hydration status of the protein derived from the MD analyses, crystallographic water 
molecules were removed from the starting model. The simulations were carried out in the 
NPT ensemble with periodic boundary conditions at a constant temperature of 300 K by 
using a weak coupling with external bath (V-rescale method) (43) and a constant pressure 
of 1 atm (berendesen pressure coupling)(44). A rectangular box was used to 
accommodate the protein, water molecules, and ions. The system included 28827 water 
molecules and a total of 120438 atoms.  
 Bending angles between CL and Scl2.3-V, or between regions of the collagen triple 
helix were defined between centre of masses of three group of atoms. For the definition 
of the global inter-domain angle, these atoms are the Cα atoms of residues 57 and 60 of 
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each chain (from Scl2.3-V), residues 75-77 (hinge region) and residues 82-84 (from CL). 
For the bending angle between three zones of the CL domain, we selected the Cα atoms 
of residues 77-78 of each chain (bottom region), residues 94 and 95 (hinge region) and 
residues 112 and 113 (top region). 
 
RESULTS 
Expression of Scl2.3 protein by M3-type GAS 
Expression of the Scl2 proteins is regulated at the level of translation and depends on a 
number of pentanucleotide repeats CAAAA found downstream to a GTG start codon 
(12,14,15). Based on the number of these repeats, the scl2-coding sequence may be in-
frame, resulting in expression of the full-length protein, or out-of-frame, leading to early 
translation termination. We assessed the cell-surface expression of Scl2.3 protein by 
MGAS315, a strain representative of global invasive M3 organisms.  
To generate tools for the detection of Scl2.3 protein, we cloned, expressed, and 
purified the recombinant Scl2.3-V protein (rScl2.3-V), corresponding to the V region of 
Scl2.3 from MGAS315. SDS-PAGE analysis of purified rScl2.3-V shows a single protein 
band of the expected size of about 10.1 kDa (Figure 1B), as further confirmed by 
sequencing. Rabbits were immunized with rScl2.3-V to generate specific anti-Scl2.3 
antibodies, which we used to test the presence of the Scl2.3 in the cell wall-associated 
protein fraction of MGAS315 by western immunoblotting (Figure 1C). In addition to 
positive control (rScl2.3-V lane), we detected a prominent immunoreactive band of 
approximately 65 kDa in the cell-wall fraction (Scl2.3 lane) using post-immune rabbit 
serum, while probing with control pre-immune serum was negative for the rScl2.3 and 
Scl2.3 bands. Based on sequence analysis, the predicted molecular mass of the mature 
Scl2.3 protein is ~52.5 kDa. However, an aberrant migration of Scl proteins has been well 
documented (11,13). Altogether, our data show that the Scl2.3 protein is expressed on 
cell surface of invasive M3-type strain MGAS315 of S. pyogenes.  
 
Structural studies in solution 
Structural features of rScl2.3-V in solution were checked using circular dichroism (CD) 
and light scattering studies. As previously shown (22), Scl2-V has a typical α-helical CD 
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spectrum (Figure 2A). Thermal stability curves, determined by monitoring the CD signal 
at 222 nm, evidences a cooperative unfolding with melting transition at Tm=50°C. 
Consistent with previous data, denaturation of rScl2.3-V is fully reversible (Figure 2B). 
Analytical size-exclusion chromatography (SEC), coupled with multiangle light scattering 
(MALS) was carried out to investigate the oligomerization state of rScl2.3-V in solution. 
The on-line measurement of the intensity of the Rayleigh scattering as a function of the 
angle as well as the differential refractive index of the eluting peak in SEC was used to 
determine Mw. This analysis produced an Mw value of 26600 ±107 Da, which 
corresponds to a trimeric organization of the molecule (Figure 2C). 
  
Overall structure of rScl2.3-V 
rScl2.3-V was crystallized in the space group H32. The structure was solved by single-
wavelength anomalous dispersion (SAD) analysis of europium-derivatized crystal and 
refined to a resolution of 1.6 Å (Table 1). Analysis of crystal packing using the software 
PISA confirms that the biologic unit of rScl2.3-V is a trimer. Consistently, a large surface 
area is buried (32% of the total surface, 5470 Å2) upon trimer formation, with a strong 
gain of free energy of solvation (∆iG=-42.1 kcal/mol). rScl2.3-V molecules are organized 
about three-fold crystallographic axes to form a six helical bundle structure (Figure 3A). 
The inner core of this bundle consists of a parallel, trimeric structure in which helices are 
wrapped in a gradual left-handed super-helix. Three further helices wrap antiparallel to 
the internal helices in a left-handed direction around the exterior of the central trimer. The 
six-helix bundle forms an elongated cylinder measuring about 30 Å in diameter and 60 Å 
in height. Interestingly, external helices are shifted with respect to internal ones, as a 12-
residue-long loop, embedding residues from Lys31 to Asp42, connects internal and 
external helices in each monomer. This region, which contains Pro34 and Pro36, adopts 
a well-defined polyproline II conformation (Figure 3B).  
The V-domain of Scl2 was proposed to be stabilized by coiled coil interactions (23), 
although prediction servers do not provide a clear answer. We searched rScl2.3-V crystal 
structure for the typical structural features of coiled coils, named knobs-into-holes, using 
the software SOCKET (45). In typical coiled coils, hydrophobic side chains at ‘a’ and ‘d’ 
positions on one helix act as knobs and dock into holes formed by diamonds of four 
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residues on the partnering helix. This analysis shows that rScl2.3-V does not contain 
coiled coils.  
Interactions between inner helices of the rScl2.3-V six-helix bundle involve 
different types of contacts along the bundle. Hydrophobic interactions exist at the two 
poles of the molecule, whereas an intricate pattern of salt bridges is formed in the central 
part (Figure 4). In this pattern, Arg56 bridges Glu60 of two adjacent protomers and 
interacts with Asp61 of an adjacent protomer. Further salt bridges exist between the 
central Glu60 and Arg64 and between Asp61 and more peripheral Lys57 (Figure 4). As 
a result, as many as 16 salt bridges stabilize the central region of the bundle.  
Three outer N-terminal helices (residues 7-38) pack obliquely against the outside 
of the inner trimer in an antiparallel orientation. As such, they interact through hydrophobic 
interactions and salt bridges with residues in three grooves on the surface of the central 
helical trimer, whereas interactions mediated by the PPII strand are mostly hydrophobic 
(Figure 5A). The analysis of the electrostatic potential surface reveals an uneven 
distribution of charged patches, with a concentration of negative charges in the region 
opposite to the origin of the collagen triple helix (Figure 5C, D). The negatively charged 
patch generated by Asp42 and Asp43 of each chain surrounds a solvent exposed 
hydrophobic region, generated by Leu41 and Met46. Of these residues, the position of 
Met46 is occupied by hydrophobic residues in all members of a subgroup of Scl2 
sequences, identified by phylogenetic analysis (branch C in Figure 6). In the same 
subgroup, negatively charged residues are often occurring in a region embedding Asp42 
and Asp43. Different features characterize the other two subgroups, but all sequences 
present both charged and hydrophobic residues in loop regions (either experimentally 
determined or predicted), indicating that these features may be functionally important. 
 
Sequence alignments 
Several sequences of both Scl2 and Scl1, deriving from different S. pyogenes strains, 
have been identified. Multiple sequence alignment shows that a hallmark of all Scl2 
sequences is the occurrence of hydrophobic residues at regular positions, most of which 
are conserved in all analyzed sequences. An analysis of rScl2.3-V structure shows that 
these residues constitute the inner core of the 6-helix bundle fold (Figure 4). This finding 
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suggests that all Scl2 proteins share the same 6-helix bundle fold we observe in rScl2.3-
V structure. The same considerations apply to Scl1 sequences, since most conserved 
hydrophobic residues are also conserved in Scl1 (data not shown). Phylogenetic analysis 
shows that Scl2 sequences can be subdivided into three main branching groups (A, B 
and C in Figure 6). In each branch, specific characteristics are conserved. For example, 
a striking difference between branches A-B and branch C, which contains Scl2.3, is the 
presence of a fully conserved Pro residue in A-B in a position corresponding to Scl2.3 
Ser26, which belongs to the α-helix α2 in Scl2.3 structure. Another almost conserved Pro 
residue characterizes branch B, in place of Scl2.3 Ser48, which is embedded in α-helix 
α2. These considerations suggest that the structures of proteins in each branch differ in 
the boundaries of α-helices constituting their six-helix bundle fold. Compared to Scl2.3, 
secondary structure predictions suggest that branch A and B are characterized by shorter 
α1 and α2 helices, connected by a longer loop in branch A, and by a loop-helix-loop motif 
in branch B (Figure 6). 
 
Scl2.3-V structurally resembles gp41 
A search for similar folds in structural data bases revealed a strong structural relationship 
between rScl2.3-V and subunit gp41 of the envelope glycoprotein from human 
immunodeficiency virus 1 (HIV-1) (PDB code 3o40, Z=12.1, r.m.s.d. 2.8 Å), with 
sequence identity between the two proteins of 9%, after alignment of 165 residues. In 
addition, the 3-carboxy-cis,cis-muconate lactonizing enzyme from Agrobacterium 
radiobacter (PDB code 2fen, Z=10.0, r.m.s.d. 3.3 Å) and the adenylosuccinate lyase from 
E. coli (PDB code 3gzh, Z=10.0,  r.m.s.d. 3.4 Å) also show structural relationship with 
Scl2.3-V fold, with sequence identities in the range 9-10%. In the case of the two bacterial 
proteins identified by DALI (PDB codes 2fen and 3gzh), only five of the six helices of 
rScl2.3-V six-helix bundle are conserved. On the contrary, the superposition of rScl2.3-
V structure on that of gp41 evidences a striking similarity in the helical arrangement of 
the two six-helix bundles (Figure 7). However, the three inner α-helices of gp41 are 
packed together in the ‘knobs-into-hole’ arrangement typical of coiled coils whereas 
coiled coil interactions were not found in rScl2.3-V structure. This feature is likely 
responsible for a more compact arrangement of inner helices in gp41, compared to 
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rScl2.3-V (Figure 7). Also, whereas gp41 fold is a highly regular six-helix bundle, rScl2.3-
V presents a polyproline region at the N-terminal side of external helices. Although the 
position of these proline residues is not conserved among Scl2 sequences (Figure 6), 
their presence in the region connecting the two main helices forming protomers of the 
six-helix bundle is a distinctive feature of all Scl2 sequences. 
 
Modeling of triple helical regions and MD simulations  
Good quality electron density maps allowed us to define the conformation of rScl2.3-V 
C-terminal ends, up to Leu76. In Scl2, this is the site of attachment of the collagen-like 
triple helix. Notably, whereas all three Leu76 residues from rScl2.3-V are in a plane, the 
triplets of the collagen triple helix are typically staggered by one residue. This poses a 
question whether the asymmetry of the triple helix is accommodated by the rScl2.3-V 
structure or if a kink of the two domains is necessary, as previously observed for the 
engineered foldon-collagen (46). To tackle this question, we modeled the triple helical 
part of Scl2.3, thus producing the first structural description of a Scl (Figure 8A), and 
carried out Molecular Dynamics (MD) simulations. To assess the evolution of the 
structure in the simulation timescale (100 ns), a number of stereo-chemical parameters 
(gyration radius, secondary structure and RMSD) were monitored along the trajectories. 
The evaluation of root-mean-square deviations (RMSD) (calculated on the Cα atoms) 
from the starting structure evidences that large motions characterize the simulated 
system (Figure 8B). The RMSD values are smaller when they are separately computed 
for Scl2.3-V and Scl2.3-CL regions. Of these, RMSD values for the Scl2.3-V region are 
on average smaller than those of the Scl2.3-CL region (Figure 8B). Likely, the difference 
in the RMSD behavior for the two regions is in its structural characteristics. Indeed, local 
fluctuations on an elongated structure (i.e. Scl2.3-CL) propagate into larger effects on 
the RMSD than in globular structures (i.e. Scl2.3-V). The RMSD data are consistent with 
the presence of a principal motion involving a global inter-domain bending motion 
between Scl2.3-CL and Scl2.3-V (Figure 8C). Analysis of the MD trajectory structures 
evidences a continuous evolution from linear conformations, in which the Scl2.3-V and 
Scl2.3-CL domains are coaxial, to a more ‘bent’ state. In particular, the bending angle 
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between the axis of the Scl2.3-V and Scl2.3-CL domains (See Methods for definition) 
ranges from 143° to 180° in an elastic fashion (Figure 8C).  
A direct indicator of the stability of the triple helix motif is the number of conserved 
main-chain hydrogen (H)-bonds along the trajectory (Figure 9A). These intermolecular H-
bonds are distinctive of the triple helix motif and are established between the amide group 
of the Gly residues and carbonyl groups from complementary peptides that form the triple 
helix. The analysis confirms that the force field and simulation setup used were able to 
maintain the initial H-bonding pattern of the structure: on average, 87.5% of the native 
main-chain H-bonds were maintained. In addition to the observed inter-domain 
rearrangements along the trajectory, MD data also evidence a high flexibility of the Scl2.3-
CL domain, with a bending angle around the center of the Scl2.3-CL region ranging 
between 152 and 180° (Figure 8D). The increased flexibility of amino-acid-rich triple 
helices, compared to imino-acid rich ones, is in line with previous MD analyses of other 
collagen-like polypeptides (47-49).  
 
DISCUSSION 
The arsenal of virulence factors deployed by streptococci include streptococcal collagen-
like (Scl) proteins, which arm the cell wall of the bacterium and establish multiple 
functions, like host-adhesion (29-31), evasion of host immune defenses (27,28), or biofilm 
formation (50,51). There are nearly 300 collagen-like proteins annotated to streptococci 
(52), including several pathogenic organisms like S. pyogenes (11-15), S. pneumoniae 
(53), and S. equi (54,55). In addition to a signature collagen-like domain, Scl proteins 
contain a globular domain (V domain) and both Gram-positive signal peptide (YSIRK) and 
cell-wall anchor (LPXTG) domains, predicting that they are all cell-surface proteins. 
Despite their established importance in bacterial pathogenesis, no three-dimensional 
structural information is available so far for any of the Scl proteins. In this work, we 
formally demonstrate that the Scl2 protein is expressed by invasive M3-type strain 
MGAS315 and is found on the bacterial cell surface (Figure 1). By combining x-ray 
crystallography with computational techniques, we provide a structural description of the 
entire Scl2.3 molecule.  
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Scl2 is known to be regulated at the level of translation by the varying number of 
CAAAA pentanucleotide repeats directly downstream of the start codon, which may result 
in frameshift of the scl2-gene reading frame and early translation termination (12,14,15). 
Analysis of scl2 within 50 GAS strains representing 21 different M types showed that the 
scl2 allele is present in virtually all strains tested, though the number of the repeats, as 
well as resulting Scl2 expression, varied among strains. For example, none of the M1-
type strains, whereas about half of the M28- and M12-type strains were predicted to 
express the full-length Scl2 variants. Interestingly, all of the M3-type strains initially tested 
(15) and 84% of 255 M3 global isolates (7) were found to contain in-frame scl2.3 alleles. 
This suggests that there may be a selective advantage in M3 strains to express Scl2, and 
it may have an important role in the pathogenesis of M3-type GAS.  
Previous binding studies have delineated roles for Scl1 and Scl2 in both host 
colonization and immune evasion. Thus, some Scl1 variants may aid host colonization by 
binding to cellular fibronectin and laminin, which are major components of human 
extracellular matrix, and integrins α2β1 and α11β1, which are present on the host cell 
surface (24,31). Scl1 has also been shown to bind the plasma lipoproteins and 
complement regulators of the immune system (18,27,28). Furthermore, both Scl1 and 
Scl2 proteins have been shown to bind thrombin-activatable fibrinolysis inhibitor, 
interfering with the normal fibrinolytic breakdown of blood clots (26), which may resemble 
a role of staphylococcal coagulases that produce clots as protective barrier against the 
immune response (56). These observations suggest Scl2 is involved in evasion or 
modulation of the immune response, rather than in host colonization. Though the role of 
Scl2 during infection is currently unclear, the structural data gained from this study 
provides very interesting clues into its possible function. The crystal structure of the V 
domain of Scl2.3 (rScl2.3-V) unveils a compact trimeric six-helix bundle fold. Consistently, 
light scattering experiments evidence that rScl2.3-V exhibits a trimeric arrangement also 
in solution (Figure 2). Trimeric six-helix bundle folds are, to date, not observed in bacteria, 
but typically characterize several glycoproteins involved in viral fusion, including the gp41 
subunit of the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1), the 
glycoprotein B of Herpes Simplex virus (57) and the GP2 domain of  the envelope 
glycoprotein GP from the Marburg and Ebola viruses (58-61). However, different than 
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gp41 and from previously reported data on Scl2 (23), the structure of rScl2.3-V does not 
contain coiled coils, but it is stabilized by both hydrophobic and ion pair interactions 
(Figure 4). Alignment of proteins with known structure shows that, even with low 
sequence identity (9%), rScl2.3-V structurally resembles the gp41 subunit of HIV-1, a 
subunit responsible for membrane fusion of the HIV virus (62,63). Since gp41 functions 
as a viral entry protein into CD4+ T lymphocytes, this might suggest a novel potential role 
for Scl2 in interacting with T cells and causing hyper-activation of the immune response, 
which is a hallmark of the STSS infections that are often associated with M3-type strains.  
We modeled the triple helical region of Scl2 and performed MD analysis with the 
aim of investigating structural and dynamic features of Scl2.3. Scl2.3-V is located at the 
tip of an extremely elongated triple helical structure (about 1030 Å, Figure 8A) and 
exposes highly hydrophobic residues, like Leu41 and Met46 (Figure 5), a feature which 
may play a role in Scl2.3-mediated interaction of S. pyogenes with the hydrophobic milieu 
in the host. MD data evidenced an extremely flexible nature of Scl2, with a dynamic kink 
of the inter-domain organization (Figure 8). A kinked structure was previously observed 
for the an engineered foldon-collagen (46) and reflects the need of the structure to fit the 
three-fold symmetry of the V domain (which brings the site of attachment of the three 
collagen-like chains in a plane) with the one-residue stagger of the collagen-like chains. 
Our data show that the Scl2.3 structure can undertake both kinked and linear 
conformations, in a rapid equilibrium between them (Figure 8). The high structural 
flexibility we observed in Scl2.3 is likely instrumental to its biological function in mediating 
adhesive or immune-modulatory functions in host-pathogen interactions. 
The V domain of Scls has been proposed as a trimerization domain which helps 
collagen folding. Indeed, different than for globular proteins, misfolding of the collagen 
triple helix is a likely event because of its repeating structure, whose stability is relatively 
insensitive to lateral shifts by one or more Gly-X-Y repeats. Consistently, trimerization 
domains have been found in many different proteins containing collagen triple helices. 
However, it has been shown that the V domain of Scls is not needed in vivo, since the 
CL region of Scl1 can be expressed in a folded triple helical state (16,23). This 
observation highlights a different folding mechanism of Scl proteins, compared to human 
collagen, for which trimerization domains are crucial to the correct triple helical 
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arrangement (64). Likely, V-domains of Scls display dichotomous functions by acting as 
triple helix stabilization domains, since they exhibit higher folding temperature than the 
CL regions (23), and by mediating host-pathogen interaction (29-31). 
To date, there are five known atomic structures of trimerization domains of 
collagen, the NC1 domain of collagen IV (65), the homologous NC1 domain of collagens 
VIII and X (66,67) and the trimerization domains of collagen XV and XVIII (68,69). A 
trimerization domain was also characterized for BclA, the major component of the 
exosporium of the B. anthracis spore (70). All of them have a high content of β-structure 
but share no structural homology. The structure of rScl2.3-V presents novel features as 
it is mainly composed of α-helices. Multiple sequence alignment suggests that the 6-helix 
bundle fold exhibited by Scl2.3 is conserved in all Scl2 sequences, albeit with different 
α-helix boundaries and length of the loop connecting alpha helices α1 and α2 (Figure 6).  
Phylogenetic analyses of variation in Scl2 V region among different M types 
revealed several interesting observations. Scl2 sequences from different M types formed 
three separate clades, referred to as A, B, and C (Figure 6). The invasive M type 3, found 
in branch C, clustered with M types 1 and 28, which are also associated with invasive 
infections, including streptococcal toxic shock syndrome and necrotizing fasciitis 
(5,71,72). Our analysis additionally evidenced that cluster C contains M types associated 
with rheumatic fever, including types 1, 3, 6, and 18 (71,73), thus suggesting a possible 
role of Scl2.3 in this disease. Altogether, our work delivers the first atomic description of 
a Scl protein. This structural information, which can be extended to other members of the 
Scl family, is precious to the understanding the structural basis of Scl-mediated 
streptococcal infection. 
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Figure 1 
Expression of Scl2.3 surface protein by the invasive M3-type strain MGAS 315. (A) 
Domain organization of Scl2.3, according to the PFAM database. (B) Characterization of 
recombinant Scl2.3-V protein (rScl2.3-V). rScl2.3-V polypeptide expressed in E. coli and 
affinity purified was resolved on 4-20% SDS-PAGE gradient gel and stained. Purified 
rScl2.3-V was used to immunize rabbits and the resulting post-immune sera were used 
to detect native Scl2.3 protein expressed by MGAS315. (C) Surface expression of Scl2.3 
protein by GAS. Cell wall-associated protein fraction of MGAS315 was analyzed by 
Western immunoblotting to detect native Scl2.3 protein using anti-rScl2.3-V post-immune 
rabbit sera. The same blot developed with pre-immune sera from the same rabbit is 
shown as a negative control. PageRuler™ Plus Prestained Protein Ladder was used as 
a molecular weight marker. 
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Figure 2 
Structural characterization of Scl2.3-V in solution. (A) CD spectra of Scl2.3-V at 20°C 
after refolding are shown as solid and dashed lines, respectively. (B) Denaturation (solid 
line) and refolding (dashed line) of Scl2.3-V followed at λ=222 nm. (C) Analytical SEC-
MALS; The black curve represents the Rayleigh ratio (left scale) against the retention 
time. Molecular mass (right scale) values correspond to a trimeric state of Scl2.3-V. 
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Figure 3 
Cartoon representation of the crystal structure of Scl2.3-V trimer. (A) Top view of 
Scl2.3-V six-helix bundle. (B) A detail of (2Fo-Fc) Electron density on the polyproline II 
(PPII) region. 
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Figure 4 
Main interactions stabilizing the six-helix bundle of Scl2.3-V. (A) Three regions are 
identifiable, with the central one stabilized by salt bridges and the external ones stabilized 
by hydrophobic interactions. (B) A detail of salt bridge interactions in the central part of 
the six-helix bundle. 
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Figure 5 
Surface features of Scl2.3-V. (A) Side and (B) top view of Scl2.3-V surface. Hydrophobic 
and hydrophilic residues are colored yellow and gray, respectively. Charged residues are 
colored blue. (C, D) Side and top views of Scl2.3-V electrostatic potential surface. The 
positive and negative charges are colored blue and red, respectively. 
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Figure 6 
Multiple sequence alignment analysis of Scl2-V region variants. (A) Sequence 
alignment was performed using CLUSTALW. Conserved residues are shown in green 
(hydrophobic), blue (positively charged), red (negatively charged), and grey (polar); Pro 
residues are shown in cyan. A, B and C refer to the three respective branches calculated 
by phylogenetic analysis using CLUSTALW. Secondary structure prediction, according to 
JPRED, is reported in magenta whereas the secondary structure based on Scl2.3-V 
crystal structure is reported in blue. 
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Figure 7 
Scl2.3-V structural alignment with the HIV protein gp41. Side (A) and top (B) views of 
the superposition between Scl2.3-V (orange) with gp41 (blue, PDB code 3o40). 
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Figure 8 
Modeling and molecular dynamics analyses. (A) Modeling of Scl2.3 structure: a view 
of the entire Scl2.3 structure; The cyan region (residues 7-123 of each chain of the Scl2.3 
trimer) was used for MD studies. (B) Evolution of the RMSD calculated on Cα atoms, 
throughout the MD trajectory for the entire model (black), the Scl2.3-V (red) and Scl2.3-
CL (green). (C) Evolution of the bending angle between the Scl2.3-V and Scl2.3-CL 
domains throughout the MD trajectory; (D) Evolution of the bending angle between three 
zones of the Scl2.3-CL domain throughout the MD trajectory; The insets of panels C and 
D show atoms used for the computation of the bending angle as red balls. 
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Table 1. Data collection and refinement statistics 
aValues in parentheses are for highest resolution shells: 1.90-1.87 Å for EuCl3 
derivative and 1.55-1.52 Å for the native crystal.
A. Data collectiona   
 Europium chloride 
derivative 
Native 
Space group H32 H32 
a, b, c (Å),  (°) 44.3, 44.3, 228.0, 120.0 44.4, 44.4, 227.8, 120.0 
Resolution (Å) 1.87 1.52 
Average redundancy 9.5 (7.5) 5.3 (2.6) 
Completeness (%) 100 (99.9) 99.2 (86.7) 
Rmerge (%) 0.043 (0.419) 0.061 (0.345) 
Average I/σ(I) 47.7 (5.1) 49.2 (3.1) 
   
B. Refinement   
Resolution range (Å) 15.00-1.52 
Rwork, Rfree (%) 18.5, 23.3 
No. atoms (protein, ligands, 
water) 
r.m.s. deviations 
623, 13, 100 
Bond lengths (Å) 0.02 
Bond angles (°) 1.6 
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CHAPTER 6 
REVERSIBLE PHOSPHOLIPID NANOGELS FOR DEOXYRIBONUCLEIC ACID 
FRAGMENT SIZE DETERMINATIONS UP TO 1,500 BASE PAIRS AND 
INTEGRATED SAMPLE STACKING 
Brandon C. Durney, Beth A. Bachert, Hillary S. Sloane, Slawomir Lukomski, James P. 
Landers, and Lisa A. Holland 
Published in Analytica Chimica Acta 2015 880: 136-144 
 
ABSTRACT 
Phospholipid additives are a cost-effective medium to separate deoxyribonucleic acid 
(DNA) fragments and possess a thermally-responsive viscosity. This provides a 
mechanism to easily create and replace a highly viscous nanogel in a narrow bore 
capillary with only a 10 °C change in temperature. Preparations composed of dimyristoyl-
sn-glycero-3-phosphocholine (DMPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine 
(DHPC) self-assemble, forming structures such as nanodisks and wormlike micelles.  
Factors that influence the morphology of a particular DMPC-DHPC preparation include 
the concentration of lipid in solution, the temperature, and the ratio of DMPC and DHPC. 
It has previously been established that an aqueous solution containing 10% phospholipid 
with a ratio of [DMPC]/[DHPC] = 2.5 separates DNA fragments with nearly single base 
resolution for DNA fragments up to 500 base pairs in length, but beyond this size the 
resolution decreases dramatically. A new DMPC-DHPC medium is developed to 
effectively separate and size DNA fragments up to 1,500 base pairs by decreasing the 
total lipid concentration to 2.5%. A 2.5% phospholipid nanogel generates a resolution of 
1% of the DNA fragment size up to 1,500 base pairs. This increase in the upper size limit 
is accomplished using commercially available phospholipids at an even lower material 
cost than is achieved with the 10% preparation. The separation additive is used to 
evaluate size markers ranging between 200 and 1,500 base pairs in order to distinguish 
invasive strains of Streptococcus pyogenes and Aspergillus species by harnessing 
differences in gene sequences of collagen-like proteins in these organisms. For the first 
time, a reversible stacking gel is integrated in a capillary sieving separation by utilizing 
the thermally-responsive viscosity of these self-assembled phospholipid preparations. A 
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discontinuous matrix is created that is composed of a cartridge of highly viscous 
phospholipid assimilated into a separation matrix of low viscosity. DNA sample stacking 
is facilitated with longer injection times without sacrificing separation efficiency.  
 
INTRODUCTION 
Estimating the size of DNA is critical in genetic analysis associated with human 
identification (1), species identification (2,3), detecting personal biomarkers (4), analyzing 
food (5), and categorizing pathogenicity (6). Moreover, following sample preparation, 
accurate determination of the size of DNA fragments is a mandatory analytical step in 
sophisticated high-throughput sequencing techniques. It is also a critical endpoint for 
methods based on PCR amplification, where the length of the product is used to 
determine the presence of a specific target sequence in the DNA template. Confirmation 
of size is achieved by comparing the fragment migration time during electrophoretic 
sieving using various sieving agents. Slab gel electrophoresis, the workhorse of modern 
analytical science, is a commonly used tool for DNA sizing due to the simplicity and low 
cost of the method. Sizing is achieved by comparing the migration time of the targeted 
DNA with a DNA ladder that contains a mixture of fragments of known size. The DNA 
ladder standard is run in a separate lane. A serious disadvantage of slab gels is the poor 
separation efficiency and the reduced throughput even when completed in parallel lanes 
in the gel (7,8). Although more expensive than slab gel methods, capillary gel 
electrophoresis provides a size discrimination that is improved substantially, and higher 
sample throughput. Sequencing of the human genome provides direct proof of this (9). 
Capillary gel electrophoresis separations of DNA fragments are accomplished 
using polymer solutions that provide a size-based separation of DNA fragments by 
creating networks or matrices that form dynamic pores for sieving (10-12), or separation 
through DNA entanglement (13). DNA fragments ranging from 50-1,500 bases are often 
present in an electropherogram, but the resolution obtained for the larger DNA fragments 
is poor and accurate sizing is limited to DNA fragments that are shorter than 500 bases 
in length. Ultra-high resolution separations were achieved with 0.75% hydroxyethyl 
cellulose used to size a 256 base pair (bp) DNA fragment (14). Although larger fragments 
could not be sized, 1,078 bp and 1,353 bp DNA were baseline resolved (14). A 
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commercial system utilized hydroxyethyl cellulose to separate 50 bp to 10 kbp DNA and 
to accurately size 275 to 815 bp DNA (15). In another case, a matrix of 2% linear 
polyacrylamide was used to sequence a DNA fragment 1,300 bases long (16). Several 
polymer properties dictate the utility of the material and the useful size range of the 
separation (17). Increasing the upper fragment size limit of the separation can be 
accomplished by increasing the length of the polymer and maintaining the concentration 
of the gel at or above the entanglement threshold (10). This increase in concentration is 
accompanied by an increase in viscosity (11), which provides challenges for the 
introduction to or replacement of, the gel in the separation capillary.  
Temporary gels, which rupture and reform during the separation, are an exciting 
alternative to permanent gels because the upper size limit increases when the rate of gel 
rupture is optimized (18). Wormlike micelles form large self-assembled structures that 
dynamically rupture and reform. Aqueous solutions of the long-chain phospholipid 
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the short-chain phospholipid 1,2-
dihexanoyl-sn-glycero-3-phosphocholine (DHPC) are known to form wormlike micelles 
(19,20). A dynamic sieving matrix of 10% phospholipid with [DMPC]/[DHPC] = 2.5 was 
optimized for single-base pair resolution that was adequate for detection of short tandem 
repeats (STR) in selected loci utilized for human identification using a 100 cm long 
capillary within a 30 minute run time (21). This is comparable to separations on 
commercial capillary electrophoresis instruments for forensic STR analyses (22). What 
makes this particularly attractive, is that the phospholipid nanogel is substantially more 
cost-effective at roughly one-fourth the cost of commercial gels utilized for human 
identification (23-25). A significant advantage of the dynamic sieving matrix is the 
thermally-responsive viscosity. The sieving matrix has low viscosity below the gel-phase 
transition temperature of the phospholipids and becomes gel-like at higher temperatures.  
As a result, the sieving agent is easily introduced into or expelled from the narrow bore 
separation capillary at a temperature of 19 °C. Prior to the separation, the matrix is 
transformed into a viscous gel in-capillary at a separation temperature of 30 °C.  
While a phospholipid additive has been previously described for the separation of 
DNA fragments below 500 bp (21), we show that the DNA sizing range of the separation 
can be extended by reducing the concentration of wormlike micelles in solution. The size, 
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shape, and stability of the phospholipid structures depend upon the phospholipid 
concentration, the ratio of DMPC and DHPC, and the temperature. The effect of these 
parameters on the size limit of DNA separations was evaluated, and the linear range for 
size separation was extended to 1,500 bp by tuning the concentration of the phospholipid 
nanogel and the ratio of [DMPC]/[DHPC]. This preparation was used to compare the size 
of the DNA fragments to internal standards. The effectiveness of the sieving matrix was 
demonstrated with the analysis of PCR-amplified DNA sequences specific to select 
pathogens. The difference between the true size of a DNA fragment and the size 
calculated from internal standards is less than 2.3% for fragment sizes between 200-500 
bp. For fragments that range from 600-1,500 bp this difference between the true size and 
measured size is less than or equal to 4%. Different properties of the high and low 
concentration phospholipids were exploited by integrating both dynamic sieving matrices 
into a single capillary to create a discontinuous gel in-capillary used to concentrate DNA 
samples through gel stacking.  
 
MATERIALS AND METHODS 
Chemicals and reagents 
The fluorescently labeled DNA ladder (catalog # MM-1000-FAM, 50-1,000 bp) was 
purchased from BioVentures (Murfreesboro, TN). The fluorescent intercalating dye SYBR 
Green 1 nucleic acid gel stain (catalog # S-7567), 1 Kb Plus (catalog # 10787-018, 100-
12,000 bp), and 100 bp (catalog # 15628-019, 100-2,072 bp) DNA ladders were 
purchased from Life Technologies (Grand Island, NY). The methanol was purchased 
through Calbiochem/EMD (Gibbstown, NJ). The DMPC and DHPC phospholipids were 
purchased through Avanti Polar Lipids (Alabaster, AL), and the 3-(N-morpholino)-
propanesulfonic acid (MOPS) was purchased from Alfa Aesar (Ward Hill, MA). Sodium 
hydroxide was obtained from Sigma-Aldrich (St. Louis, MO). All deionized water used 
was obtained from an ELGA PURELAB ultra water filtration system (Lowell, MA). 
 
Preparation of phospholipid mixture 
The phospholipid preparations were made as described previously (26) to obtain molar 
ratios of [DMPC]/[DHPC] = 0.5 and [DMPC]/[DHPC] = 2.5. The phospholipids were stored 
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at -20 °C and thawed before being weighed out.  Once they were weighed, an aqueous 
buffer of 100 mM MOPS (pH 7.0) was added to obtain the appropriate concentration of 
phospholipid per volume of aqueous diluent (% w/v). The solution was then mixed using 
a vortex mixer for several minutes to dissolve the phospholipids. The phospholipid 
medium was then exposed to three rapid freeze thaw cycles using liquid nitrogen followed 
by centrifugation (10,000 rpm at 4 °C) for 10 minutes. The matrix was then portioned into 
working volume aliquots of 200 μL [DMPC]/[DHPC] = 0.5 (5% w/v) and 100 μL 
[DMPC]/[DHPC] = 2.5 (10% w/v). The [DMPC]/[DHPC] = 2.5 lipids were then diluted with 
the same 100 mM MOPS (pH 7.0) buffer to obtain the 7.5, 5.0, and 2.5% phospholipid 
used for electrophoresis. No freeze thaws were done after the dilution from the 10% 
phospholipid. The additional phospholipid matrices with [DMPC]/[DHPC] = 3.0, 4.0, and 
5.0 used in the study were prepared the same manner. The MOPS buffer was also used 
for capillary rinses between runs and served as the solution in the anodic and cathodic 
reservoirs during electrophoresis separations. 
 
PCR amplification 
Primers were based on scl2 genes with the following gene bank accession numbers and 
genome locations; M3: AE014074, location 791329-793050; M12: CP000259, location 
862738-863880; M28: CP000056, location 781169-782437. Forward primers specific for 
each scl2 allele, are as follows: M3-Scl2.3_CLflank_2F,  
5’-AGGCATACAAGATCATGTCCTTGA-3’; M12-Scl2.12_CLfl_1F,  
5’-AAGAGTGGGATATCTTTAGGC-3’; M28-Scl2.28_CLfl_1F,  
5’-CTACAGGAACGAGAACAAGC-3’. A single reverse primer Scl2.3_CLflank_2R,  
5’-TTTGGTGTATGTGCTGCGGT-3’, targeting a conserved 3’ region of scl2 gene was 
paired with each forward primer. Genomic DNA was purified and isolated as described 
previously (27). PCR reactions were carried out with 1.5 units of Taq DNA polymerase 
(Qiagen, Germantown, MD) in a final volume of 50 µL per reaction and DNA template in 
the nanogram range using a C1000 Touch Thermal Cycler (BioRad, Hercules, CA). The 
manufacturer’s PCR buffer was supplemented with 0.2 µM concentration of each primer 
and 0.2 mM deoxynucleotide triphosphates (Bioline, Taunton, MA). Amplification 
conditions consisted of an initial denaturation step at 94 °C for 3 min, followed by 30 
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cycles of 1 min at 94 °C, 1 min at 51 °C, and 1 min 45 s at 72 °C, followed by a final 
extension step at 72 °C for 7 min. The amplicons were analyzed by agarose gel 
electrophoresis and the true size of each scl2-PCR product was determined by Sanger 
DNA sequencing (Eurofins Genomics, Huntsville, AL). The DNA sequences were 
assembled and analyzed with the Lasergene 11 Genomics Suite (DNASTAR, Inc., 
Madison, WI) software, as previously described (28). Isolation of genomic DNA and 
purification from fungal cultures, PCR primers (Eurofins Genomics, Huntsville, AL), 
amplification conditions, and verification of conserved amplicon sizes for acl-based 
detection of Aspergillus species were previously established (29). 
 
Gel extraction of DNA ladder standards 
Fragments from the two unlabeled DNA ladders were separated using a VWR horizontal 
gel box Midi Plus 15x10cm connected to a Hoefer hsi (San Francisco, CA) power supply 
using a 1% agarose (CalbioChem/EMD Chemicals) in 1X TBE buffer (G Biosciences, St. 
Louis, MO) gel. Slab gel electrophoresis was accomplished using an applied voltage of 
110 V for 3 hours, and alternate gel lanes were stained using ethidium bromide (part # 
15585011, Life Technologies) for UV visualization. Extraction and purification of DNA 
bands in unstained lanes was done using the illustraTM GFXTM PCR DNA and Gel Band 
Purification Kit manufactured by GE Healthcare (Buckinghamshire, UK) prior to analysis 
on the P/ACE MDQ Capillary electrophoresis instrument (Beckman Coulter, Fullerton, 
CA). DNA that was isolated and recovered from the agarose gel was then utilized as an 
internal standard to size PCR amplicons. The 600, 1,000, 1,500, and 1,650 bp fragments 
were used as internal standards to size S. pyogenes and B. anthracis amplicons, whereas 
the 150, 450, and 500 bp were used to size Aspergillus spp. amplicons. 
 
Pre-treating the separation capillary 
Separations were performed using fused silica capillary with an outer diameter of 360 µm 
and an inner diameter of 25 µm (Polymicro Technologies, Phoenix, AZ). The separation 
capillary had a total length of 40 cm, and an effective length of 30.2 cm. New capillary 
was conditioned with a 4-step rinse procedure performed at 140 kPa with (1) 1N NaOH 
for 30 min, (2) deionized water for 15 min, (3) methanol for 15 min, (4) deionized water 
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for 15 min. The conditioned capillary was then passivated with a semi-permanent 
phospholipid coating to suppress electroosmotic flow as previously described (30). This 
was accomplished using a 2-step rinse at 140 kPa with (1) 5% phospholipid of 
[DMPC]/[DHPC] = 0.5 containing 1.25 mM Ca2+ for 20 min and (2) a 2 min flush with 100 
mM MOPS buffered to pH 7. This passivation rinse is repeated once (i.e., 4-steps). The 
capillary was then filled with phospholipid nanogel at an ambient temperature of 19 °C. 
Once filled with the phospholipid, the capillary temperature was increased to the desired 
separation temperature. A reverse polarity voltage of 20 kV was applied for 5 min prior to 
the first run of the day. 
 
Capillary electrophoresis sample introduction and separation 
Sample was injected by first introducing a pre-plug of run buffer at 6.9 kPa for 7 sec, then 
applying a reverse polarity electrokinetic injection of DNA for the specified time, and finally 
by inserting a post-plug of run buffer at 3.4 kPa for 5 sec. The purpose of these pre- and 
post-plugs was to facilitate stacking and improve the theoretical plate count (31). 
Separations were performed at 4 kV under reverse polarity conditions. Between each 
separation the capillary was flushed at 140 kPa for 3 min with 5% [DMPC]/[DHPC] = 0.5, 
2 min MOPS (pH 7), and 3 min with the phospholipid preparation used to separate DNA. 
 
Fluorescence detection and analysis of DNA 
The Beckman Coulter P/ACE MDQ was equipped with a laser induced fluorescence 
detection module and an air cooled argon ion laser (λex=488 nm and λem=520 nm). The 
optimization of concentration and composition of phospholipid nanogel was accomplished 
using a fluorescein end-labeled DNA ladder. The intercalating dye SYBR Green 1 was 
utilized for separations of PCR amplicons. SYBR dye was diluted to a concentration of 20 
μM SYBR in phospholipid preparations of [DMPC]/[DHPC] = 2.5 at a concentration equal 
to that used for the separation. The concentration of the plug was calculated based on a 
literature estimate of 20 mM stock concentration from the manufacturer (32). Unless 
otherwise stated, a 7 second 34.5 kPa plug of phospholipid modified with dye was pushed 
toward the detection window in the separation capillary prior to sample injection. Under 
an applied field, the positively-charged dye and negatively-charged DNA migrated toward 
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each other and the two bound effectively upon contact as the Kd is 3.1 nM (33). Any 
variation in the ratio of dye and DNA in a separation will change the migration time of the 
DNA. Reproducible run times are achieved by utilizing a dye concentration compatible 
with the detector output, in this case an output of approximately 1-5 relative fluorescent 
units was achievable with a plug of 20 μM SYBR Green 1. As summarized in Table S-1, 
the reproducibility in migration time is less than or equal to 5% for separations with a 7 
second dye plug. The use of internal size standards in each separation further mitigates 
any bias in migration time due to variation in the ratio of dye to DNA. 
The size of the PCR amplicons was calculated using internal standards purified 
from the DNA ladders listed in the materials section. Sizing of fragments was 
accomplished using two DNA standards that bracketed the size of the PCR amplicon. All 
DNA fragments were co-injected and a linear fit was used to relate the migration time to 
the known size in bp of the DNA standards. Using this fit, the size of each PCR amplicon 
was calculated based on the migration time. Resolution between fragments was 
calculated using the expression Rs = 0.589*(Δt/w1/2av), where Δt is the difference in 
migration time between the two peaks of interest, and w1/2av is the average width at half 
height for the same two peaks. Resolution in base pairs was calculated by dividing the 
difference in the number of base pairs for the two fragments (Δbp) by the calculated 
resolution. Therefore, base pair resolution can be expressed as 
Rsbp=(Δbp)/(0.589*(Δt/w1/2av)). Data collection and analysis were performed using 32 
Karat Software version 7.0 (Beckman Coulter), and peak width at 50% height as well as 
theoretical plate count were calculated using the “USP” criterion. 
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RESULTS AND DISCUSSION 
Effect of gel concentration on the separation 
The total lipid concentration (% w/v) determined the number of ‘ribbons’ or ‘disks’ in 
solution and the degree of long-range interaction, including the extent of lipid 
entanglement of the nanogel.  Using a fluorescently-labeled DNA ladder, the separations 
were examined in the 500-1,000 bp range to quantify the effect of phospholipid 
concentration on separation performance. Our previous literature reported the effect of 
concentrations of phospholipid ranging from 5-15% for separations based on subtle 
difference in hydrodynamic volume (26) and from 6-12% for separations based on sieving 
(21). For both studies (21,26) a 10% phospholipid concentration generated the most 
effective separation efficiency and peak resolution. In the current study concentrations of 
2.5, 5.0, 7.5, and 10% were used to evaluate the effect of phospholipid concentration on 
the useful upper size limit for DNA separations. Preparations below 2.5% phospholipid 
did not generate reproducible DNA separations, presumably because wormlike micelles 
are not stable under these conditions, and consequently, these were not assessed. The 
peak resolution summarized in Table 1 was measured for a set of DNA fragments at 450 
and 475 bp as well as a set at 900 and 950 bp. There was no significant improvement in 
resolution of DNA fragments with a length of 450 and 475 bp for separations 
accomplished at 23 °C. When the separation was performed at the optimum temperature 
for each lipid preparation, which was 25 °C for 5% nanogel, and 30 °C for both 7.5% and 
10% nanogel, the resolution of DNA fragments smaller than 500 bp was similar when 
comparing a 2.5% to a 10% phospholipid nanogel (see Table S-2 in the supporting 
information). The resolution between the DNA fragments with a length of 900 and 950 bp 
improved substantially (2.3-fold) when comparing a nanogel of 2.5% phospholipid to one 
of 10% phospholipid. When the separation was performed at the optimum temperature 
for each lipid preparation (i.e., 25 °C for 5% nanogel, and 30 °C for both 7.5% and 10% 
nanogel), the resolution between fragments of 900 and 950 bp improved 1.8-fold (see 
Table S-2 in the supporting information). These results indicated that the lipid 
preparations should be maintained at a concentration of 2.5% lipid. 
 
 170 
The effect of temperature and composition, factors that impact nanogel 
morphology, on separation 
The ratio of long-to-short-chain lipid determines the shape of the self-assembled 
aggregate formed in solution. When the relative amount of long chain lipid increases, the 
aggregates are transformed from a bilayer disk conformation with a small diameter, to 
disks with larger diameters and ‘ribbons’ (19,20). The temperature also impacts the 
transformation from nanodisks to nanoribbons and a substantial change in apparent 
viscosity is observed over a temperature range specific to the preparation (34-36). The 
morphologies adopted by the matrix were dependent on the ratio of long-to-short chain 
lipid as well as the temperature of the preparation. At a total lipid concentration of 2.5%, 
preparations were examined with a ratio of long-to-short chain lipid of 2.5, 3.0, and 4.0. 
The results, summarized in Table 2, revealed that the lipid composition had no significant 
effect on the resolution of DNA fragments under these conditions. When the ratio of long-
to-short chain lipid was 5.0, the separation performance decreased. The resolution 
improved marginally for nanogels with different lipid composition when the optimum 
performance was observed at a temperature different from 23 °C (see Table S-3 in the 
supporting information). Although, the performance of the separation matrix was tolerant 
of changes in lipid composition, the preparation made with a 2.5 ratio of long-to-short 
chain lipid was used for analytical separations and the effect of temperature on separation 
performance was tested. The results for a 2.5% w/v preparation composed of 
[DMPC]/[DHPC] equal to 2.5 are summarized in Table S-4 in the supporting information. 
The best resolution for both the 450 and 475 bp DNA and the 900 and 950 bp DNA was 
obtained at 23 °C. At this temperature 450 and 475 bp DNA fragments were separated 
with 5 bp resolution, and 900 and 950 bp DNA fragments were separated with 8 bp 
resolution. For both size domains the resolution obtained using a 2.5% nanogel is 1% 
when normalized by dividing the resolution (in bp) by the size of the separated DNA 
fragments. This is a substantial increase over the 10% resolution obtained with a 
commercial system that utilizes a hydroxypropylmethylcellulose matrix for DNA shorter 
than 1,000 bp (15). This improved sizing obtained with the phospholipid nanogel is an 
extraordinary advantage for DNA analyses with sieving that require accurate size 
determinations. 
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Expanded size range of sieving using a wormlike nanogel 
These optimization studies confirmed that decreasing the concentration of the lipid 
preparation separated a wider range of DNA fragments than previously reported. This is 
demonstrated in Figure 1, which depicts the separation of the 1kilobase DNA ladder. The 
separation performance obtained with the DNA size ladder improves by successively 
decreasing the viscosity of the nanogel used for sieving DNA. Figure 1 trace A is of 10% 
lipid with [DMPC]/[DHPC] equal to 2.5 at 30 °C, which is the higher viscosity formulation 
and provides accurate sizing for DNA fragments smaller than 500 bp in length. When the 
temperature of the 10% nanogel matrix is decreased the viscosity is decreased as well. 
The trace in Figure 1 B obtained using a 10% nanogel matrix at a separation temperature 
of 23°C demonstrates some improvement in the resolution of larger fragments ranging 
from 1,000 to 12,000 bp in length. The trace in Figure 1C is obtained using a 2.5% 
nanogel matrix at a separation temperature of 30°C. This material has a lower viscosity 
than the 10% nanogel matrix and relative to the 10% nanogel the resolution is improved 
for the fragments ranging from 1,000 to 12,000 base pairs. Figure 1 trace D is of the 
optimized preparation of 2.5% lipid with [DMPC]/[DHPC] equal to 2.5 at 23 °C. This 
nanogel has the lowest viscosity and generates the best resolution for DNA fragments 
larger than 500 bp. For DNA fragments shorter than 500 bp, the performance of the 
optimized preparation was similar. The resolution of 450 and 475 bp fragments decreased 
from 6.2, using the 10% phospholipid preparation with [DMPC]/[DHPC] = 2.5 at 30 °C 
(see Table S-2), to 5.0, using the optimized preparation of 2.5% phospholipid with 
[DMPC]/[DHPC] = 2.5 at 23 °C. This slight decrease in resolution performance to 78% of 
the previously reported value of 6.2, did not limit the application of the material to analyze 
and accurately calculate the size of these PCR amplicons. 
 
Application to assess length polymorphism of PCR amplicons derived from 
pathogenic bacteria 
PCR amplicons were identified using bioinformatics to predict unique DNA biomarkers of 
different strains of Streptococcus pyogenes ranging from 634 to 1,332 bp in length. Over 
700 million infections annually are attributed to this pathogenic bacterium associated with 
common throat and skin diseases with more than 0.5 million deaths resulting from 
 172 
invasive and autoimmune complications (37). Strains are typically characterized 
epidemiologically by serological typing of the M protein or, more recently, by sequencing 
of the emm gene (38-40). However, epidemiological surveillance during outbreaks of 
infection requires additional tools to distinguish between strains of the same M-type. The 
scl2 gene, encoding a common S. pyogenes surface protein, exhibits significant length 
polymorphism between strains of the same M-type, due to the presence of repetitive Gly-
X-Y motifs in the collagenous domain (28,41). Strain typing by length variation in collagen-
like genes has been successfully demonstrated for the bcl genes of Bacillus anthracis 
(42) and is a viable strategy for typing S. pyogenes. The scl2 alleles from strains of M-
types 3, 12, and 28 were selected here as epidemiological markers since these are 
among the most prevalent M-types causing infection in the United States and globally 
(43,44). Importantly, M3-type strains are associated with invasive diseases like 
necrotizing fasciitis and streptococcal toxic shock syndrome (43,45-47). 
Primers were designed to generate PCR amplicons of scl2 alleles associated with 
each M-type. The 2.5% phospholipid preparation was utilized to evaluate the applicability 
of the method for the analysis of PCR amplicons. Three amplicons were separated, as 
shown in Figure 2a, and sized with internal standards of 600 and 1,000 bp. The 634 bp 
and 715 bp amplicons, which were sequenced in the genome of three different M12-type 
strains, and the 842 bp amplicon, which was sequenced in the M28-type strain, were 
detected and sized using the phospholipid nanogel. The remaining amplicons (1,071, 
1,152, and 1,332 bp) sequenced in the M3-type strains were detected and sized (see Fig. 
2b) using internal standards of 1,000 and 1,500 bp. The extended sizing range of the 
phospholipid nanogel enabled detection of larger scl2-derived amplicons to generate 
unique DNA markers that distinguish strains of S. pyogenes. To further demonstrate the 
effectiveness of the phospholipid nanogel for size determination, a previously reported 
amplicon of bcl gene that is 1,446 bp in length (42) was analyzed using internal standards 
of 1,000 and 1,650 bp as shown in Figure 2c. 
 
Characterization of the difference between true and measured size (bias) 
To demonstrate that the phospholipid preparation optimized for the separation of large 
DNA fragments remained effective for the analysis of DNA fragments below 500 bp in 
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size, unique biomarkers of several Aspergillus species were analyzed (see Figure S-1 in 
the supporting information). This fungus leads to increased mortality among 
immunocompromised patients suffering from invasive aspergillosis (48-51) and is also 
associated with crop contamination (52). Detection of Aspergillus through unique DNA 
sequences is significant because PCR methods are faster and more conclusive than the 
traditional means of identifying Aspergillus species based on morphology observed in 
microbiology laboratory cell cultures. Unique sequences in Aspergillus collagen-like 
genes (acl) found in five pathogenic species were targeted by PCR resulting in amplicons 
of distinct lengths: A. nidulans 227 bp; A. terreus 262 bp; A. niger 297 bp; A. flavus 402 
bp; and A. fumigatus 338 and 489 bp. Using internal standards of 150 and 450 bp to 
calculate the size, these six biomarkers were resolved in a capillary with 30.2 cm effective 
length and a separation additive containing 2.5% phospholipid preparation of 
[DMPC]/[DHPC] equal to 2.5 at 23 °C. This separation additive optimized for larger DNA 
fragments estimated the size with a bias ranging from 0-6 bp (see Table 3), which 
represented a size accuracy within 2.5% of the true fragment size. Previously, these 
biomarkers were separated using a 40 cm effective length and a 10% phospholipid 
preparation of [DMPC]/[DHPC] equal to 2.5 at 30 °C (29). In that study, the amplicon size 
was estimated using three size standards of 150, 250, and 350 bp with a bias ranging 
from 1-7 bp, which represented a size accuracy within 2% of the true fragment size. 
The analysis of DNA biomarkers for strains of S. pyogenes revealed that the 
phospholipid nanogel generated a relative bias in size accuracy less than 1% (2-4 bp 
bias) of the total fragment size for 634, 715 and 842 bp, and increased to 2%, 3%, and 
4% (19-48 bp bias) of the total fragment size for 1,071, 1,152, and 1,332 bp, respectively 
(Table 4). The analysis of the 1,446 bp PCR amplicon for the bcl C gene of Bacillus 
anthracis shown in Figure 2c had an estimated size of 1,449 ± 8 bp (n = 5), generating a 
size bias of less than 1%. Each single Gly-X-Y repeating unit in scl2 or bcl is encoded by 
9 bp. Thus, the phospholipid nanogel will separate two distinct scl2 or bcl alleles differing 
only by one Gly-X-Y repeat at the ~500-850-bp range and by 1-5 Gly-X-Y repeats at the 
~1,000-1,400-bp range. The phospholipid nanogel performance is similar to the values 
reported for a commercial system that utilizes hydroxyethyl cellulose, which generated a 
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size bias ranging from 0-7% for 119 to 1270 bp DNA fragments (15). Clearly, the material 
can be used for DNA fragments approaching 1,500 bp. 
This is a valuable assay to be used alone or in combination with other 
epidemiological markers to trace the emergence of new strains with a higher 
discriminatory power. Accurate size evaluation for any extended repeating sequence will 
also be an important tool assisting in long-range genomic assemblies produced from short 
(50-150 bp) DNA sequences obtained using next generation sequencers (53). 
 
Advanced material properties enable in-capillary sample stacking 
Continuous nanogels were used to generate the data in Figures 1 and 2 as well as Tables 
1-4; however, the separations in Figure 1 confirmed that DNA had a faster mobility in the 
2.5% phospholipid preparation than in the 10% preparation, which also has a substantially 
higher apparent viscosity. The different viscosity of the 10% vs the 2.5% phospholipid 
nanogels was integrated to create a discontinuous nanogel to stack DNA within a small 
plug of the highly viscous 10% phospholipid nanogel and then separate the DNA in the 
low viscosity 2.5% nanogel that yielded higher separation performance. These two 
nanogel preparations were introduced serially into the separation capillary. DNA was 
stacked using a 10 kV, 30 second injection in the discontinuous nanogel as shown in 
Figure 3A. At a temperature of 19 °C, the capillary was first filled with the 2.5% nanogel 
for 3 minutes at 140 kPa (20 psi). This was followed by a small plug of 10% nanogel 
introduced for 10 seconds at 69 kPa (10 psi), and finally a pre-plug of aqueous buffer was 
introduced for 15 seconds at 34 kPa (5 psi). The temperature was raised to 30 °C to 
increase the viscosity, which caused the 10% phospholipid to form a highly viscous 
nanogel. The DNA was electrokinetically-injected at 30 °C and stacked. The temperature 
was then dropped to 23 °C and the separation proceeded. The enhancement in peak 
area achieved with stacking is apparent by comparing the electropherograms shown in 
Figure 3A with 3B and 3C. The DNA in the electropherogram in Figure 3B, obtained with 
a 10 kV, 2 second injection in a discontinuous nanogel, was difficult to detect. The peaks 
were broad when the large 10 kV, 30 second injection was performed in the absence of 
the stacking gel as shown in Figure 3C. The plate count of the 600 bp peak in Figure 3C 
(40,000 theoretical plates) was 12-fold lower than that obtained with stacking in Figure 
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3A (500,000 theoretical plates). Integrating both materials offered a means to harness 
advantages of each medium for unique processes of injection and separation of large 
DNA fragments. 
 
CONCLUSIONS 
A practical alternative to slab gels was developed to separate and size DNA fragments 
as large as 1,500 bp, with a size accuracy ranging from 1-4%. The material was 
compatible with the higher concentration medium reported previously (21) and was 
suitable for thermally controlled gel-stacking and separations. By decreasing the 
concentration of the phospholipid preparation from 10% to 2.5%, the net cost of the 
dynamic sieving gel was reduced. The ease with which the dynamic sieving nanogel was 
introduced into capillary channels was ideal for microscale separations because the low 
flow resistance required only nominal pressures for loading. This holds potential to benefit 
microfluidic separations as well because when the separation device can be used 
repeatedly, the lifetime of the device is increased, which in turn decreases the overall cost 
of the analytical measurement. 
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Figure 1 
Separations obtained at different phospholipid concentration and run temperature. 
Electropherograms of a 1 kilobase DNA ladder are detected using SYBR Green 1 
fluorescent dye using a phospholipid nanogel with [DMPC]/[DHPC] = 2.5: (A) at a 
concentration of 10% and temperature of 30 °C, (B) at a concentration of 10% and 
temperature of 23 °C, (C) at a concentration of 2.5% and temperature of 30 °C, and (d) 
at a concentration of 2.5% and temperature of 23 °C. The DNA fragments in the ladder 
(Life Technologies, #10787-018) range from 100-12,000 bp and the size in bp specified 
by the manufacturer is indicated above each corresponding peak. 
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Figure 2 
Separation of PCR amplicon obtained with the phospholipid nanogel optimized for 
DNA up to 1,500 bp in length. Electropherograms detected using SYBR Green 1 
fluorescent dye and a phospholipid nanogel with [DMPC]/[DHPC] = 2.5 at a concentration 
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of 2.5% and temperature of 23 °C. The true sizes are specified above each peak while 
the measured sizes are denoted in the brackets.  The peaks for each marker are labeled 
to indicate: (A) the three scl2 strains designated 6166, 6140, 6180 (B) the three scl2 
strains designated 9716, 10118, 9842, and (C) bcl C. The separation is accomplished 
using a capillary that is 40 cm long, 25 m id, with an effective length of 30.2 cm and Eapp 
= 100 V/cm. 
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Figure 3 
DNA stacking with phospholipid additives. Depicts the process of (A) discontinuous 
phospholipid nanogels in which the DNA is stacked in the 10% phospholipid and 
separated in the 2.5% phospholipid, (B) discontinuous phospholipid nanogels in which 
the 10 kV 2 sec injection is too short to stack DNA, and (C) a continuous nanogel using 
a 10 kV 30 sec injection without a stacking plug. The separation is accomplished using a 
capillary that is 40 cm long, 25 m id, with an effective length of 30.2 cm and Eapp = 100 
V/cm. 
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Table 1. Effect of concentration on resolutiona 
aSeparations (n = 5) of DNA base ladder MM-1000-FAM are achieved at 23 °C with 
[DMPC]/[DHPC] = 2.5 in a 40 cm long, 25 m id capillary. The effective length is 30.2 cm 
and Eapp = 100 V/cm. 
bResolution is calculated as 0.589(Δt/w1/2av), where Δt is the difference in peak migration 
times and w1/2av is the average peak width at half height 
cResolution in base pairs is calculated as the difference in base pairs/resolution. 
Phospholipid 
(%) 
 Resolution 450/475 bp DNA  Resolution 900/950 bp DNA 
  Resolution (CV)b  in bpc  Resolution (CV)b  in bpc 
2.5  5.0 (6)  5  6.4 (7)  8 
 
5.0  4.6 (10)  5  4.3 (10)  12 
 
7.5  4.5 (9)  6  3.4 (10)  15 
 
10.0  4.4 (10)  6  2.8 (9)  18 
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Table 2. Effect of [DMPC]/[DHPC] ratio on resolution at 23°Ca 
 aSeparation conditions, calculation of resolution, and calculation of resolution in bp are 
identical to that reported in Table 1. 
[DMPC] 
[DHPC] 
 Resolution 450/475 bp DNA  Resolution 900/950 bp DNA 
  Resolution (CV)  In bp  Resolution (CV)  In bp 
2.5  5.0 (6)  5  6.4 (7)  8 
 
3.0  4.4 (10)  6  5.2 (10)  10 
 
4.0  4.8 (10)  5  5.5 (10)  9 
 
5.0  1.1 (20)  23  1.2 (20)  42 
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Table 3. Performance of 2.5% phospholipid for Aspergillus biomarkers 
Species  True size in bpa  Measured size in bpb (CV) Bias in bpc 
A. nidulans  227  227 (0.3) 0 
  
A. terreus  262  256 (0.4) 6 
  
A. niger  297  301 (0.3) 4 
  
A. fumigatus  338  333 (0.5) 5 
  
A. flavus  402  402 (0.1) 0 
  
A. fumigatus  489  495 (0.4) 6 
 aTrue size established as described in [26]. A. fumigatus derived amplicons of gene 
aclF1-5' and -3' were sequenced and represent true sizes of 338, 489 bp. Amplicons 
derived from A. terreus (gene aclT2-5'), A. nidulans (gene aclNl-3'), and A. niger (gene 
aclNi-5') were based on bioinformatics and were also partially sequenced with forward, 
but not with reverse, primers that were used to generate these amplicons. The amplicon 
from A. flavus (gene aclFL-3') was sequenced in full and the size of this amplicon is 402 
bp. 
bSeparation conditions are identical to those reported in Table 1. Size standards of 150 
and 450 bp are used. 
cBias is calculated as the difference between the true fragment size and the measured 
size. 
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Table 4. Performance of 2.5% phospholipid for Streptococcus biomarkers 
Strain, type True size in bpa Measured size in bpb (CV) Bias in bpc 
6166, M12 634 630 (0.2) 4 
6144, M12 715 717 (0.4) 2 
6180, M28 842 844 (0.5) 2 
9716, M3 1071 1090 (0.4) 19 
10118, M3 1152 1185 (0.3) 33 
9842, M3 1332 1380 (0.2) 48 
aTrue size established using DNA sequencing as reported in reference [27]. 
bSeparations conditions are identical to those reported in Table 1. For strains 6166, 6144, 
and 6180 the size is determined using 600 and 1,000 bp standards. For strains 9716, 
10118, and 9842, the size is determined using 1,000 and 1,500 bp standards 
cBias is calculated as the difference between the true fragment size and the measured 
size.
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CHAPTER 7 
A UNIQUE SET OF THE BURKHOLDERIA COLLAGEN-LIKE PROTEINS PROVIDES 
INSIGHT INTO PATHOGENESIS, GENOME EVOLUTION AND NICHE 
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ABSTRACT 
Burkholderia pseudomallei and Burkholderia mallei, classified as category B priority 
pathogens, are significant human and animal pathogens that are highly infectious and 
broad-spectrum antibiotic resistant. Currently, the pathogenicity mechanisms utilized by 
Burkholderia are not fully understood, and correct diagnosis of B. pseudomallei and B. 
mallei infection remains a challenge due to limited detection methods. Here, we provide 
a comprehensive analysis of a set of 13 novel Burkholderia collagen-like proteins (Bucl) 
that were identified among B. pseudomallei and B. mallei select agents. We infer that 
several Bucl proteins participate in pathogenesis based on their noncollagenous domains 
that are associated with the components of a type III secretion apparatus and membrane 
transport systems. Homology modeling of the outer membrane efflux domain of Bucl8 
points to a role in multi-drug resistance. We determined that bucl genes are widespread 
in B. pseudomallei and B. mallei; Fischer’s exact test and Cramer’s V2 values indicate 
that the majority of bucl genes are highly associated with these pathogenic species versus 
nonpathogenic B. thailandensis. We designed a bucl-based quantitative PCR assay 
which was able to detect B. pseudomallei infection in a mouse with a detection limit of 50 
CFU. Finally, chromosomal mapping and phylogenetic analysis of bucl loci revealed 
considerable genomic plasticity and adaptation of Burkholderia spp. to host and 
environmental niches. In this study, we identified a large set of phylogenetically unrelated 
bucl genes commonly found in Burkholderia select agents, encoding predicted 
pathogenicity factors, detection targets, and vaccine candidates. 
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INTRODUCTION 
Collagen structure is formed by three polypeptide chains of continuous repetitive Gly-
Xaa-Yaa (GXY) sequence, each adopting left handed polyproline II type helices that 
combined form a right-handed superhelix (1). It is a universal structure that is broadly 
found among members of all three domains of life. It is the most abundant protein in 
mammals where it harbors important structural functions in the extracellular matrix and in 
support of cell adhesion, differentiation and growth (2,3). The prokaryotic collagen was 
identified and studied more recently, and has similar GXY sequence and triple helical 
structure (4-8). In mammalian collagens, proline (Pro) in the Y position is hydroxylated 
post-translationally and resulting Hyp (hydroxyproline) residues confer the maximum 
stability to the triple helix. As bacteria lack the prolyl hydroxylase required for these 
residues, bacterial collagens must be stabilized by other mechanisms, including 
increased proline content and electrostatic interactions between amino acid side chains 
(9-12). Several bacterial collagen-like proteins have been shown to form stable triple 
helices, including streptococcal collagen-like proteins 1 and 2 of Streptococcus pyogenes 
(4,13), rCLCp from Clostridium perfringens (14), and BclA of Bacillus anthracis (15,16). 
Bacterial collagen-like proteins are found in species that are pathogenic to humans and 
animals (5-8,16-22). They are often surface-exposed and participate in important 
pathogenesis processes, including adherence and biofilm formation, host colonization 
and immune evasion (6,7,18,19,23-30). Several collagen-like genes have been evaluated 
as biomarkers for pathogen detection by targeting their conserved non-collagenous 
regions (31,32) and for strain fingerprinting by targeting highly polymorphic repetitive 
collagen-like sequences (32-35). 
The Burkholderia species are ubiquitous in the environment but also include 
animal and plant pathogens. A group of 17 closely related species, designated B. cepacia 
complex organisms, cause pulmonary infections primarily in patients with cystic fibrosis 
(36). Two other species, Burkholderia pseudomallei and Burkholderia mallei, are 
significant human and animal pathogens in endemic regions and also represent 
biowarfare threats. These bacteria have been classified as category B priority pathogens, 
in part due to their high infectivity, an intrinsic broad-spectrum antibiotic resistance, and 
previous use as biological weapons during wartime (37). B. pseudomallei is a soil 
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saprophyte endemic to southeastern Asia and northern Australia, which causes 
melioidosis in humans. Melioidosis has a variety of clinical outcomes, from localized skin 
infection to pneumonia and acute septicemia, as well as chronic illness with abscess 
formation in major organs (38). As 50% of patients with septicemic melioidosis die within 
48 hours, rapid diagnosis is crucial to patient survival (39). B. pseudomallei has a large 
genome of about 7.2 Mb, which undergoes frequent horizontal gene transfer as 
evidenced by multiple genomic islands that differ between strains (40). B. mallei is a 
closely related bacterium with a smaller genome, ~5.8 Mb (41). It is the causative agent 
of glanders in horses and other animals that can be transmitted to humans. It has been 
demonstrated by multi-locus sequence typing analysis that B. mallei is a clonal derivative 
of B. pseudomallei (42), which has undergone significant genomic reduction and 
rearrangement during host-adaptation (41). Consequently, B. mallei is unable to survive 
outside the host. B. mallei was one of the first microbes to be weaponized during World 
War I to infect livestock and humans (37). A third closely related organism, B. 
thailandensis, is considered non-pathogenic for humans (43). B. thailandensis is also a 
soil saprophyte with a large genome of ~6.7 Mb, which is endemic to geographical regions 
coinciding with B. pseudomallei (43,44); therefore, it is necessary to differentiate between 
the two species. 
In this study, we identified and characterized an unexpectedly large set of 13 
distinct Burkholderia collagen-like (bucl/Bucl) genes and proteins that are conserved in 
pathogenic B. pseudomallei and B. mallei species. We report the widespread presence 
of bucl genes in B. pseudomallei and B. mallei assessed by bioinformatics and analytical 
PCR, explore their phylogenetic relationships, infer important pathogenicity traits and 
antibiotic resistance mechanisms associated with Bucl proteins, and demonstrate the use 
of bucl genes as detection markers for these select agents in an animal model of infection. 
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RESULTS 
Identification of Burkholderia collagen-like (bucl) genes  
An increasing number of collagen-like proteins have recently been identified and studied 
in a variety of bacterial species, including Gram-positive pathogenic group A (5-8,17), B 
(SL, unpublished data), C (20,45) streptococci and pneumococci (18), bacilli and 
clostridia (16,21,32), as well as Gram-negative respiratory pathogen Legionella 
pneumophila ((19); SL, unpublished data). Here, we assessed the presence and 
distribution of the collagen-like proteins among Burkholderia species in the Pfam collagen 
family database (PF01391). We identified a total of 85 sequences among the members 
of the Burkholderiaceae family, with 77 of these sequences designated Burkholderia 
collagen-like (Bucl) proteins, among various species of the Burkholderia genus. We next 
focused on 59 protein sequences found in three closely related species of Burkholderia, 
B. pseudomallei (Bp), B. mallei (Bm), and B. thailandensis (Bt) that we initially categorized 
into 16 (Bucl1-16) protein types, based on domain organization and GXY-repeat types in 
their collagen-like (CL) regions; subsequent refinement eliminated three Bucl types, 
resulting in 13 Bucl proteins 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, and 16. To assess their 
distribution, nucleotide sequences of these 13 bucl genes were used as independent 
queries to BLASTn-search the NCBI nonredundant database. Though we observed 
collagen-like sequences in other Burkholderia species, this set of 13 bucl genes and 
proteins were unique to Bp, Bm, and Bt species.  
 
Identification of bucl genes in Bp K96243, proof of principle  
A BLAST search of bucl alleles from various strains against the genome sequence of the 
reference strain Bp K96243 revealed that all 13 bucl genes were present and were 
distributed around both chromosomes (Fig. 1A). Six bucl genes were localized on 
chromosome one and seven bucl genes on chromosome two, and were found on both 
plus and minus strands (Fig. 1A, B). The presence of each bucl gene in Bp K96243 
genome was confirmed by PCR with primers targeting the noncollagenous regions (Fig. 
1C). Mapping of bucl genes in additional seven Bp and four Bm fully sequenced genomes 
revealed significant intra- and inter-species genomic rearrangements involving bucl loci 
(Fig. 2). For example, the region encoding bucl genes 6, 8, and 10 in Bp 668 was inverted 
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compared to Bp K96243 genome (Fig. 2A). Additionally, we observed both 
rearrangements (Fig. 2B, C) and deletions of bucl loci (Fig. 2C) in Bm genomes, 
compared to Bp, which is consistent with Bm-genomic plasticity as well as the evolution 
of Bm from Bp through genome reduction (41,46). To further characterize the genomic 
organization of these strains, organizational patterns (OP) of bucl biomarkers were 
assigned according to their position and orientation on each chromosome (Table 1). In 
aggregate, chromosomal rearrangements occur more frequently on chromosome one (six 
distinct organizational patterns were observed for both Bp and Bm strains analyzed) 
compared to chromosome two (three organizational patterns observed). While only one 
major organizational pattern on chromosome 1, Ch1 OPII, was found exclusively among 
Bp strains, major organizational pattern on chromosome 2, Ch2 OPI, was found in both 
Bp and Bm genomes. All observed rearrangements were intrachromosomal in both 
species, indicating no exchange of genetic material involving bucl markers occurred 
between the chromosomes. In summary, consistent with bioinformatic data, we here 
confirmed by PCR the presence of all 13 bucl genes in Bp K96243. We also captured 
significant genomic plasticity of the Bp and Bm species by employing bucl markers. 
 
Characterization of Bucl proteins 
Overall characteristics of Bucl proteins were examined in a set of geographically diverse 
Burkholderia strains sequenced, including 13 Bp, 11 Bm, and 9 Bt strains (Table 2, Table 
3). All 13 Bucl proteins identified contained a collagen-like region (CL) flanked by 
noncollagenous N- and C-terminal regions. The noncollagenous regions were conserved 
among all three species within each Bucl with sporadic length variations observed (Table 
2). As expected, the CL regions of the same Bucl varied significantly in length between 
strains due to differing numbers of GXY repeats. For example, Bucl3 varied from 38 
repeats to 63 repeats in different strains of Bp, Bm, and Bt (Table 2). The triplet usage 
was unique to each Bucl across species and usually one or two GXY-repeat types 
dominated each CL region. For example, Bucl1 and Bucl8 contained exclusively GAN 
and GAS repeats, respectively, while Bucl3 contained predominantly GTS repeats and 
Bucl10 had predominantly GIH triplets.  
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In order to assess whether the Bucl proteins will form collagen-like triple helices, 
stability predictions were performed on representative Bucl-CL amino acid sequences. 
GXY repeat number in Bucl proteins varies from 2 in Bucl14 to 63 in Bucl3 (Table 2). 
Stability of the predicted collagenous regions of each Bucl was computed using an 
approach derived from host-guest peptide studies (47). Examination of the stability 
profiles shows highest stabilities for Bucl2, Bucl5, Bucl13, and Bucl15, with predicted 
melting temperatures ranging between 35-38°C, while all other Bucl proteins had melting 
temperatures between 20-35°C (Fig. 3). Transmembrane regions were predicted in CL 
domains of Bucl proteins 4, 6, 7, 8, 14, 15, and 16, whose stability ranks low (Fig. 3). 
Hydrophobic interactions occurring in a membrane environment likely stabilize these triple 
helices.   
 
Structural Predictions  
In addition to the CL region, four Bucl proteins were predicted to contain putative domains 
proven to participate in pathogenesis in other bacterial species (Table 2, Fig. 4A). Bucl3 
contains a putative Talin-1 domain; Talin-1 is a cytoskeletal protein that binds and 
activates integrins in mammals and talin-1-integrin interaction links the cytoskeleton with 
the extracellular matrix, allowing cell adhesion and migration (48-50). Bucl4 contained a 
Bac_export_1 domain (Bacterial export proteins, family 1; PF01311) found in members 
of type III secretion protein family, including the SpaR of Shigella and Salmonella, and 
the YscT of Yersinia. These proteins form the inner-membrane part of the needle 
complex, which transports bacterial effector proteins to afflict host cells. Bucl8 contained 
the OEP domain; the members of outer membrane efflux protein family (PF02321) form 
channels that allow export of various compounds, including anti-microbial agents, in 
Gram-negative bacteria across the outer membrane (51). Bucl13 contained a SBP_bac_3 
domain (Bacterial extracellular solute-binding proteins, family 3; PF00497), which is found 
in periplasmic proteins that bind specific solutes within the periplasmic space and are 
often associated with ABC-type transporters (52). 
Signal sequences were predicted in Bucl proteins 3, 4, 8, and 15, additionally 
supporting extracellular location for Bucl4 and Bucl8 (Table 2). Most Bucl proteins had 
transmembrane regions, interestingly, often associated with the CL regions (Table 2). 
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Modeling of the OEP domains in Bucl8 
The OEP domains found in Bucl8 are inferred in the formation of an efflux pump, thus, 
contributing to multi-drug resistance of Bp and Bm species (53). Two tandem OEP 
domains were predicted with high confidence (E-values 7x10-22 and 4.5x10-18). The Bucl8 
is also predicted to be a lipoprotein with an amino-terminal lipid-binding cysteine residue 
and a transmembrane region predicted with TMpred (54).  
HMM search in the PDB database using Bucl8-OEP region as a query identified 
closest similarity (E-value=6.6x10-53) to the drug discharge outer-membrane lipoprotein 
OprM of P. aeruginosa (55,56). Using OprM structure as a template (pdb code 3d5k, 
sequence identity 27%), the model of Bucl8 was generated with MODELLER 9 v.9 (57).  
The OEP domains of Bucl8 form a trimeric structure containing the characteristic 
α-barrel, which spans the periplasmic space, and the β-barrel, which spans the outer 
membrane (Fig. 4B). In OprM, the β-barrel is known to anchor the protein to the outer 
membrane, and also contains a series of surface exposed loops that are involved in 
constriction of the β-barrel pore, thereby preventing influx of xenobiotics at the resting 
state (56,58). The α-barrel contains an arrangement of twelve short helices and six long 
helices that form a bundle which is constricted at both ends but contains a bulge in the 
middle that can accommodate antibiotics. Twisting of the helices to loosen the pores 
forms a funnel-channel structure allowing for the active transport of antibiotics across the 
outer membrane outside of the bacterial cell (56).  
The bucl8 gene was found in all Bp and Bm strains tested by PCR and 
bioinformatics (Table 4), signifying the potential importance of Bucl8-efflux pump in the 
survival and pathogenesis of these species. Interestingly, all Bt strains analyzed 
contained DNA sequence homologous to the OEP-domain of Bucl8 in Bp and Bm but 
lacked the sequence corresponding to the Bucl8-collagenous domain; thus, it could not 
be recognized as a true Bucl. Additionally, a single nucleotide insertion at position 52, 
directly preceding the OEP-encoding region, was found, causing a frameshift mutation, 
which resulted in an altered amino acid downstream sequence.  
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Phylogenetic analyses of bucl genes 
To better understand the relationship of bucl genes among Burkholderia spp., parsimony 
and model-based phylogenetic analyses were performed. All 13 bucl sequences, 
originally identified in collagen Pfam database, were BLASTn-searched against 
completed genomes of Bp, Bm, and Bt, and each bucl sequence was downloaded. The 
13 bucl genes demonstrate no sequence similarity, indicating these are non-homologous 
genes, whereas alleles encoding the same bucl gene were orthologous across species. 
Nucleotide sequence alignments were generated for each bucl gene present in 13 Bp 
and 11 Bm strains; analysis of bucl3 and bucl4 also included 9 Bt strains (S1 data set). 
Pairwise alignments of each bucl among the different strains revealed that percent 
identities ranged from 42%-100%, with the average percent identity for each bucl ranging 
from 76.5-94.9% (S2 data set). In general, the non-collagenous regions of bucl genes 
were conserved, while the CL regions showed significant length polymorphisms. 
Consequently, the bucl1 phylogeny based on non-CL region sequence produced a star 
pattern, while the bucl1 phylogeny generated based on the entire bucl1 sequence showed 
more extensive branching patterns, most of which were supported by Bayesian Posterior 
Probability values and several of which were also supported by maximum parsimony 
bootstrap values (S1 Fig). The CL region of bucl1 encodes a single GAN-repeat type, 
therefore, the only difference between bucl1 alleles from different strains represented in 
this tree arises from different GAN-repeat numbers. Since this is a common feature of all 
bucls, and incorporation of these regions would likely lead to long branch attraction, only 
the non-CL regions were used in further analyses. Multiple sequence alignments of bucl 
genes 2, 5, 6, 7, 10, 13, 14, 15 and 16 showed highly conserved nucleotide sequence, 
similar to bucl1, therefore phylogenetic analysis was not performed.  
Phylogenetic trees were generated for individual and concatenated bucl3, bucl4, 
and bucl8, as these genes were present in all three species and contained the most 
informative characters. We included the OEP-encoding sequence of bucl8 from Bt strains 
in this analysis, despite the lack of CL-encoding sequence and conserved frameshift 
mutation, because of significant sequence similarity to bucl8-OEP sequences shared with 
Bp and Bm. The phylogeny generated from concatenated sequences showed similar 
associations as phylogenies for the individual genes, although usually with higher 
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statistical support. All analyses showed Bp and Bm strains were more closely related to 
each other than to Bt strains, which formed a main separate branch (Fig. 5, 6, S2). This 
observation is consistent with the hypothesis that the pathogenic Bp and Bm strains 
diversified from Bt (42,59-61). On the concatenated tree, Bm strains formed a single clade 
without further resolution that was strongly supported by both Bayesian posterior 
probability (PP, 100) and maximum parsimony (MP, 100) bootstrap values (Fig. 5). This 
observation indicates either inadequate time for the diversification of Bm strains or 
purifying selection for the retention of nucleotide identity due to importance in adapting to 
its host pathogen niche (41). In contrast, Bp strains exhibited higher diversification as 
shown by the presence of multiple clades. Four supported clusters were observed, two 
of which, Cluster 1 and Cluster 4, showed geographical associations as these strains 
were all Australian isolates. Cluster 1 (PP 98, MP 100) contained Bp strains 20B16, 
MSHR146, MSHR511, and NCTC 13178, all isolates obtained from Australia. Cluster 2 
(PP 58, MP 100) contained Bp strains NCTC13179 and 1026b, isolated from human 
infections in Australia and Thailand, respectively. Cluster 3 (PP 100, MP 100) contained 
Bp strains 1106a and BPC006, obtained from northeast Thailand and China, respectively. 
Finally, Cluster 4 (PP 100, MP 100) contained Bp strains MSHR305 and MSHR520, which 
are both human infection isolates from Australia. Clusters 1 and 4 were also supported 
by trees based on individual bucl3, bucl4, and bucl8 genes, although strain NCTC 13178 
as part of Cluster 1 was only supported by the tree based on bucl4 (Fig. 6, S2). Similar to 
Bp, Bt strains showed significant diversification as evidenced by the formation of three 
supported clusters in the concatenated tree. These clusters were numbered 
consecutively Cluster 5, Cluster 6, and Cluster 7 (Fig. 5). Clusters 5 and 7 were supported 
by individual bucl3 and bucl4 phylogenies (Fig. 6), while only Cluster 5 was supported by 
bucl8 phylogeny (S2 Fig). Analysis performed using amino acid sequences of Bucl 
proteins generated phylogenetic trees with similar patterns, though the support values 
were lower (S3 Fig), indicating many of the nucleotide changes were synonymous.  
Overall, most bucl genes were highly conserved among Bp and Bm with most of 
the variation occurring in the CL region due to differing numbers of GXY repeats. Variation 
in non-CL regions of bucl3, bucl4, and bucl8 revealed divergence between Bt and select 
agents Bp and Bm, as well as diversification among Bt strains. Bp and Bm appear more 
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closely related, but only Bp strains showed diversification across the bucl loci by the 
formation of multiple distinct clades with strong statistical support. 
 
Assessment of bucl distribution across Burkholderia spp. 
In order to assess the distribution of bucl genes across Burkholderia, nucleotide BLAST 
searches were performed using bucl-gene sequences from the reference strain Bp 
K96243, as queries against completed genomes of 13 Bp, 11 Bm, and 9 Bt strains. All 13 
bucl genes were present in all Bp genomes, while the majority of bucl genes were 
maintained within Bm genomes (Table 4). Up to three bucl genes were missing in 8 Bm 
genomes, which is consistent with the reduced genetic material in this species (41,46). In 
contrast, only complete open reading frames of bucl3 and bucl4 were present in Bt 
genomes, presumably encoding a lipoprotein with a putative Talin-1 domain and a type 
III secretion inner membrane protein (Table 2, Fig. 4A), respectively.  
In addition to bioinformatic data, we tested distribution of bucl genes by standard 
PCR in a collection of genomic DNA from 25 Bp and 20 Bm strains, as well as the DNA 
from non-select agent controls 4 Bt, 3 B. cepacia (Bc), 5 B. cenocepacia (Bce), and 6 B. 
multivorans (Bmv) strains (Table 5, Table 6). Consistent with bioinformatic data, virtually 
all 25 Bp strains were found to contain all 13 bucl genes, with the exception of strain 
China 3 (BpCh3) which was missing bucl1 and bucl4 (Table 4, Fig. 7, S4 Fig). Almost all 
Bm strains tested (15 out of 20) were lacking up to three bucl genes, in agreement with 
bioinformatic results. We calculated bucl frequencies as the proportion of Bp and Bm 
strains positive for each bucl, as tested by both PCR and bioinformatics. High frequencies 
were observed for bucl3, bucl4, bucl7, and bucl15 (0.90-0.98), while lower frequencies 
were observed for bucl2 (0.85) and bucl10 (0.82). The bucl2 and bucl10 genes were most 
frequently absent from Bm strains, missing in about one-third of strains analyzed, 
indicating these genes are nonessential for Bm survival in mammalian host. Finally, all Bt 
strains contained only bucl3 and bucl4, while no amplification of these two bucl genes 
was obtained for other control Burkholderia spp. (Table 4, Fig. 7, S4 Fig).  
We next evaluated the association of bucl presence with pathogenicity among Bp, 
Bm, and Bt strains. The Fisher Exact Probability Test and Cramer’s V analysis were 
performed on the number of bucl genes present and absent among two groups: 1) 
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pathogenic Bp and Bm strains and 2) nonpathogenic Bt strains. The Fisher test provides 
a measure of the statistical significance between two groups, and Cramer’s V squared 
(V2) is a value, which measures the degree of association between two variables on a 
scale of zero (no association) to one (perfect association). The Fisher test showed 
significant differences between group 1 and 2 for all bucl genes, except for bucl3 and 
bucl4, indicating the presence of collagen-like genes is significantly associated with 
pathogenic B. pseudomallei and B. mallei species as compared with non-pathogenic B. 
thailandensis (Table 4). Further calculation of Cramer’s V2 showed perfect association 
(V2=1) for bucl genes 5, 6, 8, 13, 14, and 16 that were present in all Bp and Bm strains, 
while absent in all Bt strains. High V2 values were calculated for bucl1 (V2=0.829), bucl7 
(V2=0.829), and bucl15 (V2=0.908), indicating positive association with these bucl genes 
with pathogenic Bp and Bm, as compared with nonpathogenic Bt lacking them. The 
remaining bucl genes, 2, 3, 4, and 10, had little or no association with pathogenic Bp and 
Bm compared to Bt (V2<0.5). Hence, our statistical analyses strongly infer association 
between the presence of the majority of Bucl proteins and pathogenicity.   
 
Detection of Burkholderia select agents by analytical PCR  
Four conserved amplicons generated from bucl genes that were uniformly found in all Bp 
and Bm strains, but were absent in Bt, Bc, Bce, and Bmv strains, were assessed for select 
agent detection by standard agarose gel electrophoresis and capillary gel 
electrophoresis: bucl5 (216 bp), bucl13 (212 bp), bucl14 (178 bp), and bucl16 (123 bp) 
(Fig. 7C). Size-identification of bucl-based amplicons by capillary gel electrophoresis was 
performed in a 10% phospholipid nanogel, allowing near single base pair resolution (62), 
including bucl5 and bucl13 amplicons that differ by 4 bp. Sizing of the target DNA 
fragments was accomplished by linear regression analysis for DNA size (in bp) versus 
migration time. The bucl gene amplicon sizes were calculated using the linear fit obtained 
for the migration times of internal standards with lengths of 100 bp and 250 bp, and the 
standard deviation calculated from 5 replicate measurements. The bias is calculated as 
the difference between the true fragment size and the measured size. Sizing results are 
reported as follows for n=5 separations: [gene name (true size): calculated size ± 
standard deviation, percent relative size bias defined as bias divided by the true size]; 
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bucl5 (216 bp): 218 ± 2 bp, 0.9%; bucl13 (212 bp): 215 ± 1 bp, 1%; bucl14 (178 bp): 181 
± 1 bp, 2%; bucl16 (123 bp): 120 ± 1 bp, 2%. 
 
Detection of Burkholderia select agents by quantitative PCR  
Identification of molecular targets for Burkholderia select agents is challenging due to the 
high genomic plasticity reported in these organisms that include significant genomic 
rearrangements and deletions. PCR assays developed for Burkholderia detection include 
BurkDiff, a dual-probe assay able to detect and differentiate Bp and Bm (63,64), and the 
TTS1 assay targeting orf2 of type three secretion system I, detecting Bp only (64-66). 
Here, we developed a qPCR assay for the detection of Bp and Bm based on bucl16 target. 
A locked nucleic acid hydrolysis probe specific for bucl16 gave robust amplification using 
DNA of Bp K96243 (Cq= 21.85±1.37). This probe was then tested against the genomic 
DNA collection, providing amplification of all Bp and all Bm strains, with no amplification 
from non-select agent controls including Bt, Bce, and Bmv, as well as a no DNA template 
control (Fig. 8A). 30 ng of DNA was used for each strain and Cq values ranged from 
23.42- 29.05.  
We next tested the bucl16-based qPCR assay towards detection of an infection 
with Burkholderia select agents by employing samples spiked with human plasma, and 
with samples obtained from experimental animals. PCR reactions performed with 30 ng 
Bp K96243 DNA and spiked with 5% human plasma produced positive amplification with 
average Cq=24.28±2.14 (Fig. 8B), whereas reactions spiked with 10% and 20% human 
plasma produced averaged Cq= 25.89±1.76 and Cq=27.96±1.82, respectively.  
Next, Bp strain HBPUB10134a was used for the detection of Burkholderia infection 
in vivo. Our recent studies have shown that Bp HBPUB10134a was the most virulent in 
the intraperitoneal infection model among a panel of 11 Bp strains, with an LD50 of 10 
CFU at day 21 post-infection (67). Following the injection, mice presented common 
clinical manifestations, including abscess and pyrogranuloma formation in the spleen and 
liver, and in some cases lesions and inflammation in the eyes and tail. A common 
pathological observation was the loss of rear limb function occurring between 6 and 30 
days post-infection, associated with the pyrogranulomatous inflammation in the skin, 
skeletal muscle, bone, and peripheral nerves in the hind limbs. Here, mice that were 
 201 
injected intraperitoneally, were euthanized and sampled after 3, 7, or 14 days 
postinfection. Homogenized spleen samples were plated on blood agar to assess 
bacterial loads and 1 µL samples of irradiated sterile spleen extracts were used directly 
in qPCR reactions. Four samples, with original bacterial loads of 5x107, 5x106, 2x105, and 
103 CFU/ mL, thus, presumably corresponding to 5x104, 5x103, 2x102, and 10 CFU per 1 
µL added to each qPCR reaction, respectively, were tested using our bucl16-based 
assay. When crude spleen extracts were used in qPCR, positive detection was obtained 
for 5x103 CFU and 5x104 CFU samples with averaged Cq values of 29.49±1.67 and 
26.39±1.71, respectively (Fig. 8B). Importantly, we observed that 1:10 dilution of the 
sample containing 5x104 CFU/ µL, resulted in improved amplification, as evidenced by 
lower Cq value (23.32±0.42), while 1:100 dilution resulted in similar amplification as 
undiluted crude sample (Cq= 27.23±1.10) (Fig. 8B, red curves). Further 1:1000 dilution 
of spleen extract provided detection level as low as 50 CFU per reaction with a Cq value 
of 32.63 ±1.57. On the other hand, 1:10 dilution of the sample originally containing 5x103 
CFU/ µL resulted in poorer amplification (Cq= 32.66±2.46) than crude undiluted sample 
(gray curves). We think that crude spleen extracts contained varying levels of inhibitors 
that differentially affected amplifications in these two samples. Finally, in addition to 
bucl16, bucl genes 5, 6, 8, 13, and 14 that were found in all Bp and Bm strains are similarly 
good candidate markers for the development of diagnostic qPCR assays.  
 
DISCUSSION 
Traditionally, collagen has been associated with multicellular animals, although, the 
number of collagen-like proteins identified in bacterial genomes has recently increased 
with 2554 sequences currently (search on 04/12/15) deposited in the Pfam collagen data 
base. The distribution of these collagen-like proteins is not uniform, however; they are 
absent in some bacteria and are overrepresented in other species. Here, we identified 
and characterized a group of 13 discrete collagen-like proteins in Burkholderia, referred 
to as Bucl, which are largely found in the pathogenic Bp and Bm species. Furthermore, 
we found that bucl genes provided important clues on the genomic plasticity and evolution 
of Burkholderia select agents. We observed Bucl proteins contained domains that are 
known to be involved in pathogenesis and antibiotic resistance, including an outer 
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membrane efflux protein which we modelled. Finally, we utilized bucl genes as detection 
targets and successfully detected Bp infection in a mouse model.  
 
Characterization of Bucl-CL Region  
Collagen-like sequences, embedding the typical repetition of triplets of the type Gly-X-Y 
(2,68-70) have been identified in all Bucl sequences. We observed that for each Bucl, 
one or two GXY types predominated the CL region. This limited variation in GXY content 
resembles that seen in Bcl proteins of Bacillus anthracis (32) but is in contrast to Scl 
proteins of Streptococcus pyogenes, whose GXY sequence varies significantly within the 
CL region (13). Typical of prokaryotic collagens, these sequences do not contain triple-
helix-stabilizing hydroxyprolines, since bacteria lack the prolyl-hydroxylase enzyme 
necessary for post-translational modification of Pro to Hyp. The highest triple helix 
stabilities were predicted for Bucl2, Bucl5, Bucl13 and Bucl15, within the range of 35-38°, 
which is similar to that of previously studied bacterial collagens as well as human collagen 
(11,13,71,72). Similar to the CL regions of other prokaryotic proteins, like Scls from S. 
pyogenes (7,8), the CL regions of these proteins share the common characteristics of 
possessing charged residues GEX, GLE and GXR triplets, respectively (Fig. 3, Table 2). 
Indeed, ion pairs play a major role in stabilizing the triple helix, with an enthalpic 
stabilization, which likely involves interactions of polar groups with an ordered hydration 
network (9,10,12). Additionally, specific GXY triplets were found to have favorable 
enthalpy values, corresponding to increased hydrogen bonding potential, including GPE 
(71), which is a common GXY triplet in the Bucl5 CL region. These regions are likely to 
be of biological importance in establishing interactions with charged counterparts. 
Interestingly, bacterial collagens have been shown to have relatively high proline content, 
20% in S. pyogenes and up to 40% in B. anthracis (11), especially in the X position (73), 
whereas Bucl proteins lack Pro residues; only Bucl5 contains GPE repeats, likely 
contributing to its predicted high stability. Other Bucl proteins with lower thermal stability 
may rely on the hydrophobic membrane environment for triple helix stabilization, as those 
were predicted to have transmembrane regions, especially within the CL regions. Stability 
predictions shown here were computed using long CL sequences, whereas some Bucl 
variants had short CL regions, which may not form triple helices. This is substantiated by 
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the fact that few triplets may also exist in other folds e.g., G5 domain, whose structure 
presents a pseudo-triple helix (74). In summary, while overall characteristics of the Bucl 
proteins we identified were similar to previously described bacterial collagen-like proteins, 
i.e., presence of collagenous and non-collagenous domains and length variation in 
collagen region, the GXY content observed in Bucls was unique and likely impacts the 
structural stability of the Bucl-CL triple helix. 
  
Characterization of Bucl non-collagenous domains and their inferred roles in 
Burkholderia pathogenesis 
It has been observed that collagen-like proteins are often surface associated. Indeed, 
among 53 bacterial and viral collagen-like proteins analyzed in an initial genome-based 
study, 16 were annotated as cell-wall attached or membrane associated (73). 
Additionally, surface expression of collagen-like proteins including Scls of S. pyogenes, 
PclA of S. pneuomonia, and Lcl of L. pneumophila, has been demonstrated 
experimentally (7,8,18,19). Structural predictions performed for Bucl proteins revealed 
that their majority, 10 out of 13, have transmembrane regions, supporting the location of 
Bucl proteins in the inner or outer membrane of Burkholderia spp. Moreover, four of these 
proteins were predicted to contain both signal sequences and transmembrane domains, 
further supporting surface association. Further non-collagenous features include well-
conserved domains (in Bucl3, Bucl4, Bucl8 and Bucl13), which are inferred in 
pathogenesis.  
Bucl3 was predicted to have a Talin-1 domain. Talin-1 in eukaryotes is known to 
bind and activate integrins as well as link the cell cytoskeleton to the extracellular matrix 
(50). Cell-to-cell invasion by Burkholderia is largely achieved by the disruption of the host 
cytoskeletal network, as well as the fusion of host cells resulting in the formation of 
multinucleated giant cells, mediated mainly by type III and type VI secretion systems 
(75,76). The intra- and inter-cellular spread is facilitated by the formation of actin tails 
which propel the bacterial cells. Thus far, several type III secretion effector proteins are 
known to be involved with host actin polymerization allowing cell invasion, including BimA, 
BopE, and BipD (43). The putative Talin-1 domain found in Bucl3 may also be involved 
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in interactions with host actin that allow for cell invasion or the formation of actin tails 
during infection.  
The Bucl4 protein is putative inner membrane protein part of the type III secretion 
T3SS-2 system (77). There are three known type III secretion gene clusters (T3SS-1, 
T3SS-2, and T3SS-3) distributed among Bp, Bm, and Bt species. T3SS-1 is specific to 
Bp while T3SS-2 and 3 are found ubiquitously in all three species (78). The T3SS-3 is 
known to be important for virulence in Bp (44,75,79), as mutants deficient in the T3SS-3 
have reduced replication in host cells, and are unable to escape endocytic vacuoles, and 
to form membrane protrusions and actin tails (80). The other two secretion systems are 
less well characterized, and the role of the T3SS-2 secretion system in pathogenesis is 
not known. The unique association of a collagenous domain with Bac_export_1 domain 
in this inner membrane protein of T3SS-2 has not been previously acknowledged.  
Bucl13 contains the SBP_bac_3 domain, and is predicted to be a bacterial 
periplasmic solute binding protein. Binding of the solute causes a conformational change, 
which allows interaction of the solute with inner membrane proteins and subsequent 
transport of the solute into the cell. Family 3 solute-binding proteins are known to bind 
polar amino acids and opines (52), therefore Bucl13 is likely associated with amino acid 
transport; interestingly, Bucl13 is present in all Bp and Bm strains tested, while it is absent 
in non-pathogenic Bt. Bucl13 was also predicted to have a collagenous domain with a 
relatively high thermal stability, possibly contributing to its function.  
Of particular interest is the Bucl8 protein, which was found to contain two tandem 
outer membrane efflux protein (OEP) domains that are known to contribute to the 
multidrug resistant phenotype of Bp and Bm species. These organisms are intrinsically 
resistant to multiple antibiotics including aminoglycosides, macrolides, and β-lactams 
(53,81). The outer membrane protein is an integral component of a tripartite Resistance-
Nodulation-Division (RND) efflux pump that also requires an accessory protein in the 
periplasm and an inner membrane transport protein. It is known that there are 10 RND 
efflux pumps annotated in the Bp K96243 strain, many of which have not been explored 
(40). Currently, only three of these systems, BpeAB-OprB, AmrAB-OprA, and BpeEF-
OprC, have been investigated for their roles in multidrug resistance (82-84). Interestingly, 
Bucl8 was found to be present in all Bp and Bm strains and absent in the non-pathogenic 
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Bt, suggesting selective pressure for the Bucl8-OEP in human or animal infection. We 
homology-modeled the Bucl8-OEP region based on OprM protein of Pseudomonas 
aeruginosa and observed a trimeric arrangement forming an outer membrane-spanning 
β-barrel and periplasmic α-barrel. The presence of the CL domain in Bucl8 is an 
unexpected observation, as collagenous regions have not been reported as part of efflux 
pump systems. On the other hand, the trimeric arrangement of Bucl8 is consistent with 
the formation of a collagen triple helix. TMPred predicted a transmembrane region, albeit 
with lower score, for a part of the collagen-like region (amino acids 539-557) indicating 
the CL region folds back across the membrane. The CL region is then predicted to extend 
into the extracellular space, projecting the carboxyl-terminal region from the cell surface. 
The triple-helical CL region may have a number of functions: i) to project the C-terminal 
region, which may serve as a surface adhesin, ii) to stabilize the trimeric arrangement of 
the OEP, and iii) may assist in blocking the β-barrel pore at the resting state, thus, 
preventing entry of xenobiotics into the cell. Ongoing studies will determine the potential 
role of Bucl8-OEP in drug resistance, Bp and Bm pathogenesis, as well as a potential as 
vaccine candidate.  
 
Bucl phylogeny  
The presence of 13 collagen-like genes in Bp and Bm genomes poses the question how 
have these unique sequences been acquired in Burkholderia? The GXY repeats found in 
bacterial collagens may have arisen through mechanisms including de novo spontaneous 
mutation and subsequent triplet repeat expansion independent within each gene, or by 
horizontal gene transfer. It has been initially suggested that collagen sequences are 
acquired by horizontal transfer from eukaryotes to prokaryotes based on the lack of 
collagen sequences in ancestral archaeal genomes and relatively few sequences 
identified in bacterial genomes (73). However, current collagen Pfam contains 2,554 
bacterial collagen sequences, as well as 14 archaeal. A recent study, focused on bacterial 
molecular mimics of host proteins, proposed that collagen-like sequences found in 
pathogens evolved independently to mimic human host proteins (85). The uniformity of 
GXY content within each Bucl indicated they are likely to have evolved from the 
accumulation of repeats within each gene, resulting in diverse Bucl proteins that share 
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the GXY motif but with different GXY composition. Additionally, gene-enrichment analysis 
showed that collagen-like proteins were related to extracellular matrix mimicry and cell 
adhesion, supporting the evolution of repetitive sequences in virulence factors. Our 
phylogenetic analyses show that 13 collagen-like genes observed in numerous Bp and 
Bm genomes are unrelated to each other, which supports their independent acquisition, 
as well as selective adaptation of their collagen-like sequences in the host environment. 
This is further supported by the lack of collagen-like proteins (11 out of 13) in the closely 
related environmental species of Bt, indicating these sequences were acquired after 
divergence of Bp and Bm from Bt. Since Bucl proteins are unrelated and encoded in 
various locations in the genome, within-gene expansion of GXY-repeat motifs may point 
to convergent evolution of collagenous sequences to fulfill a similar function.  
Phylogenetic trees based on three bucl loci showed Bt strains formed a distinct 
separate branch from Bp and Bm strains. This is consistent with previous studies based 
on phylogenetic analyses of seven MLST loci (42) and over 11,000 SNPs (60) which 
showed Bp and Bt isolates were resolved into two groups that were supported in 100% 
of bootstrap replicates. We also observed Bm strains share high sequence similarity, 
while Bp strains exhibited more intraspecies diversity, forming more extensive clusters 
that often corresponded to geographical associations. Previous phylogeographic 
reconstruction of Burkholderia strains based on over 14,000 SNPs showed that Bp and 
Bm strains formed separate clusters. The same study also showed Bp strains were 
significantly divided between those originating from Australia and Asia (60), in agreement 
with our observation that Australian isolates formed distinct clusters in bucl-based 
phylogenetic trees.  
 
Bucl distribution  
Both bioinformatic and PCR analyses showed that the majority of bucl genes are unique 
to Bp and Bm strains, with the exception of bucl3 and bucl4. This observation may indicate 
these two genes are selected for in the environment of Bp and Bt, as several genomes of 
host-adapted Bm, lack these genes. The absence of most bucls from Bt is a surprising 
observation since its genome is overall similar to that of Bp (59), which may suggest either 
the acquisition of bucls in Bp or the loss of bucls in Bt after divergence of the two species. 
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Both Bp and Bt species have large genomes of approximately 7.2 and 6.7 Mb, 
respectively, divided between two chromosomes. Comparative genomics showed that Bp 
and Bt genomes share a large number of conserved genes involved in both core and 
accessory functions, while genes associated with virulence in Bp have increased diversity 
(59). Interestingly, bucl3 and bucl4, encoding proteins potentially involved in 
pathogenesis, are found in the avirulent Bt. It has been shown that 71% of virulence-
related genes in Bp are conserved in Bt with similarities of over 80%, including type III 
secretion gene clusters (59). Amino acid differences in virulence proteins present in both 
species may confer functional differences impacting virulence in Bp vs. Bt. Lastly, the 
presence of bucl3 and bucl4 alone in Bt was not sufficient to cause pathogenesis, a new 
biological trait acquired by Bp and Bm after the acquisition of additional virulence factors, 
including additional Bucls. A prominent feature of Burkholderia genomes is the presence 
of multiple horizontally acquired genomic islands that differ between Bp and Bt (40,59). 
These genomic islands are associated with survival in the soil environment and are 
absent in Bm genomes, possibly explaining why Bm cannot persist in the environment 
(46). The presence of most bucl biomarkers in both Bp and Bm genomes indicates they 
are not located within genomic islands but are rather a part of the core genome.  
 Previously, it has been reported that Bm is a clonal derivative of Bp, which has evolved 
to adapt to the host environment. Multilocus sequence typing analyses show that, in 
contrast to Bp, Bm strains are genetically homogenous, while relatively few new genes 
are being identified, as additional genomes are sequenced (46). However, the variable 
portion of the genome, though not acquiring new genetic information, is continuing to alter 
via expansion of IS elements and chromosomal rearrangements. Our phylogenetic 
analysis of bucl genes within Bm supports the genetic homogeneity among Bm strains, 
and mapping of bucl markers showed considerable chromosomal rearrangements 
occurring between Bm strains.  
Different collagen-like proteins, unrelated to 13 Bucls characterized here, were 
also present in other Burkholderia species. We noticed these collagen-like proteins found 
in B. cepacia, B. cenocepacia, B. multivorans, B. ambifaria, B. glumae, B. gladioli, and B. 
xenovorans, contained GTS repeats within the CL region, similar to Bucl3. However, 
outside of the CL region, sequence identity was very low, therefore these proteins were 
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not included in the Bucl3 group. Given the importance of Burkholderia species as human 
pathogens and part of the Burkholderia cepacia complex (B. cepacia, B. cenocepacia, B. 
multivorans, and B. ambifaria), plant pathogens (B. glumae and B. gladioli), and plant 
symbionts (B. xenovorans), investigation of these collagen-like proteins is an interesting 
area for further study.  
 
bucl-based infection detection  
Bp and Bm are reported to have fatality rates up to 80% and 95%, respectively (86,87), 
making early diagnosis and treatment critical for patient survival. Currently, culture-based 
identification of Burkholderia select agents remains the gold standard for diagnosis 
(86,88). Highly variable genomes present a challenge in finding reliable genetic targets 
that are not subjected to chromosomal deletion, especially for B. mallei. Although a few 
laboratory-developed qPCR tests have been reported, there are no FDA-approved 
assays for the detection of Burkholderia select agents. The TTS1 assay (65,66) detects 
specifically Bp, and the BurkDiff assay (63) detects both organisms and differentiates 
them based on a SNP-associated shift of approximately 1 ΔCt (64). Here, we assessed 
bucl markers as detection targets. Standard PCR performed on a large collection of gDNA 
yielded specific amplicons for bucl5, 13, 14, and 16 from Bp and Bm but not from the non-
select agent controls. This PCR test with 4 bucl targets detected Bp infection in laboratory 
animals using spleen extracts as a specimen. Separation of these conserved amplicons 
by capillary electrophoresis in a phospholipid nanogel matrix allowed for size-based 
identification, similarly to previously described identification of Aspergillus spp. (31) and 
Streptococcus pyogenes (35). Precise microfluidic separation could be used for strain 
fingerprinting based on multiplexed amplicons generated with primers flanking the 
repetitive CL region, as previously tested with B. anthracis strains (32). Our achieved 
resolution <9 bp along a wide range of amplicon sizes will allow to differentiate two strains 
that differ by a single GXY repeat. We further developed a qPCR assay for bucl16, which 
detects both Bp and Bm; it was tested with purified genomic DNA templates, gDNA spiked 
with 5% human plasma, and spleen extracts from infected mice. The bucl16 assay was 
able to detect as low as 50 CFU per reaction in diluted spleen samples; however, it should 
be noted that sample-to-sample variation was observed. The specimen type will also 
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affect detection outcome. For example, sputum and pus typically contain high bacterial 
loads (102-109 CFU/ mL) (89), whereas blood of 45% of patients with septicemic 
melioidosis had less than 1 CFU/ mL bacteria in the blood (90), which presents a 
sensitivity challenge, even for highly performing qPCR assays. In as much as current 
work was focused on a single assay, which would simultaneously detect both select 
agents similarly to BurkDiff assay, the ongoing research is focused on the development 
of a probe-based qPCR assay targeting nucleotide polymorphisms identified in bucl3 and 
bucl4 genes. In summary, selected bucl genes represent promising detection targets as 
they are both specific to and ubiquitously found in Bp and Bm strains.  
 
MATERIALS AND METHODS 
Ethics statement   
Animal Studies: Animal research at the United States Army Medical Research Institute 
of Infectious Diseases (USAMRIID) was conducted under an animal use protocol 
approved by the USAMRIID Institutional Animal Care and Use Committee (approved by 
the USAMRIID-IACUC) in compliance with the Animal Welfare Act, PHS Policy, and other 
Federal statutes and regulations relating to animals and experiments involving animals. 
The facility where this research was conducted is accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and 
adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, 
National Research Council, 2011. Tissue samples used in this study were generated in a 
previously published work (67). Briefly, challenged mice were observed at least daily for 
14 days for clinical signs of illness. Humane endpoints were used during all studies, and 
mice were humanely euthanized when moribund, according to an endpoint score sheet. 
Animals were scored on a scale of 0–11: 0–2 = no significant clinical signs; 3–7 = 
significant clinical symptoms; such as subdued behavior, hunched appearance, absence 
of grooming, and impacted hind limb function and hind limb paralysis (increased 
monitoring was warranted and mice were checked at least twice per day); 8–11 = distress. 
Those animals receiving a score of 8–11 were humanely euthanized by CO2 exposure 
using compressed CO2 gas followed by cervical dislocation. The mice that were serially 
sampled were deeply anesthetized and then euthanized by exsanguination followed by 
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cervical dislocation. However, even with multiple observations per day, some animals 
died as a direct result of the infection in between observation periods. 
 
Human plasma collection: Anonymized human plasma samples were utilized in 
quantitative PCR experiments. Plasma samples were obtained from an already-existing 
collection, which was established by the corresponding author (SL; IRB Protocol Number: 
1308076685). Collection of human blood of healthy adults was performed in accordance 
with the Human Research Protections Policy at West Virginia University. This study was 
approved by the Institutional Review Board at West Virginia University (IORG0000194) 
and written informed consent was obtained from all participants. 
 
Bioinformatic analyses 
Burkholderia collagen-like proteins, designated Bucl, were identified by searching the 
Sanger Institute Pfam collagen database (PF01391). Bucl proteins found in B. 
pseudomallei, B. mallei, and B. thailandensis were categorized into 13 Bucl-protein types 
based on similar domain organization and primary sequence similarity. Next, nucleotide 
BLASTn search was performed using each of 13 bucl-gene sequence as a query against 
the NCBI Nucleotide collection (nr/nt) database, as well as whole genome shotgun 
contigs (wgs) database, to determine bucl distribution in completed Burkholderia spp. 
genomes. DNA analyses were performed using the Lasergene Core Suite v. 12 
(DNASTAR, Inc., Madison, WI).   
 
Protein structure prediction and modeling 
Domain organization of Bucl proteins was adapted from the Pfam collagen database (91) 
and verified independently using the Fugue 2.0 Server (92), which additionally identified 
the putative Talin-1 domain within Bucl3. Presence of a signal peptide was predicted with 
the hidden Markov model component of the SignalP 3.0 Server 
(http://www.cbs.dtu.dk/services/SignalP-3.0/) (93-95). The presence of transmembrane 
domains was predicted with TMpred (96). 
When possible, as in the case of Bucl8, a 3D model was generated by homology 
modeling. Best template was identified by employing profile hidden Markov models 
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(profile HMMs) and the program HMMer (97). Once the best template was identified (pdb 
code 3d5k, sequence identity 27%, residues 51-516), the model of Bucl8 outer membrane 
efflux protein (OEP) domains was generated using MODELLER 9V9 (57). Stereo-
chemical quality of the model was improved by energy minimization using GROMACS 
(98).   
Thermal stability along the predicted triple helices of Bucl-collagen domains was 
assessed with an algorithm developed by Persikov et al. 2005 (47). With this approach, 
a stability coefficient is assigned for every GXY triplet and averaged over a window of 5 
tripeptide units. The averaged relative stability values are plotted against the tripeptide 
number in the collagen sequence. 
 
Phylogenetic analyses 
Both individual (with and without the collagen-like domains) and concatenated nucleotide 
sequences were aligned with ClustalV in the Megalign module in DNASTAR® Lasergene 
software, and verified manually. Maximum parsimony analyses were performed with 1000 
bootstrap replicates using MEGA 6.06 (99), with the Tree-Bisection Reconnection 
heuristic search and 200 max trees saved. The evolutionary models used for each data-
set were determined by MrModelTest 2.3 (100) with the Akaike Information Criterion 
(AIC). Bayesian analyses were performed within MrBayes 3.1.2 (101) implementing six 
Markov chains, 1000000 generations, with trees sampled every 100 iterations. Posterior 
probabilities were calculated using the last 20% of saved trees (burnin=8000). Cutoff 
values for significance were assigned 95 for Bayesian analysis and 70 for maximum 
parsimony analysis. All phylogenetic trees were constructed using the majority rule 
consensus. Trees were viewed in FIGTREE v1.3.1 
(http://tree.bio.ed.ac.uk/software/figtree/). Phylogenies were constructed based on single 
bucl genes as well as concatenated bucl genes.  
 
bucl distribution among Burkholderia species 
bucl distribution was assessed in a broad collection of Burkholderia strains using genomic 
DNA (Table 2) obtained from: (i) NIH Biodefense and Emerging Infections Research 
Resources Repository, NIAID, NIH, (ii) Dr. Christopher Cote (The United States Army 
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Medical Research Institute of Infectious Disease), and (iii) Dr. Joanna Goldberg (Emory 
University). The total collection consisted of DNA from 25 B. pseudomallei and 20 B. 
mallei strains, and non-select agent control DNA from 4 B. thailandensis, 3 B. cepacia, 5 
B. cenocepacia, and 6 B. multivorans strains. Analytical PCR was performed with primers 
targeting conserved non-collagenous regions of bucl alleles present in the reference 
strain B. pseudomallei K96243. PCR buffer (10 mM Tris-HCl, 1.5 mM MgCl2, 50 mM KCl, 
pH 8.3) included 0.2 µM primers, 0.2 mM dNTP’s, and 1.5 M betaine (Sigma-Aldrich, St. 
Louis, MO) to ameliorate amplification problems associated with high GC content (~68%) 
of Burkholderia genomes (41). A temperature gradient of 50-65°C was tested for each 
primer pair and gDNA of B. pseudomallei K96243 harboring all 13 bucl genes as a 
template; uniform amplification conditions were established for all bucl genes at an 
annealing temperature of 64°C. Amplification was performed with an in-house Taq 
polymerase as follows: 95°C, 5 min-[95°C 30 sec, 64°C 30 sec, 72°C 45 sec] x30 cycles- 
72°C, 10 min. 40 ng of template DNA was used for screening genomic DNA collection 
and reactions were carried out on a Bio-Rad S1000 thermal cycler. Resultant PCR 
products were analyzed on a 2% agarose gel with a 50-bp ladder DNA standard (New 
England Biolabs Inc., Boston, MA). Gels were imaged using the Eagle Eye II (Stratagene, 
La Jolla, CA), and FOTO/ Analyst Investigator/ Eclipse gel documentation workstation 
(Fotodyne, Harland, WI).  
 
qPCR amplification of bucl targets 
Testing of selected bucl amplicons by real-time PCR with SYBR green intercalating dye 
was performed to assess potential candidates for probe-based detection of B. 
pseudomallei and B. mallei species. Reactions were carried out with SsoAdvanced™ 
SYBR® Green Supermix (Bio-Rad, Hercules, CA), 0.5 µM concentration of each primer 
and 25 ng of gDNA from strain B. pseudomallei K96243 as a template in a total volume 
of 20 µL. Amplification curves were obtained with the following program: 95°C, 3 min-
[95°C 5 sec, 64°C 10 sec]x35 cycles. qPCR was performed using a Bio-Rad CFX96 
instrument and data analyzed with the CFX Manager™ software Version 3.0. 
PrimeTime® qPCR probe was developed for the bucl16 gene, which yielded robust 
amplification in 5’ nuclease qPCR assays, to detect B. pseudomallei and B. mallei 
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species. Locked nucleic acid (LNA) bucl16-based probe (Table 4) contained a 5’-FAM 
fluorophore and a 3’-Iowa Black fluorescent quencher. Reactions were carried out using 
SsoAdvanced™ Universal Probes supermix (Bio-Rad), 0.5 µM primers, 0.2 µM 
concentration of probe and 25 ng of gDNA template in a total volume of 20 µL. 
Amplification curves were obtained with the following program: 95°C 3 min-[95°C 5 sec, 
64°C 10 sec]x35 cycles.  
 
Capillary gel electrophoresis 
Reagents for separation of DNA by capillary gel electrophoresis included the nanogel 
matrix composed of the phospholipids dimyristoyl-sn-glycero-3-phosphocholine (DMPC) 
and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC) (Avanti Polar Lipids, Alabaster, 
AL), 3-(N-morpholino)-propanesulfonic acid (MOPS) (Alfa Aesar, Ward Hill, MA) buffer, 
and SYBR green 1 (Life Technologies, Grand Island, NY). The phospholipid pseudogel 
was prepared at a molar ratio of [DMPC]/[DHPC] =2.5 at 10% wt/vol in an aqueous 
solution of 100 mM MOPS buffer (pH 7) in order to generate the nanogel separation 
matrix. Intercalating dye was incorporated into the nanogel at 1x concentration to enable 
fluorescent DNA detection. The 50-bp DNA ladder (New England BioLabs, Ipswich, MA) 
was used as a molecular size marker.  
Separations were performed on a Beckman Coulter P/ACE MDQ system equipped 
with a laser-induced fluorescence detection module and a 3 mW air-cooled argon ion 
laser (λex = 488 nm and λem = 520 nm). The fused silica capillary was conditioned prior to 
electrophoresis separation of DNA using previously described rinsing (62) and coating 
(102) procedures. The capillary was filled with liquid nanogel solution a temperature 
below 24°C (19-21°C); then the temperature was increased to 30°C in order to form the 
sieving gel for accurate sizing separations of PCR amplicons. DNA samples were 
electrokinetically injected under reverse polarity as previously described (103). Data 
collection and analysis were performed with 32 Karat Software version 5.0 (Beckman 
Coulter). Sizing was accomplished by co-injecting the bucl5, 13, 14, and 16 amplicons 
with two internal standards of known length that bracketed the size of the DNA targets. 
Internal standards of 100 bp and 250 bp were used to create a linear fit for DNA size (in 
bp) versus migration time.  The resulting slope and intercept were then used to calculate 
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the size (length in bp) of the bucl gene targets based on their migration times. The 
reported values for the calculated DNA size and standard deviation (in bp) are an average 
for n=5 consecutive separations. 
 
Detection of B. pseudomallei gDNA in infected mice and human plasma using bucl 
markers 
BALB/c mice (female 7-10 weeks of age at time of challenge-National Cancer Institute, 
NCI-Frederick, MD) were injected by the intraperitoneal (i.p.) route. Mice were infected 
with a dose equivalent to approximately 6 times the LD50 of B. pseudomallei 
HBPUB10134a (LD50 is 10 CFU) (67). At various time points after infection mice were 
euthanized by exsanguination under deep anesthesia and spleens were harvested. 
Spleens were weighed and homogenized in RPMI 1640 medium (Life Technology, Grand 
Island, NY). Bacterial load in the freshly prepared spleen extracts was determined by 
plating serial dilutions on sheep blood agar (ThermoScientific Remel Products, KS). 
Plates were incubated at 37°C for two days before determining CFU counts. The spleen 
extracts were irradiated and confirmed sterile before use in PCR assays, and were stored 
at -70°C. Standard PCR for bucl genes 5, 13, 14, and 16, and probe-based qPCR for 
bucl16 were performed as described above using 1 µL of DNA-containing spleen 
specimen. Additionally, qPCR reactions were performed with 30 ng B. pseudomallei 
K96243 gDNA spiked with 5% human plasma collected in EDTA tubes to test the 
feasibility of the assay on clinical samples containing plasma. qPCR experiments were 
performed in triplicate and Cq values were averaged.  
 
Statistical analyses 
Statistical significance of bucl presence in pathogenic B. pseudomallei and B. mallei 
strains vs. nonpathogenic B. thailandensis was performed using the Fisher Exact 
Probability Test, followed by calculation of Cramer’s V squared. 
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Figure 1 
 
Identification and characterization of bucl genes in B. pseudomallei reference 
strain K96243. (A) Schematic representation of bucl distribution. Relative position and 
orientation of each bucl gene is shown; six bucl genes are present on chromosome one 
and seven on chromosome two. (B) Summary table of bucl distribution. bucl location, 
orientation, and length are mapped to the genome of Bp K96243. Molecular weight of 
each Bucl protein encoded by each bucl allele is shown. (C) PCR amplification of 13 bucl 
genes from Bp K96243. Primers were designed targeting the non-collagenous conserved 
regions, and PCR conditions were established for all bucl amplicons at a uniform 
annealing temperature of 64°C. Amplicon sizes; bucl1, 123 bp; bucl2 133 bp; bucl3, 166 
bp; bucl4, 176 bp; bucl5, 216 bp; bucl6, 115 bp; bucl7, 264 bp; bucl8, 96 bp; bucl10, 109 
bp; bucl13, 212 bp; bucl14, 178 bp; bucl15, 95 bp; and bucl16, 123 bp ; M, 50-bp DNA 
size marker.  
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Figure 2 
 
Chromosomal rearrangements and deletions involving bucl loci. Relative positions 
and orientations of each bucl gene was rendered from the NCBI database, and used for 
chromosomal mapping. (A) Intraspecies chromosomal inversion (inv) between B. 
pseudomallei strains K96243 and 668 involving the region encoding bucl genes 6, 8, and 
10. (B) Interspecies chromosomal inversion between Bp K96243 and Bm ATCC 23344 
involving the region encoding bucl genes 2, 3, and 5 on chromosome 2. (C) Interspecies 
chromosomal inversion involving bucl genes 6, 8, and 15, and deletion of bucl10 between 
Bp K96243 and Bm ATCC 23344 on chromosome 1. Ch, chromosome. 
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Figure 3 
 
Thermal stability of the Bucl collagen regions. (A) The CL region sequences, 
representative of all 13 Bucl proteins, plotted in B) are shown with averaged stability 
values calculated for the entire CL region. (B) Triple helix thermal stability plot. Amino 
acid sequences for Bucl-CL regions shown in A) were used to model thermal stability with 
an algorithm developed by Persikov et al. 2005. Relative thermal stability is shown as the 
melting temperature for each GXY triplet along each Bucl-CL region. 
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Figure 4 
 
Characterization of Burkholderia collagen-like proteins. (A) Architecture of Bucl 
proteins identified in collagen Pfam data base (not to scale). Proteins were categorized 
into 13 distinct Bucl types based on sequence similarities and domain organization. 
Predicted domains in each Bucl are shown: SS, signal sequence; CL, collagen-like 
domain; Talin-1 domain; Bac_export_1, bacterial export protein family 1; OEP, Outer 
Membrane Efflux Protein; and SBP_bac_3, bacterial extracellular solute-binding protein 
family 3. (B) Cellular organization of Bucl8 and homology modelling of the OEP domains. 
Bucl8 protein schematic is shown above homology model of OEP domains generated 
with MODELLER. Three monomers, each containing two OEP domains, assemble to 
form a homotrimer. Shown from top to bottom are the cell-surface exposed loops, the β-
barrel spanning the outer membrane and the α-barrel spanning the periplasmic space, 
corresponding to the predicted OEP domains. The two OEP domains from a single 
monomer are highlighted in orange and purple, and the remaining monomers are colored 
gray. Following the OEP domains, the CL region is predicted to be partially extracellular 
with an additional C-terminal non-collagenous domain. 
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Figure 5 
 
Phylogenetic analysis of B. pseudomallei, B. mallei, and B. thailandensis strains 
by bucl-locus typing. Bayesian analysis was performed on concatenated nucleotide 
sequences of the non-collagenous regions of bucl3, bucl4, and bucl8 present in a set of 
13 B. pseudomallei, 11 B. mallei, and 9 B. thailandensis strains (as shown in Table 3). 
Support values for each branch are shown as posterior probability from Bayesian analysis 
and bootstrap values from maximum parsimony analysis, respectively (PP/MP). Posterior 
probability value which was not supported by maximum parsimony analysis is shown in 
red. Phylogenetic Clusters 1-4 (C1-C4) correlated with geographic location of B. 
pseudomallei strains, whereas Clusters 5-7 (C5-C7) contained B. thailandensis strains 
that made up a separate branch from B. pseudomallei and B. mallei strains. Scale bar is 
representative of evolutionary distance in substitutions per nucleotide. 
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Figure 6 
 
Phylogenetic analysis of B. pseudomallei, B. mallei, and B. thailandensis strains 
using individual bucl3 and bucl4 genes. Bayesian analysis was performed on 
nucleotide sequences of non-collagenous regions of a set of Burkholderia strains 
described in Table 3. Support values for each branch are shown as posterior probability 
from Bayesian analysis and bootstrap values from maximum parsimony analysis, 
respectively (PP/MP). Posterior probability values not supported by parsimony analysis 
are shown in red. Scale bar is representative of evolutionary distance in substitutions per 
nucleotide. Several clusters of strains corresponding to those observed in the 
concatenated analysis, C1-C7 in Fig. 5, were also observed in the individual trees. 
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Figure 7 
 
Distribution of bucl genes among Burkholderia spp. select agents by PCR. 
Presence of bucl genes was assessed by PCR on (A) a collection of genomic DNA from 
25 B. pseudomallei and 16 B. mallei strains, as well as (B) in control strains of B. 
thailandensis, B. cepacia, B. cenocepacia, and B. multivorans; selected bucl genes 5, 13, 
14, and16 are shown. (C) Detection and separation of selected bucl amplicons generated 
from the B. pseudomallei reference strain K96243 by traditional 2% agarose gel 
electrophoresis (left) or by capillary gel electrophoresis (right). Electropherogram 
generated by capillary gel electrophoresis with phospholipid nanogel matrix shows 
separation of amplicons over time. Amplicon sizes: bucl5, 216 bp; bucl13, 214 bp; bucl14, 
178 bp; and bucl16, 123 bp. M, 50-bp DNA ladder. PCR data shown in Panel A for 25 Bp 
strains come from two merged gel images. 
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Figure 8 
 
Detection of B. pseudomallei and B. mallei by qPCR. (A) Real-time qPCR detection 
of bucl16-gene target. Genomic DNA of 25 B. pseudomallei (red) and 15 B. mallei strains 
(blue), and control DNA from 4 B. thailandensis, 4 B. cenocepacia, and 6 B. multivorans 
strains (gray). (B) qPCR detection of bucl16 target in the presence of human plasma and 
in spleen extracts from infected mice. 25 ng of gDNA from Bp K96243 was used as a 
positive control (blue line). Amplification of bucl16 in qPCR reaction spiked with 5% 
human plasma is shown (green line). Mice were infected with Bp HBPUB10134a and 
CFU counts used in each qPCR reaction were based on plating spleen extracts on blood 
agar. Positive amplification is shown for spleen samples with 5x104 CFU (red lines: 
square, undiluted; triangle, 1:10 dilution; circle, 1:100 dilution; diamond, 1:1000 dilution) 
and 5x103 CFU (gray lines: square, undiluted; triangle, 1:10 dilution), while no 
amplification was obtained for crude spleen samples with original 2x102 CFU and 10 CFU 
per reaction and no template control, NTC (black lines). Inset; amplification of bucl 
markers 5, 13, 14, and 16 by standard PCR using crude spleen samples containing 5x104 
CFU per reaction. M, 50-bp DNA ladder. 
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Table 1. Assessment of genomic plasticity of B. pseudomallei and B. mallei using 
biomarkers. 
aOrganizational patterns (OP) of bucl genes were assigned to each chromosome, Ch1 
and Ch2, according to position and orientation. OPs were labeled I-VI for chromosome 1, 
and I-III for chromosome 2. bucl position on the plus or minus strand is shown 
corresponding to each OP. 
   bucls on 
Chromosome 1 
   bucls on 
Chromosome 2 
OPa Strains plus 
strand 
minus 
strand 
Ch2 
OP 
Strains plus 
strand 
minus 
strand 
Ch1 
OPI 
BpK9624 6, 8, 
16 
10, 14, 
15 
Ch2 
OPI 
BpK9624, Bp668, 
Bp1026b, Bp1106a, 
Bp1710b, BpBP006, 
Bp305, Bp146, Bp511, 
Bp520, Bp20B16, 
Bp78, Bm10229, 
Bm10247, BmSAVP1 
2, 3, 4, 
5 , 7 
1, 13 
Ch1 
OPII 
Bp668, Bp1026b, 
Bp1106a, Bp1710b, 
BpBP006, Bp305, 
Bp79, Bp146, Bp511, 
Bp520, Bp20B16, Bp78 
10, 16 6, 8, 
14, 15 
Ch2 
OPII 
Bp79 2, 3, 4, 
5 
1, 7, 
13 
Ch1 
OPIII 
Bm23344 15, 16 6, 8, 14 Ch2 
OPII
I 
Bm23344 4, 7 1, 2, 
3, 5, 
13 
Ch1 
OPIV 
Bm10229 6, 8, 
14, 
15, 16 
10 
 
   
Ch1 
OPV 
Bm10247 10, 15 6, 8, 
14, 16 
       
Ch1 
OPVI 
BmSAVP1 15 6, 8, 
10, 14, 
16 
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Table 2. Characterization of Bucl proteins in Burkholderiaa. 
 
No. of amino acids  Collagen-like region (CL)  Structural predictions 
Bucl  
No. 
Total N-
terminus 
C-
terminus 
 No. of GXY 
repeats 
GXY type  Putative 
domains 
bSS cTM 
Bucl1 152-
197 
42 80-89  7-22 GAN  N/A No Yes 
Bucl2 171-
228 
141 21  3-19 GEV. GEA  N/A No No 
Bucl3 551-
640 
44 372-405  38-63 GTS. GSS  Talin-1 Yes Yes 
Bucl4 297-
379 
271 9-18  7-30 GVS. GAS  Bac_export_1 Yes Yes, CL 
region 
Bucl5 168-
230 
35-41 114  7-25 GLE. GPE. 
GLD. GFD 
 N/A No No 
Bucl6 40-
88 
1 27  4-20 GAL. GAS. 
GAA. GAE 
 N/A No Yes, CL 
region 
Bucl7 188-
212 
134 36  5-14 GLS. GSS. 
GAS. GVA 
 N/A No Yes, CL 
region 
Bucl8 608-
677 
522 74  4-24 GAS  OEP Yes Yes, CL 
region 
Bucl10 92-
155 
2-8 63  8-25 GIH. GMH. 
GMR 
 N/A No No 
Bucl13 385-
433 
24 318  12-25 GIR. GVR. 
GSG. GGS. 
 SBP_bac_3 No Yes 
Bucl14 83-
191 
11 69  2-37 GWC. GRC. 
GRR. GRH 
 N/A No Yes, CL 
region 
Bucl15 56-
91 
21-69 4  5-14 GVL. GAL. 
GML. GAT. 
GAI. GAA 
 N/A Yes Yes, CL 
region 
Bucl16 227-
307 
65-67 148  4-30 GFG. GVD. 
GFD. GAF 
 N/A No Yes, CL 
region 
aCharacteristics of Bucl proteins are shown based on analysis of completed genomes of 
13 Bp, 11 Bm, and 9 Bt strains (see Table 3). The total protein length and length of protein 
sequences that are amino- and carboxyl-terminal to CL regions in each Bucl protein is 
shown as amino acid number, whereas the length of each CL region, which varies 
between strains, is expressed as the number of GXY repeats. Predominant GXY repeats 
are represented in bold text. Putative domains in the noncollagenous regions of each Bucl 
are shown: Talin-1 domain; Bac_export_1, bacterial export protein family 1; OEP, outer 
membrane efflux protein; and SBP_bac_3, bacterial extracellular solute-binding protein 
family 3.  
bSS; Signal sequence predictions are based on hidden Markov model predictions in the 
SignalP 3.0 server.  
cTM; Transmembrane domain predictions were made using TMPred. 
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Table 3. Burkholderia strains used in this studya. 
Species Abbreviation Strain Isolate information 
B. 
pseudomallei 
BpK9624b K96243 female diabetic patient- Khon Kaen hospital, Northeast 
Thailand 
1996 
B. 
pseudomallei 
Bp1710bb 1710b relapse of same patient infected with 1710a, blood 
culture, Northeast Thailand, Sappasithiprasong 
hospital 
1999 
B. 
pseudomallei 
Bp305b MSHR305 brain sample, fatal encephalomyelitis, Australia, Royal 
Darwin hospital 
1994 
B. 
pseudomallei 
Bp1026bb 1026b blood culture from 29-year old female rice farmer with 
diabetes milletus, Northeast Thailand, 
Sappasithiprasong hospital 
1993 
B. 
pseudomallei 
BpBP006 BPC006 Blood from patient with Type I diabetes and multiple 
abscesses, China, Baoting Town, Hainan 
2008 
B. 
pseudomallei 
Bp1106ab 1106a female rice farmer, Northeast Thailand, 
Sappasithiprasong hospital 
1993 
B. 
pseudomallei 
Bp79 NCTC 
13179 
skin ulcer, Australia 2014 
B. 
pseudomallei 
Bp668b 668 blood culture from 53-year old male patient with 
severe melioidosis encephalomyelitis, Darwin Australia 
1995 
B. 
pseudomallei 
Bp146 MSHR146 goat udder, Australia 1992 
B. 
pseudomallei 
Bp511 MSHR511 throat of goat, Australia 1997 
B. 
pseudomallei 
Bp520 MSHR520 human blood culture, Australia 1998 
B. 
pseudomallei 
Bp20B16 NAU20B-16 soil, Australia 2006 
B. 
pseudomallei 
Bp78 NCTC 
13178 
human post-mortem brain, Australia N/A 
          
B. mallei BmSAVP1 SAVP1 pathogenic strain which became avirulent after 
passage through 6 equids, originally caused disease in 
a mule in India 
  
B. mallei Bm10229 NCTC 
10229 
Europe   
B. mallei Bm10247 NCTC 
10247 
Europe   
B. mallei Bm23344b ATCC 
23344 
human post-mortem knee fluid, skin pustules and 
blood, Burma 
1944 
B. mallei Bm21280b 2002721280 Iran 1952 
B. mallei BmA188 A188 >8 passages   
B. mallei BmA193 A193 Pasteur Institute, France 1964 
B. mallei Bm10399b ATCC 
10399 
horse lung, Southern China 1949 
B. mallei BmPRL20 PRL-20 blood of a gelding from the Lahore Polo Club, Lahore, 
Pakistan 
2005 
B. mallei Bm11 strain_11 human, Turkey 1949 
B. mallei Bm6 strain_6 human 1950 
          
B. 
thailandensis 
BtE264 E264 rice field soil sample, Central Thailand   
B. 
thailandensis 
Bt121 MSMB121 soil, Australia 2007 
B. 
thailandensis 
BtH0587 H0587 human pleural wound, LA, United States 1997 
B. 
thailandensis 
BtE444 E444 soil, Thailand 2002 
B. 
thailandensis 
Bt43 MSMB43 bore water source in Darwin, Australia; first isolate of 
B. thailandensis in Australia 
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B. 
thailandensis 
BtTXDOH TXDOH United States   
B. 
thailandensis 
Bt21723 2002721723 Human, CDC 2010 
B. 
thailandensis 
Bt4 4     
B. 
thailandensis 
BtE555 E555     
a13 Bp, 11 Bm, and 9 Bt strains listed in this table were used for analysis of Bucl 
characteristics (Table 2), in part for distribution assessment (Table 4), and for 
phylogenetic analyses. Strain abbreviations listed in this table are used in all figures.  
bStrains which were also tested by PCR for bucl distribution. 
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Table 4. Distribution of all bucl genes in Burkholderia spp. as assessed by 
bioinformatics and PCR amplificationa. 
  bucl No. 
Strain 
Abbreviatio
n 
1 2 3 4 5 6 7 8 10 13 14 15 16 
BpBP006b + + + + + + + + + + + + + 
Bp79b + + + + + + + + + + + + + 
Bp146b + + + + + + + + + + + + + 
Bp511b + + + + + + + + + + + + + 
Bp520b + + + + + + + + + + + + + 
Bp20B16b + + + + + + + + + + + + + 
Bp78b + + + + + + + + + + + + + 
Bp1026bb + + + + + + + + + + + + + 
BpE203 + + + + + + + + + + + + + 
Bp4845 + + + + + + + + + + + + + 
Bp1152 + + + + + + + + + + + + + 
Bp1992 + + + + + + + + + + + + + 
BpE8 + + + + + + + + + + + + + 
Bp423 + + + + + + + + + + + + + 
Bp6068 + + + + + + + + + + + + + 
BpS13 + + + + + + + + + + + + + 
Bp1710a + + + + + + + + + + + + + 
Bp1710bb + + + + + + + + + + + + + 
BpK9624b + + + + + + + + + + + + + 
Bp1106b + + + + + + + + + + + + + 
BpCh3 - NT NT - + + + + NT + + + + 
Bp121 + + + + + + + + + + + + + 
Bp1112 + + + + + + + + + + + + + 
Bp305b + + + + + + + + + + + + + 
Bp668b + + + + + + + + + + + + + 
Bp406e + + + + + + + + + + + + + 
Bp1106ab + + + + + + + + + + + + + 
Bp5855 + + + + + + + + + + + + + 
Bp5848 + + + + + + + + + + + + + 
Bp5858 + + + + + + + + + + + + + 
Bp0134a + + + + + + + + + + + + + 
Bp0303a + + + + + + + + + + + + + 
Bm10229b + - + + + + + + + + + + + 
Bm10247b + + + + + + + + + + + + + 
BmA188b + - - + + + + + + + + + + 
BmA193b + - - + + + - + + + + + + 
Bm10399b + + + + + + + + + + + + + 
BmPRL20b + - + + + + + + + + + + + 
Bm6b + - + - + + + + + + + + + 
Bm11b + + + + + + + + + + + + + 
BmSAVP1b - + + - + + - + + + + + + 
BmGB3 + - - - + + + + + + + + + 
BmGB4 + + + - + + + + + + + + + 
BmISU + + + + + + + + - + + + + 
BmTurk1c + + + + + + + + + + + + + 
Bm234 + + + + + + + + - + + + + 
Bm235 + + + + + + + + - + + + + 
BmHI533 + + + + + + + + - + + + + 
BmGB11 + - + + + + + + + + + + + 
BmNBL7 + + + + + + + + - + + + + 
BmGB8 + + + + + + + + - + + + + 
Bm23344b + + + + + + + + - + + + + 
BmTurk2c + + + - + + + + + + + + + 
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BmFMH + + + + + + + + - + + + + 
Bm21280b + + + + + + + + - + + - + 
Bm85567 + + + + + + + + + + + + + 
Bm2700C + - + + + + + + + + + + + 
BmCh7 + + + + + + + + - + + + + 
BmCh5 + + + + + + + + + + + + + 
Bm10230 + - + + + + + + + + + + + 
BmGB8 + + + + + + + + - + + + + 
Bt21723b - - + + - - - - - - - - - 
BtH0587b - - + + - - - - - - - - - 
BtE444b - - + + - - - - - - - - - 
Bt121b - - + + - - - - - - - - - 
BtE555b - - + + - - - - - - - - - 
Bt43b - - + + - - - - - - - - - 
Bt4b - - + + - - - - - - - - - 
BtTXDOHb - - + + - - - - - - - - - 
BtE264b - - + + - - - - - - - - - 
BtDW503 - - + + - - - - - - - - - 
BtE421 - - + + - - - - - - - - - 
BtE426 - - + + - - - - - - - - - 
Fisher p-
value <0.0001 0.581 0.353 <0.0001 
Cramer’s V2 0.829 0.486 0.009 0.018 1 1 0.829 1 0.426 1 1 0.908 1 
Bc706 - - - - NT NT NT NT - NT NT NT NT 
Bc709 - - - - - - - - - - - - - 
Bc710 - - - - - - - - - - - - - 
Bce6656 - - - - - - - - - - - - - 
BceBC7 - - - - - - - - - - - - - 
BceK562 - - - - - - - - - - - - - 
BceJ2315 - - - - - - - - - - - - - 
Bce103a2 - - - - NT NT - NT - NT - NT - 
BmvCF2 - - - - - - - - - - - - - 
BmvCGD1 - - - - - - - - - - - - - 
BmvCGD2 - - - - - - - - - - - - - 
BmvCF1 - - - - - - - - - - - - - 
Bmv17616 - - - - - - - - - - - - - 
Bmv13010 - - - - - - - - - - - - - 
aPresence or absence of bucl amplicons are indicated by + or –, respectively. NT, not 
tested (not sufficient amount of gDNA available). Association of bucl presence with 
pathogenic Bp and Bm species, compared to nonpathogenic Bt strains, was assessed 
using the Fisher Exact Probability Test and Cramer’s V2 analysis.  
bStrains for which bucl presence was determined by bioinformatics. 
cSmaller-sized amplicons observed for bucl2 amplicon (S4 Fig. 4A). 
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Table 5. Primers and probe used for bucl amplificationa. 
bucl# Primer name  Primer sequence 5'-3' Amplicon size 
bucl1 Bucl1_4F GTGGCGCTGGCGCATCGTGAACGGC 103 bp 
  Bucl1_4R CTTCGTCGGTTGCGTGTCGTCCGTTGC   
bucl2 Bucl2_1F CGGCGTGCGACGGAA 133 bp 
  Bucl2_1R GCCCACTTCGCGATTCTTC   
bucl3 Bucl3_2F CTGCTCGGCGGCCTGTCGGGTTCGG 166 bp 
  Bucl3_2R CGGGCGCGGTCGTCGTCGA   
bucl4 Bucl4_2F_ext GACGAATTCATCCGCTTCATCGTG 176 bp  
  Bucl4_2R_ext2 CCGCTGCGCATCGGGCCTTTCA   
bucl5 Bucl5_2F AACTCGACGAACTCAACGCGAATCGAC 216 bp 
  Bucl5_2R GCGCGCCGTTCTTTCTAGCGCTGC   
bucl6 Bucl6_CL flank_F AGGAGCGGCGCTTGCCGGGCG 115 bpb  
  Bucl6_Clflank_2R GAACGGCGACGGTCCGACGCAGC   
bucl7 Bucl7_2F ATGGACACGACCACGCAGGACGGG 264 bp 
  Bucl7_2R CCAATGAACGGCCCGCGTCGCTTTC   
bucl8 Bucl8_2F GCAGCTCGATTCGTGGAT 243 bp 
  Bucl8_2R AGGTGGTACGACAGGCTCAG   
 Bucl8_3F CTACGCGCTCCTCGACATCGCGC 96 bp 
 Bucl8_3R TGCGTGCCGATGCCCGCGCGCA  
bucl10 Bucl10_1F GCATGCGTTGGACACGA 109 bp 
  Bucl10_1R GCAACGTCGTCATCTCGTC   
bucl13 Bucl13_2F GTTCGATTTCACGACGTACCGGCTCG 212 bp 
  Bucl13_2R CGTCGTCGTCGAAGTACAGCACGTC   
bucl14 Bucl14_1F TCGGCACATCTGTCGCCGCGAACC 178 bp 
  Bucl14_1R CGTATGGCCGCCGTGTCGATCGG   
bucl15 Bucl15_1F GATCGCTCGACGCGCCCGRCGTGC 95 bpb 
  Bucl15_1R CTAAAACCGCCGGCGYGCCGCGC   
bucl16 Bucl16_2F CCGGCAGCACCGACTCGAGCGTGCG 123 bp 
  Bucl16_2R CGTCGTTCGMGCTCGCCGATCGCTCG   
 cBucl16_5'FAM_3'IBQ TCTGCA+CG+G+CG+GTG+AGCCGCTTCA  
aPrimers were designed to generate conserved amplicons within the non-collagenous 
region of each bucl gene. Primers for bucl6 and bucl15 were designed flanking the 
collagenous region, which varies in size among strains (S4 Fig. 4B). Primers Bucl8_3F/3R 
were used to generate amplicon from Bp K96243 reference strain, whereas primers 
Bucl8_2F/2R  selectively amplify products from Bp and Bm gDNA and were used in large-
scale PCR screening (S4 Fig. 4B). 
bAmplicon sizes expected for the Bp K96243 reference strain.  
cLNA probe for bucl16 detection; + symbols precede LNA bases.
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Table 6. Genomic DNA collection. 
Species Abbreviation Strain Isolate information Source of 
DNA  
 
 
Alternative designations Source of isolate Year 
 
B. pseudomallei  Bp1026b 1026B   blood culture from 29-year old female rice farmer with 
diabetes milletus, Northeast Thailand, 
Sappasithiprasong hospital 
1993 USAMRIIDa 
B. pseudomallei BpE203 E203    Soil sample from Roi Et, Thailand  1997 USAMRIID 
B. pseudomallei Bp4845 NCTC4845 (S. 397, NRRL B-1112, 
CCEB 472) 
Monkey, Singapore 1935 USAMRIID 
B. pseudomallei Bp1152 STW-115-2   water, Thailand 1965 USAMRIID 
B. pseudomallei Bp1992 STW-199-2   water, Thailand 1965 USAMRIID 
B. pseudomallei BpE8 E8    Soil sample obtained on road to Trakan Phuet Phon 
District, Ubon Ratchathani Thailand 
  USAMRIID 
B. pseudomallei Bp423 423   Blood culture, Cambodia  2008 USAMRIID 
B. pseudomallei  Bp6068 Pasteur 
6068  
2002721763 Vietnam   BEI 
Resourcesb 
B. pseudomallei  Bp13 S13   muicodal strain, environmental isolate, Singapore   BEI Resources 
B. pseudomallei  Bp1710a 1710a   blood culture of 52-year old male rice farmer with 
diabetes milletus, Northeast Thailand 
1996 BEI Resources 
B. pseudomallei  Bp1710b 1710b   relapse of same patient infected with 1710a, blood 
culture, Northeast Thailand, Sappasithiprasong 
hospital 
1999 BEI Resources 
B. pseudomallei  BpK9624 K96243   female diabetic patient- Khon Kaen hospital, 
Northeast Thailand 
1996 BEI Resources 
B. pseudomallei  Bp1106b 1106b   relapse of same patient infected with 1106a- female 
rice farmer, pus aspirated from liver abscess, 
Northeast Thailand, Sappasithiprasong hospital 
1996 BEI Resources 
B. pseudomallei  BpCh3 China 3   septicemia of American soldier, Burma   BEI Resources 
B. pseudomallei  Bp121 NBL 121 strain 286, MP-S chronic melioidosis case, infection acquired while 
living in Far East, Louisiana, United States 
1953 BEI Resources 
B. pseudomallei Bp1112 NRRL B-
1112 
strain S 397, CCEB 472 naturally infected lab monkey, Singapore 1935 BEI Resources 
B. pseudomallei  Bp305 MSHR305   brain sample, fatal encephalomyelitis, Australia, Royal 
Darwin hospital 
1994 USAMRIID 
B. pseudomallei  Bp668 MSHR668   blood culture from 53-year old male patient with 
severe melioidosis encephalomyelitis, Darwin 
Australia 
1995 USAMRIID 
B. pseudomallei  Bp406e 406e   disseminated melioidosis patient, toe swab, Ubon 
Ratchathani province, Northeast Thailand 
1988 USAMRIID 
B. pseudomallei  Bp1106a 1106a   female rice farmer, Northeast Thailand, 
Sappasithiprasong hospital 
1993 USAMRIID 
B. pseudomallei  Bp5855 MSHR5855   Australia 2011 USAMRIID 
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B. pseudomallei  Bp5848 MSHR5848   inhalational melioidosis, Australia 2011 USAMRIID 
B. pseudomallei  Bp5858 MSHR5858       USAMRIID 
B. pseudomallei  Bp0134a HBPUB 
10134a 
  sputum, Thailand, Mahidol University 2010 USAMRIID 
B. pseudomallei  Bp0303a HBPUB 
10303a 
  sputum, Thailand, Mahidol University 2011 USAMRIID 
B. mallei BmGB3 GB3 2002734306, 
2002734311, strain A, 
NCTC120  
Lister Institute, London 1920 USAMRIID 
B. mallei BmGB4 GB4 M4, 2002734304, strain 
6, NCTC10248 
human, Ankara, Turkey 1950 USAMRIID 
B. mallei BmISU ISU   Iowa State University   USAMRIID 
B. mallei BmTurk1 Turkey 1 2000031065, #1 Turkey Turkey, isolated by Dr. Linda Schlater  2003 USAMRIID 
B. mallei Bm234 KC234 2002721273, 3783  human, Burma- isolated via CA Gleisser Army 
Medical School 
1956 USAMRIID 
B. mallei Bm235 KC235 2002721274 Fort Detrick, Maryland, United States 1956 USAMRIID 
B. mallei BmHI533 HI533 2000031304, 
2000031281 
human liver abscess drainage, Maryland, United 
States 
2000 USAMRIID 
B. mallei BmGB11 GB11  NCTC 10245, 
2002721275, China 5, 
ATCC10399 
horse lung, Southern China 1949 USAMRIID 
B. mallei  BmNBL7 NBL 7  China 7 Prep of B mallei China 7 derived from ATCC23344 via 
passage through several individuals  
  BEI Resources 
B. mallei  BmGB8 GB8 horse 
4  
  derivative of ATCC23344 passaged through horse 
and isolated from the lung as a single colony, 
Manitoba, Canada 
  BEI Resources 
B. mallei Bm23344 ATCC 
23344 
  human post-mortem knee fluid, skin pustules and 
blood, Burma 
1944 BEI Resources 
B. mallei BmTurk2 Turkey 2 T2 Turkey   BEI Resources 
B. mallei BmFMH FMH   derivative of ATCC23344 passaged through human, 
laboratory acquired infection- blood 
2000 USAMRIID 
B. mallei Bm21280 2002721280 KC1092, 52-236 Iran 1952 BEI Resources 
B. mallei Bm86567 86-567 India86-567-2, 
2000031064 
mule, East India   BEI Resources 
B. mallei Bm2700C SR092700C       BEI Resources 
B. mallei  BmCh7 China 7 NBL7 preparation produced directly from ATCC 23344 1942 BEI Resources 
B. mallei  BmCh5 China 5 MM-A, NBL4 lung and nose of infected horse, Kweiyang, China 1942 BEI Resources 
B. mallei  Bm10230 NCTC 
10230 
strain Ivan horse with glanders, Hungary 1961 BEI Resources 
B. mallei BmGB8** GB8 
(atcc23344) 
  Laboratory passage of ATCC 23344 in mouse 1997 USAMRIID 
B. thailandensis  BtE264 E264   rice field soil sample, Central Thailand   BEI Resources 
B. thailandensis  BtDW503 DW503   Derived from E264; (∆amrR-oprA) (Kms Gms Sms); 
rpsL (Smr), Central Thailand 
  BEI Resources 
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B. thailandensis  BtE421 E421   rice field soil sample from Ubon Ratchathani province, 
Northeast Thailand 
2001 BEI Resources 
B. thailandensis BtE426 E426   rice field soil sample from Ubon Ratchathani province, 
Northeast Thailand 
2001 BEI Resources 
B. cepacia Bc706 DD-706       BEI Resources 
B. cepacia Bc709 DD-709       BEI Resources 
B. cepacia Bc710 DD-710       BEI Resources 
B. cenocepacia Bce6656 LMG16656   sputum of cystic fibrosis patient, Edinburgh, United 
Kingdom 
1989 BEI Resources 
B. cenocepacia BceBC7 BC7   sputum from 15-year old patient with "cepacia 
syndrome", Canada 
  Emory Uc 
B. cenocepacia  BceK562 K56-2   less antibiotic resistant derivative of BC7, Canada   Emory U 
B. cenocepacia  BceJ2315 J2315   sputum from cystic fibrosis patient, Edinburgh, United 
Kingdom 
1989 Emory U 
B. cenocepacia Bce103a2 DD-707       BEI Resources 
B. multivorans BmvCF2 CF2   sputum from cystic fibrosis patient, NIH Clinical 
Center 
  Emory U 
B. multivorans  BmvCGD1 CGD1   sputum from chronic granulomatous disease patient, 
NIH Clinical Center 
  Emory U 
B. multivorans BmvCGD2 CGD2   blood from chronic granulomatous disease patient, 
NIH Clinical Center 
  Emory U 
B. multivorans  BmvCF1 CF1   sputum from cystic fibrosis patient, Belgium   Emory U 
B. multivorans Bmv17616 ATCC 
17616 
  soil sample, United States   Emory U 
B. multivorans  Bmv13010 LMG13010 CCUG 34080, Lauwers 
Cepa 002, CIP 105495, 
DSM 13243, NCTC 
13007 
sputum of cystic fibrosis patient, Belgium 1992 BEI Resources 
aUSAMRIID; United States Army Medical Research Institute of Infectious Disease.  
bBEI Resources; NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH.  
cEmory U; Dr. Joanna Goldberg, Emory University School of Medicine, Atlanta, GA. 
 241 
CONCLUSIONS 
 
Adhesion and biofilm formation: friend or foe? 
The main goal of this work was to investigate the role of the major surface adhesin of 
GAS, streptococcal collagen-like protein 1 (Scl1), in host tissue attachment, biofilm 
formation, and virulence. Specifically, our studies focused on the invasive M3-type strains 
that form poor biofilms in vitro and harbor a unique scl1.3 allele, which encodes a 
truncated cell-free protein variant. Biofilm formation by bacteria is typically considered 
disadvantageous to the host because biofilm-embedded bacteria are considerably more 
resistant to phagocytosis by PMNs and antibiotic treatment (104). However, it has been 
an emerging concept that adherence and biofilm formation are inversely related to 
invasiveness and virulence during bacterial infection. Specifically, up to 99.5% of GAS 
infections are superficial infections of the throat and skin that are associated with localized 
tissue microcolonies or biofilms, whereas the remaining 0.5% are invasive infections that 
are not biofilm-associated (105). Our unique observations in biofilm-deficient M3-type 
strains led us to devise the following hypothesis to explain this phenomenon: Invasive 
M3-type GAS, devoid of Scl1 surface adhesin, have reduced adherence to host 
ECM proteins, including cellular fibronectin (cFn) and laminin (Lm), and reduced 
biofilm capacity, thus circumventing the formation of stable tissue microcolonies 
and shifting the balance towards invasive dissemination instead of localized 
infection. Our major findings, summarized below in the context of relevant literature, 
support this model. 
 
Poor biofilm formation and the unique scl1.3 allele of M3-type GAS 
Our initial study demonstrated that Scl1 significantly contributes to biofilm formation by 
GAS on inanimate surfaces (Chapter 1). We showed that deletion of scl1 in strains of M1, 
M28 and M41 type resulted in decreased biofilms, with at least 50% reduced average 
thickness. Heterologous complementation of the biofilm-deficient Lactococcus lactis with 
scl1 conferred biofilm formation. Although the mechanism of Scl1-mediated biofilm 
formation was not fully established, Scl1 expression was correlated with increased 
surface hydrophobicity in these strains. Notably, several invasive M3 wild-type strains had 
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diminished biofilms in comparison to biofilm-capable M1-, M28-, and M41-type strains. 
We hypothesized that poor biofilm formation was associated with the predicted lack of 
surface Scl1, based on the presence of a unique null mutation in the scl1.3 allele of the 
M3-strains. The nonsense mutation occurred in the 11th Gly-X-Y repeat of the collagenous 
region, presumably resulting in a truncated secreted Scl1 variant. This unique scl1.3 allele 
was conserved in >98% of invasive M3 isolates (Chapter 3). Our successive studies 
confirmed the lack of Scl1 expression on the surface of M3 strains by flow cytometry, and 
in cell wall extracts of M3 strains by western blot. Interestingly, the truncated Scl1.3 
variant was not detected in supernatant fraction, likely a result of the diminished 
expression of the scl1.3 transcript that was also perceived for these strains in comparison 
to other M-types (Chapter 2). Altogether, association between the lack of Scl1 expression, 
accompanied by limited biofilm formation, prompted further investigations into the 
invasive traits of M3-type strains.  
 
Scl1-mediated biofilm and ECM binding: implications in tissue microcolony formation 
Accumulating evidence has supported the importance of Scl1 in mediating the formation 
of in vivo tissue microcolonies, or biofilms, during infection. First, previous data showed 
that Scl1-mediated biofilms were enhanced on cFn and Lm coatings, as well as on a 
complex ECM matrix deposited by human fibroblasts (54). Next, Scl1 specifically binds 
to extra domain A-containing isoforms of cellular fibronectin (EDA/cFn) and basement 
membrane laminin (Lm), which are both ECM components found in wounded tissue 
(54,60). Consequently, both binding functions could foster ligand recognition at the 
pathogen portal of entry, which supports bacterial adherence and formation of stable 
tissue microcolonies. Here, we used an in vitro model of wounded human skin equivalents 
to compare wound colonization and tissue invasion by GAS. The Scl1-lacking biofilm-
poor M3-type GAS invaded wound bed in a form of loose chains and cells, whereas Scl1-
expressing biofilm-capable M41-type GAS formed large rounded microcolonies encased 
in glycocalyx, as imaged by two-photon microscopy (Chapter 2). These results 
demonstrated striking phenotypic difference in tissue invasion by M3 and M41 GAS.  
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Full-length surface-attached Scl1.3 supports adherence and biofilm formation 
To test our hypothesis shown in Figure 1, we 
first had to assess whether full-length Scl1.3 
variant binds cFn and Lm, and second, if it 
restores biofilm formation of M3-type GAS on 
cFn- and Lm-coated surfaces (Chapter 2). 
First, recombinant full-length Scl1.3 
(rScl1.3FL) protein was generated, following 
the reversion of the null mutation and 
restoring the open reading frame, and tested 
for ECM binding. Positive binding of rScl1.3FL 
to cFn and Lm was demonstrated by ELISA, 
surface plasmon resonance, and tryptophan 
fluorescence binding assays. These results 
support the concept that Scl1.3FL on the GAS 
cell surface would behave as an adhesin 
conferring adherence to EDA/cFn and Lm. 
Interestingly, rotary shadowing and electron 
microscopy of rScl1.3 proteins showed 
aggregates mediated by V-to-V domain 
interactions that could stabilize biofilm 
structure. 
A second set of experiments was 
designed to test the effect of Scl1.3FL surface 
expression on GAS biofilm formation. 
Homologous complementation of two invasive 
M3-type strains with Scl1.3FL conferred biofilm formation on cFn- and Lm-coated 
surfaces. Additionally, heterologous complementation of a ∆scl1 mutant of M41-type 
strain with Scl1.3FL restored biofilm formation to the wild-type level. Biofilms formed by 
the complemented strains were at least two-fold thicker on average, compared to vector-
complemented controls. Overall, these results reinforce our hypothesis that M3-type 
 
Figure 1. Hypothesis model. Top: Infection 
of wounded skin with wild-type M3-type GAS. 
Inherent lack of surface-expressed Scl1.3 
causes decreased binding to cFn and Lm 
expressed in wounded tissue, and reduces 
biofilm and tissue microcolony formation by 
M3-type bacteria (red circles). Bottom: In-trans 
complementation of M3-type GAS with full-
length cell-associated Scl1.3, Scl1.3FL, 
restores binding to cFn and Lm in tissue, which 
confers biofilm and tissue microcolony 
formation during infection. 
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strains have reduced adherence and microcolony formation due to a natural lack of 
surface Scl1 with intrinsic capacity for ECM binding and biofilm support (Figure 1). 
 
Inactivation of Scl1 in GAS results in hypervirulent phenotype  
If our hypothesis is correct, the inactivation of scl1 in biofilm-capable GAS strains should 
result in increased virulence during infection. We validated this concept by demonstrating 
that scl1-inactivated isogenic mutants of the M28- and M41-type strains produced larger 
skin lesions during subcutaneous infection of mice than the wild-type parental strains 
(Chapter 2). A similar phenotype was displayed by Scl1-deficient M3-type GAS in 
comparison to M3 strain containing a rare cell-attached Scl1 variant. While the majority 
of M3-type strains harbor the scl1.3 allele containing the null mutation, ~1.3% of M3 
strains harbor a “scl1.3 carrier allele” containing an in-frame deletion encompassing the 
null mutation, and thus, express a cell-attached variant. An isoallelic replacement strain, 
harboring the carrier allele, formed a limited abscess compared to the invasive parental 
M3 strain (Chapter 3). The carrier strain also exhibited increased adherence to human 
epithelial cells.  
 
Adherence and biofilm formation: an inverse relationship with invasiveness 
Overall, our results support the hypothesis that M3-type GAS, naturally lacking surface 
Scl1, are reduced in adherence and microcolony formation, thus resulting in bacterial 
dissemination and invasive infection. Figure 2 depicts a model for Scl1-mediated 
adhesion and microcolony formation during infection, comparing M28- and M41-type GAS 
expressing Scl1 to M3-type GAS lacking Scl1.  
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The main hypothesis presented in my thesis, which postulates an inverse 
relationship between strain invasiveness and its capacity to form biofilm, has gained 
recent support from several studies. Streptococcus pneumoniae grown in biofilm was less 
able to disseminate to the blood in mouse models of intranasal and intratracheal infection 
(106). Biofilm-grown bacteria also had increased adherence to host epithelial cells, as 
compared to bacteria grown in culture (106). Another study showed that biofilm-deficient 
mutants of S. pneumoniae elicited greater cytokine responses in a mouse model of 
intranasal infection colonization, and had decreased adherence and increased invasion 
of epithelial cells in vitro (107). Destabilization of S. pneumoniae biofilm and subsequent 
dissemination was triggered by co-infection with influenza A virus in vivo, as well as febrile 
temperatures and nutrient availability in vitro. The dispersed bacteria had altered gene 
expression profile and enhanced dissemination in mice (108). Similarly, GAS cells that 
formed biofilm in vitro on epithelial cells had downregulated expression of virulence 
genes, including streptolysins, emm, and hyaluronic acid capsule gene hasA, and showed 
enhanced colonization of nasal-associated lymphoid tissue, while dissemination to distant 
 
Figure 2. Model of Scl1-mediated GAS adhesion, biofilm formation, and host colonization. M28- 
and M41-type GAS express full-length cell-attached Scl1, which mediates adherence to cFn and Lm. ECM 
binding promotes biofilm formation in wounded tissue and allows the formation of superficial tissue 
microcolonies resulting in non-invasive colonization. On the contrary, in M3-type GAS, naturally lacking 
full-length cell-attached Scl1.3 adhesin, bacterial cells have reduced adherence to cFn and Lm and 
reduced capacity for biofilm formation, thereby circumventing the formation of localized tissue 
microcolonies; infection balance is shifted towards dissemination through tissue, promoting invasive 
spread. 
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organs was decreased (109). Likewise, the cleavage of bacterial surface adhesins by the 
potent GAS protease SpeB, resulted in dispersal of biofilm, which was associated with 
increased lesion sizes in mice (110).  
  
Scl variants of GAS- a shared structure with diverse ligand binding properties 
The majority of our work has focused on adherence and biofilm conferred by the Scl1 
protein, functions that are lacking for the Scl2 protein; however both Scl proteins are 
ubiquitous among GAS strains and share a similar overall structure. Early studies based 
on recombinant Scl proteins of GAS showed they harbor a conserved lollipop-like domain 
organization with a globular variable domain and stalk-like collagenous domain (20,21). 
Additionally, multiple sequence alignment and secondary structure analyses of the Scl1- 
and Scl2-variable regions predicted two conserved α-helices interspaced by the 
hypervariable sequence (51). A major contribution that came from current work was the 
report of the crystal structure for the V domain of the Scl2 protein of M3-type GAS, which 
provided insights into possible ligand binding sites and function of the Scl proteins 
(Chapters 4 and 5). The Scl-globular (homotrimeric) domain folds into unique six helical 
bundle structure, which is predicted to be conserved across all Scl1 and Scl2 variants. 
The two antiparallel α-helices that are conserved in all variants form a structural core for 
the exposed variable loops that are likely involved in ligand binding. The V domain was 
also found to be structurally similar to the gp41 subunit of the envelope glycoprotein of 
HIV-1, a membrane fusion protein involved in viral entry into CD4+ T cells, although the 
two proteins had low sequence identity. The six-helix bundle structure is largely absent in 
bacteria, with the exception of the cholix toxin which was reported to contain a bundle of 
six helices within the translocation domain (111). Membrane fusion and entry or 
translocation across the membrane seems to be a function offered by this structural 
element. Since internalization of GAS by host cells has been reported (112), it would be 
interesting if the V domain of Scl also mediates an interaction with host cell membranes 
to accomplish host cell entry. 
  
 247 
SUPPLEMENTARY MATERIAL FOR CHAPTER 1 
 
THE STREPTOCOCCAL COLLAGEN-LIKE PROTEIN-1 (SCL1) IS A SIGNIFICANT 
DETERMINANT FOR BIOFILM FORMATION BY GROUP A STREPTOCOCCUS 
Heaven A Oliver-Kozup, Meenal Elliott, Beth A Bachert, Karen H Martin, Sean D Reid, 
Diane E Schwegler-Berry, Brett J Green, and Slawomir Lukomski 
Published in BMC Microbiology 2011 11:262 
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Figure S1 
 
Figure S1 (a). Confocal laser scanning microscopy (CLSM) of GFP-expressing M41 WT 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 1 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4d). Thickness is indicated in micrometers.  
 
  
M41 WT
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Figure S1 (b). Confocal laser scanning microscopy (CLSM) of GFP-expressing M41Δscl1 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 0.75 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4d). Thickness is indicated in micrometers.   
M41Δscl
1 
M41∆scl 
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Figure S1 (c). Confocal laser scanning microscopy (CLSM) of GFP-expressing M28 WT 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 1 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4e).  Thickness is indicated in micrometers.  
M28 WT
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Figure S1 (d). Confocal laser scanning microscopy (CLSM) of GFP-expressing M28Δscl1 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 1 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4e). Thickness is indicated in micrometers.  
 
 
  
M28Δscl
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Figure S1 (e). Confocal laser scanning microscopy (CLSM) of GFP-expressing M1 WT 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 1 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4f). Thickness is indicated in micrometers.   
M1 WT
M1 WT 
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Figure S1 (d). Confocal laser scanning microscopy (CLSM) of GFP-expressing M1Δscl1 
GAS biofilm at 24 h. Panels represent a gallery view of consecutive images taken at 1 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 4f). Thickness is indicated in micrometers. 
  
M1Δscl1 M1∆scl
1 
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Figure S2 
 
 
Figure S2 (a). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis MG1363 WT biofilm at 24 h. Panels represent a gallery view of 
consecutive images taken at 0.25 micrometer increments. Panel shown in lower right 
corner represents an X-Y orthogonal Z-stack view (Fig. 5e). Thickness is indicated in 
micrometers.   
MG1363 WT 
MG1363 WT 
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Figure S2 (b). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis biofilm at 24 h. L. lactis was transformed with the shuttle vector 
pJRS525 (MG1363::pJRS525). Panels represent a gallery view of consecutive images 
taken at 0.25 micrometer increments. Panel shown in lower right corner represents an X-
Y orthogonal Z-stack view (Fig. 5e). Thickness is indicated in micrometers.   
MG1363::pSL525 
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Figure S2 (c). Confocal laser scanning microscopy (CLSM) of GFP-expressing 
Lactococcus lactis expressing Scl1.41 protein (MG1363::pSL230) biofilm at 24 h. L. lactis 
was transformed with the plasmid construct pSL230 encoding Scl1.41 protein 
(MG1363::pSL230). Panels represent a gallery view of consecutive images taken at 0.5 
micrometer increments. Panel shown in lower right corner represents an X-Y orthogonal 
Z-stack view (Fig. 5e). Thickness is indicated in micrometers. 
 
  
MG1363::pSL230 
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SUPPLEMENTARY MATERIAL FOR CHAPTER 2 
 
UNIQUE FOOTPRINT IN THE SCL1.3 LOCUS AFFECTS ADHESION AND BIOFILM 
FORMATION OF THE INVASIVE M3-TYPE GROUP A STREPTOCOCCUS 
Beth A. Bachert, Soo Jeon Choi, Paul R. LaSala, Tiffany Harper, Dudley H. McNitt, Dylan 
T. Boehm, Clayton C. Caswell, Pawel Ciborowski, Douglas R. Keene, Anthony R. Flores, 
James M. Musser, Flavia Squeglia, Daniela Marasco, Rita Berisio, and Slawomir 
Lukomski 
Published in Frontiers in Cellular and Infection Microbiology 2016 6:90 
 
  
 258 
 
 
Figure S1. Analytical PCR of scl1.3 and scl2.3 in M3-type GAS. (A) PCR of scl1.3 in 42 
M3-type strains was performed with primers 232Up and 232Rev flanking the scl1 locus 
(Table S1). Expected size based on MGAS315: 1,010 bp. M, 1 kb Plus DNA Ladder. (B) 
PCR of scl2.3 in 42 M3-type strains was performed with primers Scl2.3 F and Scl2.3 R 
flanking the scl2.3 collagen-like region (Table S1). Expected size based on MGAS315 
genome is 1,125 bp. M, 1 kb Plus DNA Ladder. MGAS designation applies to all strain 
numbers shown above gel wells, with the exception of strain AM3. 
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Figure S2. Domain organization of rScl1.3FL and rScl2.3 proteins. Rotary shadowing 
of rScl proteins demonstrates the conserved lollipop-like domain organization. Aggregates 
mediated by the interactions between V regions of rScl1.3FL are seen in the top panels 
(depicted by arrows). No apparent aggregation was observed in the rScl2.3 preparation 
(single lollipops are depicted by arrowheads). All scale bars reflect 100 nm.   
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Figure S3. Colocalization of glycocalyx staining with GFP-expressing M41-type GAS 
during in vitro infection of skin equivalent. Representative TPF gallery image of z-stack 
layers from 3D projection (Figure 5 of manuscript), showing colocalization of TRITC-
concanavalin A staining of glycocalyx (red) with GFP-expressing GAS microcolonies 
(green). Z-stack step size: 1 µm; 600x magnification. 
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Figure S4. Strategy for C-C’ loop peptide design. Cartoon model of the EDA domain of 
cFn (PDB code 1J8K) used for the C-C' peptide design. The designed peptide includes the 
C-C' beta-hairpin (orange). The terminal residues of the beta-hairpin (magenta) were 
mutated to cysteine to induce a disulfide bond and mimic the conformation of the peptide 
in the protein. The key residue for recognition, Asp41, is reported in ball-and-stick along 
with the residues Arg33 and Glu45, which form a salt bridge, and the terminal residues 
mutated to cysteine. 
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Table S1. Primers used in this study 
Primer name Sequence (5’-3’) Use  
Analytical PCR   
IS1548F GCCGTCTGCGTGCCCATTGCGTCTA Detection of 
IS1548  Scl1 R ACTAGATCTGAGATTATGGTGCTTTGATGTC 
232 Up CTCCACAAAAGAGTGATCAGTC Amplificatio
n of scl1.3 232 Rev TTAGTTGTTTTCTTTGCGTTT 
Scl2.3 F AGGCATACAAGATCATGTCCTTGA Amplificatio
n of scl2.3  Scl2.3 R TTTGGTGTATGTGGTGCGGT 
Scl Up CTTTCAATGGATGACGATACC Amplificatio
n of scl2.3 Scl Rev ACTTTCCATCAGTTAGGTAGC 
   
Cloning   
Scl1.3 M3VF GAGATGGCCGAGACTCCTATGACATCAAAGG Cloning of 
scl1.3V 
region  
Scl1.3 M3VR CAGCGTCTCAGCGCTCTTTGTTGCACCTTTTTC
AATCAG 
232 Up CTCCACAAAAGAGTGATCAGTC Cloning of 
scl1.3WT  ME7 TCAGTGAATTCTCTTTAGAGGATTAG 
pJRS525F1 GGGTTTTCCCAGTCACG Repair of 
scl1.3 null 
mutation 
ME6a TCCAGCAGGACCTCGAGGTGAACGC 
Scl1.3 M3VF GAGATGGCCGAGACTCCTATGACATCAAAGG Cloning of 
scl1.3FL  Scl1.28WMR GTCAAGCTTATTATTTTTCGAACTGCGGGTGG
CTCCAAGGTTTTTCTGGAGCTGGAGTTACC 
Scl1.3 M3VF ext GAGATGGCCGAGACTCCTATGACATCAAAGGA
GAGACAAG 
Cloning of 
scl1.3WT  
Scl1.3 truncR2 GGTCTCAGCGCTACCTCGAGGTCCTGCTGGA
CCTTG 
Scl2 M3VF GAGATGGCCGATGGTGAAGATGCCCAAAAAAG Cloning of 
scl2.3  Scl2.28_WMR GTCAAGCTTATTATTTTTCGAACTGCGGGTGG
CTCCAT 
   
qRT-PCR analysis   
tufA_F CAACTCGTCACTATGCGCACAT qRT-PCR of 
tufA tufA_R GAGCGGCACCAGTGATCAT 
Scl1_WMR_exp_F TGCTGACAAAGAAGCTAACCAAAC qRT-PCR of 
scl1  Scl1_WMR_exp_R GTGGTTGTTGGCTACAGGTGTCT 
Scl2_WMR_exp_F TCCTAAAACACCAGAGGTCC qRT-PCR of 
scl2  Scl2_WMR_exp_R
2 
TGTGTGTGTCGTGAGCTGC 
emm3_exp_F2 AACAAATCTCAGACGCAAGCCGTC qRT-PCR of 
emm  emm3_exp_R2 TTCAAGCTCTTTGTTWAGTTTTTCAAG 
Mga_TMF CAAGTCAACAGTGGAGAGAACTAAAATT qRT-PCR of 
mga  Mga_TMR ATGGAGATGTTGAGAGCTTTGCT 
Mga_F1 ATCAGACAAAAACATTAAATTGCATG Sequencing 
of mga 
promoter 
Mga_R1 TTGCATGTTAGTGAGACAAGTTTGC 
a Bolded GAA in primer ME6 indicates codon for glutamine in place of the original TAA stop 
codon.  
  
 263 
Table S2. Variation in scl2.3 gene among M3 strains 
Strain  No. of GXY 
repeats 
No. of bp in the  
CL region 
Amplicon size 
(bp)a 
No. of 
CAAAA 
repeats 
GTG in 
frameb 
MGAS274 ~125 ~1125 ~1206  8 yes 
MGAS315   116   1044   1125  5 yes 
MGAS335 ~135 ~1215 ~1296  4 no 
MGAS1313 ~119 ~1071 ~1152  8 yes 
AM3 ~129 ~1161 ~1242  10 no 
MGAS3375   17   153   234   5 yes 
MGAS9517   113   1017   1098 8 yes 
MGAS9622   111   999   1080 11 yes 
MGAS9631   113   1017   1098  18 no 
MGAS9716   110   990   1071 14 yes 
MGAS9726   111   999   1080 11 yes 
MGAS9739   119   1071   1152 5 yes 
MGAS9760   113   1017   1098 11 yes 
MGAS9780   106   954   1035 14 yes 
MGAS9842   139   1251   1332 9 no 
MGAS9852   103   927   1008 8 yes 
MGAS10080   117   1053   1134 5 yes 
MGAS10118   119   1071   1152 5 yes 
MGAS10220   110   990   1071 12 no 
a Amplicons were generated using primers Scl2.3 F/ R (Table S1) 
b GTG is scl2 start codon 
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Table S3. Mass spectrometry identification of rScl and native Scl proteinsa 
Sample No. of 
peptides 
>95% 
confident 
Peptide Confidence Sequence 
coverage 
Confident 
ID 
rScl1.3V 4 EENSQEELK 99% 40% yes 
EENSQEELKNFTEER 99%   
LKEILDLIEK 99%   
WYGTYFKEENSQEELK 99%   
rScl2.3 2 GIQDHVLDGQDGDR 99% 18% yes 
EELLSALIDGTSR 98.13%   
      
MGAS315 WT 
Scl2.3 in Sup 12 DVTPAPQNPSN 99% 17% yes 
DVTPAPQNPSNR 99%   
EELLSALIDGTSR 99%   
GEAGPAGPR 99%   
GIQDHVLDGQDGDR 99%   
GIQDHVLDGQDGDRGEAGPA
GPR 
99%   
GLNKPQTQGGNQL 99%   
GLNKPQTQGGNQLAK 99%   
NKPQTQGGNQLAK 99%   
REELLSALIDGTSR 99%   
TPEVPQKPDTAPHTPK 99%   
TPQIPGQSK 99%   
Scl2.3 in CW 7 DVTPAPQNPSNR 99% 15% yes 
EELLSALIDGTSR 99%   
GIQDHVLDGQDGDR 99%   
GIQDHVLDGQDGDRGEAGPA
GPR 
99%   
GLNKPQTQGGNQLAK 99%   
REELLSALIDGTSR 99%   
TPEVPQKPDTAPHTPK 99%   
 
Scl1.3FL- complemented GAS 
315WT :: 
scl1.3FL 
5 EENSQEELKNFTEER 99% 17% yes 
EILDLIEK 99%   
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
LKEILDLIEK 99%   
10870∆scl1 :: 
scl1.3FL 
4 EILDLIEK 99% 11% yes 
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
LKEILDLIEK 99%   
M41∆scl1 :: 
scl1.3FL 
3 EENSQEELKNFTEER 99% 13% yes 
GDKGETGLAGPVGPAGK 99%   
GETGLAGPVGPAGK 99%   
a Protein identification is confident by the presence of at least two distinct peptides with 
>95% confidence each. Sup, supernatant protein fractions; CW, cell-wall association 
protein fractions. 
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Table S4. Summary table of fold-changes in scl1 and scl2 expressiona 
Strain Gene Fold change +SE - SE P value Significance 
M1 scl1 21.05195084 -2.33583 -2.62734 0.001184755 **  
scl2 -23.6920597 -1.97551 -1.82347 0.01549836 * 
M28 scl1 6.237987683 -1.1098 -1.34997 0.01395444 * 
 scl2 -7.25032516 0.960352 1.106978 0.034822349 * 
M41 scl1 7.787441864 -0.82018 -0.91673 0.004897482 ** 
 scl2 -3.22615419 0.376259 0.425935 0.141911016 N.S. 
M3 MGAS: 
10870 scl1 -25.2160816 1.366976 1.445328 5.48581E-06 *** 
 scl2 -1.84753589 -0.01174 -0.01166 0.077646106 N.S. 
158 scl1 -45.8489636 -0.86051 -0.84465 0.000121468 ***  
scl2 1.077129939 0.059307 0.056212 0.753558444 N.S. 
335 scl1 -42.9309881 -4.03211 -3.68593 5.18378E-05 ***  
scl2 -2.44408041 -1.65928 -0.98832 0.283398851 N.S. 
1313 scl1 -43.929358 0.938527 0.959016 5.45812E-06 ***  
scl2 -3.89390614 -2.38312 -1.47835 0.117229672 N.S. 
aFold-changes in scl1 and scl2 expression relative to M3 MGAS315 are shown for each 
strain. Data is based on qRT-PCR analysis of RNA isolated during exponential growth 
phase and expression is normalized to the expression of tufA gene. +SE, positive standard 
error; -SE, negative standard error. Significance is calculated based on three independent 
experiments, each performed in triplicate wells. *P<0.05, **P<0.01, ***P<0.001; student’s 
t-test.   
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SUPPLEMENTARY MATERIAL FOR CHAPTER 3 
 
NATURAL VARIANT OF COLLAGEN-LIKE PROTEIN A IN SEROTYPE M3 GROUP A 
STREPTOCOCCUS INCREASES ADHERENCE AND DECREASES INVASIVE 
POTENTIAL 
Anthony R. Flores, Brittany E. Jewell, Erika M. Versalovic, Randall J. Olsen, Beth A. 
Bachert, Slawomir Lukomski and James M. Musser 
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Table S1. Strains and plasmids used in this study 
Strain Description Source 
MGAS315 Serotype M3 invasive strain (1) 
MGAS10870 Serotype M3 invasive strain (2) 
MGAS23440 Serotype M3 invasive strain (3) 
MGAS10870sclACarrier Isoallelic mutant with sclACarrier This study 
MGAS10870∆sclA Isogenic deletion mutant lacking sclA This study 
MGAS10870∆sclA:: 
pDCsclAInvasive 
Isogenic deletion mutant complemented in 
trans with pDCsclAInvasive 
This study 
MGAS10870∆sclA:: 
pDCsclACarrier 
Isogenic deletion mutant complemented in 
trans with pDCsclACarrier 
This study 
Plasmid Description Source 
pDC123 E. coli/S. pyogenes shuttle vector used 
for trans-complementation and 
expression 
(4) 
pJL1055 E. coli/S. pyogenes shuttle vector used 
for allelic exchange in GAS 
 
pCR2.1 E. coli cloning vector Invitrogen 
pET15b E. coli expression vector Novagen 
pDCsclAInvasive pDC123 shuttle vector with sclAInvasive allele 
and native promoter from 
MGAS10870 
This study 
pDCsclACarrier pDC123 shuttle vector with sclACarrier 
allele and native promoter from carrier 
strain MGAS23440 
This study 
pJSF41 pJL1055 with sclACarrier from MGAS23431 This study 
pJSF66 pET15b containing sclAInvasive from 
MGAS10870 used for overexpression and 
subsequent antibody generation 
This study 
pJRS525 E. coli/ S. pyogenes shuttle vector used 
for cloning and repair of sclAInvasive allele 
from MGAS315 to generate sclAM3-FL 
(5) 
pSL501 pJRS525 with sclAInvasive from MGAS315 This study 
pSL502 pSL501 with repaired allele sclAM3-FL 
generated by PCR mutagenesis 
This study 
pASK-IBA2 E. coli expression vector used for generation 
of rSclAM3-FL 
IBA, Gӧttingen 
pSL503 pASK-IBA2 with sclAM3-FL This study 
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Table S2. Primers used in this study 
Primer Use Sequence (5’-3’) 
2902F 
 
3’ end of sclA used to amplify sclA from invasive 
and carrier strains 
ATTTTTGCCATTTCGTT
CCT 
2487R  
 
5’ end of sclA upstream of promoter used to 
amplify sclA from invasive and carrier strains 
CGAATTTTCCAAGATT
GACGA 
2901F 
 
Downstream of sclA used to generate in-frame 
allelic replacement of sclA with aad9 
GAAATGCGCTCTTGTT
TGTC 
MSP166  
 
Forward primer used for PCR amplification and 
sequencing of sclA in invasive GAS 
TCTTTTGGGATCTCTC
AGGC 
MSP167 
 
Reverse primer used for PCR 
amplification and sequencing of sclA in invasive 
GAS 
TAAATAATCAGGTCTA
GCTACC 
MSP183 
 
Used with 2901F to generate 3’- 
flanking region overlapping with 
aad9 
CTATTTAAATAACAGA
TTAAAAAAATTATAAC
GCAAAGAAAACAACTA
ATCCTCTAAATTGAG 
MSP181 
 
Used with MSP182 to amplify aad9; contains 18-
bp at end of sclA ORF 
 
CTCAATTTAGAGGATT
AGTTGTTTTCTTTGCG 
TTATAATTTTTTTAATC
TGTTATTTAAATAG 
MSP182 
 
Used with MSP181 to amplify aad9; contains 18-
bp at beginning of sclA ORF 
 
GAAAGAGAGAACAAC
ATATGTTGACATCAAA 
GCACAATACATGTTAT
AATAACTATAAC 
MSP184 
 
Used with primer 0488R to generate 5’-flanking 
region overlapping with aad9 for in-frame 
deletion of sclA 
 
GTTATAGTTATTATAAC
ATGTATTGTGCTTTGA
TGTCAACATATGTTGT
TCTCTCTTTC 
0488R 
  
Upstream of sclA used to generate in-frame 
allelic replacement of sclA with aad9 
TATGAACAGGCTTCTG
ATTT 
MSP204 sclA forward TaqMan primer TGAAAAAGGTGCAACA
AAGGGCGATA 
MSP205 sclA reverse TaqMan primer GTCCTGCTGGACCTT
GTGCG 
MSP206 
 
Probe for sclA TaqMan transcript analysis. 
Contains 5’- FAM and 3’-BHQ1 labels 
CTGGGCCTACTGGAC
CGGCT 
MSP263  
 
5’-end of sclA and excluded signal sequence 
used for cloning of sclA for expression; contains 
NdeI site 
GCAGCGTTAAGCATAT
GACTCCTATG 
MSP264  
 
3’-end of sclA used for cloning of sclA for 
expression; contains XhoI site 
CCTTGCTCCTCGAGTT
AACCTCGTGGTCC 
MSP275  
 
5’-end – including native promoter – of sclA and 
used with MSP277 to amplify for cloning into 
pDC123; contains EcoRV site 
TATCCAACGATATCAG
AAGGTACAAG 
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MSP277  
 
3’-end of sclA used with MSP275 to amplify for 
cloning into pDC123; contains HindIII site 
ACCTTGAAAAGCTTGC
TCACCGCG 
232Up  
 
5’ end of sclA used for amplification of MGAS315 
sclAInvasive allele 
CTCCACAAAAGAGTGA
TCAGTC 
ME7  
 
Used with 232Up to generate sclAInvasive from 
MGAS315 for cloning into pJRS525 
TCAGTGAATTCTCTTT
AGAGGATTAG 
pJRS525
F1  
Used with ME6 to generate repaired full-length 
sclA fragment from MGAS315 (sclAM3-FL) 
GGGTTTTCCCAGTCAC
G 
ME6  
 
Reverse primer used for PCR mutagenesis to 
repair null mutation in sclAInvasive 
TCCAGCAGGACCTCG
AGGTGAACGC 
M3VF  
 
5’ end of sclA for cloning sclAM3-FL into pASK-
IBA2 expression vector 
GAGATGGCCGAGACT
CCTATGACATCAAAGG 
Scl1.28W
MR 
 
3’ end of sclA containing StreptagII 
sequence for cloning sclAM3-FL into pASK-IBA2 
expression vector 
 
GTCAAGCTTATTATTTT
TCGAACTGCGGGTG 
GCTCCAAGGTTTTTCT
GGAGCTGGAGTTACC 
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Figure S1. Separation of (a) 5 amplicons unique to different species of Aspergillus as well 
as electropherograms that contain internal standards of 150, 450, and 500 base pairs as 
well as a single amplicon for (b) A. nidulans (227 bp); (c) A. terreus (262 bp); (d) A. niger 
(297 bp); (e) A. fumigatus (338 and 489 bp); (f) A. flavus (403 bp).  
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Figure S-1: Separation of (a) 5 amplicons unique to different species of Aspergillus as well
electropherograms that contain internal standards of 150, 450, and 500 base pairs as well as a single
amplicon for (b) A. nidulans (227 bp); (c) A. terreus (262 bp); (d) A. niger (297 bp); (e) A. fumigatus (338
and 489 bp); (f) A. fl vus (403 bp).
Figure S-1: Separation of Aspergillus species markers
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Table S1. Effect of SYBR Green 1 concentration on migration time of 650 bp DNAa 
Concentration Injection size Migration time in minutes Chromatographic2 
resolution (CV) 
2 µM 5 psi 7 sec 27.9 (4) 
20 µM 5 psi 7 sec 27.8 (2) 
100 µM 5 psi 7 sec 26.1 (5) 
a[DMPC]/[DHPC] = 2.5, 2.5% phospholipid.  Separations (n = 5) are accomplished in a 25 
m id capillary with a total length of 40 cm capillary and effective length of 30.2 cm, with 
Eapplied = 100 V/cm.  The DNA base ladder (1Kb+ DNA ladder, Life Technologies) is 
detected with LIF at 520 nm using SYBR green 1 nucleic acid stain at different 
concentrations positioned before the detection window. 
  
 274 
Table S2. Effect of phospholipid concentration on resolution1 
  Resolution 450/475 base pair 
DNA2 
 Resolution 900/950 base pair 
DNA3 
Hydration 
(%) 
Temp 
(°C) 
Chromatographic2 
resolution (CV) 
In base 
pairs3 
 Chromatographic2 
resolution (CV) 
In base 
pairs3 
2.5 23 5.0 (6) 5  6.4 (7) 8 
5.0 25 5.1 (10) 5  4.5 (10) 11 
7.5 30 5.4 (7) 5  4.2 (20) 12 
10.0 30 6.2 (7) 4  3.6 (20) 14 
1Separations (n = 5) are achieved at the specified temperature with [DMPC]/[DHPC] = 2.5 
in a 40 cm long, 25 m id capillary.  The effective length is 30.2 cm and Eapp = 100 V/cm.   
2Resolution is calculated as 0.589(Δt/w1/2av), where Δt is the difference in peak migration 
times and w1/2av is the average peak width at half height 
3Resolution in base pairs is calculated as the difference in base pairs/resolution. 
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Table S3. Effect of [DMPC]/[DHPC] on resolution1 
  Resolution 450/475 base pair 
DNA2 
 Resolution 900/950 base pair 
DNA3 
Hydration 
(%) 
Temp 
(°C) 
Chromatographic2 
resolution (CV) 
In base 
pairs3 
 Chromatographic2 
resolution (CV) 
In base 
pairs3 
2.5 23 5.0 (6) 5  6.4 (7) 8 
3.0 21 5.1 (8) 5  5.3 (10) 9 
4.0 21 5.5 (10) 5  5.5 (10) 9 
5.0 21 1.4 (20) 18  2.6 (20) 36 
1Separations (n = 5) are achieved at the specified temperature with [DMPC]/[DHPC] = 2.5 
in a 40 cm long, 25 m id capillary.  The effective length is 30.2 cm and Eapp = 100 V/cm.   
2Resolution is calculated as 0.589(Δt/w1/2av), where Δt is the difference in peak migration 
times and w1/2av is the average peak width at half height 
3Resolution in base pairs is calculated as the difference in base pairs/resolution. 
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Table S4. Effect of temperature on resolution1 
 Resolution 450/475 base pair 
DNA2 
 Resolution 900/950 base pair DNA3 
Temp 
(°C) 
Chromatographic2 
resolution (CV) 
In base 
pairs3 
 Chromatographic2 
resolution (CV) 
In base 
pairs3 
19 1.2 (20) 22  1.8 (20) 27 
20 3.2 (10) 8  5.3 (10) 9 
21 4.5 (9) 6  5.7 (10) 9 
22 4.5 (8) 6  5.8 (10) 9 
23 5.0 (6) 5  6.4 (7) 8 
24 2.7 (10) 9  4.2 (20) 12 
25 2.5 (10) 10  3.3 (20) 15 
1Separations (n = 5) are achieved at the specified temperature with [DMPC]/[DHPC] = 2.5 
in a 40 cm long, 25 m id capillary.  The effective length is 30.2 cm and Eapp = 100 V/cm.   
2Resolution is calculated as 0.589(Δt/w1/2av), where Δt is the difference in peak migration 
times and w1/2av is the average peak width at half height 
3Resolution in base pairs is calculated as the difference in base pairs/resolution. 
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Figure S1. Phylogenetic analyses of bucl1 in B. pseudomallei and B. mallei strains. 
Nucleotide sequences encoding (A) the noncollagenous domain and (B) entire gene 
of bucl1 alleles were used. Support values for each branch are shown as posterior 
probability from Bayesian analysis and bootstrap values from maximum parsimony 
analysis, respectively (PP/MP). Scale bar is representative of evolutionary distance in 
substitutions per nucleotide. 
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Figure S2. Phylogenetic analysis of bucl8 among Burkholderia strains. Bayesian 
analysis was performed on nucleotide sequences of bucl8 non-collagenous regions of a 
set of Burkholderia strains described in Table 3. Support values for each branch are shown 
as posterior probability from Bayesian analysis. Several clusters of strains, C1, C4, and C5, 
corresponding to those observed in the concatenated analysis were also observed. Scale 
bar is representative of evolutionary distance in substitutions per nucleotide.  
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Figure S3. Phylogenetic analysis of Bucl3 and Bucl4 amino acid sequences 
among Burkholderia strains. Bayesian analysis was performed on amino acid 
sequences of (A) Bucl3 and (B) Bucl4 non-collagenous regions of a set 
of Burkholderia strains described in Table 3. Support values for each branch are shown as 
posterior probability from Bayesian analysis and bootstrap values from maximum 
parsimony analysis, respectively (PP/MP). Posterior probability value, which was not 
supported by maximum parsimony analysis is shown in red. Scale bar is representative of 
evolutionary distance in substitutions per nucleotide. 
 282 
 
 
 283 
Figure S4. Distribution of bucl genes among Burkholderia spp. select agents by 
PCR. Presence of (A) bucl genes 2, 3, and 10 and (B) bucl genes 6, 7, 8, and 15, was 
assessed by PCR on a collection of genomic DNA 
from B. pseudomallei and B. mallei select agents (top panels), as well as in control strains 
of B. thailandensis, B. cepacia, B. cenocepacia, and B. multivorans (bottom panels). 
Amplicon sizes based on Bp K96243: In A) bucl2, 133 bp; bucl3, 166 bp; and bucl10, 109 
bp; In B) bucl6, 115 bp; bucl7, 264 bp; bucl8, 243 bp; and bucl15, 95 bp.M, 50-bp DNA 
ladder. PCR data shown in panels A and B for 25 Bp strains come from two merged gel 
images. 
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